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Introduction 

Introduction 
1 Introduction 
1.1 Atherosclerosis 
Atherosclerosis is a progressive disease of the large and medium-sized arteries. The disease 
is characterised by endothelial dysfunction, inflammation and the accumulation of fatty 
and fibrous substances in the vessel wall, resulting in thickening and loss of elasticity of 
the arteries. The word atherosclerosis has been derived from the Greek words "athera", 
porridge or gruel, and "skleros", hard or stiff. These words describe the external features 
of the lipid-loaded lesions that characterize the disease. Although atherosclerosis has been 
discovered in blood vessels of people living more than 3000 years ago, until the end of 
the 18th century its prevalence was very rare. During the 20th century, mortality caused 
by atherosclerosis strongly increased. Nowadays, complications of atherosclerosis are the 
main cause of death in the developed world, and are predicted to be the leading cause of 
death worldwide by the year 2020 (Fonarow, 2007). 
It is difficult to accurately determine the true frequency of atherosclerosis because it is a 
predominantly asymptomatic condition (Kavey et al., 2006). Early atherosclerotic lesions 
can already be found in the aorta shortly after birth, increasing in number during childhood. 
More advanced lesions begin to develop at an age of approximately 25 years. Generally, 
the clinical manifestations of the disease become apparent in the sixth decade of life. 
Symptomatic atherosclerotic disease most often involves the arteries supplying the heart, 
brain, kidneys, and lower extremities, and becomes apparent when arterial blood flow is 
obstructed. Complete occlusion of an affected artery can result in myocardial infarction, 
cerebral infarction, or peripheral vascular disease. 
Both genetic and environmental risk factors contribute to the susceptibility to develop 
atherosclerosis, such as male gender, family history of atherosclerotic disease, hypertension, 
diabetes mellitus, dyslipidemia, obesity, and high age, but also personal attributes like 
tobacco smoking, physical inactivity, high fat diet and stress or mental depression. The 
pathophysiology of atherosclerosis is complex, multifactorial and reflexes an interaction 
between vessel wall and plasma. Three main processes involved in the development of 
atherosclerosis are hypercholesterolemia (Steinberg, 2005), injury of the endothelial lining 
(Ross and Glomset, 197 6), and inflammation of the vascular wall (Stoll and Bendszus, 2006) 
There is no need to consider these processes as three alternative hypotheses to explain. 
the pathogenesis of atherosclerosis; each of the processes may be involved. However, the 
'classical' risk factor for atherosclerosis development is hypercholesterolemia. For already 
almost a hundred years scientists are focussing on the relationship between plasma lipid 
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metabolism and atherogenesis. With the discovery of the low-density lipoprotein (LDL) 
receptor, responsible for the clearance of plasma cholesterol (Brown and Goldstein, 1976), 
strong evidence was provided for a causal relationship between elevated LDL-cholesterol 
levels and atherosclerosis. Small dense LDL particles can infiltrate the arterial wall, where 
they undergo progressive oxidation. Oxidized cholesterol is highly toxic, and as part of a 
defense mechanism, it gets internalized by macrophages through the scavenger receptors, 
leading to the formation of lipid-rich foam cells (Han eta!., 1997; Morel et a!., 1983; 
Steinberg, 1997). Accumulation of these foam cells forms the earliest atherosclerotic 
lesions, called "fatty streaks". Besides the accumulation of macrophage foam cells, 
inflammatory cells such as T lymphocytes, and smooth muscle cells are observed in the 
lesions. By progressive lipid accumulation and the interplay between various immunologic 
and inflammatory processes, the fatty streak may further progress to eventually become a 
vulnerable plaque. After evidence was provided for a causal relationship between elevated 
LDL-cholesterollevels and the onset of atherosclerosis as described above, cardiovascular 
research focused on the relationship between lipoprotein metabolism and atherosclerotic 
disease. In the next paragraph, the different lipoprotein subclasses, their metabolism, and 
their relationship with cardiovascular disease will be described in detail. 
1.2 Lipoprotein metabolism 
1.2.1 Lipoproteins 
Cholesterol, phospholipids and triglycerides are the main lipids in the circulation. 
Lipid molecules are relatively insoluble in water because they consist largely of long 
hydrophobic hydrocarbon tails. To transport plasma lipids through the body, they are 
packaged into water-soluble complexes, so-called lipoproteins. Plasma lipoproteins are 
complex, spherical particles that consist of a hydrophobic core of neutral lipids ( cholesteryl 
esters and triglycerides) surrounded by a polar shell of free cholesterol, phospholipids and 
apolipoproteins (Figure 1). Apolipoproteins serve as enzyme co-factor, receptor ligand, 
and structural component regulating the intravascular metabolism oflipoproteins and their 
ultimate tissue uptake. Lipoproteins constitute a heterogeneous population of particles, 
which can be classified according to their densities. Five main categories are distinguished, 
listed with increasing density: chylomicrons, very low-density lipoproteins (VLDL), 
intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL), and high-density 
lipoproteins (HDL) (Davis, 1996) (Table 1 ). The individual functions of these lipoprotein 
subclasses in lipid metabolism will be discussed in the following sections. Lipoprotein 
metabolism can be divided into two major pathways: the transport of dietary lipids taken 
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up from the intestine, described as the exogenous pathway, and the transport of liver-
synthesized lipids, the endogenous pathway. The transport of cholesterol from peripheral 
tissues to the liver, where it is converted into bile acids and excreted, is called reverse 
cholesterol transport. 
phospholipid 
cholesteryl esters and triglycerides 
apolipoprotein 
Figure 1. Schematic illustration of a lipoprotein particle. Modified from Oxford University Press. 
1.2.2 Exogenous pathway 
The exogenous pathway describes the process in which dietary lipids are taken up from the 
intestine and transported to the liver and peripheral tissues (Figure 2). Before transport over 
the intestinal membrane and uptake by enterocytes, dietary cholesterol, phospholipids and 
triglycerides are hydrolyzed in the intestinal lumen into monoacylglycerols and free fatty 
acids. Intracellularly, these compounds are transformed into triglycerides and packaged 
into chylomicrons. Nascent chylomicrons are primarily composed of triglycerides (86%) 
together with some free cholesterol and cholesteryl esters. The main apolipoprotein 
components are apoB48, apoAI and apoAN (Hussain et al., 1996). Chylomicrons are 
released by exocytosis from enterocytes and secreted into lymphatic vessels originating 
in the villi of the small intestine, after which they are secreted into the bloodstream. After 
entering the bloodstream, chylomicrons exchange apolipoproteins with HDL. Chylomicrons 
transport exogenous lipids to adipose tissue, and to a lesser extent to cardiac and skeletal 
muscle. In the capillary beds of these tissues, chylomicron triglycerides are hydrolyzed by 
the lipolytic action of lipoprotein lipase (LPL), present at the surface of endothelial cells 
(Redgrave, 2004). This results in the generation of free fatty acids, which can be used as 
energy source for muscles or stored in adipocytes. Once the triglyceride content of the 
chylomicrons has been distributed among tissues, remnant particles are left, enriched in 
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cholesteryl esters and apoE. ApoE is an important factor for facilitating the clearance of 
chylomicron remnants from the circulation by the liver via remnant receptors, i.e. the low-
density lipoprotein receptor (LDLR) and the LDLR-related protein (LRP) (Cooper, 1997; 
Herz et al., 1995; Mahley et al., 1989; Rohlmann et al., 1998). In addition, scavenger 
receptor-class B type I (SR-BI) might be involved in the hepatic uptake of chylomicron 
remnants (Out et al., 2004). 
Table 1. Physical properties and composition of human plasma lipoproteins. Based on (Alonzi 
et al., 2008; Wasan and Cassidy, 1998). 
Chylomicrons VLDL IDL LDL HDL 
Density (g/ml) <0.95 0.95-1.006 1.006-1.019 1.019-1.063 1.063-1.21 
Diameter (nm) 75-1200 30-80 25-35 18-25 5-12 
Composition (% w/w) 
Triglycerides 85-88 50-55 25-30 10-15 3-15 
Phospholipids 8 18-20 25-27 20-28 26-46 
Cholesterol 4 20-25 40-45 45-58 17-40 
Protein 1-2 7-10 10-12 20-22 33-57 
Apolipoproteins 
apoA AI, All, AIV, AV AV AI, All, AIV, AV 
apoB B48 BlOO B100 BlOO 
apoC CI, en, CUI CI, CII, CUI cr, en, em CI, CII, CIII 
a poE E E E E 
1.2.3 Endogenous pathway 
The endogenous lipoprotein pathway describes the metabolic fate of lipoproteins that are 
synthesized by the liver (Figure 2). In the liver, VLDL is synthesized by a process consisting 
of two separate steps (Shelness and Sellers, 2001). In the first step, a partially lipidated 
apoB-containing VLDL precursor is formed by the action of the microsomal triglyceride 
transfer protein (MTP). In the second step, VLDL-sized triglyceride droplets (derived 
from the uptake of plasma remnants or free fatty acids) fuse with the apoB-containing 
precursor particles. Under the influence of the intracellular cholesterol-esterifying enzyme 
Acyl-CoA:cholesterol acyl-transferase (ACAT), the nascent VLDL is further lipidated with 
cholesterol (derived from remnant uptake or de novo synthesis) resulting in mature VLDL, 
which is subsequently secreted into the circulation. Upon entering the circulation, nascent 
16 
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VLDL is enriched with apoAV, apoCs and apoE, mainly acquired from HDL. Triglycerides 
in the core of the VLDL particle are hydrolyzed by LPL, thereby generating free fatty acids 
Exogenous pathway Endogenous pathway 
. t~· bile acid~~® m es me and : 
' cholesterol : 
®""- : 
CD 
1 
peripheral cell 
chylomicron , LDL 
remnant, VLDL. : 
Figure 2. Schematic and simplified representation of human lipoprotein metabolism. 
I) uptake of dietary lipids from the intestine and secretion of chylomicrons into the blood; 
2) lipolysis of triglyceride-rich lipoproteins by endothelial LPL; 3) uptake of apoB-containing 
lipoproteins by liver receptors; 4) hepatic VLDL secretion into the blood; 5) lipolysis ofiDL by 
LPL and HL, generating LDL; 6) uptake of LDL-cholesterol by peripheral cells; 7) cholesterol 
efflux from peripheral cells to lipid-poor apoAI and HDL; 8) selective uptake ofHDL-cholesterol 
by the liver; 9) excretion of cholesterol into bile and faeces. 
1.2.4 Reverse cholesterol transport 
For processing, degradation and secretion into bile, cellular cholesterol must be transported 
from peripheral tissues via the blood back to the liver. This process is called reverse 
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cholesterol transport (Fielding and Fielding, 1995) (Figure 3). Because the liver is 
considered as the most important organ for cholesterol synthesis in the body, and the site 
from where cholesterol is transported to the peripheral tissues, cholesterol that moves from 
peripheral tissues to the liver is moved in the reverse direction. In relation to atherosclerosis, 
reverse cholesterol transport has been postulated to play an important atheroprotective 
role, because it stimulates the efflux of accumulated cholesterol from macrophage foam 
cells in the arterial wall, thereby preventing the formation of atherosclerotic lesions 
(Tall, 2008). The initial step in reverse cholesterol transport is the efflux of cellular free 
cholesterol and phospholipids to acceptor particles. ATP-binding Cassette transporter Al 
(ABCAl) mediates lipid efflux to lipid-poor apoAI (Jessup et a!., 2006). This lipid-poor 
apoAI may be secreted by the liver or intestine, it may be released from triglyceride-rich 
lipoproteins during lipolysis, or it may be generated during remodelling of mature HDL 
particles (Rye and Barter, 2004). In this way, a nascent discoidal HDL is formed, so-called 
preP-BDL. By the action ofthe enzyme lecithin:cholesterol acyl-transferase (LCAT), free 
cholesterol in prep-HDL is converted into cholesteryl esters, resulting in the formation of 
mature a-migrating spherical HDL (Zannis et a!., 2006). In this way, LCAT maintains a 
concentration gradient of free cholesterol between peripheral cells and plasma HDL and 
has a key role in the maturation of HDL particles. Cholesterol efflux from macrophages 
is further enhanced by passive diffusion or active efflux through ATP-binding Cassette 
transporter G 1 (ABCG 1) or scavengerreceptor BI (SR-BI) to mature a-HDL particles (Jessup 
et al., 2006). In plasma, continuous extensive remodeling of HDL particles takes place. 
Apolipoproteins are exchanged between different plasma lipoprotein particles and lipids 
are transferred by a range of plasma factors, resulting in changes in size and composition 
oflipoprotein particles. In the process ofHDL remodeling, mature HDL particles are fused 
to form larger HDL particles, with the release of lipid-poor apoAI, serving as initiator of 
reverse cholesterol transport. The main plasma lipoprotein remodeling proteins are LCAT, 
phospholipid transfer protein (PLTP), cholesteryl ester transfer protein ( CETP), lipoprotein 
lipase (LPL) and hepatic lipase (HL) and endothelial lipase (EL). 
The final steps of reverse cholesterol transport involve uptake of HDL-cholesterol by the 
liver, and subsequent excretion of cholesterol and bile acids in the bile and faeces. HDL-
cholesterol may be removed from the circulation by different pathways. One of these is the 
selective uptake by hepatic SR-BI, which has been identified as an HDL receptor (Acton 
et al., 1996). SR-BI removes cholesteryl esters from the HDL particle without the uptake 
of HDL proteins. In humans, a second pathway for removal of HDL-cholesterol from the 
circulation involves the action of CETP (Tall, 1995). By the action of this lipid transfer 
protein, cholesteryl esters, in exchange for triglycerides, can be transferred from HDL 
particles to apoB-containing lipoproteins, such as VLDL and LDL. Subsequently, cholesteryl 
esters in these particles can be taken up by the liver via hepatic LDL receptors and LRP. 
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Once cholesterol has been taken up by the liver it may be secreted into the bile either as bile 
acids or as free cholesterol, by a process in which the bile canalicular transporters ABCG5 
and ABCGS are involved, or it may be re-used for lipoprotein assembly. Cholesterol and 
bile acids can be either reabsorbed from the intestine, or excreted into the faeces. 
Proteins with a central role in reverse cholesterol transport will be discussed in more detail 
in section 1.3. 
peripheral cell 
VLDL LDL 
liver 
Figure 3. Schematic and simplified representation of reverse cholesterol transport. 
1) ABCAl-dependent lipid efflux to lipid-poor apoAI with the formation of pre~-HDL; 2) 
maturation of HDL particles through esterification of free cholesterol by LCAT; 3) lipid efflux 
to mature a-HDL viaABCG 1 or SR-BI; 4) PLTP-mediated HDL remodeling with the generation 
of large fused HDL and pre~-HDL; 5) selective uptake of HDL-cholesterol by hepatic SR-
BI; 6) CETP-mediated transfer of cholesteryl esters from HDL to VLDL/LDL in exchange for 
triglycerides; 7) uptake ofLDL by hepatic receptors; 8) excretion oflipids into bile and faeces. 
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1.2.5 The role of HDL in macrophage reverse cholesterol transport 
The fact that elevated levels of HDL have been associated with a reduced risk for 
cardiovascular disease might be explained at least partly by the key role ofHDL in reverse 
cholesterol transport. In patients with heterozygous familial hypercholesterolemia, infusion 
of human pro-apoAI, a precursor of apoAI, resulted in a transient rise in HDL levels 
followed by an increase in faecal neutral sterol and bile acid excretion, suggesting a potential 
stimulation of reverse cholesterol transport with HDL level as an important determinant 
(Eriksson et al., 1999). Rader and colleagues developed a method to quantifY macrophage 
reverse cholesterol transport in animal models. By injecting radiolabeled lipid-loaded 
macrophages into the peritoneal cavity and subsequently tracing cholesterol radioactivity in 
plasma and faeces, macrophage lipid efflux to the plasma and overall macrophage reverse 
cholesterol transport can be quantified. Using this approach, overexpression of human 
apoAI in mice (Zhang et al., 2003b) or treatment of mice with a synthetic LXR agonist 
(Naik et al., 2006) has shown to result in the increase of macrophage reverse cholesterol 
transport, likely attributable to increased plasma HDL levels. However, mice lacking SR-BI 
had a reduced macrophage reverse cholesterol transport despite higher plasma HDL levels 
(Zhang et al., 2005), and expression of CETP in mice reduced HDL levels but promoted 
macrophage reverse cholesterol transport (Tanigawa et al., 2007). Moreover, wild type 
mice with ABCA1 or ABCG 1 deficient macrophages had an impaired macrophage reverse 
cholesterol transport, whereas plasma lipid levels were not different (Wang et al., 2007c). 
These findings indicate that reverse cholesterol transport rate is not simply a function of 
HDL plasma concentration. A complex network of cellular and plasma proteins is involved 
in the process of reverse cholesterol transport, and the interplay of these factors may 
determine the efficiency ofreverse cholesterol transport. 
The pool of HDL particles is structurally and functionally diverse, consisting of many 
highly dynamic particle subpopulations that differ in their capacity to mediate reverse 
cholesterol transport and protect against atherosclerosis (Rye et al., 2008). In the first step 
ofreverse cholesterol transport, small pre~-migrating lipid-free/lipid-poor apoAI could be 
a more efficient acceptor of cellular cholesterol than large a-migrating HDL, implying that 
smaller particles may be more cardioprotective than larger particles (Oram and Vaughan, 
2006). However, recently it was demonstrated that mature a-HDL is more important 
than pre~-HDL in controlling reverse cholesterol transport in vivo (Wang et al., 2007b ). 
Importantly, epidemiological evidence supporting a cardioprotective role for pre~-HDL 
is lacking. On the contrary, a recent analysis of data collected in a large intervention trial 
demonstrated that subjects with new cardiovascular events had significantly lower levels 
of a-HDL, and significantly higher levels of pre~-HDL compared to event-free subjects 
(Asztalos et al., 2008). These studies demonstrate that although the importance ofHDL for 
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reverse cholesterol transport is commonly accepted, the exact physiological involvement of 
different HDL subpopulations in reverse cholesterol transport and atherosclerotic disease 
should be clarified. Importantly, reverse cholesterol transport is only one mechanism by 
which HDL may protect against atherosclerosis. HDL displays a variety of other properties 
that could contribute to its anti-atherogenicity, such as anti-oxidative, anti-inflammatory 
and anti-thrombotic effects. HDL protects against harmful effects of oxidized LDL. These 
anti-oxidative properties may be in part related to its content of apoAI and paraoxonases 
(PON), enzymes that remove the lipid hydroperoxides that oxidize LDL phospholipids 
(Banka, 1996). The anti-inflammatory properties of HDL are related to its ability to 
remove cholesterol and oxysterols from cells in the arterial wall, thereby inhibiting the 
formation of foam cells and subsequent increase in expression of inflammatory proteins 
(Tall, 2008). HDL can also repress the induction of cell-adhesion molecules and inhibit 
monocyte accumulation (Barter et al., 2002). In addition, several anti-thrombotic properties 
of HDL have been described, including inhibition of platelet aggregation and activation, 
downregulation of cell-adhesion factors, inhibition ofthe activation of coagulation factors, 
and stimulation of the upregulation of anticoagulant factors (Hausenloy and Yellon, 2008; 
Sviridov et al., 2008). 
1.2.6 Lipoprotein metabolism and cardiovascular research in mice 
During the last twenty years, the ability to create transgenic animals has largely increased 
the scientific opportunities to perform functional studies of a gene of interest. A frequently 
used organism in transgenic research is the mouse. There is a strong genetic resemblance 
between mice and men, and physiology and metabolic processes are comparable. When 
performing functional studies with mice, the genetic variability and inter-individual 
differences regarding life style and environmental factors can be reduced to a minimum, 
because inbred strains are used and living conditions can be strictly controlled. The 
genetic map of the mouse is well described, and special techniques have become available 
to manipulate mouse genes by transgenesis and gene targeting. Also in the field of 
cardiovascular research the mouse is a frequently used modeL Atherosclerosis is a complex 
process with an onset decades before the acute manifestation of cardiovascular disease. 
Studying atherogenic mechanisms in humans is hindered by the complexity of the disease 
process, combined with the difficulty to characterize lesions in patients. These practical 
problems can be overcome by using the mouse as a research modeL However, in general, 
mice are highly resistant to develop atherosclerosis. Only the C57BL/6 strain, when fed a 
very high cholesterol diet containing cholic acid, develops atherosclerotic lesions (Jawien 
et al., 2004; Paigen et al., 1985). These lesions are small, largely confined to the aortic 
root, and generally do not develop beyond the stage of fatty streak (Paigen et al., 1987). 
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The inability to induce pronounced atherosclerosis in most mouse strains is caused by the 
atheroprotective murine lipoprotein profile, with the main plasma lipoprotein class being 
HDL. In contrast, in humans the predominant lipoprotein classes are VLDL and LDL, 
which are considered atherogenic (Ishida et al., 1991). These major differences in plasma 
lipoprotein distribution could be explained by marked differences in lipoprotein metabolism 
between mice and man, which are summarized in Table 2. 
Table 2. Lipoprotein metabolism in mice and men. 
Characteristic Mouse Human Reference 
apoB editing liver and intestine intestine (Arrant and Davidson, 2001) 
VLDL lipidation of lipidation of (Greeve eta!., 1993) 
synthesis apoBlOO and apoBlOO 
apoB48 
apoE gene one isoform polymorphic (Knouff et al., 1999) 
(apoE2, -E3, -E4) 
hepatic lipase circulating in bound to vascular (Dallinga-Thie et al., 2007; 
plasma endothelium Peterson et al., 1986) 
CETP absent present (Guyard-Dangremont et al., 1998; 
Speijer et al., 1991) 
lp(a) absent present (Berglund and Ramakrishnan, 
2004) 
Different targeted mouse models have been developed to overcome the discrepancy between 
the murine and the human lipoprotein profile (Jawien et al., 2004). Of these genetically 
engineered mouse models, the apoE deficient model is the only one that develops extensive 
atherosclerotic lesions on a chow diet (Plump et al., 1992; Zhang et al., 1992). The LDLR 
deficient model has elevated LDL levels, but no lesions form on a chow diet (Ishibashi et 
al., 1993). In this model, advanced atherosclerotic lesions only develop when a high fat, 
high cholesterol diet is provided to the animals (Ishibashi et al., 1994). When mice with 
only one functional LDLR allele (LDLR+1-) are used, administration of a cholate-enriched 
high fat, high cholesterol diet is required. In addition to these most commonly used mouse 
models, a wide variety of other mouse models with affected lipoprotein metabolism has 
been developed to study cardiovascular disease (Jawien et al., 2004). 
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1.3 Proteins involved in reverse cholesterol transport 
Reverse cholesterol transport involves a series of steps, beginning with the efflux of 
cholesterol from the peripheral cell and ending with its uptake by the liver, degradation into 
bile acids and excretion into the faeces. A wide variety of cellular and plasma proteins is 
involved in this pathway. In this section, the key players in reverse cholesterol transport are 
discussed, divided by their role in the pathway: mediators of cholesterol efflux, lipoprotein 
remodeling proteins, and mediators of hepatic cholesterol uptake and biliary excretion. 
1.3.1 Mediators of cellular cholesterol efflux 
ABCAJ 
ATP-binding cassette (ABC) transporters constitute a large family of transmembrane proteins 
that use ATP as an energy source to translocate a wide variety of substrates across cellular 
membranes. One of the best characterized ABC transporters is the ubiquitously expressed 
ABCAl. ABCAl is highly expressed in macrophages, and transcription of ABCAl is 
markedly induced by overloading cells with cholesterol (VanEck et al., 2005). In addition, 
ABCA 1 is also highly expressed in the liver, where it plays a role in the lipidation of apoAI 
(Oram and Heinecke, 2005). ABCA 1 mediates the unidirectional transport of phospholipids 
and cholesterol to lipid-free and lipid-poor apolipoproteins, preferentially apoAI (Jessup et 
al., 2006). ApoAI can bind directly to ABCAl, thereby stabilizing ABCAl and enhancing 
lipid efflux (Arakawa and Yokoyama, 2002; Wang et al., 2001). 
Mutations in ABCA 1 were discovered as the genetic defect in Tangier disease, characterized 
by an almost complete deficiency of plasma HDL, accumulation of cholesterol in peripheral 
macrophages, and premature cardiovascular disease (Bodzioch et al., 1999). In mouse 
models, absence of ABCA1 strongly reduces plasma HDL levels (McNeish et al., 2000; 
Orso et al., 2000), while overexpression of ABCAl increases plasma HDL levels (Cavelier 
et al., 2001; Singaraja et al., 2001; Vaisman et al., 2001 ). Studies determining the effect of 
ABCAl overexpression on atherosclerosis development provided conflicting results (Joyce 
et al., 2002; Singaraja et al., 2002). 
The role ofmacrophageABCA1 in lipoprotein metabolism and reverse cholesterol transport 
is well-described. Macrophage-specific deletion ofABCAl results in an impaired cholesterol 
efflux in vitro (Haghpassand et al., 2001) and a decreased reverse cholesterol transport in 
vivo (Wang eta!., 2007a; Wang et al., 2007c). Furthermore, macrophage-specific ABCAl 
deficiency resulted in accelerated atherosclerosis in mice (Aiello et al., 2002; van Eck 
et al., 2002). In accordance with these findings, overexpression of macrophage ABCA1 
stimulated lipid efflux in vitro (Singaraja et a!., 2002; VanEck et al., 2006). 
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ABCGJ 
Another member of the superfamily of ABC transporters is ABCG1, which is found 
throughout the whole body, but particularly in macrophage-rich tissues (Jessup et al., 2006). 
Like for ABCAl, expression ofmacrophageABCG1 is also strongly responsive to cellular 
cholesterol status (Venkateswaran et al., 2000). Whereas ABCA1 exports cholesterol and 
phospholipids to lipid-poor apolipoproteins, ABCG 1 mediates unidirectional efflux of 
cholesterol to mature HDL particles (Kennedy et al., 2001; Klucken et al., 2000). ABCAl 
and ABCG 1 might act together in exporting cellular lipids: by loading lipid-poor apoAI 
with cellular lipids, ABCA1 generates particles which serve as acceptors for ABCG1-
mediated cholesterol efflux (Gelissen et al., 2006). 
ABCG 1 deficient mice accumulate cholesterol in macrophages within multiple tissues, 
whereas mice overexpressing ABCG 1 have diminished cholesterol accumulation 
(Kennedy et al., 2005). This can be explained by the importance of ABCG 1 for an efficient 
reverse cholesterol transport. ABCG 1 deficiency in macrophages resulted in an impaired 
macrophage reverse cholesterol transport, whereas ABCG 1 overexpression in macrophages 
promoted reverse cholesterol transport in vivo. Double knockdown ofABCA1 andABCG1 
in macrophages greatly impaired macrophage reverse cholesterol transport compared to 
macrophage-ABCG 1 deficiency alone, indicating that ABCAl and ABCG 1 cooperatively 
contribute to macrophage reverse cholesterol transport (Wang et al., 2007c). The exact 
physiologic role ofmacrophageABCG1 in atherogenesis remains uncertain: as investigated 
by three independent research groups, mice with ABCG 1 deficient macrophages had either 
decreased (Baldan et al., 2006; Ranalletta et al., 2006) or modestly increased (Out et 
al., 2006) atherosclerosis. A dramatic increase in atherosclerosis was found in mice with 
macrophages lacking both ABCA1 and ABCG 1 (Yvan-Charvet et al., 2007). 
SR-BI 
Scavenger Receptor-BI (SR-BI) or CLA-1 (its human analogue) is a multiple transmembrane 
receptor that can bind modified forms ofLDL and native HDL, LDL, and VLDL, with the 
highest affinity for HDL (Acton et al., 1996). SR-BI was initially identified as a protein 
taking up cholesterol esters, phospholipids and triglycerides from lipoproteins. Now it is 
clear that SR-BI also mediates the bidirectional exchange of free cholesterol between cells 
and lipoprotein particles, in which the overall direction of cholesterol movement depends 
on its concentration gradient. SR-BI is highly expressed in the liver and macrophages, 
and in steroidogenic tissues such as the adrenal glands, ovaries, and testes (Van Eck et al., 
2005). 
Expression of SR-BI in macrophages is considered to have an atheroprotective effect, 
as mice with SR-BI deficient macrophages develop more atherosclerosis compared to 
mice with SR-BI-expressing macrophages (Covey et al., 2003; Zhang et al., 2003a). 
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This atheroprotective effect was explained by the fact that macrophage SR-BI could 
promote cholesterol efflux to mature HDL particles, as demonstrated in vitro (Ji et al., 
1997). However, in another study, cholesterol efflux from SR-BI deficient macrophages 
to HDL3 or whole mouse serum was found to be similar compared to efflux from SR-BI 
expressing cells, and reverse cholesterol transport in vivo was not impaired in mice after 
transfer of bone marrow-derived SR-BI deficient macrophages (Wang et al., 2007c). These 
findings suggest that the SR-BI might have anti-atherogenic effects that are independent of 
cholesterol efflux from macrophages. 
1.3.2 Lipoprotein remodeling proteins 
CETP and PLTP 
The exchange of lipids between lipoprotein subclasses is performed by two closely 
related proteins, named CETP and PLTP. PLTP and CETP belong to the lipid transfer/ 
lipopolysaccharide binding protein (LT ILBP) family, which also includes lipopolysaccharide 
binding protein (LBP) and bactericidal permeability-increasing protein (BPI). LBP and BPI 
are able to bind and transfer bacterial endotoxins and lipopolysaccharide (LPS), thereby 
modulating the response to bacterial infection (Schumann et al., 1990). CETP is a plasma 
protein that is able to transfer neutral lipids, triglycerides and cholesteryl esters between 
lipoprotein particles, while PLTP transfers phospholipids, free cholesterol and vitamin E. 
The molecular characteristics and function of PLTP will be discussed in detail in the next 
chapter. 
CETP 
CETP was discovered in the late 1970s (Pattnaik et al., 1978; Zilversmit et al., 1975). In 
contrast to human plasma, mouse, pig and rat plasma do not display CETP activity, which 
demonstrates that CETP activity varies largely between mammalian species (Guyard-
Dangremont et al., 1998; Speijer et al., 1991). CETP mediates the transfer of HDL-
cholesteryl esters to apoB-containing lipoproteins in exchange for triglycerides (Ohta et 
al., 1995). The resulting HDL particles have a decreased cholesterol content and particle 
size, and are enriched with triglycerides. Cholesteryl esters in apoB-containing lipoproteins 
can be removed from plasma through receptor-mediated uptake by the liver. 
In humans, CETP deficiency results in elevated plasma HDL levels (Inazu et al., 1990; 
Koizumi et al., 1985; Kurasawa et al., 1985). Clinical studies showed that elevated plasma 
CETP activity or concentration levels are associated with increased cardiovascular risk 
(Dullaart et al., 2007). In general, expression of CETP in mice resulted in the reduction 
of HDL levels, but also in the stimulation of macrophage reverse cholesterol transport 
(Tanigawa et al., 2007). The effect of CETP expression on atherosclerosis susceptibility 
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in animal models has been studied extensively and appears highly dependent on the level 
of CETP expression and on the genetic and metabolic context (Parini and Rudel, 2003). 
Dependent on the background of the mice, and efficacy of clearance of apoB-containing 
lipoproteins, CETP might be either pro- or anti-atherogenic (Tanigawa et al., 2007). 
Studies in human subjects showed that an elevated plasma CETP activity or concentration 
is associated with increased cardiovascular risk (Dullaart et al., 2007). As plasma HDL 
levels are elevated in CETP deficiency (Inazu et al., 1990; Koizumi et al., 1985; Kurasawa 
et al., 1985), much effort is being paid to therapeutic CETP inhibition. CETP inhibition 
by monoclonal antibodies or synthetic compounds in animal models and preclinical trials 
demonstrated clinical efficacy on plasma lipid levels (Vourvouhaki and Dedoussis, 2008). 
However, a study with CETP inhibitor torcetrapib in patients with coronary artery disease 
was recently stopped because of increased mortality, despite a significant increase in HDL 
level and decrease in LDL level (Kontush et al., 2008). 
LCAT 
Another protein with an important function in HDL metabolism is lecithin cholesterol 
acyl-transferase (LCAT). After secretion by the liver, LCAT circulates in the blood, bound 
to HDL. The main activator of LCAT is apoAI. LCAT mediates the esterification of free 
cholesterol, mainly derived from cellular membranes, primarily at the surface of HDL. 
After esterification, the formed cholesteryl esters migrate to the inner core ofthe lipoprotein 
particle. In this way, LCAT converts pre~-HDL into a-HDL, thereby contributing to the 
maturation ofHDL particles. LCAT has been suggested to play a role in reverse cholesterol 
transport by maintaining a free cholesterol gradient between peripheral cells and plasma 
HDL and by maintaining HDL acceptor particle shape and structure (Glomset, 1968). 
Animal studies elucidating the role of LCAT in reverse cholesterol transport (Alam et al., 
2001; Berard et al., 1997; Francone et al., 1997) and in the development of atherosclerosis 
have provided conflicting results (Berard et al., 1997; Foger et al., 1999; Furbee and Parks, 
2002; Mehlum et al., 1997). Modest plasma levels ofLCAT protect against atherosclerosis, 
but when plasma LCAT levels exceed a certain level, this could result in the development 
of atherosclerosis (Hovingh et al., 2005). Coexpression of both human LCAT and CETP 
in mice resulted in reduced atherosclerosis development compared to overexpression of 
LCAT alone (Foger et al., 1999; Rigotti et al., 1997). 
HL 
Lipases are water-soluble proteins that hydrolyze ester bonds of water-insoluble substrates 
such as triglycerides, phospholipids and cholesteryl esters, thereby generating free fatty 
acids. Lipases are involved in a diversity of biological processes ranging from metabolism 
of dietary triglycerides to cell signalling and inflammation. The lipase gene family consists 
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of multiple members that originated from a common ancestral precursor and evolved into 
proteins with distinct organ-specific expression and functions. One of these is hepatic 
lipase (HL), a glycoprotein that is synthesized mainly by hepatocytes. After secretion it 
binds to heparan sulfate proteoglycans on the surface of sinusoidal endothelial cells and 
parenchymal cells in the space ofDisse (Hasham and Pillarisetti, 2006). The main function 
of HL is to hydrolyze triglycerides and phospholipids in VLDL remnants, IDL, LDL and 
HDL. During HDL remodeling, triglyceride-enriched HDL particles formed by CETP 
activity are substrates for HL. By mediating the hydrolysis ofHDL-triglyceride, HL reduces 
the size of the HDL core. In addition to its role as a lipolytic enzyme, lipoprotein-bound 
HL serves as a ligand for the binding of lipoproteins to the surface of the hepatocytes, 
thereby facilitating the uptake of lipids via cell surface receptors (Krapp et al., 1996). The 
expression of macrophage-derived HL in apoE deficient and LCAT overexpressing mice 
enhanced atherosclerotic lesion formation (Nong et al., 2003). Although the role ofHL in 
cardiovascular disease has been studied extensively, the question whether HL is a pro-or 
anti-atherogenic enzyme has still not been answered satisfactory (Gonzalez-Navarro et al., 
2002; Jansen et al., 2002; Lambert et al., 2000; Santamarina-Fojo et al., 2004). 
LPL 
Lipoprotein lipase (LPL) is synthesized in parenchymal cells of tissues that use free fatty 
acids as energy source (heart, skeletal muscle) or for storage purposes (adipose tissue). In 
addition, LPL is expressed by macrophages in the vascular wall (Hasham and Pillarisetti, 
2006). LPL is secreted and attached to the luminal side of the vascular endothelium via 
charged heparan sulfate proteoglycans. Lipolysis is initiated when circulating triglyceride-
rich lipoproteins interact with endothelial cell-associated dimeric LPL. The enzyme is 
activated by apoCII on the surface of these lipoprotein particles. LPL is the rate-limiting 
enzyme in the hydrolysis of triglycerides in chylomicrons and VLDL, thereby generating 
non-esterified fatty acids (Santamarina-Fojo and Brewer, 1994). In addition to its role as an 
enzyme, LPL has been proposed to be a bridging factor that facilitates the uptake ofHDL-
cholesterol esters by the liver and by macrophages (Beisiegel, 1996; Mulder et al., 1993; 
Rinninger et al., 2001). 
The tissue site of LPL expression appears to be a key determinant of its effects on 
atherosclerosis (Tontonoz P, 2003). While the main effect ofLPL, lipolysis, is per se athero-
protective by lowering plasma triglycerides and generating material for HDL formation, 
macrophage expression ofLPL in the artery wall could also have a pro-atherogenic effect due 
to prolonged exposure of the endothelium to lipolysis products. Systemic overproduction 
of human LPL in mice resulted in decreased plasma triglyceride and cholesterol levels, 
and protected against atherosclerosis (Shimada et al., 1996; Yagyu et al., 1999). However, 
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macrophage-specific overexpression of LPL accelerated atherosclerosis in atherosclerosis-
prone mice (Babaev et al., 2000; Wilson et al., 2001 ). Recently, spontaneous atherosclerosis 
in aged LPL-deficient mice was reported, mediated by the oxidation of chylomicrons and 
the activation of vascular endothelial cells (Zhang et al., 2008). The option of gene therapy 
for LPL deficiency has been studied in mouse models. Intramuscular injection of a natural 
variant ofLPL resulted in an efficient trans gene expression and reduction of fasting plasma 
triglycerides in wild type, LPL deficient and LDLR deficient mice (Rip et al., 2005; Ross et 
al., 2004). However, this local overexpression of LPL in skeletal muscle did not influence 
plasma cholesterol levels or atherosclerosis development, confirming the importance of 
extent and site ofLPL expression in these processes (Rip et al., 2007). 
EL 
As its name implies, endothelial lipase (EL) is mainly synthesized by endothelial cells. 
In contrast to HL and LPL, the triglyceride hydrolase activity of EL is low. EL primarily 
has phospholipase activity, thereby promoting the turnover of HDL components and 
increasing the catabolism of apoAI (Jaye and Krawiec, 2004; McCoy et al., 2002). Hepatic 
overexpression of EL in mice resulted in strongly reduced HDL levels and increased HDL 
catabolism (Jaye et al., 1999). Expression ofEL at the atherosclerotic lesion site may have 
direct pro-atherogenic effects (Lamarche and Paradis, 2007). Inhibition of EL in mice, 
either by antibody injection or by targeted gene deletion, results in a strong increase in 
HDL-cholesterollevels (Ishida et al., 2003; Jin et al., 2003). 
1.3.3 Mediators of hepatic cholesterol uptake and biliary excretion 
LDLR 
The removal oflarge cholesterol-rich lipoproteins from the circulation is mainly mediated 
by the hepatic LDL receptor (LDLR), binding both apoB 100 and apoE. A genetic defect in 
this receptor is the underlying pathological mechanism of familial hypercholesterolemia, 
a disease in which plasma concentrations of apoB 1 00-containing lipoprotein particles 
are dramatically increased (Brown and Goldstein, 1986). The LDLR binds circulating 
cholesteryl ester-rich lipoprotein particles, with apoB 100 or apoE as protein component. Up 
to 70% of the circulating LDL particles are taken up by the LDLR via apoB100-mediated 
endocytosis (Kong et al., 2006). After internalization, lipoprotein particles are degraded in 
the lysosomes and cholesterol is either degraded to bile acids or excreted as free cholesterol 
in the bile, or it is re-used for lipoprotein assembly. The LDLR deficient mouse is a frequently 
used model in cardiovascular research. This mouse model has elevated LDL levels, but no 
atherosclerotic lesions develop on a chow diet. A humanized lipoprotein profile can be 
mimicked in these animals when a high fat high cholesterol diet is administered, resulting 
in advanced atherosclerotic lesion formation (Ishibashi et al., 1994). 
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LRP 
LDLR-related protein (LRP), present in numerous cell types, is a membrane receptor 
with various cellular functions. It has multiple extracellular ligands, including apoE and 
LPL (Overton et al., 2007). In the liver, LRP plays a important role in the clearance of 
chylomicron remnants, suggesting an atheroprotective role of hepatic LRP via reduction 
of plasma lipid levels (Field and Gibbons, 2000; Rohlmann et al., 1998). In addition, LRP 
plays an important atheroprotective role in macrophages, attributable to an inhibition of the 
autocrine cellular inflammatory response (Gaultier et al., 2008). 
SR-BI 
Besides expression in peripheral tissues, SR-BI is highly expressed in the liver. SR-BI 
binds HDL with high affinity, thereby facilitating the selective delivery of cholesterol to 
the liver. In contrast to the endocytic cholesterol uptake by the LDL receptor, uptake of 
HDL-cholesterol by SR-BI occurs via selective transfer ofHDL-derived cholesteryl esters 
into cells without degradation of HDL particles. Studies in SR-BI deficient and SR-BI 
overexpressing animal models demonstrated the physiological importance of the protein 
in HDL metabolism. SR-BI knockout mice suffer from hypercholesterolemia primarily 
because of increased HDL levels and reduced biliary cholesterol secretion (Rigotti et al., 
1997; Varban et al., 1998), whereas SR-BI overexpressing mice have decreased HDL 
levels due to an accelerated hepatic HDL clearance (Kozarsky et al., 1997; Mardones et al., 
2001; Ueda et al., 1999; Wang et al., 1998). Importantly, hepatic overexpression of SR-BI 
results in an increased macrophage reverse cholesterol transport, despite reduced plasma 
HDL levels (Zhang et al., 2005). In line with this finding, reverse cholesterol transport is 
impaired in SR-BI deficient mice. The role of SR-BI in reverse cholesterol transport may 
explain the results of atherosclerosis studies in mice. SR-BI overexpression in mice resulted 
in a reduced susceptibility to atherosclerosis (Arai et al., 1999; Kozarsky et al., 2000; Ueda 
et al., 2000), while SR-BI deficiency increased atherogenesis (Braun et al., 2002; Covey 
et al., 2003; Trigatti et al., 1999). CETP expression in SR-BI deficient mice increased 
macrophage reverse cholesterol transport and attenuated the development of atherosclerosis 
(Harder et al., 2007; Tanigawa et al., 2007), which suggests that clearance of plasma lipids 
via CETP can act as an alternative pathway of SR-BI-mediated lipid excretion. 
ABCG5 and ABCG8 
In addition to ABCAI and ABCGI, ABCG5 and ABCG8 are two other members of the 
superfamily of ABC transporters. ABCG5 and ABCG8 are highly expressed in the intestine 
and the liver, where they have a key role in the excretion of cholesterol and other sterols 
from the body. Both transporters limit cholesterol and plant-sterol absorption in the gut, and 
facilitate biliary excretion by hepatocytes (Graf et al., 2002; Yu et al., 2002a). Mutations 
29 
Chapter 1 
in either one of them cause accumulation of plant sterols in the body (Berge et al., 2000; 
Lee et al., 2001 ). Deficiency of both genes simultaneously strongly inhibits hepatobiliary 
cholesterol excretion in mice (Yu et al., 2002a), whereas overexpression of promotes 
lipid excretion and reduces fractional absorption of cholesterol in the intestine (Yu et al., 
2002b ). In a recent report, it was demonstrated that liver X receptor -mediated activation 
of macrophage reverse cholesterol transport requires ABCG5 and ABCG8 (Calpe-Berdiel 
et al., 2008). 
1.4 Phospholipid transfer protein 
In the early eighties, in addition to CETP a second lipid transfer protein was discovered in 
human plasma. This protein was named lipid transfer protein-II (LTP-II). LTP-II directly 
facilitated the transfer of phospholipids from apoB-containing lipoproteins to HDL, but 
it was incapable of transferring cholesteryl esters or triglycerides (Albers et al., 1984; 
Tollefson et al., 1988). The term "LTP-II" is not used anymore; nowadays the protein is 
referred to as phospholipid transfer protein (PLTP) (van Tol, 2002). 
1.4.1 Molecular characteristics 
The human PLTP gene is located on chromosome 20 (Whitmore et al., 1995). It has a 
size of approximately 13.3 kb, containing sixteen exons (Tu et al., 1995). The functional 
promoter region of the human PLTP gene consists of a TATA box, a high GC region, and 
multiple consensus sequences for the potential binding of transcription factors (Tu et al., 
1997; Tu et al., 1995). mRNA expression analysis shows a single transcript of 1.8 kb. The 
PLTP complementary DNA (eDNA) encodes a hydrophobic signal peptide of 17 amino 
acids and a mature protein of 476 amino acids. The calculated molecular mass of PLTP 
is 55 kDa, but due to glycosylation the mature plasma protein weights approximately 81 
kDa (Day et al., 1994; Huuskonen et al., 1998). PLTP has a two-domain structure with 
conserved lipid-binding pockets consisting of apolar residues in each domain (Huuskonen 
et al., 1999). TheN-terminal pocket plays an essential role in the transfer of phospholipids, 
the C-terminal pocket is important for the association of PLTP with HDL (Desrumaux 
et al., 2001; Huuskonen et al., 1999; Ponsin et al., 2003). It has been demonstrated that 
this association takes place via binding of PLTP to apoAI and apoAII, the two main 
apolipoprotein classes in HDL particles (Pussinen et al., 1998). A disulfide bridge between 
cysteine residues 146 and 185 is necessary for the correct folding ofPLTP, resulting in its 
specific boomerang-shaped appearance. 
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The presence of PLTP has been demonstrated in plasma from a variety of species (Albers 
et al., 1995; Day et al., 1994; Jiang and Bruce, 1995; Speijer et al., 1991). In contrast to 
CETP, the absence of PLTP has not been described in any species. The organization of 
the mouse gene encoding PLTP, located on chromosome 2, is strikingly similar to that 
encoding the human PLTP, as the exon-intron junctions of the PLTP gene in these two 
species are completely conserved (Tu et al., 1997). Mouse and human PLTP genes share an 
81% nucleotide sequence identity in the promoter region (LeBoeuf et al., 1996; Tu et al., 
1997). The mature mouse and human PLTP protein both contain 476 amino acids. Mouse 
PLTP shares 83% amino acid sequence identity with human PLTP, and has a computed mass 
of 52.7 kDa. Most sequence differences between mouse and human PLTP are conserved 
substitutions (Albers et al., 1995). 
1.4.2 Transcriptional regulation of PLTP by nuclear receptors 
Transcription of PLTP is known to be regulated by the nuclear receptors famesoid X 
receptor (FXR), peroxisome proliferator-activated receptor a (PPARa), and liver X re-
ceptor (LXR). These transcription factors belong to the nuclear receptor superfamily 
comprising metabolite-activated transcription factors that form permissive heterodimers 
with retinoid X receptor (RXR). In the absence of ligands, most RXR heterodimers 
are bound to specific response elements in the promoter regions of the target genes in 
association with co-repressors, maintaining active repression of these genes. Upon ligand 
binding, a conformational change in the receptor takes place, resulting in the exchange of 
co-repressors for co-activators, and the subsequent initiation of target gene transcription 
(Glass and Rosenfeld, 2000; Zelcer and Tontonoz, 2006). Ligand binding can also inhibit 
the transcription of certain genes via process named trans-repression. 
FXR forms a heterodimer with RXR upon binding to bile acids, the natural ligand ofFXR. 
FXR might protect the liver against the toxic effects of bile salts by reducing their synthesis 
and uptake, and increasing their excretion (Goodwin et al., 2000; Lu et al., 2000; Plass et 
al., 2002). In mice, bile salt synthesis is repressed upon binding of cholate to FXR (Li-
Hawkins et al., 2002). Hepatic PLTP expression has been demonstrated to be regulated by 
FXR in vitro and in vivo (Kast et al., 2001; Tu and Albers, 2001; Urizar et al., 2000). 
PPARa is mainly expressed in tissues where fatty acids are catabolised, such as the 
liver, brown adipose tissue, heart and muscle. PPARa is involved in mitochondrial and 
peroxisomal ~-oxidation of fatty acids, thereby regulating cellular energy metabolism, as 
well as in systemic regulation of cholesterol and fatty acid homeostasis, and apoptosis 
upon inflammation. Polyunsaturated fatty acids serve as endogenous PPARa ligands. Well-
characterized synthetic ligands for PPARa are fibrates, a class of drugs that efficiently 
decrease triglycerides and increase plasma HDL levels (Heller and Harvengt, 1983; Staels 
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et al., 1998). Regulation ofPLTP expression by PPARa is species-specific, as fenofibrate 
treatment of human PLTP transgenic mice increased the hepatic expression of endogenous 
PLTP, but not human PLTP (Lie et al., 2005). Furthermore, fenofibrate treatment 
significantly reduced promoter activity of the human PLTP gene (Tu and Albers, 1999), 
but significantly increased transcriptional activity ofPLTP and plasma PLTP activity levels 
in mice, accounting for a marked enlargement ofHDL (Bouly et al., 2001; Tu and Albers, 
2001). 
In addition to FXR and PPARa response elements, the PLTP promoter region also contains 
LXR-binding sequences. Two LXR subtypes are known: LXRa, which is highly expressed 
in the liver, and LXRJ3, which is expressed ubiquitously (Repa and Mangelsdorf, 2000). 
LXRs are activated by oxysterols, formed as by-products during cholesterol synthesis as 
well as by oxidation of dietary cholesterol (Lehmann et al., 1997). LXR functions as a 
nuclear cholesterol sensor that is activated in response to elevated intracellular cholesterol 
levels in multiple cell types. It induces the transcription of genes involved in cholesterol 
absorption, efflux, transport, and excretion. In addition to its ability to modulate cholesterol 
metabolism, LXR stimulates hepatic lipogenesis. Furthermore, LXRs have also been 
found to modulate immune and inflammatory responses in macrophages (Castrillo and 
Tontonoz, 2004). Upon LXR activation, PLTP expression is increased in human and 
murine macrophages and in primary human hepatocytes (Laffitte et al., 2003; Mak et al., 
2002). Pharmacological activation of LXR in mice resulted in an increased hepatic PLTP 
expression, a dose-dependent increase of plasma PLTP activity, increased HDL levels, and 
a PLTP-dependent enlargement of HDL particles (Cao et al., 2002). Coadministration of 
a synthetic LXR and PPARa ligand to mice resulted in elevated HDL levels and enlarged 
HDL particles, and increased hepatic PLTP expression and plasma PLTP activity levels 
(Beyer et al., 2004). 
1.4.3 Tissue expression of PLTP 
PLTP is widely expressed in human tissues, pomtmg at a crucial cellular role or 
multifunctional role of the protein. Relatively high mRNA levels are found in ovary, thymus, 
and placenta, suggesting a role for PLTP in reproduction and foetal development (Albers et 
al., 1995). PLTP mRNA is also relatively high in pancreas, lung, as well as in subcutaneous 
and visceral adipose tissue (Dusserre et al., 2000). Furthermore, PLTP is expressed at 
moderate levels in, testes, and prostate, and at low levels in kidney, liver, spleen, heart, 
colon, skeletal muscle, leukocytes and brain (Albers et al., 1995). PLTP activity in the 
cerebrospinal fluid represents 15% ofthe plasma activity, indicating active PLTP synthesis 
in the brain (Vuletic et al., 2003). In addition, human seminal plasma displays significant 
phospholipid transfer activity due to the presence of active PLTP, possibly for maintenance 
32 
Introduction 
of the lipid composition of the cell membranes of spermatozoa (Masson et al., 2003). 
Furthermore, human tear fluid contains catalytically active PLTP, suggesting that PLTP 
plays a role in the formation of the tear film (Jauhiainen et al., 2005). 
PLTP was detected in human atherosclerotic lesions, where it colocalised with macrophages, 
indicating that this cell type is an important source of PLTP (Desrumaux et al., 2003; 
Laffitte et al., 2003; O'Brien et al., 2003). In addition to macrophages, PLTP can also be 
detected in smooth muscle foam cells in human atherosclerotic lesions, suggesting that 
cellular cholesterol accumulation increases PLTP expression in both cell types (O'Brien 
et al., 2003). The distribution of PLTP within human atherosclerotic lesions suggests 
that PLTP plays a role in cellular cholesterol metabolism and lipoprotein retention on the 
extracellular matrix. 
Like in humans, also murine PLTP expression is widely distributed among tissues (Albers 
et al., 1995). In mice, relatively high PLTP mRNA levels are detected in lung, brain and 
heart. The lung is the major site expressing PLTP, suggesting an important role for PLTP 
in maintaining normal function of this organ. In human collagenase transgenic mice, an 
emphysematous animal model, lung PLTP expression is increased. Remarkably, there is 
no effect ofPLTP deficiency on lung function in PLTP knockout mice (Jiang et al., 1998). 
Furthermore, PLTP is widely expressed in the brain where it transfers alpha-tocopherol, the 
main isomer of vitamin E. This is a key process in preventing oxidative damage in the brain 
(Desrumaux et al., 2005). The ability ofPLTP to transfer alpha-tocopherol also plays a role 
in fertility, both in male and female mice. PLTP is highly expressed in epididymis and in the 
embryo-containing oviduct, implicating a role for PLTP in the motility of spermatozoa and 
preimplantation embryonal development (Drouineaud et al., 2006; Lee et al., 2005). 
1.4.4 Functions of plasma PLTP: data from in vitro studies 
Phospholipid transfer 
In the early eighties, Tall and Green showed that egg phosphatidylcholine is transferred 
to spherical and discoidal HDL particles when it is incubated with isolated human HDL3 
or with plasma (Damen et al., 1982; Tall and Green, 1981). At this time, the mechanism 
behind the incorporation of phospholipids into HDL particles was not known. Although 
phospholipids exchange between plasma lipoproteins spontaneously, the transfer rate 
would be too slow to be a physiologically important mechanism (Massey, 1984). Several 
studies showed that PLTP is responsible for the specific transfer of phospholipids between 
lipoprotein subclasses (Albers et al., 1984; Tall et al., 1983; Tu et al., 1993). During 
lipolysis, human PLTP is able to enhance the net transfer ofVLDL phospholipids into HDL 
and the exchange of phospholipids between VLDL and HDL (Tall et al., 1985). PLTP is 
able to transfer all common phospholipid classes non-specifically (Huuskonen et al., 1996). 
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However, lipoprotein class and composition determines the rate of phosphatidylcholine 
transfer by PLTP (Rao et al., 1997). The exact mechanism ofPLTP-mediated phospholipid 
transfer is still not completely understood. It is unlikely that PLTP forms a tight complex 
with its substrate as no PLTP-phospholipid intermediates were detected during an 
incubation of phospholipid vesicles with human HDL in the presence of purified PLTP 
(Huuskonen et al., 1996). Possibly, PLTP functions as a bridging molecule between donor 
and acceptor particle to facilitate the transfer of phospholipids. However, it has also been 
suggested that active PLTP is able to transfer lipids by a shuttle mechanism. In that case, the 
formation of a complex between PLTP, acceptor, and donor particle should not be required 
for phospholipid transfer (Setala et al., 2007). 
In addition to facilitate the transfer of phospholipids, PLTP is also able to transfer other 
hydrophobic compounds, such as alpha-tocopherol, cholesterol and lipopolysaccharide 
(LPS). Alpha-tocopherol is an important anti-oxidant of plasma lipoproteins and cell 
membranes. It is secreted by the liver into the blood stream, together with VLDL. PLTP 
catalyzes the exchange and transfer of alpha-tocopherol between plasma lipoprotein classes 
and cells (Kostner et al., 1995). Furthermore, purified human PLTP is able to enhance 
the transfer of cholesterol from vesicles containing phosphatidylcholine and cholesterol to 
HDL3. However, PLTP possesses a considerably higher affinity and binding capacity for 
phosphatidylcholine than for cholesterol (Nishida and Nishida, 1997). In addition, PLTP 
is able to transfer LPS, the major outer membrane component of gram-negative bacteria, 
and a potent endotoxin that triggers cytokine-mediated systemic inflammatory responses in 
the host. Incubation ofLPS with purified recombinant PLTP resulted in the inhibition LPS-
mediated inflammatory responses (Hailman et al., 1996). In human whole blood, PLTP 
induced the transfer ofLPS from HDL to LDL, resulting in the remodeling ofHDL into two 
subpopulations (Levels et al., 2005). 
HDL conversion 
PLTP acts as an HDL conversion factor (Albers et al., 1995; Jauhiainen et al., 1993; 
Pussinen et al., 1995; Settasatian et al., 2008; Tu et al., 1993; von Eckardstein et al., 
1996). The two main activities of PLTP, phospholipid transfer and HDL conversion, are 
closely interrelated. Two recombinant PLTP mutant proteins, defective in phospholipid 
transfer activity due to a mutation in the N-terminal lipid-binding pocket, were unable 
to convert human HDL3, demonstrating that phospholipid transfer is a prerequisite for 
HDL conversion (Huuskonen et al., 2000b ). Particle fusion is the main process involved in 
PLTP-mediated HDL remodeling (Korhonen et al., 1998; Lusa et al., 1996; Settasatian et 
al., 2001). After fusion ofHDL particles, which requires the presence of apoAI, the fusion 
product is rearranged into small and large particles (Lusa et al., 1996; Settasatian et al., 
2001). The small particles that are generated during HDL conversion only contain some 
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phospholipid and apoAL By generating small HDL particles during HDL conversion, PLTP 
may increase reverse cholesterol transport, as these particles are the initial acceptor for 
efflux of cellular cholesterol in peripheral tissues. 
Cholesterol efflux 
The role of PLTP in HDL remodeling may be directly connected to an indirect role of 
PLTP in cellular cholesterol efflux. Plasma PLTP stimulates the formation of pre~-HDL, 
which can serve as cholesterol acceptor particles in vitro (Jessup et al., 2006). Cholesterol 
efflux from fibroblasts to plasma isolated from subjects with increased plasma PLTP 
activity levels, as in diabetes mellitus or metabolic syndrome, was increased, or at least not 
defective despite low HDL levels (de Vries et al., 2007; de Vries et al., 2005; Dullaart et al., 
2008b ). The hypothesis that PLTP may play a role in cholesterol efflux is supported by the 
finding that cholesterol efflux from cholesterol-loaded fibroblasts to total plasma increased 
by 40% when PLTP was added during the incubation (von Eckardstein et al., 1996). In a 
more recent study, it was shown that macrophage cholesterol efflux to HDL was increased 
after preincubation ofHDL with purified active PLTP, through the formation ofpre~-HDL 
and large fused HDL particles, both efficient cholesterol acceptors in vitro (Vikstedt eta!., 
2007a). 
In addition to the generation of lipid acceptor particles, PLTP might have a direct role 
in lipid efflux by increasing the cellular binding of HDL. Exposure of cholesterol-loaded 
fibroblasts to PLTP increased specific HDL binding to the cells and enhanced cholesterol 
and phospholipid efflux to small HDL particles (Wolfbauer et al., 1999). This effect was not 
seen when fibroblasts of Tangier disease patients, lacking fi.mctional ABCAl expression, 
were used, which led to the hypothesis that cellular PLTP might play a role in ABCAl-
dependent lipid efflux. This was confirmed in a later study, in which purified PLTP, added to 
cultured macrophages, enhanced cellular cholesterol efflux to HDL particles, by promoting 
cell-surface binding, interacting with and stabilizing ABCAl (Oram, 2003). Recently, an 
amphipathic helical region of the N-terminal barrel of PLTP was shown to be critical for 
ABCAl-dependent cholesterol efflux (Oram et al., 2008). 
In addition to investigation of the role of exogenously added PLTP, also the role of 
macrophage-derived PLTP in lipid efflux has been studied. Cholesterol efflux to apoAI and 
HDL from cholesterol-loaded peritoneal macrophages isolated from PLTP deficient mice 
was decreased compared to wild type macrophages (Lee-Rueckert et al., 2006). However, 
in three other studies, no effect on cholesterol efflux was found towards apoAI (Cao et 
al., 2002; Ogier et al., 2007) or towards HDL (Valenta et a!., 2006). The importance of 
peripheral PLTP for macrophage cholesterol efflux is still poorly understood. 
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1.4.5 Human studies 
Despite a relatively low PLTP expression level, the liver and intestine are major contributors 
to plasma PLTP concentration due to their large organ mass (Albers et al., 1995). In human 
plasma, mean PLTP concentrations are found in a range of 4-15 mg/1 (Desrumaux et al., 
1999; Huuskonen eta!., 2000a; Oka eta!., 2000b). PLTP activity level can be determined 
by different methods, resulting in varying values (Cheung et al., 1996; Colhoun eta!., 2001; 
Desrumaux et al., 1999). In a study in a Finnish population, mean plasma activity was either 
6.6 J.lmol/mL/h or 1.4 J.lmoVmL/h, quantified with an exogenous, lipoprotein-independent 
radiometric assay or an endogenous, lipoprotein-dependent radiometric assay, respectively 
(Janis eta!., 2004). The exogenous assay measures phospholipid transfer from phospholipid-
liposomes to exogenously added HDL (Damen et al., 1982), while the endogenous assay 
measures transfer to endogenous serum HDL (Lagrost et al., 1999a). PLTP activity levels 
are comparable between men and women (Cheung et al., 2002; Colhoun et al., 2001; 
Janis eta!., 2004). The absence of a correlation between human plasma PLTP mass and 
phospholipid transfer activity led to the identification of a low-active form of plasma PLTP 
besides the catalytically active form (Huuskonen eta!., 2000a; Oka et al., 2000b). Both 
forms were found associated with different types of lipoprotein particles. Complexes with 
active PLTP had an average molecular mass of 160 kDa, whereas complexes with low-active 
PLTP had an average mass of 520 kDa, indicating that low-active PLTP is associated with 
larger particles. The low-active form of PLTP has been reported to be 46 to 70% of total 
PLTP mass (Janis eta!., 2004; Oka et al., 2000a). Contradictory results have been reported 
in literature regarding the association of active and inactive PLTP fractions with different 
apolipoprotein classes. One research group suggested that PLTP with low activity forms a 
complex with apoAI, and highly active PLTP with apoE (Janis et al., 2005; Karkkainen et 
al., 2002; Siggins et al., 2003). In contrast, another group reported that active plasma PLTP 
is associated primarily with apoAI- but not with apoE-containing lipoproteins (Cheung and 
Albers, 2006). Until now, no function of inactive PLTP has been described. 
Although there are no reports of human PLTP deficiency until today, genetic variation 
of the human PLTP gene has been reported, in most cases not affecting plasma PLTP 
activity (Aouizerat et al., 2006; Bosse eta!., 2005; Engler et al., 2008; Palmen eta!., 2005; 
Tahvanainen et al., 1999). In a population study in subjects with hypoalphalipoproteinemia, 
four missense mutations in the PLTP gene were discovered, of which one was associated 
with a low binding capacity for HDL and strongly decreased phospholipid transfer activity 
(Aouizerat et al., 2006). 
Several factors affect PLTP activity and concentration. Plasma PLTP activity increases 
with age and correlates with body mass index and subcutaneous fat area, fasting blood 
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glucose, plasma triglycerides, and nonesteri:fied fatty acids (Dullaart et al., 1994b; Kaser 
et al., 2001; Murdoch et al., 2003; Riemens et al., 1998). Plasma PLTP activity can be 
affected by life style. Increased PLTP activity levels have been reported in subjects after 
consumption of French-press coffee (DeRoos et al., 2000). Moderate alcohol consumption 
does not affect plasma PLTP activity (van Toland Hendriks, 2001), but increased levels 
were reported in alcohol abusers (Liinamaa et al., 1997), and after a large intravenous fat 
load or by increasing the fatty acid content of the diet (Lagrost et al., 1999b; Riemens et 
al., 1999). Smoking has been associated with reduced plasma PLTP activity levels (Mero et 
al., 1998; Zaratin et al., 2004), although there is also one report of increased plasma PLTP 
activity levels in smokers (Dullaart et al., 1994a). 
Various pathophysiological conditions associated with altered plasma lipid levels and 
lipoprotein subclass distribution, have also been associated with changes in phospholipid 
transfer activity of PLTP. High PLTP activity levels are frequently found in plasma of 
subjects suffering from familial combined hyperlipidemia (Soro et al., 2003 ), obese subjects 
(Dullaart et al., 1994b; Kaser et al., 2001; Riemens et al., 1998), and patients with diabetes 
mellitus type 1 and type 2 (Colhoun et al., 2001; de Vries et al., 2007; de Vries et al., 2008; 
Dullaart et al., 2008a). In diabetic patients, an independent association between C-reactive 
protein and PLTP activity has been reported, suggesting that subclinical inflammation may 
influence PLTP activity (Tan et al., 2005). Also in patients with systemic inflammation 
or severe sepsis, plasma PLTP activity levels are increased (Barlage et al., 2001; Levels 
et al., 2007). Probably, the decrease of HDL levels observed during a severe acute phase 
inflammation response is caused by a combination of reduced LCAT and increased PLTP 
activities (Pussinen et al., 200la; Pussinen et al., 200lb). In patients with Alzheimer's 
disease, PLTP levels in brain tissue are significantly increased, whereas in cerebrospinal 
fluid PLTP activity is reduced compared to control subjects (Vuletic et al., 2003). A role of 
PLTP-mediated apoE secretion is suggested in the pathogenesis of the disease (Vuletic et 
al., 2005). 
The relationship between plasma PLTP activity levels and cardiovascular disease is not 
unequivocal. Increased plasma PLTP activity has been demonstrated in patients with 
increased risk for cardiovascular disease, implying that the protein could play a role in 
the development of the disease (Ruhling et al., 1999; Schlitt et al., 2003; Schlitt et al., 
2007). However, another study indicated that low rather than high PLTP activity is a marker 
for peripheral atherosclerosis and that the distribution of PLTP between high-activity and 
low-activity forms may be disturbed in peripheral artery disease (Schgoer et al., 2008). A 
prospective study in a cohort of Japanese men indicated that an elevated concentration of 
PLTP may be a protective marker of cardiovascular heart disease (Yatsuya et al., 2004). 
Taken together, literature demonstrates that changes in PLTP activity can be associated 
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with pathophysiological conditions such as hyperlipidemia, inflammation, and diabetes, 
but there is no consensus about the relationship between PLTP and cardiovascular disease. 
1.4.6 Mouse studies 
PLTP deficient mice 
The physiological role of PLTP in lipoprotein metabolism has been studied extensively 
using PLTP-deficient mouse models, as summarized in Table 3. To evaluate the role of 
PLTP in lipoprotein metabolism, Jiang et al. created a PLTP knockout mouse model (Jiang 
et al., 1999). In chow-fed mice, targeted mutation of the PLTP gene resulted in a strong 
decrease in HDL phospholipid (60%), cholesterol (65%) and apoAI (85%), but no changes 
in non-HDL lipid or apoB levels. Low HDL levels in PLTP deficient mice arise from a 
marked increase in HDL catabolism, both of the protein and cholesteryl ester content of 
the particles (Qin et al., 2000). The increased HDL catabolism is possibly related to a 
decrease in phospholipid content of the HDL particles. In addition, PLTP deficiency might 
lead to destabilization of liver-secreted apoAI, due to defective phospholipidation. This 
indicates a possible intracellular role for PLTP in the formation of nascent HDL particles 
(Siggins et al., 2007). On a high fat diet, next to decreased HDL levels, also non-HDL 
levels are significantly altered in PLTP deficient mice (Jiang eta!., 1999). VLDL and LDL 
phospholipids, free cholesterol and cholesteryl esters levels are largely increased without 
changes in apoB levels, suggesting accumulation of surface components of triglyceride-
rich lipoproteins. These findings show the importance of PLTP activity for the transfer of 
surface components of triglyceride-rich lipoproteins to HDL. Although non-HDL levels 
are significantly increased in PLTP knockout mice on a high fat diet, when crossed into an 
apoB transgenic or an apoE deficient background, PLTP deficiency reduced plasma levels of 
apoB-rich lipoproteins (Jiang eta!., 2001 ). Isolated hepatocytes from these mice revealed a 
decreased secretion rate of apoB-rich lipoproteins, probably explained by the fact that newly 
synthesized apoB is destructed by reactive oxygen species, generated due to decreased 
vitamin E content (Jiang et a!., 2005). The decreased plasma levels and production rate 
of apoB-containing lipoproteins could explain the finding that PLTP deficient mice have a 
decreased susceptibility to develop atherosclerosis compared to mice expressing PLTP (Jiang 
eta!., 2001). An additional explanation for the atheroprotective effect ofPLTP deficiency 
is the fact that circulating apoB-containing lipoproteins are protected from oxidation due to 
an increase in the bioavailability of plasma vitamin E (Jiang eta!., 2002; Yan et al., 2004). 
Isolated LDL from PLTP deficient mice induced significantly less monocyte chemotactic 
stimulation (MCS) than LDL isolated from wild type mice. Furthermore, the ability of 
isolated HDL from PLTP deficient mice to remove oxidized phospholipids from LDL was 
significantly increased. In addition, Schlitt et al. stated that PLTP deficiency has an anti-
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Table 3. Studies in PLTP deficient mouse models. 
Bacl•ground Pro-atherogenic characteristics Anti-atherogenic characteristics Atherogenicity Reference 
wild type non-HDL t (diet), HDL t NID (Jiang et al., 1999) 
wild type HDL t, HDL catabolism t N/D (Qin eta!., 2000) 
wild type plasma vitamin E t, oxidation VLDLILDL t NID (Jiang et al., 2002) 
wild type IL-6 t NID (Schlitt eta!., 2005) 
wild type HDL, apoAI L non-HDL t, NID (Siggins et al., 2007) 
hepatic lipids t 
wild type intestinal chol uptake t, chol secretion from N/D (Liu eta!., 2007b) 
enterocytes t 
LDLR -/- HDLt decreased (Jiang et al., 2001) 
LDLR -/- plasma vitamin E t, oxidation VLDLILDL t N/D (Jiang et al., 2002) 
LDLR -/- HDL L HDL catabolism t anti-inflamm properties ofHDL t, N/D (Yan eta!., 2004) 
LDL-induced MCS t 
apoE -/- apoB secretion t, apoB levels L non-HDL t decreased (Jiang et a!., 2001) 
apoE -/- plasma vitamin E t, oxidation VLDLILDL t N/D (Jiang et al., 2002) 
apoB tg HDLt apoB secretion L apoB levels L non-HDL t decreased (Jiang et al., 2001) 
apoB tg HDL L HDL catabolism t anti-inflamm properties ofHDL t, N/D (Yan et al., 2004) 
LDL-induced MCS t 
CETP tg HDL, apoAI t N/D (Kawano eta!., 2000) 
apoB*CETP tg plasma vitamin E t, oxidation VLDLILDL t N/D (Jiang et al., 2002) I~ g. 
"' w MCS: monocyte chemotactic stimulation I§· 
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inflammatory effect per se, as mice lacking PLTP have significantly lower IL-6 levels than 
wild type mice, and a reduced inflammatory response to IL-6 treatment (Schlitt et al., 
2005). Liu et al. demonstrated that PLTP deficient mice have a diminished cholesterol 
absorption, attributable to a decreased cholesterol uptake by enterocytes, and subsequently 
a reduced cholesterol secretion from these cells (Liu et al., 2007b ). 
PLTP overexpressing mice 
Also experimental work in different mouse models overexpressing PLTP has greatly 
contributed to the clarification of the role of PLTP in lipoprotein metabolism and the 
development of atherosclerosis. Table 4 summarizes the different studies that have been 
performed in PLTP overexpressing mouse models. The first transgenic mice expressing 
human PLTP were generated by Albers eta!. (Albers et al., 1996). In these transgenic mice 
expression levels of human PLTP were minimal, and transgenic mice and control mice had 
similar plasma PLTP activity levels. Not surprisingly, no marked differences in lipoprotein 
levels were observed. Shortly after, Jiang et al. generated another human PLTP-transgenic 
mouse (Jiang eta!., 1996). This transgenic mouse showed a broad human PLTP mRNA 
expression. Plasma PLTP activity was increased by 29% in transgenic mice, but plasma 
lipoprotein analysis did not reveal significant changes in plasma lipids or apolipoprotein 
levels. When these human PLTP-transgenic mice were crossbred with human apoAI 
transgenic mice, PLTP activity levels were increased by 4 7% and. A 56% increase in pre~­
HDL was observed, indicating a potential anti-atherogenic effect of increased plasma PLTP 
activity levels. Foger et al. used a recombinant adenoviral vector containing human PLTP 
eDNA to establish the role of PLTP in lipoprotein metabolism. In line with the findings 
of Jiang eta!., PLTP induced the generation of pre~-HDL. However, induction of human 
PLTP expression also strongly lowered total plasma HDL levels in a dose-dependent way, 
due to an accelerated fractional catabolism of HDL (Foger et al., 1997). These findings 
demonstrated the involvement of PLTP in HDL remodeling in vivo. Also the group of 
Ehnholm used an adenoviral gene transfer system, resulting in the liver-specific expression 
of human PLTP in wild type mice (C57/Bl) and human apoAI transgenic mice (Ehnholm 
et al., 1998). Overexpression of human PLTP, resulting in 4-fold increased plasma PLTP 
activity levels, strongly reduced total plasma cholesterol and phospholipid levels, due to 
a dramatic reduction of HDL levels. Overexpression of PLTP in apoAI transgenic mice 
redistributed HDL particles, with the formation oflarger HDL species. 
To further elucidate the involvement ofPLTP in lipoprotein metabolism, our group generated 
human PLTP transgenic mice with a 2.5- to 4.5-fold increase in plasma PLTP activity, 
resulting in a 30% to 40% decreased HDL-cholesterol level (van Haperen et al., 2000). 
Absolute pre~-HDL levels were not increased in PLTP overexpressing mice compared to 
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wild type mice, as was the case in the mouse models of Jiang et al. and Foger et al., but the 
formation of pre~-HDL in plasma ofhuman PLTP expressing mice was 2- to 3-fold increased. 
On the absolute level, pre~-HDL is only a minor subfraction of the total HDL level, but as a 
very efficient acceptor of cellular cholesterol it is a key mediator in the reverse cholesterol 
transport. Therefore, it was suggested that although PLTP lowers absolute HDL levels, 
it might have an atheroprotective potential by induction of pre~-HDL generation, in this 
way preventing cellular cholesterol overload and foam cell formation. An increased faecal 
bile acid excretion in human PLTP transgenic mice supported this hypothesis (Post et al., 
2003). In order to provide more insight into the relationship between plasma PLTP activity, 
lipoprotein levels, and atherogenesis, different human PLTP transgenic mouse lines were 
generated with varying levels of PLTP activity (van Haperen et al., 2002). These mouse 
lines were crossed into a hemizygous LDL receptor knockout background and fed a high fat/ 
high cholesterol diet. Overexpression of human PLTP dose-dependently deceased plasma 
HDL levels. In addition, increased plasma PLTP activity resulted in a moderate stimulation 
of hepatic VLDL secretion. Importantly, elevation of PLTP activity levels increased the 
susceptibility to develop atherosclerosis in a dose-responsive manner, regardless of the site 
ofPLTP production (ubiquitous expression versus liver-specific expression). In accordance 
with this study, long-term adenoviral overexpression of PLTP in apoE deficient mice 
resulted in an increase in atherosclerotic lesions in the proximal aorta (Yang et al., 2003). 
The increased PLTP activity in these mice resulted in a decrease in plasma vitamin E levels 
and vitamin E content of individual lipoprotein fractions, thereby increasing lipoprotein 
oxidizability. Also human PLTP transgenic mice in a CETP transgenic/LDLR deficient 
background had an increased atherosclerosis susceptibility, even despite lower levels of 
apoB-containing lipoproteins (Lie et al., 2004). 
Macrophage-specific targeting of PLTP in mice 
All of the above mentioned studies focused on the effects of systemic PLTP on lipoprotein 
metabolism and atherogenesis. However, during the last three years, much attention has been 
paid specifically to the functionality of macrophage-derived PLTP. Macrophages, being a 
key component of atherosclerotic lesions, have been demonstrated to highly express PLTP 
(Desrumaux et al., 2003; Laffitte et al., 2003; O'Brien et al., 2003). Cholesterol loading 
of macrophages results in an increase in PLTP mRNA, protein expression, and activity 
(Desrumaux et al., 2003; O'Brien et al., 2003). Plasma PLTP has been shown to enhance 
preB-HDL formation, thereby generating efficient acceptor particles for cholesterol efflux 
from macrophages. However, it is uncertain whether macrophage-derived PLTP within the 
artery wall influences the development of atherosclerosis. In order to elucidate the role of 
macrophage-derived PLTP in atherogenesis, a series of bone marrow transplantation studies 
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.,. Table 4. Human PLTP overexpressing mouse models. I! N PLTP construct Background PLTP act Phenotype Atherogenicity Reference 
endogenous promoter wild type no effect HDLt N/D (Albers et al., 1996) 
+human PLTP gene non-HDL t 
endogenous promoter wild type +29% no effect N/D (Jiang et al., 1996) 
+human PLTP gene 
endogenous promoter apoAI tg +47% HDL, apoAI t N/D (Jiang et al., 1996) 
+human PLTP gene prep-HDL t 
endogenous promoter wild type no effect no effect N/D (Tu et al., 1999) 
+human PLTP gene 
endogenous promoter wild type + 250-450% TC t N/D (van Haperen eta!., 
+human PLTP gene HDL, apoAI t 2000) 
preP-HDL formation t 
endogenous promoter CETP tg +400% HDLt N/D (Lie et a!., 2001) 
+human PLTP gene preP-HDL formation t 
endogenous promoter wild type +150-350% TC t N/D (van Haperen eta!., 
+human PLTP gene apoAI t 2002) 
endogenous promoter LDLR +/- +200-250% HDLt increased (van Haperen et al., 
+human PLTP gene VLDL secretion I 2002) 
endogenous promoter CETPtg +200% TC t N/D (Lie eta!., 2002) 
+human PLTP gene HDLt 
VLDL secretion I 
endogenous promoter CETP tg*LDLR +/- +150% Tq increased (Lie eta!., 2004) 
+human PLTP gene HDLt 
non-HDL t 
(continued) Background PLTPact Phenotype Atherogenicity Reference 
PLTP construct 
albumin promoter wild type +250-900% TC t N/D (van Haperen eta!., 
+human PLTP gene apoAI t 2002) 
albumin promoter LDLR +/- +300-800% HDLt increased (van Haperen eta!., 
+human PLTP gene VLDL secretion t 2002) 
albumin promoter CETP tg*LDLR +/- +600% TC t increased (Lie eta!., 2004) 
+human PLTP gene HDLt 
non-HDL t 
albumin promoter wild type +1500% TC t N/D (Post eta!., 2003) 
+human PLTP gene HDLt 
faecal bile acids excr t 
CMV wild type + 1300-4000% HDL, apoAI t N/D (Foger eta!., 1997) 
+human eDNA# HDL catabolism t 
preP-HDL formation t 
CMV wild type +350% HDLt N/D (Jaari eta!., 2001) 
+ human eDNA# prep-HDL formation t 
CMV wild type +300% TC t N/D (Ehnholm eta!., 1998) 
+human eDNA# HDLt 
CMV apoAI tg +165% TC t NID (Ehnholm eta!., 1998) 
+human eDNA# HDLt 
redistribution ofHDL 
albumin promoter apoE -/- +130-200% HDL, apoAI t increased (Yang eta!., 2003) 
+mouse eND A# plasma vitamin E t 
lipoprotein oxidation t 
# adenovirus-mediated ·~ & 
0 g-
~ 
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has been performed in which bone marrow of mice either lacking or expressing PLTP was 
transplanted into acceptor mice. An overview of these studies is provided in Table 5. Both in 
LDLR knockout and in apoE knockout mice, macrophage-specific PLTP deficiency resulted 
in an increase in atherosclerosis development (Liu et al., 2007a; Valenta et al., 2006). The 
transplantation of either PLTP deficient or wild type bone marrow into PLTP deficient mice 
in an LDLR knockout background confirmed the atheroprotective potential of macrophage-
derived PLTP (Valenta et al., 2008). Different mechanisms have been suggested to explain 
a possible atheroprotective role of macrophage-derived PLTP. Macrophage-derived PLTP 
may have an indirect role in cellular cholesterol efflux by the generation of preP-HDL 
particles. However, this atheroprotective effect could be neutralized by the presence 
of abundant apoAI (Valenta et al., 2006). In addition, PLTP might stimulate ABCAI-
dependent lipid efflux from macrophages (Lee-Rueckert et al., 2006). Another explanation 
for the possible anti-atherogenic properties of macrophage-derived PLTP might be the 
ability of macrophage-derived PLTP to reduce cholesterol accumulation in macrophages 
through changes in the alpha-tocopherol content and oxidative status of the cells. Ogier et 
al. demonstrated that macrophages isolated from PLTP deficient mice have an increased 
basal cholesterol content and an increased cholesterol accumulation in the presence ofLDL 
(Ogier et al., 2007). Furthermore, macrophage-PLTP might play a role in apoE secretion 
and the clearance of lipids from the circulation. PLTP-deficient macrophages were shown 
to secrete significantly less apoE than wild type macrophages, which was associated with 
the accumulation of cholesterol in the circulation (Liu et al., 2007a). 
In contrast, there is also evidence for a possible pro-atherogenic role for macrophage-
derived PLTP. Vikstedt et al. used a comparable experimental setup as Valenta et al. to 
study the effect of macrophage-specific PLTP deficiency. Macrophage-specific PLTP 
contributed significantly to plasma PLTP activity level (Vikstedt et al., 2007b ). In contrast 
to Valenta's finding, in this study PLTP deficiency in macrophages resulted in a decreased 
atherosclerotic lesion development, increased apoAI levels and lower VLDLILDL levels, 
suggesting a pro-atherogenic role for PLTP in the vessel wall. The contribution of PLTP 
to atherosclerosis development might be determined by the balance between the pro-
atherogenic properties of plasma PLTP activity and the anti-atherogenic properties oflocal 
PLTP activity in the vessel wall. The fact that the net result of this balance is opposite in 
the studies of Valenta and Vikstedt might be due to differences in experimental setup, such 
as recovery time after irradiation, diet composition, and gender of recipient mice. As a 
consequence, the extent to which macrophage-derived PLTP contributed to systemic PLTP 
levels differed significantly between these studies. Overall, the contradictory results of 
these bone-marrow transplantation studies indicate that the role of macrophage-PLTP in 
lipoprotein metabolism and the development of atherosclerosis is far from resolved. 
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Table 5. Macrophage-specific targeting ofPLTP in mice. 
Donor# Recipient PLTP Phenotype Athero- Reference 
act genicity 
PLTP -/- LDLR-/- -32% minimal increased (Valenta 
wild type et al., 2006) 
PLTP-/- apoAI-/-*LDLR -/-*hapoAI tg -12% minimal not (Valenta et 
wild type affected a!., 2006) 
PLTP -/- apoE -/- -20% plasma TC, PL I increased (Liu eta!., 
wild type plasma apoE t 2007a) 
PLTP -/- LDLR-/- -50% plasma TC, PL t decreased (Vikstedt et 
wild type plasma TG t a!., 2007b) 
apoAI t 
PLTP -/- LDLR -/-*PLTP -/- N/D plasma TC, TG t increased (Valenta et 
wild type plasmaHDLt a!., 2008) 
apoAI t 
#Note: all comparisons in the table are PLTP -/-versus wild type bone marrow 
1.5 Outline of the thesis 
The exact role of PLTP in lipoprotein metabolism and cardiovascular disease is far from 
resolved. On the one hand, PLTP clearly possesses several properties that can be considered 
pro-atherogenic. Increased plasma PLTP activity levels result in decreased plasma HDL 
levels. In addition, PLTP stimulates the production of apoB-containing lipoproteins. 
Furthermore, PLTP might directly influence the inflammatory response and oxidation 
of lipoproteins. On the other hand, the ability of PLTP to enhance the net transfer of 
phospholipids from VLDL to HDL during lipolysis might provide a gradient that maintains 
the flux oflipids from peripheral cells to the liver for breakdown and excretion. In addition, 
during HDL conversion PLTP generates preB-HDL, a quantitatively minor HDL subclass 
that is an efficient cholesterol acceptor in vitro. PLTP might stimulate the efflux of cholesterol 
and phospholipids from cells to lipoprotein particles, clearly an anti-atherogenic effect. By 
the experiments described in this thesis, we tried to further elucidate the exact role ofPLTP 
in lipoprotein metabolism and atherogenesis. For this purpose, we focussed on the systemic 
and cellular effects of abundant PLTP expression, using the mouse as research model. 
Despite potential anti-atherogenic effects of PLTP, different studies in atherosclerosis-
prone mouse models revealed that overexpression of PLTP increases the susceptibility to 
develop atherosclerosis. This implies that the pro-atherogenic properties ofPLTP outweigh 
its anti-atherogenic properties, suggesting that an increase in PLTP activity might be a 
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long-term risk factor for atherosclerosis development in humans. However, the effect 
of PLTP overexpression on lipoprotein metabolism and atherogenesis might be strongly 
influenced by metabolic status and experimental setup. A different and more controlled 
experimental approach could further explain the impact ofPLTP on lipoprotein metabolism 
and atherogenesis. The effects of acute changes in plasma PLTP expression have not been 
addressed before, and could provide important insights into the physiological role ofPLTP. 
For this purpose, we generated a new mouse model with conditional expression of the human 
PLTP gene, using the tetracycline-responsive gene system. In chapter 2 we describe the 
development and characteristics oftransgenic mice with conditional PLTP overexpression. 
Using this model we studied the effects of acute changes in PLTP activity on lipoprotein 
metabolism. In a consecutive study, we used the model to investigate the effects of PLTP 
expression on lipoprotein metabolism under diet-induced lipidemic conditions, and to 
determine the effects ofPLTP expression on pre-existing atherosclerosis (chapter 3). 
The role of PLTP in atherosclerosis development has been studied extensively in many 
different mouse models, focussing either on the complete absence of plasma PLTP, or on the 
overexpression of PLTP, which results in increased plasma phospholipid transfer activity 
levels. The importance of this lipid transfer activity in vivo is not completely understood. In 
human plasma, two forms ofPLTP have been described; the catalytically active form, and 
an inactive form. In order to provide more insight into the role ofPLTP transfer activity and 
PLTP mass, we generated a new mouse model with overexpression of mutant human PLTP, 
deficient in phospholipid transfer activity but still capable of binding to HDL (chapter 
4). Using this mouse model we investigated the importance of PLTP transfer activity in 
lipoprotein levels, pre~-HDL formation, hepatic VLDL secretion and the development of 
atherosclerosis. 
It is important to note that PLTP is a lipid transfer protein and thus very sensitive to 
environmental changes in the plasma compartment. The absence or presence of certain 
proteins that act in close relationship with PLTP might strongly influence the action of 
human PLTP. Therefore, we assessed the effects of increased PLTP expression in two 
'humanized' mouse models: the human apoAI transgenic and the human CETP transgenic 
mouse. In chapter 5, we studied the effect of increased human PLTP expression on different 
HDL properties (size, density, functionality) in a human apoAI transgenic mouse model. In 
addition, the effect of the introduction ofthe human PLTP gene in a human apoAI transgenic 
mouse on atherosclerotic lesion development was determined. In chapter 6 we describe the 
effects of PLTP in another humanized mouse model, the human CETP transgenic mouse. 
In this mouse model, we studied which of two main pro-atherogenic effects of PLTP, either 
lowering of plasma HDL levels or stimulation of apoB-containing lipoproteins production, 
might be of more importance for the increased atherosclerosis development in PLTP 
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transgenic mice. For this purpose, we studied sex differences in lipoprotein metabolism and 
linked these differences to atherosclerosis development in human PLTP transgenic mice. 
Combining transgenic traits by cross-breeding is not only a good approach to generate 
a 'humanized' mouse model in which the role of PLTP can be studied, but it is also an 
interesting way to study a possible functional interaction between PLTP and another 
protein. Hepatic lipase is such a protein that might affect the function of PLTP in plasma. 
Hepatic lipase is a lipolytic enzyme that is involved in the conversion ofVLDL into LDL, 
and in HDL remodeling, two pathways that the enzyme shares with PLTP. We investigated 
the possibility of a functional relationship between PLTP and hepatic lipase, as described 
in chapter 7. We assessed the effect of PLTP overexpression on hepatic lipase activity, 
and the effect of hepatic lipase deficiency on PLTP activity. Furthermore, we investigated 
whether the presence of hepatic lipase is required for the PLTP-dependent increase in 
hepatic triglyceride secretion or for PLTP-mediated HDL catabolism. 
In another set of experiments, described in chapter 8, we focussed on the relationship 
between PLTP expression and plasma HDL levels. In Tangier disease patients, extremely 
low HDL levels are found due to a defective ABCAl transporter. In these patients, plasma 
PLTP activity levels are strongly reduced. A comparable phenotype is observed inABCAl 
knockout mice. We investigated how ABCAl deficiency affects PLTP expression in mice 
by studying PLTP synthesis, secretion and plasma distribution. In addition, we treated 
different mouse models with varying plasma HDL and PLTP levels with a synthetic ligand 
of the liver X receptor (LXR), thereby inducing changes in lipoprotein metabolism and 
PLTP expression. We investigated whether induced PLTP levels and PLTP distribution in 
plasma were influenced by plasma lipoprotein levels and distribution. 
In the last part of this thesis, we focussed on the functionality of cellular, macrophage-
PLTP besides its systemic role in lipid metabolism and atherogenesis. For decennia, 
atherosclerosis was defined as a disease of the liver. Liver and plasma lipoprotein 
metabolism took the main role in investigation of atherogenesis. However, during the last 
10 years, increasing attention has been paid to inflammatory and local processes in the 
vessel wall. In earlier chapters, we extensively clarified the effect of elevated systemic 
PLTP levels on lipoprotein metabolism and atherosclerosis development in mice. However, 
the macrophage is a key component of the atherosclerotic lesion and PLTP has been shown 
to colocalise with foam cells in atherosclerotic lesions. In chapter 9, we demonstrated 
the contribution of macrophage-derived PLTP to plasma phospholipid transfer activity 
levels and atherosclerosis development. Therefore, bone marrow transplantations from 
PLTP transgenic mice or wild type mice to LDLR-deficient mice were performed, and 
the development of diet-induced atherosclerosis was studied. Different research groups 
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suggest that macrophage-derived PLTP could have an atheroprotective role by enhancing 
cholesterol efflux and reverse cholesterol transport through the generation of preB-HDL. 
PLTP has been shown to play a key role in HDLmetabolism and reverse cholesterol transport 
in vitro. However, until recently, quantification of reverse cholesterol transport in vivo was 
performed using techniques determining the transport rate of cholesterol derived from the 
whole body. The recent development of an assay in which lipid-loaded macrophages are 
injected intraperitoneally in mice, with subsequent monitoring of the efflux of cholesterol 
from these cells to the plasma compartment and subsequent faecal excretion, allowed us 
to measure reverse cholesterol transport specifically from macrophages. In chapter 10, 
we studied the effect of high systemic PLTP levels on macrophage reverse cholesterol 
transport, as well as the effect of elevated macrophage-derived PLTP expression on reverse 
cholesterol transport in mice. 
In chapter 11, the results of all these studies are reviewed. The new insights into the role 
ofPLTP in lipoprotein metabolism and atherogenesis, and perspectives for future research 
are discussed. 
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Abstract One main determinant in high-density 
lipoprotein (HDL) metabolism is phospholipid trans-
fer protein (PLTP). a plasma protein that is associated 
with HDL. In transgenic mice overexpressing human 
PLTP we found that elevated plasma PLTP levels 
dose-dependently increased the susceptibility to diet-
induced atherosclerosis. This could be mainly due to 
the fact that most functions of PLTP are potentially 
atherogenic, such as decreasing plasma HDL levels. 
To further elucidate the role of PL TP in lipoprotein 
metabolism and atherosclerosis we generated a novel 
transgenic mouse model that allows conditional 
expression of human PLTP. In this mouse model a 
human PLTP encoding sequence is controlled by a 
Tet-On system. Upon induction of PLTP expression, 
our mouse model showed a strongly increased PLTP 
activity (from 3.0 ± 0.6 to 11.4 ± 2.8 AU, p < 0.001). 
The increase in PLTP activity resulted in an acute 
decrease in plasma cholesterol of 33% and a compa-
rable decrease in phospholipids. The decrease in total 
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plasma cholesterol and phospholipids was caused by 
a 35% decrease in HDL-cholesterol level and a 41% 
decrease in HDL-phospholipid level. These results 
demonstrate the feasibility of our mouse model to 
induce an acute elevation of PLTP activity, which is 
easily reversible. As a direct consequence of an 
increase in PLTP activity, HDL-cholesterol and 
HDL-phospholipid levels strongly decrease. Using 
this mouse model, it wiii be possible to study the 
effects of acute elevation of PLTP activity on 
lipoprotein metabolism and pre-existing atheroscle-
rosis. 
Keywords PLTP ·Inducible expression· HDL · 
Cholesterol · Atherosclerosis · Lipoprotein 
metabolism 
Introduction 
Over the last years, in vitro studies and studies in 
mice showed that phospholipid transfer protein 
(PL TP) plays several key roles in lipoprotein metab-
olism. These include the transfer of phospholipids 
from triglyceride-rich lipoproteins to high-density 
lipoproteins (HDL) during lipolysis (Tall eta!. 1985), 
the remodeling of HDL-particles (Jauhiainen et a!. 
1993; Tu eta!. 1993), the stimulation of hepatic very 
low-density lipoprotein (VLDL) secretion (Jiang 
et a!. 2005, 2001; Lie et a!. 2002; van Haperen 
eta!. 2002), and the modification of the inflammatory 
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and oxidative state of lipoproteins (Jiang et al. 2005; 
Jiang eta!. 2002; Schlitt et al. 2005; Yan et al. 2004; 
Yang et al. 2003). 
Diet studies in different atherosclerosis-prone 
mouse models showed that PLTP deficiency resulted 
in a decreased development of atherosclerosis (Jiang 
et al. 2001). Overexpression of human PLTP in low-
density lipoprotein receptor (LDLR) deficient mice 
resulted in a dose-responsive increase in susceptibil-
ity to atherosclerosis (van Haperen et al. 2002). Most 
functions of PLTP are potentially atherogenic: over-
expression of human PL TP dose-dependently de-
creases HDL levels, resulting in a more atherogenic 
lipoprotein profile (Albers et a!. 1996; van Haperen 
et al. 2002); overexpression of human PLTP stimu-
lates VLDL secretion by the liver (Lie et al. 2002; 
van Haperen et al. 2002); lipoprotein oxidizability 
increases following adenoviral overexpression of 
PLTP in atherosclerosis-prone mice (Jiang et al. 
2002; Yang et al. 2003). On the other hand. PLTP has 
anti-atherogenic potential as well, because it in-
creases the formation of prefl-HDL, an HDL sub-
fraction that is a very efficient acceptor of cellular 
cholesterol and therefore an important mediator in 
reverse cholesterol transport (Jiang et a!. 1996; Lie 
et al. 2001; van Haperen et a!. 2000). Apparently, 
PLTP displays both pro- and anti-atherogenic prop-
erties, of which the experimental approaches used so 
far demonstrate that the net effect is proatherogenic 
(Desrumaux et al. 2003; Jiang et al. 2001; Lie et al. 
2004; van Haperen et al. 2002; Yang et al. 2003). 
However, it is important to notice that PLTP is a lipid 
transfer protein and thus very sensitive to changes in 
lipaemia (Rye et a!. 1998). Depending on the 
metabolic status, the proatherogenic effects of PLTP 
could outweigh the antiatherogenic effects, or vice 
versa. A different experimental approach might shed 
more light on the exact physiological role of PLTP in 
lipoprotein metabolism and atherogenesis. Therefore. 
we generated a new mouse model with conditional 
expression of the human PL TP gene, using the 
tetracycline-responsive gene system that was devel-
oped by using the Escherichia coli tetracycline 
resistance Tn10 operon (Gossen and Bujard 1992). 
This mouse model consists of two transgenes. The 
first transgene is an improved version of the reverse 
tetracycline transactivator, 2S-M2 [rtTA2S-M2, 
developed by Urlinger et al. (Urlinger et al. 2000)], 
under the control of a ubiquitously expressed hnRNP 
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A2 (heterogeneous nuclear ribonucleoprotein A2) 
coding sequence. The second transgene is a human 
PL TP encoding sequence under the transcriptional 
control of a tetracycline operator and minimal cyto-
megalovirus promoter (Gossen and Bujard 1992; Orth 
et al. 2000). The crossbreeding of these two transgenic 
mouse lines results in a mouse that gives us the 
opportunity to activate the expression of human PLTP 
by administration of doxycycline. In the future, using 
this mouse model, it will be possible to use new and 
refined approaches studying the physiological role of 
PLTP. For example, we will be able to investigate the 
effect of acute elevation of PLTP activity on pre-
existing atherosclerosis. In this study, we describe the 
features of our conditional mouse model. Using this 
model we studied some effects of acute changes in 
PLTP activity on lipoprotein metabolism. 
Methods 
DNA constructs 
Two constructs were used to generate transgenic mice 
that would allow externally inducible expression of 
PLTP: (1) hnRNP-rtTA-SV40, which consists of a 
recent version of the tetracycline-controlled transac-
tivator rtTA2S-M2 (Urlinger et al. 2000) under the 
control of an hnRNP A2 coding sequence (Antoniou 
et al. 2003). This sequence consists of an 8 kB 
methylation-free island, containing the incomplete 
HP1 y (heterochromatin protein 1 y) promoter, first exon 
and a part of the first intron of genomic human hnRNP 
A2, which is expressed ubiquitously (Karnma et al. 
1999) (Fig. 1a). (2) TRE-hPLTP, which consists of a 
human PL TP encoding sequence under the transcrip-
tional control of a Tetracycline Response Element 
(TRE) containing eight tetracycline operators, and 
minimal cytomegalovirus promoter (P minCMV) 
(Gossen and Bujard 1992; Orth et a!. 2000) 
(Fig. 1b). This construct was generated using the 
pTRE vector (GenBank Accession #U89931) of 
ClonTech (ClonTech Laboratories, CA, USA). The 
human PLTP encoding sequence was constructed 
from genomic human PLTP, of which the sequences 
upstream from exon 1 were removed, and the 
genomic sequences between the Bamm sites in 
exons 5 and 8 were replaced by the equivalent eDNA 
sequence (264 bp) (Day et al. 1994 ). 
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Fig. 1 Schematic diagram showing constructs used for 
generating transgenic mice. (a) hnRNP-rtTA-SV40. which 
consists of a tetracycline-controlled transactivator (rtT A2S-
M2) under the control of an hnRNP A2 coding sequence. This 
sequence consists of an 8 kb methylation-free island, contain-
ing the incomplete HPl( and promoter. first exon and a part of 
the first intron of genomic human hnRNP A2. (b) TRE-hPLTP, 
which consists of a human PLTP encoding sequence under the 
Generation and treatment of transgenic mice 
For both constructs, vector sequences were removed 
by restriction endonuclease digestion. Linear DNA 
was dissolved in microinjection buffer (10 mmol/L 
Tris-HCl, pH 7.5, 0.1 mM EDTA) at a concentration 
of 1-2 j.!g/ml. DNA constructs were microinjected 
into fertilized oocytes from FVB mice. These oocytes 
were transferred into the oviducts of pseudopregnant 
foster females. Transgenic founder mice were bred 
with FVB mice to obtain transgenic mice. FVB 
transgenic mice were backcrossed with C57BV6 mice 
for at least ten generations. Genotypes were identified 
by polymerase chain reaction (PCR) using genomic 
DNA from tail clips of 10-day-old mice. Primers used 
for the presence of the rtTA trans gene: sense 5'-GGA 
ACA GGA GCA TCA AGT AGC-3', antisense 5'-
GCG TCA GCA GGC AGC ATA TC-3'; 32 cycles 
(45 s 94°C. 60s 62°C, 90s. 72°C). Primers used for 
the presence of the human PLTP transgene: sense 51-
GCC ACA GCA GGA GCT GAT GC-3', antisense 
5'-GCG GAT GGA CAC ACC CTC AGC-3'; 32 
cycles (45 s 94°C, 90 s 65°C, 90 s 72°C). 
Animals were kept on regular chow. Blood 
samples were collected from the orbital plexus. 
Blood was centrifuged at 2,800 rpm for 15 min at 
4 a c. Plasma samples were stored at -80°C until 
measurement of PL TP activity and quantification of 
First axon Firstintron, 
partially 
3' 
human PLTP 
transcriptional control of a Tetracycline Response Element 
(TRE) and minimal cytomegalovirus promoter. The human 
PL TP encoding sequence was constructed from genomic 
human PLTP. of which the sequence upstream from exon 1 
was removed, and the genomic sequences between the BamHI 
sites in exons 5 and 8 were replaced by the equivalent eDNA 
sequence (264 bp) 
plasma lipids. All experiments were performed in 
accordance with institutional and national regula-
tions. 
In vivo induction of PLTP activity 
Mice carrying the reverse tetracycline transactivator 
(referred to as rtTAtg mice) were crossed with mice 
carrying the human PLTP gene under the control of 
the tetracycline-responsive element (referred to as 
Tre-PLTPtg mice), resulting in Tre-PLTPtg//rtTAtg 
mice. As controls, transgenic mice were used having 
only one of the transgenes, thus either lacking the 
rtTA trans gene, or the Tre-PL TP trans gene. Induction 
of PL TP expression needs addition of doxycycline to 
the drinking water. In order to mask the bitter taste of 
doxycycline, 5% sucrose was added. First, the mice 
were kept on drinking water containing 5% sucrose 
for 3 days, followed by drinking water containing 
2 mg/ml doxycycline hydrochloride (Sigma) + 5% 
sucrose for 2 days. Doxycycline-containing drinking 
water was protected from light. PLTP activity was 
determined before the sucrose run-in period, after 
3 days of sucrose administration and after 2 days of 
doxycycline administration. In an additional experi-
ment, the turnover of the induced PLTP activity was 
determined. A group of Tre-PLTPtg//rtTAtg mice 
was treated according the regime described above, 
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followed by a 5-days period of normal drinking 
water. Every day, a small amount of blood was taken 
by tail bleeding, starting after the sucrose run-in 
period of 3 days. In these samples PL TP activity was 
measured. 
PLTP activity assay 
PLTP activity was measured using a phospholipid 
vesicle-HDL system, according to Speijer et al. 
(Speijer et al. 1991). PLTP activity is expressed as 
arbitrary units (AU). One arbitrary unit is equal to the 
level of PLTP activity found in human reference 
plasma, which is 13.9 ftmol!ml!h. 
Separation of lipoproteins 
High-density lipoprotein and non-HDL fractions 
were separated by density gradient ultracentrifugation 
of freshly isolated plasma samples using a Beckman 
42.2 Ti rotor (42,000 rpm, 2 h 50 min, l2°C) at 
d = 1.063 g/ml. 
Quantification of plasma lipids 
Cholesterol concentration was determined enzymat-
ically using a Free Cholesterol C kit (W AKO) after 
hydrolysis of cholesteryl esters with cholesterol 
esterase from Candida cylindracaea (Boehringer). 
Phospholipid concentration was measured using the 
PAP150 kit from BioMerieux. Triglycerides were 
measured using a triglyceride kit from W AKO. 
Protein analysis of plasma samples 
In order to analyze apoAI protein mass, equal plasma 
samples of individual mice were subjected to elec-
trophoresis on precast 4-15% SDS-polyacrylarnide 
gradient gels (Bio-Rad) which were subsequently 
stained with Coomassie blue (Brilliant Blue R, 
Sigma). 
mRNA expression analysis 
Mice were humanely killed and organs were quickly 
removed and homogenized. Total RNA was isolated 
using the RNeasy Mini Kit (Qiagen). Isolated RNA 
was used as a template for reverse transcription 
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primed by oligo(dT). eDNA was used as a template 
for Real-Time PCR to quantitate RNA expression 
using the MyiQ (Bio-Rad). Sample cycle threshold 
(Ct) values were determined from plots of relative 
fluorescence units versus PCR cycle number during 
exponential amplification. Relative mRNA levels 
were normalized to hypoxanthine-guanine phospho-
ribosyl transferase expression using the LJCt method 
[2(-.dCt)] and presented as arbitrary units. All exper-
iments were repeated three times. Details on the 
primer sets used and PCR conditions are available 
upon request via e-mail (m.decrom@erasmusmc.nl). 
Statistical analysis 
All values are expressed as means ± standard error of 
the mean. Statistical analyses were done by one-way 
analysis of variance with Bonferroni multiple com-
parison tests or Student's t-tests using Intercooled 
Stata 8.2/SE software (Stata Corporation, College 
Station, TX, USA). 
Results 
Induction of PL TP expression 
First, we tested whether inducible expression of 
human PLTP could be achieved in our newly 
generated mouse model. To this end, three experi-
mental groups were used: Tre-PLTPtg//rtTAtg mice, 
Tre-PLTPtg mice and rtTAtg mice. Mice were kept 
on drinking water containing 5% sucrose for 3 days 
prior to doxycycline administration, When the effect 
of sucrose on plasma PL TP activity and lipid levels 
was measured, no statistically significant differences 
in plasma PLTP activity between groups before and 
after sucrose administration were found (Fig. 2). 
PLTP activity in the Tre-PLTPtg mice or rtTAtg mice 
(PLTP activity 2.9 ± 0.7 AU and 2.8 ± 0.7 AU, 
respectively) did not differ from the activity in chow-
fed wildtype mice on normal drinking water 
(3.3 ± 0.8 AU, n = 6 mice). After 3 days, drinking 
water containing 5% sucrose was replaced with 
drinking water containing 2 mg/ml doxycycline+ 5% 
sucrose. After 2 days, plasma PLTP activity was 
measured. In the Tre-PLTPtg mice and rtTAtg mice, 
administration of doxycycline had no effect on PLTP 
16 
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Fig. 2 Plasma PLTP activity levels. PLTP was measured in 
plasma samples and expressed in arbitrary units (I AU is equal 
to the level of PL TP activity found in human reference plasma. 
13.9 filllOl/ml/h). Measurements were performed at three time 
points: .. water" (normal drinking water). "'water + suer" 
(after 3 days of drinking water containing 5% sucrose). 
activity. However, in tbe PLTPtg//rtTAtg group 
administration of doxycycline resulted in a strong 
increase in PLTP activity (from 3.0 ± 0.6 to 
11.4 ± 2.8 AU, Fig. 2). 
Next, tbe duration of tbe doxycycline-induced 
PL TP activity was determined. A group of Tre-
PL TPtg//rtTAtg mice was treated according to tbe 
regime described above, followed by a 5-days period 
on normal drinking water. During tbe 2 days of 
treatment witb doxycycline, PLTP activity increased 
from 2.3 ± 0.4 AU to 9.2 ± 2.2 AU (Fig. 3). PLTP 
activity further increased to 9.9 ± 2.3 AU after 1 day 
after on normal drinking water and subsequently 
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water+sucr water +dox/s ucr 
.. water+ do:x/sucr .. (after 2 days of drinking water containing 
2 mg/ml doxycycline + 5% sucrose). White bars indicate Tre-
PLTPtg mice, gray bars indicate rtTAtg mice, black bars 
indicate Tre-PLTPtg/lrtTAtg mice. n = 15-18 mice/group. 
*p < 0.001. versus Tre-PLTPtg//rtTAtg + dox/sucr and versus 
Tre-PLTPtg + suer and rtTAtg + suer 
started to decline. Five days after discontinuing tbe 
doxycycline treatment, PLTP activity had returned to 
tbe initial leveL 
Effects of human PLTP expression on plasma 
lipids and lipoproteins 
Cholesterol and phospholipid levels were measured 
in plasma to investigate tbe effects of an acute 
increase in plasma PLTP activity on lipid metabo-
lism. After administration of doxycycline, tbere was 
only a 10% decrease in plasma cholesterol in one of 
tbe control groups, Tre-PLTPtg mice (Fig. 4a, from 
15.-----------------------------------, 
5" 12 !'S 
::-
~ 9 
.. 
Q. 
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E 
.. 
.. 3 c:. 
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0 2 
Fig. 3 Plasma PLTP activity levels in Tre-PLTPtg!/rtTAtg 
mice. PL TP was measured in plasma samples and expressed in 
arbitrary units. Time points of measurement: t = 0 (after 3 days 
of drinking water containing 5% sucrose); t = 1 and t = 2 
* 
* 
* 
3 4 5 6 7 
time(days) 
(drinking water contammg 2 mg/ml doxycycline + 5% 
sucrose); t = 3, t = 4, t = 5. t = 7 (normal drinking water). 
n = 6 mice. *p < 0.001 versus t = 0 
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2.7 ± 0.3 rnM to 2.5 ± 0.4 rnM. p < 0.02), while 
plasma cholesterol levels in the other control group, 
rtTAtg mice, remained unchanged. In the Tre-
PLTPtg//rtTAtg mice however, induction of PLTP 
expression by doxycycline administration resulted in 
a 33% decrease in plasma cholesterol (from 
2.7 ± 0.4 rnM to 1.8 ± 0.6 rnM, p < 0.001). Plasma 
phospholipid levels were also lowered after induc-
tion of PLTP activity. by 33% (Fig. 5a, from 
2.6 ± 0.4 rnM to 1.7 ± 0.5 rnM, p < 0.001). In the 
control groups, phospholipid levels did not change 
significantly following administration of doxycy-
cline. Addition of 5% sucrose to the drinking water 
had no statistically significant effects on plasma 
cholesterol or phospholipid levels. Triglyceride 
levels are very low in chow-fed C57Bl/6 mice. 
Administration of doxycycline resulted in a decrease 
in triglyceride levels. both in the control groups 
(from 0.52 ± 0.16 to 0.35 ± 0.17 rnM in Tre-PLTPtg 
Fig.4 Cholesterol levels. ~ 
(a) Total plasma .§. 4 a 
cholesterol. (b) HDL- e 
cholesterol. (c) non-HDL- .. 3 10 
cholesterol. Measurements 
.!! 
were performed at three 0 
.<:: 2 
time points: "'water" 0 
"' (normal drinking water), E ., 
''water + suer'' (after 
"' 'li 3 days of drinking water (0 
containing 5% sucrose). :s 0 
··water+ dox/sud' (after 
2 days of drinking water 4 
containing 2 mg/ml ~ b doxycycline + 5% sucrose). 
.§. 3 White bars indicate Tre- e PLTPtg mice. gray bars 
" indicate rtTAtg mice, black 10 2 
" bars indicate Tre-PLTPtg// 0 
:: 
rtTAtg mice. n ::::: 15-
" 18 mice/group. *p < 0.05, .:.0 
**p < 0.001. versus Tre- :z: 
PL TPtg and rtTAtg + dox/ 
suer. 'p < 0.001. versus Tre· 
0 
PL TPtg//rtTAtg + suer. ~ 4 *p < 0.05. versus Tre- c 
PLTPtg and rtTAtg +suer. l .§. e 3 p < 0.01, each group versus $ 
normal drinking water (I) 
.!! 2 0 
£ 
.:. 
0 
:z: 
C: 
0 0 
"' 
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mice. p < 0.001. and from 0.48 ± 0.17 mM to 
0.35 ± 0.17 mM in rtTAtg mice, p < 0.001) as well 
as in the Tre-PLTPtg//rtTAtg mice (from 
0.54 ± 0.19 to 0.33 ± 0.17 rnM, p < 0.001). 
indicating that the decrease in plasma triglycerides 
is not caused by the action of PL TP. 
The decreases in plasma cholesterol and phospho-
lipids in the Tre-PLTPtg//rtTAtg mice were studied 
in more detail. Lipoprotein fractions were separated 
by ultracentrifugation. In all groups, administration of 
5% sucrose significantly increased total cholesterol 
and phospholipids in the non-HDL fractions, which 
remained unchanged after the subsequent addition of 
doxycycline (Fig. 4c, 5c ). Administration of doxycy-
cline + 5% sucrose had no statistically significant 
effects on total cholesterol levels or phospholipid 
levels in the HDL fractions of both control groups 
(Fig. 4b, 5b). However, in the human PLTP-express-
ing Tre-PLTPtg//rtTAtg mice, HDL-cholesterol 
water water +suer water +dox/sucr 
water water+sucr water +dox/sucr 
t 
water water+sucr water +dox/sucr 
Fig. 5 Phospholipid levels. !E 
(a) Total plasma 
.5. 4 
phospholipids, (b) HDL-
"' 
a 
'0 
phospholipids, (c) non- a. 3 
HDL-phospholipids. ~ 
.t:: 
Measurements were c. 
"' 2 performed at three time 0 
.<: 
points: "water" (normal c. 
"' drinking water). E 
"' "water + suer" (after 
"' 3 days of drinking water a. 
'iii 0 
containing 5% sucrose), £ 
.. water+ dox/sucr" (after 
4 2 days of drinking water !E b 
containing 2 mg/ml 
.5. 
doxycycline + 5% sucrose). 
"' 
3 
'0 
White bars indicate Tre- :e. 
PLTPtg mice, gray bars 0 2 
indicate rtTAtg mice, black ~ 
"' bars inclicate Tre-PLTPtg// 0 
rtTAtg mice. n = 15- ~ 
-' 18 mice/group. *p < 0.001, 0 
versus Tre-PLTPtg and ::t: 0 
rtTAtg + dox/sucr. 
"p < 0.001, versus Tre- !E 4 
PLTPtg//rtTAtg +suer. 
.5. c §p < 0.01, each group versus 
"' 
normal drinking water ~ 3 
0 
.t::; 
c. 2 
"' 0 
.t::; 
! 
0 
:,: 
" 0 0 
" 
decreased by 35% (from 1.8 ± 0.4 mM to 
1.2 ± 0.4 mM, p < 0.001), and HDL-phospholipid 
level decreased by 41% (from 2.3 ± 0.4 mM to 
1.4 ± 0.3 mM,p < 0.001). Furthermore, plasma apoAI 
protein level decreased after induction of PLTP 
expression (Fig. 6). 
mRNA expression analysis 
Liver rtTA and PLTP mRNA expression levels 
were measured by Real-Time PCR (Table 1). RNA 
was isolated from livers of Tre-PLTPtg//rtTAtg 
mice, Tre-PLTPtg mice and rtTAtg mice that had 
been treated with doxycycline for 2 days, and from 
livers of Tre-PLTPtg/ /rtTAtg mice that had not 
received doxycycline in the drinking water. rtTAtg 
mice and the Tre-PLTPtg//rtTAtg mice (with and 
without doxycycline) showed similar levels of rtTA 
expression. Induction by doxycycline gave rise to a 
Acute effects of inducible PLTP expression 
water water+sucr water +dox/sucr 
water water+sucr 
§ 
tenfold increase in PLTP mRNA (human+ murine) 
in the inducible transgenic mouse model compared 
to Tre-PL TPtg/ /rtTAtg mice that had not been 
given doxycycline and therefore expressed only 
murine PLTP (from 1.5 ± 0.9 to 11.7 ± 2.7 AU, 
p < 0.001). In the control groups there were no 
differences in PLTP expression. Induction of human 
PLTP expression did not suppress murine PLTP 
mRNA levels. 
In addition, the effect of an acute increase in 
PLTP activity on RNA expression level of various 
key players in lipoprotein metabolism was studied 
(Table 1). Compared to the control groups. induc-
tion of PL TP in the double transgenic mice did not 
result in a statistically significant change in RNA 
expression level of ATP-binding cassette AI 
(ABCAl), apolipoprotein AI (apoAI). apolipoprotein 
B (apoB) or scavenger receptor class B type I 
(SRBI). 
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Fig. 6 ApoAI protein mass in individual plasma samples of 
Tre-PLTPtg//rtTAtg mice. three mice per condition (water. 
water with sucrose, water with doxycycline and sucrose). 
Table 1 Liver mRNA analysis 
Plasma samples were subjected to electrophoresis on precast 4--
15% SDS-polyacrylamide gradient gels and subsequently 
stained with Coomassie blue 
mPLTP bPLTP m + bPLTP rtTA ABCAl apoAI apoB SRBI 
Tre-PLTPtg +dox 1.2 ± 0.4 0.0 ± 0.0* 1.2 ± 0.4* 0.0 ± 0.0 1.2 ± 0.2 0.9 ± 0.2 0.7 ± 0.4 1.0 ± 0.3 
rtTAtg +dox 0.9 ± 0.3 0.0 ± 0.0* 1.0 ± 0.2* 0.9 ± 0.1 ** 0.9 ± 0.4 0.8 ± 0.2 1.0 ± 0.9 1.1 ± 0.4 
Tre-PLTPtg//rtT Atg +dox 1.2 ± 0.5 10.5 ± 2.6 11.7 ± 2.7 1.0 ± 0.3** 1.2 ± 0.5 0.7 ± 0.2 1.0 ± 0.5 1.2 ± 0.4 
Tre-PLTPtg//rtTAtg -dox 1.5 ± 1.0 0.0 ± 0.0* 1.5 ± 0.9* 0.9 ± 0.1** 0.9 ± 0.1 0.8 ± 0.1 0.5 ± 0.1 1.0 ± 0.1 
* p < 0.001, versus Tre-PLTPtg//rtTAtg + dox 
* p < 0.001. versus Tre-PLTPtg + dox 
In another experiment, tissue distribution of 
murine and human PLTP mRNA was determined in 
a group of four doxycycline-treated Tre-PLTPtg// 
rtTAtg mice by Real-Time PCR. Murine PLTP 
mRNA was mostly present in lung tissue, followed 
by liver, adipose tissue, brain and heart (Fig. 7a). 
Lower levels of murine PL TP mRNA were found in 
adrenals. spleen and kidney. Upon doxycycline-
induction, human PLTP expression appeared to be 
strongest in liver, lung and kidney (Fig. 7b ). Low 
levels of human PLTP mRNA were detected in 
spleen, heart, adrenal and adipose tissue. Only 
negligible amounts of human PLTP mRNA were 
detected in brain. 
Discussion 
In the present study, we describe a mouse model with 
conditional induction of human PL TP expression: 
2 days of doxycycline administration resulted in a 
strong increase in plasma PLTP activity. The induc-
tion of PLTP activity not only proved to be fast, but 
also transient. Discontinuation of doxycycline adrnin-
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istration via the drinking water resulted in a decline 
of PLTP activity to basal activity levels after 5 days. 
Upon induction, PL TP mRNA level in the liver 
increased by tenfold, while in the control groups 
(Tre-PLTPtg and rtTAtg) plasma PLTP activity and 
PLTP liver mRNA did not increase. The non-induced 
double transgenic mouse line (Tre-PLTPtg//rtTAtg 
without doxycycline) did not show any significant 
differences in RNA expression compared with con-
trol mice, so our inducible mouse model does not 
show any intrinsic background activity ("leakage") 
in the non-induced state. The improved version of the 
tetracycline-controlled transactivator we used 
(rtTA2S-M2) has been reported to have a low 
background activity (Lamartina et al. 2002, 2003; 
Salucci et al. 2002). Our inducible mouse model 
shows a broad pattern of human PLTP expression 
(liver, kidney > lung > spleen, heart, adrenal, adipose 
tissue). It is not known whether this is a reflection of 
the normal regulation of PL TP expression found in 
human tissues (Day et al. 1994 ), a reflection of the 
doxycycline distribution among tissues (Michel et al. 
1984), or a combination of both. The high human 
PLTP expression levels in liver and kidney might be 
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explained by doxycycline distribution between tis-
sues: after oral doxycycline administration to rats, 
highest levels were measured in excretory organs 
(i.e., liver and kidney) (Michel et a!. 1984). No 
human PLTP mRNA was detected in brain tissue, 
probably because doxycycline poorly crosses the 
blood brain barrier (Michel et a!. 1984). The distri-
bution pattern of murine PLTP in human PLTP 
expressing PLTPtg//rtTAtg mice is comparable with 
the pattern found in C57BL/6 wildtype mice (Jiang 
and Bruce 1995). 
The increase in PLTP activity in the double 
transgenic mice resulted in a decrease in plasma 
cholesterol of 33% and a comparable decrease in 
plasma phospholipids. These effects are explained by 
a decrease in HDL-cholesterol of 35% and in HDL-
phospholipids of 41%. These results are well com-
parable with our previous studies in human PLTP 
transgenic mice, in which a 2.5- to 4.5-fold increase 
in PLTP activity in plasma resulted in a 30-40% 
decrease in plasma levels of HDL-cholesterol (van 
Haperen et a!. 2000). Concomitantly with the 
decrease in plasma HDL level, plasma apoAI protein 
level decreased. This is probably caused by a PLTP-
tat adrenal heart spleen lung kidney liver 
induced increase in HDL catabolism (Fiiger et a!. 
1997). In addition, PLTP has been reported to cause 
proteolytic cleavage of apoAI (Jauhiainen et a!. 
1999). The decrease in HDL levels cannot be 
explained by changes in expression of SRBI, apoB 
or ABCAI. Compared to the control groups, induc-
tion of PLTP in the double transgenic mice did not 
result in statistical changes of mRNA expression 
levels of these genes. Therefore, the decline in HDL 
is probably a direct effect of PLTP. 
Acute elevation of plasma PLTP activity has been 
studied before using adenovirus-mediated overex-
pression of human PLTP (Ehnholm eta!. 1998; Fiiger 
et a!. 1997; Yang et a!. 2003 ). As in our inducible 
mouse model, also in these studies an increase in 
PLTP activity resulted in an acute decrease in HDL-
cholesterol and HDL-phospholipids. An advantage of 
the inducible mouse model is that it provides a stable 
and controlled elevation of PL TP activity, which 
differs from the transient induction obtained by using 
an adenoviral transfection system. Another important 
feature of our mouse model is the efficacy to induce 
PLTP activity, which only requires the administration 
of doxycycline to the drinking water. We are well 
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aware of the fact that long-term administration of 
high doses of doxycycline might disturb intestinal 
flora (Riond and Riviere 1988), resulting in diarrhea 
and colitis. However, the doxycycline dose used in 
our present study was relatively low and symptoms 
pointing to a disturbed intestinal flora were not 
observed. In future experiments, it will be possible to 
further decrease the doxycycline dose. as maximal 
induction of PL TP activity was already reached at a 
dose of 0.25 mg/ml (data not shown). Recently, the 
2S-M2-version of the tetracycline-controlled transac-
tivator has been used in a mouse model that allowed 
ere-mediated tetracycline-dependent gene expression 
in specific embryonic tissues (Yu et al. 2005), and in 
two mouse models with inducible and tissue-specific 
gene expression in the neuronal system of adult mice 
(Kerrison et al. 2005; Michalon et al. 2005). To the 
best of our knowledge, the present study is the first 
one to describe an inducible mouse model in the field 
of cardiovascular research. 
In conclusion, the results of our study demonstrate 
the feasibility of our mouse model to induce an acute 
elevation ofPLTP activity, which is easily reversible. 
Using this mouse model, it will be possible to study 
the effects of acute elevation of PLTP activity on 
lipoprotein metabolism and pre-existing atheroscle-
rosis. 
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Acute Elevation of Plasma PL TP Activity Strongly Increases 
Pre-existing Atherosclerosis 
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Frank Grosveld, Arie van To!, Rini de Crom 
Objective-A transgenic mouse model was generated that allows conditional expression of human PL TP, based on the 
tetracycline-responsive gene system. to study the effects of an acute increase in plasma PLTP activity as may occur in 
inflanunation. 
Methods and Results-The effects of an acute elevation of plasma PLTP activity on the metabolism of apolipoprotein 
B-containing lipoproteins and on diet-induced pre-existing atherosclerosis were determined in mice displaying a 
humanized lipoprotein profile (low-density lipoprotein receptor knockout background). Induced expression of PLTP 
strongly increases plasma VLDL levels in LDL receptor knockout mice. whereas VLDL secretion is not affected. The 
elevation in plasma triglyceride levels is explained by a PL TP-dependent inhibition of VLDL catabolism. which is 
caused. at least partly. by a decreased lipoprotein lipase activity. Together with the decreased plasma HDL levels. the 
acutely increased PLTP expression results in a highly atherogenic lipoprotein profile. Induction of PLTP expression 
leads to a further increase in size of pre-existing atherosclerotic lesions, even on a chow diet. In addition. the lesions 
contain more macrophages and less collagen relative to controls. suggesting a less stable lesion phenotype. 
Conclusion-In conclusion, acute elevation of PLTP activity destabilizes atherosclerotic lesions and aggravates 
pre-existing atherosclerosis. (Arterioscler Thromb Vase Bioi. 2008;28:1277-1282) 
Key Words: atherosclerosis • lipoproteins • phospholipid transfer protein • transgenic mouse models 
• triglycerides 
S tudies in various atherosclerosis-prone mouse models have demonstrated that expression of human phospho-
lipid transfer protein (PLTP) stimulates the development of 
atherosclerosis. 1- 3 This can be explained by effects of PLTP 
activity on lipoprotein composition and metabolism. PLTP 
increases hepatic VLDL secretion4 - 7 and decreases plasma 
HDL levels. resulting in a more atherogenic lipoprotein 
profile.'-9 Furthermore. PLTP unfavorably affects the antiin-
flammatory and antioxidative properties of HDL parti-
cles.6·10-12 Recently we developed a transgenic mouse model 
that allows conditional expression of human PLTP." We 
hypothesize that the physiological effect of an acute increase 
in plasma PLTP activity differs significantly from the effects 
seen in mice overexpressing human PLTP innately and 
life-long and which may have developed compensatory 
mechanisms. We tested this hypothesis in transgenic mice 
that conditionally overexpress human PLTP and that are 
deficient for the LDL receptor. The first objective was to test 
the effects of acute elevation of plasma PLTP activity on 
lipoprotein metabolism. The second objective was to study 
the effect of the acute expression of human PLTP on 
diet-induced pre-existing atherosclerosis. 
Original received December 10, 2007: final version accepted April 9, 2008. 
Materials and Methods 
Animals 
The generation of inducible human PLTP transgenic mice is de-
scribed in detail elsewhere. 13 Briefly. 2 constructs were used to 
generate transgenic mice that allow inducible expression of PL TP: 
(1) hnRNP-rtTA-SV40. which consists of an improved version of the 
tetracycline-controlled transactivator rtTA2S-M2 under the control 
of an hnRNP A2 coding sequence, resulting in rtTAtg mice. and (2) 
pTet-PLTP-SV40. which consists of the human PLTP eDNA under 
the transcriptional control of a tetracycline operator and minimal 
cytomegalovirus promoter (TetO/Pcmv min). resulting in Tre-
PLTPtg mice. Both Tre-PLTPtg mice and rtTAtg mice were crossed 
into an LDLR_,_ background (Jackson Laboratory, Bar Harbor, ME, 
USA). Tre-PLTPtg!LDLR_,_ mice and rtTAtg!LDLR_,_ mice were 
crossbred, resulting in Tre-PLTPtg/rtTAtg!LDLR_,_ mice. For con-
venience, these mice are referred to as "indPL TP" mice. Control 
mice are animals lacking either the Tre-PLTP transgene or the rtTA 
transgene. For determination of the genotype. genomic DNA was 
isolated from tail clips of 10-day-old mice and analyzed by 
polymerase chain reaction (PCR). Annealing temperatures and 
primer sequences are available on request. 
After weaning. animals were fed a standard chow diet. Animals 
had free access to water and food. Blood samples were collected by 
orbital bleeding after removing food overnight. Male mice were used 
From the Department of Cell Biology & Genetics (M.M .. H.S., T.v.G., R.v.H .. F. G .. A.v.T .. R.d.C.). Erasmus University Medical Center. Rotterdam: 
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in all experiments. All procedures used in this study are in accor-
dance with national and institutional guidelines. 
Experimental Setup 
Animals were subjected to 2 dietary regimes, referred to as treatment 
A and treatment B (supplemental Figure I. available online at 
http://atvb.ahajournals.org). Experiments were performed with mice 
of 10 to 15 weeks. Using treatment A, PLTP expression was induced 
immediately after switching from a high cholesterol to a normal 
chow diet. and its effect on lipoprotein metabolism was investigated. 
Two weeks after the switch from the high-fat high-cholesterol diet to 
the chow diet. PLTP expression was induced using treatment B and 
maintained for 5 weeks. This treatment was used to study the effect of 
PLTP expression on pre-existing atherosclerosis. In the online supple-
mental methods. the experimental setup is discussed in more detail. 
Analysis of Plasma Activity of PLTP, Hepatic 
Lipase, and Lipoprotein Lipase 
Plasma samples were collected by orbital puncture. Activities of PL TP, 
pre- and postheparin hepatic lipase (HL), and lipoprotein lipase (LPL) 
were analyzed as described in the supplemental methods. 
Analysis of Plasma Lipids and Lipoproteins 
Measurements of plasma concentration of lipids. and isolation and 
analysis of plasma lipoproteins were performed as described in the 
supplemental methods. 
Determination of VLDL Secretion and 
VLDL Decay 
VLDL secretion experiments were performed as descnbed in the 
supplemental methods. VLDL decay experiments were performed 
with [3H]cholesteryl oleyl ether labeled murine VLDL, injected 
intravenously in mice as a tracer. See supplemental methods for 
details. 
Histology and Measurement of 
Atherosclerotic Lesions 
Histological analysis of atherosclerotic lesions were performed as 
described in the supplemental methods. 
Statistics 
Data are expressed as means±SE. Differences were analyzed by 
2-sample Wilcoxon rank sum tests using Intercooled Stata 8.2/SE 
software (Stata Corporation). 
Results 
PLTP-Effects on Lipoprotein Metabolism 
For the first set of experiments, designed to determine the 
effect of acutely increased PL TP activity on lipoprotein 
metabolism, treatment A was followed (supplemental Figure 
I). At 0 weeks, no differences were observed in plasma PLTP 
activity, triglycerides, cholesterol, or phospholipid levels 
between indPLTP and control mice (Figure 1, Table). After 9 
weeks of Western diet, PL TP activity, triglycerides, choles-
terol, and phospholipids were increased in both groups to a 
similar extent (Figure I, Table). Subsequently, Western diet 
was stopped and doxycycline was administered for 2 weeks. 
This resulted in a further 4.5-fold increase in PLTP activity in 
the indPLTP group, whereas PLTP activity remained un-
changed in the control group (Figure lA). Induction of PLTP 
in animals fed a chow diet resulted in a 3-fold increase in 
plasma triglycerides in the indPL TP mice, whereas in the 
control mice triglyceride levels returned to basal levels 
(Figure lB). Similar effects were observed for cholesterol 
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Figure 1. Plasma PLTP activity levels (A) and triglyceride levels 
{B). Measurements at 0 and 9 weeks. After 9 weeks, mice were 
subjected to either treatment A or treatment B. White bars, 
control mice; gray bars, indPLTP mice. n>10 mice per group. 
Please see supplemental materials for a detailed figure legend. 
and phospholipids levels in the control group (Table). In 
contrast, plasma cholesterol and phospholipid levels re-
mained elevated in the indPLTP group: the plasma choles-
terol was 20.0±8.3 mmol/L and the phospholipid level 
7.1±1.1 mmol/L in the indPLTP mice, versus 8.5±1.5 
mmol/L and 4.4±0.6 mmol/L in the controls. 
The effects of induced expression of human PLTP on 
plasma lipids were studied in more detail by separation of 
HDL and non-HDL using density ultracentrifugation. Feed-
ing the Western diet did not influence HDL-cholesterol or 
HDL-phospholipid levels in either group, whereas it strongly 
increased non-HDL-cholesterol and non-HDL-phospholipid 
levels (Table, 9 weeks). The subsequent 2 weeks administra-
tion of doxycycline on a chow diet did not induce any change 
in HDL levels in the control mice (Table). Non-HDL-
phospholipid levels returned to basal values, non-HDL-cho-
lesterol level strongly decreased but remained slightly ele-
vated compared to basal level (6.4±0.8 mmol/L versus 
4.3±0.7 mmol/L). In contrast, HDL levels dramatically 
decreased in the indPL TP mice on PLTP induction by 
doxycycline treatment (Table, treatment A: HDL-cholesterol 
from 2.1 ±0.5 to 0.3±0.1 mmol/L, HDL-phospholipid from 
1.9±0.4 to 0.4±0.0 mmol/L). Non-HDL-lipids remained 
increased when human PL TP expression was induced 
(Table). 
To study the effects of expression of human PLTP on 
lipoprotein distribution further, pooled plasma samples ob-
tained from 8 to 10 mice were subjected to gel filtration by 
fast protein liquid (FPLC) at 0, 9, and 11 weeks. At 0 weeks, 
Acute PLTP elevation increases atherosclerosis 
Table. Plasma Parameters 
Cholesterol Phospholipids 
11A 118 178 11A 118 178 
control 7.9±1.0 31.4±10.1§§ 8.5±1.5§§ 8.0±1.9§§ 9.6±2.2§ 4.0±0.4 8.3±2.0§§ 4.4±0.6§§ 4.0±0.6§§ 4.3±0.8 
indPLTP 8.8::!::1.3 35.1±9.3## 20.0±8.3'## 8.2±1.9## 16.9±4.0'## 3.9±0.6 8.9±1.5## 7.1::!::1.1*# 4.1 ±0.6## 6.4±1.2'## 
HDL-C HDL-PL 
11A 118 178 11A 118 178 
control 1.9±0.4 2.0±0.5 1.7±0.2 1.6±0.3§ 1.7±0.4 2.0±0.4 1.7±0.4 1.8±0.2 1.6±0.3 1.8±0.4§ 
ndPLTP 1.9±0.6 2.1±0.5 0.3±0.1*## 1.6±0.3# 0.2±0.1'## 1.9±0.5 1.9±0.4 0.4±0.0*## 1.6±0.2# 0.4±0.0'## 
Non-HDL-C Non-HDL-PL 
11A 118 178 11A 118 178 
control 4.3±0.7 24.7±8.0§§ 6.4±0.8§§ 5.8±1.4§§ 5.7±1.3 1.9±0.2 6.0±1.9§§ 2.1±0.4§§ 1.8±0.3§§ 1.9±0.3 
indPLTP 4.6±0.8 27.5±5.1## 15.4±5.2'## 5.8±1.5## 12.6±2.7'## 1.9±0.3 6.0±0.9## 5.4±1.2' 1.9±0.3## 4.7±0.8'## 
Cholesterol and phospholipid levels (expressed in mmoi/L) in plasma and in HDL and non-HDL fractions that had been separated by density gradient 
ultracentrifugation of freshly isolated plasma samples. Measurements before diet ('0') and after 9 weeks of Western diet ('9'). After stopping Western diet, mice were 
fed either chow+doxycycline for 2 weeks (treatment A: '11A') or chow without administration of doxycycline for 2 weeks (treatment 8: '11 8'), followed by doxycycline 
administration for 6 weeks (treatment B: '178'). 
n> 11 mice/group. 
'P<0.001 vs control. 
§P<0.01, §§P<0.001: 9 vs 0, 11A vs 9,118 vs 9,178 vs 118 (control). 
#P<0.01, ##P<0.001: 9 VS 0, 11A VS 9, 118 VS 9,178 VS 118 (indPLTP). 
cholesterol profiles of the control group and the indPLTP 
group did not differ (Figure 2). At 9 weeks cholesterol levels 
in the non-HDL size range (fractions 1 to 12) strongly 
increased in both groups. At 11 weeks (treatment A) the 
non-HDL peak strongly declined in the control mice, al-
though the level of LDL-sized particles remained elevated 
(Figure 2A). In the indPL TP mice the non-HDL peak overall 
also declined (Figure 2B). However. in these animals a 
substantial lipoprotein fraction with VLDL size was clearly 
present after induction ofPLTP expression (fractions 1 to 4). 
Figure 2. Cholesterol levels in FPLC fractions of plasma from 
control mice and indPLTP mice. Individual plasma samples were 
pooled ("'8 mice per pool) and subjected to FPLC at 0 (circles), 
9 (squares), and 11 weeks (triangles). 
To evaluate possible mechanisms explaining this observa-
tion. we investigated VLDL secretion in indPLTP and control 
mice at 11 weeks. All mice had been given drinking water 
containing both doxycycline and 5% sucrose during the last 2 
weeks. Plasma triglycerides (at t=O minutes) strongly dif-
fered between controls and indPL TP (Figure 3A). as observed 
before (Figure !B). However. both groups had equal rates of 
VLDL triglyceride secretion. Therefore, the increase in 
VLDL after induction of PLTP in indPLTP mice cannot be 
explained by an increase in formation and secretion of these 
particles. Next. we evaluated possible differences in VLDL 
degradation. Murine VLDL was labeled with [3H]-cholesteryl 
oleoyl ether, and tracer amounts were injected intravenously 
in doxycycline-treated control mice and indPLTP mice at 11 
weeks of treatment A. Subsequently. the disappearance of 
radioactivity from the blood was monitored (Figure 3B). 
There is a big difference between lhe 2 groups in VLDL clearance 
during lhe first 15 minutes after labeled VLDL injection. After 
15 minutes. already 39% of labeled VLDL had been cleared 
from the plasma of control mice, whereas in the indPLTP 
mice there had not been any clearance yet. At later time 
points [3H]-VLDL disappeared slowly and linearly in both 
control and indPLTP mice. Four hours after injection. 
51±5% and 84±10% of the label still remained in the plasma 
of the control mice and the indPLTP mice. respectively. 
Separation of lipoprotein particles by FPLC demonstrated 
that both in the indPLTP and the control mice a substantial 
part of the injected VLDL particles had been converted into 
IDL and LDL (data not shown). The tissue distribution of 
injected label was studied after sacrificing the animals at t=4 
hours (Figure 3C). In both groups, almost all injected label 
that had disappeared from plasma was detected in the liver. 
To get more insight in the mechanism behind the initially 
delayed decay of VLDL-particles in the human PLTP ex-
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Figure 3. A, VLDL secretion: Increase in plasma triglyceride 
level in time. B, VLDL decay in time. Open circles, control mice; 
filled circles, indPLTP mice. C, Tissue distribution of fH]-Iabel 
after last measurement at t=4 hours. White bars, control mice; 
gray bars, indPLTP mice. Please see supplemental materials for 
a detailed figure legend. 
pressing mice, we measured plasma lipase actrv1tres in 
doxycycline-treated indPL TP mice and control mice. Hepatic 
lipase activity in preheparin plasma did not differ between the 
indPL TP group and the control group. However, LPL activity 
in postheparin plasma was significantly decreased in the 
indPL TP group compared to the control group (Figure 4). 
The Effect of PLTP Expression on 
Preexisting Atherosclerosis 
The second main objective was to determine the effect of 
acute elevation of PLTP activity on pre-existing atheroscle-
rosis. For this purpose, treatment B was followed (supple-
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Figure 4. Lipoprotein lipase (LPL) and hepatic lipase (HL) activ-
ity in doxycycline-treated control mice (white bars) and indPLTP 
mice (gray bars). Lipase activity is expressed in milliunits per mL 
(mU/mL), 1 mU representing the release of 1 nmol fatty acid 
from the substrate per minute. *P<0.01 vs control. 
mental Figrue I). Plasma PLTP activity levels or triglyceride 
levels did not differ between the control mice and the 
indPLTP mice at 0. 9, and 11 weeks (ie, before PLTP 
induction: Figure 1). From 11 weeks on, doxycycline was 
administered for an additional 6 weeks. This resulted in a 
5.5-fold increase in PLTP activity in the indPLTP group. 
whereas PL TP activity did not change in the control group 
(Figure lA). The increased PL TP activity in the indPL TP 
group resulted in strongly increased plasma levels of triglyc-
erides, cholesterol. and phospholipids (Figrue lB. Table). 
Separation of lipoprotein classes using density ultracentrifu-
gation showed that on induction of PLTP activity, levels of 
HDL-cholesterol and HDL-phospholipids were substantially 
decreased whereas levels of non-HDL-cholesterol and non-
HDL-phospholipids were substantially increased (Table). 
Atherosclerotic lesion development was determined at 9 and 
17 weeks. In the control mice. discontinuing the Western diet 
for 8 weeks did not influence atherosclerotic lesion area 
significantly (Figure SA and supplemental Figure IT: 
2.8±1.5Xl04 J.Lm2 at 9 weeks and 2.4±0.7Xl04 J.Lm2 at 17 
weeks). but lesion composition changed. The macrophage 
content of the lesion decreased by 40% on switching the 
Western diet to a chow diet (Figure SB and supplemental 
Figure II). whereas the collagen content increased 4-fold 
(Figure 5C and supplemental Figure II). suggesting a signif-
icant stabilization of the lesion. In the indPLTP mice how-
ever. induction of human PLTP expression resulted in a 
further increase in mean lesion area (Figure SA and supple-
mental Figrue IT: from 3.1±1.2X104 J.Lm2 at 9 weeks to 
5.2±1.3Xl04 J.Lm2 at 17 weeks), even though the mice were 
on a chow diet. In these mice. the relative macrophage 
content of the lesion remained unchanged (Figure SB and 
supplemental Figrue ll). The collagen content increased but 
was significantly lower when compared to that seen in the 
control mice (Figure SC and supplemental Figure ll; 
38.9±14.8% versus 27.2±9.5%). 
Discussion 
Our frrst objective was to investigate the effect of conditional 
PL TP expression on lipoprotein metabolism after changing 
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from a hyperlipidaemic state, induced by a high-fat high-cho-
lesterol diet, to normolipidaemia induced by chow diet. HDL 
levels strongly decreased on induction of expression of 
human PLTP. In addition, we observed an important novel 
effect of elevated PLTP expression on VLDL catabolism, 
probably caused by induction of decreased LPL activity. 
Induction of elevated PL TP activity strongly increased 
plasma triglyceride, cholesteroL and phospholipid levels in 
the non-HDL fractions. Separation of lipoproteins by FPLC 
revealed that the majority of the lipids was present in 
VLDL-sized particles. To our knowledge this is the first 
demonstration that the plasma levels of apoB-containing 
lipoproteins or plasma triglyceride levels are actually higher 
after induction of PL TP expression. Apparently, the metabol-
ic effects of an acute increase in PL TP activity differ from the 
effect of life-long increase in plasma PLTP activity levels in 
human PLTP transgenic mice. Indeed, in the acute modeL the 
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triglyceride secretion rate by the liver was not affected by 
overexpression ofPLTP, whereas we previously showed that 
life-long enhanced PLTP expression results in increased 
hepatic triglyceride secretion.5•7 The high lipid levels in the 
non-HDL fractions therefore cannot be explained by an 
increase in VLDL production. To examine whether these 
observations could be explained by a decreased catabolism of 
VLDL, we performed VLDL decay studies using [3H]-
cholesteryl oleyl ether labeled VLDL as a tracer. The absolute 
amount of injected VLDL-cholesterol was only 0.5% to I% 
of total circulating cholesterol. an amount that was not 
expected to affect endogenous lipoprotein metabolism. We 
found that plasma clearance of [3H]-labeled VLDL was 
delayed, and that the hepatic uptake of [3H]-labeled choles-
terol was strongly decreased in indPLTP mice when com-
pared with control mice. 
It is unlikely that hepatic clearance of VLDL is inhibited 
due to a decreased apoE content in indPLTP mice, as protein 
analysis of FPLC fractions showed that VLDL in 
doxycycline-treated indPLTP mice contained normal 
amounts of apoE (data not shown). Already a very low level 
of apoE is sufficient to normalize plasma cholesterol levels in 
apoE-deficient mice. 14 Next. we examined whether PLTP 
may affect VLDL lipolysis. Lipoprotein lipase (LPL) plays an 
important role in this process by hydrolyzing the triglycerides 
in VLDL particles. 1>-17 In addition, HL and LPL may act as 
a ligand between low density lipoproteins and hepatic li-
poprotein binding sites. Indeed, plasma LPL activity mea-
sured in postheparin plasma under optimal conditions was 
significantly decreased in indPL TP mice. Thus the delayed 
VLDL clearance could, at least partly, be explained by a 
decrease in the plasma level of LPL. causing a limited 
turnover of VLDL triglycerides in peripheral tissues. 
Our second main objective was to determine the effect of 
increased PLTP activity on pre-existing atherosclerotic le-
sions, which had been induced by feeding a high-fat high-
cholesterol diet for 9 weeks. Induction of high plasma PLTP 
activity levels in the indPLTP mice not only decreased HDL 
levels but also strongly increased plasma triglyceride, cho-
lesterol, and phospholipid levels in the non-HDL fraction. In 
the control mice, the lesion size at 9 and 17 weeks was 
similar. Lesion macrophage content was strongly decreased. 
whereas collagen content was significantly increased. This is 
in accordance with previous experiments in which the regres-
sion of pre-existing atherosclerotic lesions was studied. 18- 21 
A decrease in lesion area on withdrawal of an atherosclero-
sis-inducing diet is only observed in foam cell-containing 
fatty streaks. For lesions containing more advanced charac-
teristics, such as fibrous caps and necrotic cores. a decrease in 
lesion area may not be observed. but generally macrophage 
content of the lesions strongly decreases on withdrawal of the 
high-fat high-cholesterol diet. In addition. collagen content of 
the lesions increases, 22 resulting in lesion stabilization. In 
contrast to the situation observed in the control mice. the 
unfavorable lipoprotein profile observed in the indPLTP 
resulted in a further increase in lesion area. Although the 
Western diet had been stopped, the lesion area had almost 
doubled compared to the situation seen at 9 weeks. indicating 
a strong atherogenic effect of PLTP. No regression of the 
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macrophage percentage was observed. Also the collagen 
percentage was remarkably lower than that seen in control 
mice, indicating that bigh plasma PL TP activity levels stim-
ulate an increase in lesion size and also inhibit lesion 
stabilization, which may be caused by the elevated plasma 
VLDL levels. Besides. a PLTP-induced inflammatory re-
sponse might very well contribute to the formation of 
atherosclerotic lesion. Plasma PLTP activity is increased 
during acute systemic inflammation.23 a situation that is 
comparable with the acute increase in plasma PLTP activity 
that is induced in our mouse model. 
In conclusion, using a novel mouse model with inducible 
expression of PL TP we found that increased plasma PL TP 
activity strongly enhances plasma VLDL levels by a PLTP-
dependent inhibition of VLDL catabolism. In combination 
with the PLTP-dependent decrease in plasma HDL levels, 
tbis results in a strongly atherogenic lipoprotein profile and 
may account for the PLTP-dependent size increase of pre-
existing atherosclerotic lesions and the decreased lesion 
stability, even after replacement of the Western diet by chow 
diet. Our study supplies new evidence that bigh systemic 
PLTP activity unfavorably affects the cardiovascular system. 
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Supplementary Materials and Methods 
Experimental setup 
Animals were subjected to two dietary regimes, referred to as treatment A and treatment 
B. Experiments were started after the mice reached an age between 10 and 15 weeks. 
Using treatment A, the effect ofPLTP expression on lipoprotein metabolism was 
investigated under diet-induced high lipidaemic conditions. The animals were fed a high-
fat high-cholesterol diet ('Western diet") for a period of9 weeks. After stopping the 
Western diet the mice were fed standard chow diet for 2 weeks, together with 1 mg/ml 
doxycycline+ 5% sucrose added to the drinking water. After these 2 weeks, VLDL 
secretion and VLDL decay experiments were performed (methods described below). At 0 
weeks (before Western diet), 9 weeks (after Western diet) and 11 weeks (after 
doxycycline treatment) plasma PLTP activity and plasma lipids were measured and 
lipoprotein profiles were obtained by gel filtration (methods described below). 
Using treatment B, the effect ofPLTP expression on pre-existing atherosclerosis was 
determined. The first 9 weeks the mice followed the same regime ofWestern diet as in 
treatment A. After 9 weeks of feeding Western diet, 8 mice of both the indPLTP and the 
control group were sacrificed to determine atherosclerotic lesion development. The 
remaining mice were fed standard chow diet again for 2 weeks, receiving normal 
drinking water, in order to obtain basal plasma lipid levels before induction of PL TP 
activity. After these 2 weeks, 1 mg/ml doxycycline + 5% sucrose was added to the 
drinking water. At 17 weeks, mice were sacrificed and atherosclerotic lesion 
development was determined. In addition, plasma PL TP activity and plasma lipids were 
measured (methods described below). 
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Plasma PL TP activity 
PLTP activity was measured using a phospholipid vesicle-HDL system, according to 
Speijer et al. 1 PLTP activity is expressed as arbitrary units (AU). One AU is equal to the 
level ofPLTP activity found in human reference plasma, which is 13.9 f.Lmollml!h. 
Plasma lipase activities 
Plasma lipase activities were analyzed in pre-heparin plasma and post-heparin plasma 
using a gum acacia-stabilized glycerol 14C trioleate emulsion as described by Jansen et 
al. 2. Plasma pre-heparin lipase activity reflects hepatic lipase (HL) activity. Lipase 
activity in post-heparin plasma minus pre-heparin HL activity reflects lipoprotein lipase 
(LPL) activity3. All assays were performed in the presence of heat-inactivated plasma as 
a source of apoCII. Lipase activities are expressed in milliunits (mU), 1 mU representing 
the release of l nmol fatty acid from the substrate per minute. 
Quantification of plasma lipids 
Cholesterol concentration was determined enzymatically using a Free Cholesterol C kit 
(W AKO) after hydrolysis of cholesteryl esters with cholesterol esterase from Candida 
cylindracea (Boehringer). Triglycerides were measured using a triglyceride kit from 
W AKO. Phospholipids were measured using the P AP150 kit from BioMerieux. 
Separation of lipoproteins 
HDL and non-HDL fractions were separated by density gradient ultracentrifugation of 
freshly isolated plasma samples (Beckman 42.2 Ti rotor, 42000 rpm, 2h50min, 12 °C, 
d=l.063 g/ml). 
Plasma lipoprotein profiles by gel filtration 
Lipoprotein profiles in EDT A-plasma were obtained using HR 10/30 fast performance 
liquid chromatography (FPLC) columns in tandem that were filled with Superose 6 and 
Superdex 200 (preparation grade, Pharmacia Biotechnology) respectively. Columns were 
equilibrated and run in a 2 mM phosphate buffer containing 0.9% (w/v) NaCl, 0.02% 
(w/v) NaN3 and 5 mM EDTA (pH 7.4). Pooled plasma samples obtained from 8-10 mice 
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were filtered through 0.8 !liD filters (Pall Corporation). 0.5 ml of plasma was loaded onto 
the Superose 6 column. The separation was performed at 4°C with a flow rate of0.1 
mllmin, fractions of0.8 ml were collected. 
Determination ofVLDL secretion 
VLDL secretion experiments were performed as described previously4. VLDL secretion 
was measured in mice that had overnight access to drinking water containing doxycycline 
and 5% sucrose, but no access to chow. Mice were injected intravenously with 10% (w/v) 
Triton WR1339 (Sigma, StLouis, MO) (500 mg/kg body weight) dissolved in 0.9% 
NaCl. After injection of Triton WR1339, blood samples were drawn at appropriate time 
points (up to 90 min) and triglyceride levels were measured as described above. The 
triglyceride accumulation in plasma was linear during this period. Hepatic triglyceride 
secretion rate was calculated from the slope of the line and expressed as mmol/L per 
minute. 
Determination ofVLDL decay 
VLDL was isolated by density ultracentrifugation of freshly isolated plasma ofwildtype 
mice (Beckman 70.1 Ti rotor, 40400 rpm, 20 h, 12 °C, d=l.006 g/ml). Isolated VLDL 
was radioactively labeled using an adapted protocol for the labeling ofLDL designed by 
Groener et al.5 VLDL was labeled by incubation with eH]cholesteryl oleyl ether 
containing liposomes for 24 hours at 37 °C. After labeling, VLDL was re-isolated by a 
one-step gradient ultracentrifugation as described by Redgrave et al.6 To determine the in 
vivo VLDL decay, 200 111 ofeH]-labeled VLDL (cholesterol 0.55 mM, 20*106 dpm/ml) 
was injected intravenously in mice that had access to drinking water containing 5% 
sucrose, but no access to chow. At t=2, 15, 30 and 90 minutes after VLDL injection a 
small amount of blood was taken by tail bleeding. At t=4 hours after injection a larger 
blood sample was collected from the orbital plexus after which the mice were killed by 
cervical dislocation. Liver, adrenals, kidney, gall bladder, lungs, adipose tissue and heart 
were removed. To determine VLDL decay (expressed as percentage of plasma [3H]-label 
measured at t=2 minutes), the decrease of eH]-label in the plasma samples over time was 
measured. Tissue distribution of eH]-label (expressed as percentage of the injected dose) 
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was determined by dissolving tissues overnight in Soluene 350 (Perkin Elmer), followed 
by treatment with isopropanol and peroxide, after which radioactivity was measured. 
Histology and measurement of atherosclerotic lesions 
The mice were anesthetized with isoflurane, the thorax was opened and the animals were 
subjected to perfusion fixation through the left ventricle of the heart using 4% phosphate-
buffered formalin. The heart was dissected and 7 J-Ull thick cryosections of the aortic 
valves were made. For quantification of atherosclerosis, sections were stained with Oil 
Red 0 and hematoxilin. Atherosclerotic lesion area was measured in five sections at 
intervals of90 J.Lm using image processing by NIH-based Scion Image and analyzing 
software (available at www.scioncorp.com) according to Paigen et al.7 Macrophages 
were detected by immunohistochemical analysis using an indirect peroxidase antibody 
conjugate method, with an anti-CD68 monoclonal antibody. Sections were counterstained 
with Nuclear Fast Red. Collagen was stained using the Picro-Sirius Red method and 
examined by crossed polars rnicroscopl· 9• Macrophage and collagen percentage of 
atherosclerotic lesions was measured using Clemex Vision image analysis system 
(Clemex Technologies, Quebec, Canada). 
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Detailed Figure Legends 
Figure 1. 
Plasma PL TP activity levels (A) and triglyceride levels (B). PLTP activity was measured 
in plasma samples and is expressed as arbitrary units (AU; 1 AU is equal to the level of 
PLTP activity found in human reference plasma, i.e. 13.9 f..LmollmL/h). 
Measurements at 0 (t=O) and 9 weeks (t=9; after 9 weeks of Western diet). After 9 weeks, 
mice were subjected to either treatment A or treatment B. Treatment A: measurement at 
11 weeks (t=ll; after 2 weeks of chow and drinking water containing 
doxycycline/sucrose), treatment B: measurements at 11 weeks (t=11; after 2 weeks of 
chow and normal drinking water) and 17 weeks (t=l7; after 6 weeks of chow and 
drinking water containing doxycycline/sucrose). White bars: control mice, gray bars: 
indPL TP mice. n> 10 mice per group. 
p<0.001 versus control at 0 weeks(*), at 9 weeks(**) 
p<0.001 versus indPLTP at 0 weeks(#), at 9 weeks(##), at 11 weeks/B (###) 
p<0.001 versus control at 11 weeks/A (§),at 17 weeks(§§) 
p<0.01 versus control at 9 weeks (t) 
p<0.01 versus control at 11 weeks/A (t) 
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Figure 3. 
A: VLDL secretion: Increase in plasma triglyceride level (mmoVL) in time. Open circles: 
control mice (n=4), filled circles: indPLTP mice (n=8). There is no statistically 
significant difference between the secretion rates. B: VLDL decay in time. Values are 
expressed as a percentage of eHJ-label measured at t=2 minutes. Open circles: control 
mice (n=5), filled circles: indPL TP mice (n=5). C: Tissue distribution of [3H]-label after 
last measurement at t=4 hours. Values are expressed as a percentage of the total injected 
dose. White bars: control mice (n=5), gray bars: indPLTP mice (n=5). 
* p<0.001, ** p<0.01 versus controL 
Figure 5. 
Atherosclerotic lesion development. A: Plaque area (expressed in 11m2 x 1 04), B: 
macrophage content of atherosclerotic lesions (expressed as percentage of total lesion 
area), C: collagen content of atherosclerotic lesions (expressed as percentage of total 
lesion area). Measurements were performed in sections from the aortic root (see 
Methods) at 9 weeks (after 9 weeks of Western diet) and 17 weeks (after 2 weeks of 
chow+ 6 weeks of chow and doxycycline administration). White bars: control mice, gray 
bars: indPLTP mice. 8-10 mice per group. 
p<0.001 (*), p<0.01 (**)versus control at 9 weeks 
p<0.001 (#), p<0.01 (##)versus indPLTP at 9 weeks 
p<0.001 (§), p<0.05 (§§)versus control at 17 weeks 
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Supplementary Figures 
Figure I. 
Experimental setup. Treatment A and treatment B: shared run-in period of 9 weeks on 
Western diet, followed by 2 weeks on chow with administration of doxycycline 
(treatment A), or 2 weeks on chow and subsequently 6 weeks on chow with 
administration of doxycycline (treatment B). 
D Western diet 
~ chow diet 
chow diet + doxycycline 
Treatment A 
Treatment 8 
weeks 1 3 5 
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Figure II. 
Histological staining of atherosclerotic lesions in control mice and indPL TP mice at t= 17 
weeks (9 weeks of high fat high cholesterol diet+ 2 weeks of chow+ 6 weeks of chow 
and doxycycline). A: Lipid staining (red) in representative cross-sections from the aortic 
root, B: Collagen staining (bright yellow and orange/red) in representative cross-sections 
of one aortic valve, C: Macrophage staining (black) in representative cross-sections of 
one aortic valve. See supplementary methods for details. 
control indPLTP 
A 
B 
c 
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Abstract Plasma phospholipid transfer protein (PL TP) in-
teracts with HDL particles and facilitates the transfer of 
phospholipids from triglyceride (TG)-rich lipoproteins to 
HDL. Overe>..-pressing human PLTP in mice increases the 
susceptibility to atherosclerosis. In human plasma, high-
active and low-active forms of PLTP exist. To elucidate 
the contribution of phospholipid transfer activity to changes 
in lipoprotein metabolism and atherogenesis, we developed 
mice e"''Pressing mutant PL TP, still able to associate with 
HDL but lacking phospholipid transfer activity. In mice 
heterozygous for the LDL receptor, effects of the mutant 
and normal human PLTP transgene (mutPLTP tg and PLTP 
tg, respectively) were compared. In PL TP tg mice, plasma 
PLTP activity was increased 2.9-fold, resulting in markedly 
reduced HDL lipid levels. In contrast, in mutPLTP tg mice, 
lipid levels were not different from controls. Furthermore, 
hepatic VLDL-TG secretion was stimulated in PLTP tg 
mice, but not in mutPL TP tg mice. "\Vhen mice were fed a 
cholesterol-enriched diet, atherosclerotic lesion size in PLTP 
tg mice was increased more than 2-fold compared with con-
trol mice, whereas in mutPLTP tg mice, there was no 
change.!lll Our fiodings demonstrate that PL TP trausfer ac-
tivity is essential for the development of atherosclerosis in 
PL TP transgenic mice, identifying PL TP activity as a possible 
target to prevent atherogenesis, independent of plasma 
PLTP concentration.-Samyn, H., M. Moerland, T. van 
Gent, R van Haperen,J. Metso, F. Grosveld, M.Jauhiainen, 
A. van To!, and R de Crom. Plasma phospholipid trausfer 
activity is essential for increased atherogenesis in PLTP 
trausgenic mice: a mutation-inactivation study.]. Lipid Res. 
2008. 49: 2504--2512. 
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Phospholipid transfer protein (PLTP) is a multifunc-
tional protein secreted by various cell types into the plasma, 
where it associates with HDL particles. Plasma PLTP has a 
central role in cholesterol and lipoprotein metabolism. It 
mediates the transfer of phospholipids between lipoprotein 
particles (1, 2). In addition, PLTP in vitro is able to transfer 
other lipophilic substances such as diacylglycerol (3), cho-
lesterol (4), lipopolysaccharide (5, 6), and a-tocopherol (7), 
an important anti-oxidant. Furthermore, plasma PLTP has 
been identified as an HDL conversion fuctor. It remodels 
HDL to generate large particles and small lipid-poor pre-
[3-HDL (8-10). In vitro, HDL conversion depends on phos-
pholipid transfer activity of PLTP (11). 
Studies using genetically modified mouse models have 
provided more insight into the (patho-) physiological role 
of PLTP in lipoprotein metabolism and the development 
of atherosclerosis. PLTP-deficient mice have markedly re-
duced HDL levels (12). These mice are more resistant to 
atherosclerosis development; this is partly attributable to 
diminished secretion and lower levels of apolipoprotein 
B (apoB)-containing lipoproteins and to the increase in 
bioavailability of vitamin E in these particles (13, 14). 
When overexpressing human PLTP in mice, elevation of 
plasma PLTP activity levels results in a dose-dependent 
decrease in HDL levels, despite an increased production 
ofpre-j3-HDL particles (15). Hepatic VLDL secretion rates 
are increased in PLTP transgenic mice (16). We previously 
generated different mouse lines with either ubiquitous or 
liver-specific overexpression of human PLTP. Regardless of 
the site ofPLTP production, a positive correlation between 
plasma PLTP activity and atherosclerotic plaque size was 
Abbreviations: apoA-I, apolipoproteinA-I; AU, arbitrary unit; FPLC, 
.fast-protein liquid chromatography; FXR farnesoid X receptor; HFHC, 
high-fat, high-cholesterol: IAA, iodoacetate; LDLR, LDL receptor, 
mutPLTP, mutant PLTP; PLTP, phospholipid transfer protein; TC, 
total cholesterol: tg, transgenic; TG, triglyceride. 
1 To whom correspondence should be addressed. 
e-mail: m.decrom@erasmusmc.nl 
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observed, suggesting that systemic PLTP is the cause of the 
increased susceptibility to developing atherosclerosis in 
these mouse models (16). Rxactly how elev.:tted PLTP levels 
lead to increased atherosclerosis is still not fully understood. 
Until now. studies regarding the relationship between 
PLTP and atherosclerosis in mice focused on the absence of 
PLTP protein in plasma (PLTP knockout mice) or on the pres-
ence of functional PLTP with phospholipid transfer activity. 
However. in human plasma, as well as in plasma of mice 
with adenoviral overexpression of human PLTP, two forms 
ofPLTP have been described (17, 18), which may he regu-
lated differently (19). In addition to the catalytically active 
form, a low-active form Vllith unkovm function also exists. 
To provide more insight into the role of PLTP transfer ac-
tivity and PLTP mass in vivo, we generated a new mouse 
model v..rith overexpression of a mutant human PLTP pro-
tein in the liver. The mutant has previously been described 
in vitro by Huuskonen et al. (20). The mutation in the 
N-terminallipid binding pocket of the PLTP protein inter-
fered with its phospholipid transfer activity in vitro. but did 
not affect binding to HDL. Our newly developed mouse 
model e>.presses human PLTP that associates with HDL 
in plasma. but lacks phospholipid transfer activity. 
In the present study, we investigate the importance of 
PLTP transfer activity in lipoprotein metabolism, pre-13-
HDL formation, hepatic VLDL secretion, and the develop-
ment of atherosclerosis, by comparing mice expressing 
human PLTP with and without transfer activity with their 
controllittermates. 
MATERIALS AND METHODS 
Animals 
The generation of transgenic mice with liver-specific expres-
sion of human PLTP has been described previously (16). In short, 
the complete human PLTP sequence was isolated and the geno-
mic DNA sequence bet\veen the BamBI sites in exons 5 and 8 -was 
replaced by the equivalent eDNA sequence. The albumin pro-
moter and enhancer sequences were cloned into the first exon 
of the human PLTP gene, and a 6.5 kb fragment containing 
the 3 a-fetoprotein enhancer elements was cloned downstream 
from exon 16. The PLTP transgenic (PLTP tg) mice used in 
the present study are derived from the mouse line referred to 
as A3 in our previous work (16). Mutant PLTP transgenic 
(mutPLTP tg) mice were generated as described for PLTP trans-
genic mice, but a mutation >•,>as introduced in the eDNA sequence 
of the construct. The replacement of TGG nucleotides by CTT 
through PCR-based site-directed mutagenesis changed the leu-
cine residue 196 in theN-terminal pocket of PLTP into tryp-
tophan (L196W) (20). Transgenic mice were crossed into a 
C57BL/6 background for at least eight generations. Transgenic 
mice hemizygous for human PLTP or mutant human PLTP were 
crossed v.rith LDL receptor (LDLR)-deficientmice (obtained from 
Jackson Laboratory) to obtain PLTP transgenic*LDLR+/- and 
mutant PLTP transgenic*LDLR+/-, or LDLR+/- control litter-
mates. For convenience. these mice are referred to as "PLTP tg" 
mice, "mutPLTP tg" mice, and LLcontrol" mice, respectively. All 
mice used in the study were kept on regular chow diet or on an 
atherogenic high-fat, high-cholesterol (HFHC) diet containing 
40% (w/w) sucrose, 15% (w/w) cocoa butter, 1% (w/w) choles-
104 
terol, and 0.5% (w/w) cholate (diet N; Hope Farms, VVoerden, 
The Netherlands) for 13 weeks. Only male mice were used in 
the study. The mice were 10-12 weeks old at the beginning of the 
diet studies. All animals had free access to food and water. To 
perform plasma analyses, blood was collected from the orbital 
plexus after an overnight fasting period. All animal experi-
ments were carried out in compliance with national and institu-
tional guidelines. 
PLTP mRNA expression analysis 
Mter systemic perfusion of mice v.rith PBS. organs were ex-
cised, and total RNA was isolated (RNeasy mini kit, Qiagen) 
and used as a template for reverse transcription (iScript eDNA 
synthesis kit, Biorad). Quantitative PLTP RNA expression analysis 
was performed using a MyiQ 5.0 detection system (Biorad). A 
SYBR®Green PCR reagents kit (Eurogentec), and primers spe-
cific for human or murine PLTP were used (sequences available 
upon request). eDNA quantities were normalized to the amount 
of hypoxanthine-guanine phosphoribosyl transferase eDNA, 
using the .LlCt method [2(-ACt)], and presented as arbitrary units 
(AUs). Averages were taken from at least three individual runs, 
each sample in triplicate. 
PLTP activity and mass 
Plasma PLTP activity levels were determined by measuring 
the transfer of radiolabeled phospholipid from liposomes to 
exogenous HDL, as described previously ( 15), with a minor modi-
fication: liposomes were made using [14C]-labeled instead of 
[3H]-labeled phosphatidylcholine (Amersham). Plasma PLTP ac-
tivity -was e>...'Pressed as AUs, where one AU equals 13.9 mmol/1/h. 
the level of PLTP activity that is found in human reference 
plasma. To determine the transfer of cholesterol, liposomes con-
taining radiolabeled cholesterol (Amersham) were used. The 
transfer of a-tocopherol was determined using a micromethod 
\Nith reverse-phase HPLC, with detection by fluorescence at 
292/324 nm (21). 
To determine hepatic phospholipid transfer activity levels, liv-
ers of PLTP tg, mutPLTP tg, and control mice were perfused in situ 
with ice-cold PBS, after which a section of approximately 0.2 gwas 
homogenized in a buffer containing 50 mmol/1 Tris-HCl 
(pH 7.4), 5 mmol/1 EDTA, and 250 mmol/1 sucrose. After centri-
fugation (16,000 g, 10 min, 4°C), supernatant vvas collected and 
phospholipid transfer activity -was determined using the same pro-
tocol as for plasma PLTP. PLTP activity -was calculated per milli-
gram liver tissue, and expressed as AU. Hepatic phospholipid 
transfer activity of PLTP-;- mice (kindly donated by Dr. X-C. 
Jiang, Brooklyn, NY) was subtracted in order to e;...press PLTP-
specific activity. 
Human PLTP mass in plasma was measured as described pre-
viously (22), using a sandwich-type ELISA using two monoclonal 
antibodies with specificity for human PLTP. The concentration of 
plasma PLTP \'las expressed as micrograms/milliliter. 
Separation of plasma lipoproteins 
Plasma HDL fractions and non-HDL fractions were separated 
by ultracentrifugation of freshly isolated plasma samples at a den-
sity of 1.063 g/ml as described previously (16). Lipoprotein size 
distribution was determined by gel filtration chromatography. 
Plasma samples from 10 to 15 mice were pooled and passed 
through a 0.45 IJ.ffi filter (Millipore), and 0.5 ml -was applied onto 
a fast-protein liquid chromatography (FPLC) system containing a 
Superdex 200 prepgrade column and a Superose fi prepgrade 
column connected in tandem. Columns were equilibrated with 
buffer containing 65 mmol/1 sucrose, 225 mmol/1 mannitol, 
10 mmol/1 Tris-HCl (pH 8.1), 5 mmol/1 EDTA. and 0.02% 
NaN3 to obtain optimal PLTP recovery (23). After running (at 
4°C, 0.1 ml/min), 0.8 ml fractions were collected and analyzed 
for total cholesterol (TC} levels and PLTP mass. 
Plasma liver lipid analyses 
For the measurement of TC, a Free Cholesterol C kit from 
Wako was used, with cholesterol esterase from Candida cylindracea 
(Boehringer-Mannheim) to hydrolyze cholesteryl esters. Phos-
pholipids were measured enzymatically vvith a PAP150 kit from 
BioMhiem..::. Triglycerides (TGs) were determined using a triglyc-
eride kit from Wako. 
Determination of pre-!3-HDL levels and formation 
Pre-~-HDL levels were determined by crossed immunoelectro-
phoresis. Plasma samples were incubated for 5 h at 37°C in the 
presence of 1 mmol/1 iodoacetate (IAA) to inhibit LCAT activity. 
or kept at 4°C in the absence of IA.A. Five microliters of plasma 
was loaded per welL First-dimension agarose gel (1 %) electro-
phoresis separated lipoproteins with pre~~ and a.-mobility under 
nonreducing, nondenaturing conditions and low ionic strength. 
Second-dimension electrophoresis in a 1% agarose gel contain-
ing 7.5% polyclonal rabbit anti-mouse apoA-1 antiserum quanti-
fied apoA-1 in the samples. Gels were stained with Coomassie 
Brilliant Blue R250 and dried. Areas under pre-f3- and a-HDL 
peaks were calculated for each condition. The relative pre-f3-
HDL area was expressed as a percentage of the total HDL area. 
Pre-f3-HDL formation was determined as the difference bet\Veen 
relative pre-f3-HDL levels with and without incubation with IAA 
VLDL secretion experiments 
Following an overnight fasting period, mice were injected in-
travenously with 10% (w/v) Triton WR1339 (Tyloxapol. Sigma) 
dissolved in PBS. at a concentration of 500 mg/kg body weight. 
At different time points after injection, blood samples were taken 
from the orbital ple::-.."Us, and plasma TG levels were determined as 
described above. The rate of TG secretion was calculated from 
the TG accumulation in time, and expressed as mmol/1/min. 
Quantification of atherosclerotic plaque size 
Mter 13 weeks of the HFHC diet, mice were euthanized. Perfu-
sion of hearts was performed in situ, vvith subsequent fixation 
using 4% PBS-buffered formalin. The hearts with aortic arch were 
excised and processed for cryosectioning. Serial 7 f.LID-thick sec-
tions of the valves in the aortic root were stained with Oil Red 0 
and Mayer's hematoxilin. Atherosclerotic lesion area was mea-
sured in five sections at intervals of90 J..Lm using image processing 
by National Institutes of Health-based Scion Image and analy.ling 
software (www.scioncorp.com) according to Paigen et al. (24). 
Mean lesion area per section was calculated for each mouse, 
and expressed as J..Lm2 • 
Statistics 
All values are expressed as mean ± SD. Differences were 
anayzed by two-sample Wilcoxon rank sum tests using Inter-
cooled Stata 8.2/SE sofnvare (Stata Corporation, College Station, 
TX). Statistical significance was assumed when P < 0.05. 
RESULTS 
R'q>ression of human PLTP in transgenic mice 
To investigate the role of PLTP-mediated phospholipid 
transfer in vivo, the effects of overe::-..-pressing human PLTP 
PLTP activity is essential for atherogenicity ofPLTP 
with transfer activity and mutant human PLTP "Without 
transfer activity were compared in mice with an LDLR+/-
background (PLTP tg and mutPLTP tg mice, respectively). 
First, we analyzed PLTP eA-pression in PLTP tg, mutPLTP tg, 
and control (LDLR+/-) mice. 
RNA of different tissues (liver, lung, spleen, kidney, 
adrenals, and adipose tissue) was isolated and mRNA ex-
pression of murine and human PLTP was determined by 
real-time PCR Human PLTP was e;,'Pressed specifically in 
the liver of PLTP transgenic mice, whereas endogenous 
PLTP was e>.'Pressed in all tissues tested (not shown). The 
overexpression of human PLTP in the liver did not affect 
endogenous PLTP mRNA levels, because these were not 
different between groups (Fig- lA). 
To check whether an increased PLTP e>.'Pression in the 
liver was associated with changes in phospholipid transfer 
activity, we measured hepatic PLTP activity. PLTP activity 
in the livers of PLTP tg mice was approximately 2.5-fold 
higher than in mutPLTP tg and control mice. MutPLTP tg 
and control mice showed comparable activity levels (Fig. 1B). 
Because PLTP is a protein secreted by the liver cells into 
the plasma, we quantified human PLTP protein levels as 
well as total PLTP activity levels in the mouse plasma. Be-
cause the assay to determine PLTP mass detects exclusively 
human PLTP, no signal was found in plasma from control 
mice. PLTP mass in mutPLTP tg mice was higher than in 
PLTP tg mice (Fig. 1C). Total plasma PLTP activity in PLTP 
tg mice was 2.9-fold higher than in control mice, whereas 
in mutPLTP tg mice, it did not exceed the endogenous 
mouse PLTP activity level (Fig. 1D). In addition to the re-
duced transfer activity of phospholipids, the transfer activ-
ity of cholesterol and a-tocopherol in plasma of mutPLTP 
tg mice was decreased compared with PLTP tg mice ( cho-
lesterol transfer in mutPLTP tg mice: 30% of transfer in 
PLTP tg mice; a-tocopherol transfer: 22% of transfer in 
PLTP tg mice; both P< 0.05), indicating that the mutation 
does not selectively affect phospholipid transfer. 
Effect of PL TP transfer activity on lipid metabolism 
To determine whether the mutation influenced the abil-
ity of PLTP to associate with HDL, plasma lipoproteins 
were separated by FPLC, and TC as well as human PLTP 
mass were measured in the different fractions (Fig- 2A). 
Two major cholesterol peaks were distinguished in the 
plasma of both transgenic mouse groups, one peaking in 
fraction 8 and another in fraction 15, representing LDL 
and HDL particles, respectively. In both mouse models, 
human PLTP mass peaked in fractions 11-13, where a sub-
fraction of large HDL particles, carrying PLTP, is present. 
These findings indicate that the in vivo association of PLTP 
protein with HDL particles was not affected by the mutation. 
We stndied the physiological role of PLTP transfer activ-
ity in lipid metabolism. TC, phospholipid, and TG were 
measured in total plasma samples and in plasma subfrac-
tions obtained after ultracentrifugation. Consistent with 
earlier findings, PLTP tg mice showed markedly decreased 
TC and HDL-<:holesterol (HDL-C) levels compared with 
control mice (Table 1). In mutPLTP tgmice however, lipid 
values did not differ from those of control littermates. Gel 
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Fig. 1. Phospholipid transfer protein (PLTP) e"pression. A: Hepatic 
PLTP mRNA. The expression of human and mouse PLTP in livers of 
PLTP transgenic (PLTP tg), mutantPLTP transgenic (mutPLTP tg), 
and control mice was analyzed by real-time PCR. Values are ex-
pressed as arbitrary units (A Us) ± SD, n = 4 per group. B: Hepatic 
PLTP activity. PLTP activity in the liver is represented as the total 
phospholipid transfer activity in 1 mg liver tissue subtracted from 
the phospholipid transfer activity found in 1 mg liver tissue 
of PLTP-deficient mice. Values are expressed as AUs ± SD, n = 
4-11 per group.* P< 0.05; NS, not significant C: PlasmaPLTP mass. 
Human PLTP protein was quantified using a sandffich-type ELISA. 
Values are eApressedas f.Lg/ml ± SD, n = 17-20 per group. D: Plasma 
PLTP activity. Values are expressed as AUs ± SD, n = 16-20 per 
group. *P< 0.001; NS, not significant 
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Fig. 2. Total cholesterol (TC) and PLTP distribution among plasma 
lipoprotein particles. Pooled plasma ofPLTP tg, mutPLTP tg, and con-
trol mice (n = 10-15 per group) was subjected to fast-protein liquid 
chromatography (FPLC). A: TC (circles) and PLTP mass (triangles) 
in the FPLC fractions. Values are represented as fractional per-
centages of total amount ofTC and PLTP mass measured in the col-
umn eluate. B: TC among lipoprotein particles in PLTP tg (circles), 
mutPLTP tg (triangles), and control mice (squares) onachoworhigh-
fat, high-cholesterol (HFHC) diet. values are e)-pressed as mmol/1. 
filtration profiles confirmed these findings (Fig. 2B; upper 
graph). The same was found for phospholipid levels, 
whereas plasma TG levels were not different among the 
three groups (data not shown). To investigate whether 
the liver-specific overe·•·"Pression of human PLTP in mice 
has consequences for liver lipid levels, cholesterol, phos-
pholipid, and TG levels were determined in liver extracts. 
No significant differences betw"een the mouse groups were 
observed (data not shown). 
Effect of PLTP transfer activity on pre-!3-IIDL formation 
and VIJ)L secretion 
Previous studies have shown that PLTP enhances the for-
mation of pre-!3-HDL particles (15). To investigate the im-
portance of PLTP transfer activity in this process, total 
plasma was incubated for 5 h with iodoacetic acid, an LCAT 
inhibitor, after which crossed immunoelectrophoresis ex-
TABLE!. Plasma total cholesterol 
HFHCdiet 
0 Weeks 5 Weeks 13 Weeks 
mnwl/l 
Plasma TC 
PLTP tg 1.54 ± 0.24a,b 9.90 ± 1.92 11.55 ± 3.74 
MutPLTP tg 3.54 ± 0.36 11.61 ± 1.65 9.68 ± 2.38 
Control 3.64 ± 0.49 11.10 ± 2.33 10.36 ± 2.86 
HDL-C 
PLTP tg 0.65 ± O.lS"·b 0.31 ± 0.05<1,1> 0.30 ± 0.11 a,b 
MutPLTP tg 2.10 ± 0.31 1.02 ± 0.29 1.18 ± 0.57 
Control 2.18 ± 0.41 1.27 ± 0.31 1.38 ± 0.57 
non-HDL-C 
PLTP tg 0.73 ± 0.24 9.01 ± 1.72 11.24 ± 3.81 
MutPLTP tg 1.06 ± O.o7 9.66 ± 2.17 8.34 ± 2.18 
Control 0.96 ± 0.12 9.24 ± 2.01 8.79 ± 2.87 
HFHC, high-fat, high-cholesterol; TC, total cholesterol; PLTP, 
phospholipid transfer protein; PLTP tg, PLTP transgenic; mutPLTP 
tg, mutant PLTP transgenic; HDL-C, HDL cholesterol. Values are ex-
pressed as mean ± SD. 
"P < 0.001 compared with control mice. 
b P < 0.001 compared with mutPLTP tg mice. 
periments were performed and mouse apoA-I was visualized 
(Fig. 3). In the absence of IAA, no pre-[3-HDL could be 
detected in plasma (not shown). Mter incubation, 3.1% 
of total apoA-I was found in the pre-[3-HDL subfraction 
in control mice (Fig. 3C) and 3.9% in mutPLTP tg mice 
(Fig. 3B), whereas in the PLTP tg mice, pre-[3-HDL repre-
sented 28.1% of total plasma apoA-I (Fig. 3A), demonstrat-
ing the importance of active plasma PLTP for the production 
ofpre-[3-HDL. 
To investigate the contribution of PLTP activity to the 
increased secretion of apoB-containing lipoproteins in 
mice with overexpression of PLTP, we performed VLDL-
TG secretion eA'Periments in vivo. As e:x.'Pected, TG secretion 
rates in PLTP tg mice were increased (1.4-fold) compared 
with those in control mice (Fig. 4). In contrast, mutPLTP tg 
mice without enhanced PLTP transfer activity did not stim-
ulate VLDL secretion compared with control littermates. 
These findings show the role of active PLTP in hepatic 
VLDL secretion, whereas inactive PLTP has no effect. 
PLTP activity is essential for atherogenicity of PLTP 
* 
* 
Fig. 4. Hepatic triglyceride (TG) secretion. Plasma TG levels wen 
measured in plasma ofPLTP tg (n = 6), mutPLTP tg (n = 23), anc 
control mice (n = 12), at different time points after injection oJ 
mice with Triton WR1339. TG secretion rate was calculated usin~ 
the slope of plasma TG secretion over time. Values are e),.'Pressec 
as mmol/l/min :±: SD. *P < 0.005; NS, not significant 
Effect of PL TP transfer activity on plasma lipids and the 
development of atherosclerosis in mice on a HFHC diet 
To study whether PLTP activity influences the develop 
ment of atherosclerosis, mice were fed a HFHC, cholate· 
containing diet for 13 weeks. At regular time points afte1 
starting the diet, a blood sample was taken and lipid ana, 
lyses were performed. Mter 13 weeks, mice were eutha· 
nized and the extent of atherosclerosis was quantified 
The cholesterol-enriched diet increased TC and non· 
HDL-C, whereas it decreased HDL-C in all mice. PLTP tg 
mice showed a more profound decrease in HDL-C than did 
mutPLTP tg mice or control littermates (Table 1; Fig. 2B) 
PLTP activity was increased 1.5- to 2.5-fold in hyperlipidemic 
mice compared with mice on a chow diet (P < 0.05). The 
diet also induced PLTP mass levels, 1.5- and 1. 7-fold in PLTI 
tg and mutPLTP tg mice, respectively (P < 0.05). Mter in· 
cubating plasma of hyperlipidemic mice for 5 h, pre-[3-HDI 
levels (relative to total plasma HDL) increased by 13% i" 
control mice (Fig. 5F versus 5C) and 15% in mutPLTP tE 
mice (Fig. 5E versus 5B). In PLTP tg mice, the formation ol 
pre-[3-HDL increased by 50%, and pre-[3-HDL levels, whid 
were already high before incubation, were dose to 100% oJ 
total plasma HDL after incubation (Fig. 5D versus 5A). The 
PLTPtg mutPLTP tg control 
Fig. 3. Pre~~?»-HDL formation in mice on chow diet. Plasma ofPLTP tg (A), mutPLTP tg (B), and control 
mice (C) was incubated with 1 mM iodoacetate (IAA) for 5 h at 37°C and subjected to crossed immuno-
electrophoresis. Three to five mice per group were analyzed; one representative gel per group is shown. 
a- and pre~~?rmobility of the HDL particles are indicated in A 
107 
Chapter4 
PLTPtg mutPLTP tg control 
4•c 
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Fig. 5. Pre-~-HDL levels and formation in mice fed a HFHC diet. Plasma ofPLTP tg (A. D). mutPLTP tg 
(B, E), and control mice (C, F) fed a HFHC diet for 13 weeks, was either kept at 4°C (upper panels), or 
incubated with 1 mM IAA for 5 h at 37°C (lower panels), after which it was subjected to crossed 
immunoelectrophoresis. Three to five mice per group were analyzed; one representative gel per group is 
shown. a.- and pre-[3-mobility of the HDL particles are indicated in A. 
capacity of total plasma of hyperlipidemic mice to accept 
cholesterol from loaded macrophages in vitro, as investi-
gated in cholesterol e:ffllL-x e:x.'Periments .. was not different 
among the three groups (data not shown). 
Finally, atherosclerotic lesion development was ana-
lyzed at the aortic valves. The overexpression of PLTP in 
PLTP tg mice increased the development of atheroscle-
rotic lesions more than 2-fold compared with control mice 
(Fig. 6). In mice with overexpression of the mutant 
PLTP, atherosclerotic plaque sizes were not significantly 
different from those observed in control mice. These 
findings demonstrate that overexpression of PLTP with 
transfer activity accelerates the development of athero-
sclerosis, whereas mutant PLTP lacking transfer activity 
does not. 
DISCUSSION 
In human plasma, a low-active form of PLTP has been 
described in addition to the high-active form (18). The 
role of this low-active PLTP, however, is not well under-
stood. In a Japanese cohort study, a possible protective role 
for serum PLTP mass in coronary heart disease was indi-
cated. independent of PLTP activity (25). Recently. it was 
published that distribution of PLTP between high-activity 
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and low-activity forms may be disturbed in peripheral ar-
terial disease (26). The few existing studies regarding the 
relationship between plasma PLTP activity and cardio-
vascular disease in humans show contradictory findings. 
Whereas Schlitt et a!. (27) identified PLTP activity as an 
independent predictive value for coronary artery disease, 
others found variable relationships between PLTP activity 
and peripheral artery disease (26, 28). 
In the present study, we aimed to elucidate the role of 
plasma PLTP transfer activity in 1) the modulation ofHDL 
levels, 2) pre-!3-HDL formation, 3) hepatic VLDL secre-
tion, and 4) the development of atherosclerosis in PLTP 
transgenic mice. Hence, we generated a mouse model with 
liver-specific expression of a mutant human PLTP protein, 
associating with HDL particles in plasma and lacking phos-
pholipid transfer activity, and cross-bred the animals in 
an LDL +/- background. 
The liver-specific expression is the consequence of a 
PLTP transgene driven by the albumin promoter with en-
hancers. A similar construct was used in previous studies 
for the generation of PLTP tg mice ( 16). These PLTP tg 
mice developed similar levels of atherosclerosis compared 
with mice with equal plasma PLTP activity levels as a result 
of ubiquitous expression of human PLTP, showing that in-
creased atherosclerosis development was caused by plasma 
PLTP activity. Therefore, the PLTP effects we evaluated in 
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Fig. 6. Atherosclerotic lesion development Atherosclerotic lesion 
development was induced in PLTP tg (n = 11). mutPLTP tg (n = 20), 
and control (n = 13) mice by feeding a HFHC diet for 13 weeks. 
Cross sections of the aortic root were stained with Oil Red 0 to vi-
sualize the accumulation of lipids. A: Atherosclerotic lesion area of 
aortic valves, expressed as !J..m2 X 10·1 per section. Circles indicate 
individual lesion areas; horizontal lines indicate the mean lesion 
area per group. *P < 0.001; NS. not significant B: Representative 
aortic root cross sections. 
the present study represent systemic effects. caused by 
PLTP secreted by hepatocytes into the plasma. 
We focused on the role of PLTP transfer activity in vivo 
by introducing the Ll96W mutation in the PLTP protein, 
based on a study from Huuskonen et a!. (20). This mu-
tation at the N-terminal lipid binding pocket of PLTP 
resulted in a decreased phospholipid transfer activity, with-
out affecting the HDL binding characteristics of the pro-
tein. In plasma, PLTP is found associated with plasma 
HDL particles (29, 30). Therefore, when studying the role 
of PLTP activity in lipoprotein metabolism and athero-
genesis, it is important to use a mouse model in which 
the mutation specifically affects the phospholipid transfer 
activity but not the PLTP-HDL association. 
PLTP is a well-known HDL conversion factor. It remod-
els HDL with the generation of large a-HDL particles and 
small lipid-poor pre-13-HDL, by a mechanism that involves 
fusion of unstable HDL particles and displacement oflipid-
poor apoA-I molecules in vitro (8, 31). HDL-associated 
PLTP has been shown to be an important regulator of 
plasma HDL levels in vivo. In PLTP transgenic mice, catabo-
lism of HDL particles is enhanced (32). thereby decreasing 
PLTP activity is essential for atherogenicity ofPLTP 
plasma HDL levels. In the present study, we showed that 
this PLTP-dependent HDL-lowering effect requires in-
creased PLTP transfer activity, and should therefore be dis-
tinguished from increased HDL catabolism leading to 
reduced HDL levels in PLTP-deficient mice. As revealed 
by crossed immunoelectrophoresis, the reduction in HDL 
levels in PLTP tg mice is mainly due to a decrease in a-
migrating HDL particles. In addition to its effect on the 
catabolism of mature HDL particles. PLTP plays a role in 
the formation of pre-13-HDL particles, which also requires 
PLTP transfer activity. The PLTP effects on the distribution 
and levels of a- and pre-13-HDL were more pronounced 
when mice were fed a HFHC diet. This could be explained 
by the increased PLTP levels found in mice fed a high-fat 
diet As a reaction to cholesterol loading, the production 
of pre-13-HDL might be stimulated, inasmuch as pre-13-
HDL has been shown to be an excellent acceptor of choles-
terol (33). We found that the capacity of total plasma of 
hyperlipidemic mice to accept cholesterol from loaded 
macrophages in vitro was not different among the three 
groups. The decreased a-HDL levels in plasma of PLTP tg 
mice may compensate for the increased pre-13-HDL levels 
regarding its role in cholesterol effiu.x in vitro. The role 
of systemic PLTP in cholesterol efflu.-x in vivo is yet to be de-
termined. The big decrease in a-HDL may override the po-
tentially athero-protective effect of increased pre-13-HDL 
levels in PLTP tg mice in vivo. 
When measuring hepatic phospholipid transfer activity. 
we found an increase in PLTP tg mice, possibly e· .. '-plaining 
the increase in VLDL secretion in these mice. In contrast. 
in mice expressing the mutated form of PLTP, neither 
hepatic phospholipid transfer activity nor VLDL secretion 
was altered compared with controls. Elevation of PLTP ac-
tivity in the liver was not associated with differences in liver 
lipids, suggesting that hepatic PLTP is of minor impor-
tance for lipid homeostasis in the liver of PLTP transgenic 
mice. Moreover, in PLTP-deficient mice, hepatic phospho-
lipid transfer activity is about 75% of the activity measured 
in wild-type mice (data not shown). This is not surprising, 
inasmuch as several other hepatic proteins able to transfer 
various types of phospholipids have been described (34). 
Finally, we determined the importance of PLTP activ-
ity for the development of atherosclerosis in mice fed 
a cholesterol-enriched, cholate-containing diet. In the 
mutPLTP tg mice, the extent of atherosclerosis was com-
parable to that in the controllittermates. In PLTP tg mice, 
however, increased atherosclerotic lesion sizes were found, 
consistent with earlier findings in mice overexpressing 
human PLTP (10, 16). The presence of cholate in the diet 
has been shown to regulate PLTP gene expression in vivo 
by the nuclear famesoid X receptor (FXR). because the 
PLTP promoter contains an FXR response element (35). 
However, because we used an albumin promoter to gener-
ate our transgenic mouse models, it is not likely that plasma 
levels of human PLTP are affected by cholate feeding. 
Endogenous PLTP is possibly regulated by the cholate, 
but we expect that mouse PLTP levels were affected to 
the same extent in all mice. A limitation in our study is 
the presence of mouse PLTP, with activity, in all mice. 
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Whether PLTP mass, in the absence of any transfer activity, 
contributes to atherosclerosis development should be inves-
tigated in additional studies in mice by crossing the mice 
into a PLTP knockout background However, we do not ex-
pect endogenous PLTP to influence our findings, inasmuch 
as plasma lipoprotein levels in mutPLTP tg*PLTP-/- mice 
are not different when compared with those in PLTP-;-
rnice (data not shown). 
An important issue is how increased PLTP expression 
stimulates atherosclerosis. Elevation of PLTP activity 
(2.9-fold) results in HDL hypercatabolism and enhanced 
hepatic VLDL secretion. Both aspects may be important 
in the process of atherogenesis, and our present results 
suggest that PLTP transfer activity is required for these ef-
fects. In addition to the PLTP-mediated phopholipid trans-
fer, the transfer of cholesterol and a-tocopherol was also 
inhibited. These transfer activities could account, at least 
in part, for the pro-atherogenic potential of PLTP in vivo. 
In addition, O'Brien et al. (36) suggested that PLTP may 
be pro-atherogenic by acting as a bridging protein be-
tween lipoproteins and biglycan, one of the major extra-
cellular proteoglycans found in human atherosclerotic 
lesions. It is well known that rete:ntion of lipoproteins by 
extracellular matrix molecules is critical in the pathogen-
esis of atherosclerosis ( 36, 37). This bridging effect of 
PLTP has been shown to be independent of its phospho-
lipid transfer activity in vitro (36). Furthermore, over the 
last 2 years, much attention has been paid to the function-
ality of PLTP in macrophages (38~40). However, results 
between different studies were contradictory, illustrating 
the complexity of the in vivo sitnation. Whereas Vikstedt 
et al. ( 40) demonstrated that PLTP deficiency in macro-
phages resulted in reduced plasma PLTP activity levels 
and a decreased atherosclerotic lesion development, two 
other research groups found an increased atherosclerosis 
development despite lower plasma PLTP activity levels, 
and suggested an atheroprotective role for macrophage-
derived PLTP (38, 39). The relative contribution of sys-
temic PLTP effects and local PLTP effects to atherosclerosis 
development remains unclear, and a balance between pro-
and anti-atherogenic properties of PLTP might determine 
the impact ofPLTP on atherosclerosis. In the present stndy, 
we showed the importance of plasma PLTP activity in the 
process of atherosclerosis development. Whether PLTP acts 
as a ligand binding to vascular proteoglycans, playing a role 
in the retention of HDL, and whether PLTP activity is re-
quired for local PLTP functions within the artery wall, 
needs further investigation. The use of an adapted version 
of our mutant PLTP mouse model, allowing eA'Pression of 
inactive PLTP in different tissues, might be very informative 
for future studies. 
In conclusion, this study defines the contribution of 
PLTP transfer activity in plasma to atherogenesis in PLTP 
transgenic mice. Inhibitors of plasma PLTP activity could 
prevent atherosclerosis development in humans with ele-
vated PLTP activity levels.!llll 
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Abstract In low density lipoprotein receptor (LDLR)-defi-
cient mice, overe,.:pression of human plasma phospholipid 
transfer protein (PL TP) results in increased atherosclero-
sis. PLTP strongly decreases HDL levels and might alter the 
antiatherogenic properties of HDL particles. To study the 
potential interaction between human PL TP and apolipo-
protein A-I (apoA-I), double transgenic animals (hPLTPtg/ 
hApoAltg) were compared with hApoAltg mice. PLTP ac· 
tivity was increased 4.5-fold. Plasma total cholesterol and 
phospholipid were decreased. Average HDL size (analyzed 
by gel filtration) increased strongly, hPLTPtg/hApoAltg mice 
having very large, LDLsized, HDL particles. Also, after den-
sity gradient ultracentrifugation, a substantial part of the 
apoA-I-containing lipoproteins in hPLTPtg/hApoAltg mice 
was found in the LDL density range. In cholesterol efflux 
studies from macrophages, HDL isolated from hPLTPtg/ 
hApoAltg mice was less efficient than HDL isolated from 
hApoAitg mice. Furthermore, it was found that the largest sub-
fraction of the HDL particles present in hPL TPtg/hApoAitg 
mice was markedly inferior as a cholesterol acceptor, as 
no labeled cholesterol was transferred to this fraction. In 
an LDLR-deficient background, the human PLTP-expressing 
mouse line showed a 2.2-fold increased atherosclerotic lesion 
area.IUII These data demonstrate that the action of human 
PLTP in the presence of human apoA-I results in the for-
mation of a dysfunctional HDL subfraction, which is less 
efficient in the uptake of cholesterol from cholesterol-laden 
macrophages.-Moerland, M., H. Samyn, T. van Gent, M. 
Jauhiainen,J. Metso, R van Haperen, F. Grosveld, A. van To!, 
and R. de Cram. Atherogenic, enlarged, and dysfunctional 
HDLinhuman PLTP /apoA-I double transgenic mice.]. Lipid 
Res. 2007. 48: 2622-2631. 
Supplementary key words phospholipid transfer protein • apolipo-
protein A-1 • cholesterol • high density lipoprotein • low density lipo-
protein • atherosclerosis • lipoprotein metabolism 
The incidence of coronary heart disease shows a strong 
inverse relationship with the concentration of plasma HDL 
Manuscript received 16January 2007 and in revised form 6 April2007 and 
in re-revised form 28 June 2007 and in re-re-revised form 28 August 2007. 
Published, JLR Papers in Press, August 29, 2007. 
DOl I0.1194/jlr.M700020.]LR200 
(1). Therefore, HDL is believed to have antiatherogenic 
properties, which are attributed to its effects on endothe-
lial cells, its antioxidant activity, and its role in reverse 
cholesterol transport, a pathway in which peripheral cellu-
lar cholesterol is transported to the liver (2-4). One im-
portant determinant of the plasma HDL concentration is 
phospholipid transfer protein (PLTP) activity. During lipol-
ysis, PLTP transfers phospholipids from apolipoprotein B-
containing lipoproteins to HDL (5). Furthermore, PLTP 
acts as an HDL conversion factor by remodeling HDL to 
produce large particles and small lipid-poor particles, known 
as prei3-HDL (6-9). The latter HDL subfraction is a very 
efficient acceptor of cellular cholesterol. In this way, PL TP 
plays an important role in the early steps of reverse cho-
lesterol transport (10-12). 
Although the involvement ofPLTP in the cellular efflux 
of cholesterol and phospholipids is potentially antiathero-
genic, different in vivo studies showed that an increase in 
plasma PL TP activity is associated with decreased HDL 
cholesterol levels (9, 13, 14) and increased atherosclerotic 
lesion development (15-17). The PLTP-dependent de-
crease in HDL levels was explained by an accelerated HDL 
catabolism (13). In addition to its effect on HDL choles-
terol levels, PLTP may alter the antiatherogenic proper-
ties of HDL particles. For example, anti-inflammatory 
properties ofHDL were improved in PLTP-deficient mice 
(18). To study the action of increased PLTP levels on 
HDL particles in more detail, we cross-bred human PLTP 
transgenic mice with human apolipoprotein A-I (apoA-I) 
transgenic mice, resulting in mice expressing both human 
PL TP and human apoA-1. Previous studies in transgenic 
mice showed that introduction of the human apoA-I 
transgene affected HDL subfraction distribution (19, 20). 
Expression of human apoA-1 resulted in conversion of the 
Abbreviations: AcLDL, acetylated low density lipoprotein; apoA-I, 
apolipoprotein A-I: CE, cholesteryl ester; CETP, cholesteryl ester trans-
fer protein; FPLC, fast-protein liquid chromatography; LDLR, low den-
sity lipoprotein receptor; PLTP. phospholipid transfer protein. 
1 To whom correspondence should be addressed. 
e-mail: m.decrom@erasmusmc.nl 
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normal relatively homogeneous mouse HDL population 
to a more heterogeneous population consisting of differ-
ent HDL subclasses. 
This difference in plasma HDL distribution may be 
caused by differences in physical properties between mouse 
and human apoA-I (i.e., molecular properties in solution, 
incorporation into discoidal complexes, structural stabil-
ity in HDL particles) (21). PLTP binds directly to apoA-I 
found on the surface of HDL particles (22). The specificity 
of the interaction betv.reen protein (such as transfer pro-
tein or enzyme) and HDL might strongly influence the 
action of the protein itself. For example, cholesteryl ester 
transfer protein (CETP) has a much more profound effect 
on HDL cholesterol levels in transgenic mice when human 
apoA-1 is expressed as well, as a result of an enhanced in-
teraction of CETP with human apoA-I compared with mouse 
apoA-I (23). In transgenic mice expressing both human 
LCAT and human apoA-I, human LCAT has a significant 
preference for HDL containing human apoA-I (24). 
In the present study. we investigated whether the ac-
tion of human PLTP in the presence ofHDL containing 
human apoA-I is altered compared with the situation when 
only mouse apoA-1 is present. In a human apoA-1 transgenic 
mouse model, we studied the effect of the introduction of 
the human PLTP transgene on different HDL properties: 
particle size and density and the ability to induce choles--
terol efflux from peritoneal macrophages. In addition, the 
effect of the introduction of the human PLTP gene on 
atherosclerotic lesion development was determined in low 
density lipoprotein receptor (LDLR)-<leficient mice expres-
sing human apoA-1. 
MATERIALS AND METHODS 
Animals 
Human PL TP transgenic mice were described previously (9). 
In this study, we used mice with a human genomic PLTP con-
struct in which PLTP expression is controlled by its native pro-
moter. resulting in a moderately increased PLTP activity (line P4) 
(16). Human apoA-1 transgenic mice (19) and LDLR-deficient 
mice were purchased from Jackson Laboratory. All mice were 
crossed for > 15 generations to a C57Bl/6J background. Hu-
man PLTP transgenic mice were cross-bred with human apoA-I 
transgenic mice to obtain hPLTPtg/hApoAitg mice, hemizy-
gous for both transgenes. As a control. hemizygous hApoAitg 
mice were used. For the atherosclerosis experiments, hApoAitg 
mice and hPLTPtg/hApoAitg mice were cross-bred with LDLR 
knockout mice to obtain hApoAitg/LDLR-;- and hPLTPtg/ 
hApoAitg/LDLR~;- mice. For determination of the genotype. 
genomic DNA was isolated from tail clips of 10 day old mice 
and analyzed by PCR Annealing temperatures and primer se-
quences are available upon request. 
Male mice were used in all experiments. After weaning, ani-
mals were fed a standard chow diet. E.xperiments in the hApoAitg 
and hPLTPtg/hApoAitg mice were performed at an age bet:v-/een 
10 and 15 weeks. The development of atherosclerosis was stud-
ied in hApoAitg/LDLR-;- and hPLTPtg/hApoA!tg/LDLR-/-
mice. Animals berneen 10 and 15 weeks of age were put on a 
high-fat/high-<:holesterol diet [40% (w/w) sucrose, 15% (w/w) 
fat, and 1% (w/w) cholesterol; Hope Farms] for 9 weeks. Ani-
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mals had free access to water and food. Blood samples were col-
lected by orbital bleeding after fasting the animals overnight. All 
procedures in this study were in accordance -with national and 
institutional guidelines. 
Plasma PL TP activity 
PLTP activity was measured using a phospholipid vesicle-
HDL system according to Speijer et al. (25). PLTP activity is ex-
pressed as arbitrary units. One arbitrary unit is equal to the level 
of PLTP activity found in human reference plasma, which was 
13.9 fLmOl/ml/h. 
Quantification of plasma lipids and apoA-1 
Total cholesterol concentration was determined enzymati-
cally using a free cholesterol C kit (Wako) after hydrolysis of 
cholesteryl esters {CEs) 'ivith cholesterol esterase from Candida 
cylindracea {Boehringer). Triglycerides were measured using a 
triglyceride kit from Wako. Phospholipids were measured using 
the PAP150 kit from BioMerieu.x. 
Quantification of prej3-HDL by 
crossed immunoelectrophoresis 
In pooled plasma samples obtained from 8-10 mice, prel3- and 
a.-migrating HDL were separated by agarose gel electrophoresis 
under nonreducing, non denaturing conditions as described pre-
viously (9). Proteins were transferred to nitrocellulose mem-
branes by capillary blotting, and human apoA-I was detected 
using an anti-human apoA-1 antibody. 
Plasma lipoprotein profiles by gel filtration 
Lipoprotein profiles in EDTA-plasma were obtained using 
HR 10/30 fast-protein liquid chromatography (FPLC) columns 
in tandem that were fi11ed -with Superose 6 and Superose 12 
(preparation grade; Pharmacia Biotechnology). Columns were 
equilibrated and run in a 2 mM phosphate buffer containing 
0.9% (w/v) NaG!, 0.02% (w/v) NaN3, and 5 mM EDTA (pH 7.4). 
Pooled plasma samples obtained from 8-10 mice were filtered 
through 0.45 fLm filters (Millipore). A total of 0.5 m1 of plasma 
"\\'aS loaded onto the Superose 6 column. The separation was per-
formed at4°C -with a flow rate ofO.l ml/min. Fractions of0.8 ml 
were collected for measurements of cholesterol and phospholipids. 
Plasma lipoprotein profiles by density gradient centrifugation 
Individual plasma samples freshly isolated from hApoAitg 
mice and hPLTPtg/hApoAitg mice were pooled (at least 10 mice 
per pool) and subjected to density gradient ultracentrifugation 
in a Beckman SW60 Ti rotor, adapted from the method described 
previously by Redgrave, Roberts, and West (26), at the follow-
ing densities: d < 1.006 (normally corresponding to VLDL), 
1.006 < d < 1.019 (intermecliate density lipoprotein), 1.019 < d < 
1.063 (LDL), 1.063 < d < 1.21 (HDL), and d > 1.21 (proteins). 
Protein analysis of FPLC fractions 
To determine the protein components of lipoprotein frac-
tions, FPLC fractions were subjected to electrophoresis on 4-15% 
SDS-polyacrylamide gels (Bio-Rad) (27), which were subsequently 
stained with Coomassie Brilliant BlueR {Sigma) or with the Silver 
Stain Plus Kit (Bio-Rad). 
Cholesterol efflux experiments with mouse 
peritoneal macrophages 
We determined the ability of isolated mouse HDL to induce 
the effllLX of cholesterol from acetylated low density lipoprotein 
(AcLDL)-loaded peritoneal macrophages. AcLDL was prepared 
by isolation of LDL from human plasma by differential centri-
fugation (density range, 1.019-1.063), followed by acetylation 
by means of repeated addition of acetic anhydride. C57Bl/6J 
mice were elicited by intraperitoneal injection of2 ml of 40.5 g/1 
Bacto® Brewer Thioglycollate Medium (Sigma) according to 
the manufacturer's instructions. Mter 3 days, peritoneal macro-
phages were obtained as described (28). Cultured macrophage 
monolayers were incubated with 500 1-11 of D:MEM (Gibco, Invit-
rogen) containing 50 [Lg/m!AcLDL, 2% (w/v) BSA.and I fLCi/ml 
[3H]cho1esterol for 24 h . .After lipid loading. cells were washed 
twice. followed by an overnight equilibration incubation to re-
move AcLDL from cellular membranes. Subsequently. cells were 
washed twice again, and cholesterol efflu.x was initiated by in-
cubating the macrophages for 5 h with effltLx medium consisting 
ofDMEM. 2% (w/v) BSA. and mouse HDL (4, 10. 20, or 40 J.Lg 
total cholesterol/ml). 
HDL of indi'-'dual hApoAitg and hPLTPtg/hApoAitg mice 
'vas isolated by density gradient ultracentrifugation at a den-
sity range of 1.019-1.21, and HDL of hApoAitg/LDLR-/- and 
hPLTPtg/hApoAitg/LDLR-/- mice was isolated at a density 
range of 1.063-1.21. In every experiment, incubations without 
HDL were included to measure HDL-independent cholesterol 
effllLx. EffltLx medium was collected and radioactivity V..'as de-
termined. Remaining cholesterol was extracted from the intact 
monolayers with isopropanol. Protein was measured in the cells 
after the addition of 0.1 M NaOH by the method ofLmvry et al. 
(29) using BSA as a reference. Cholesterol efflux was corrected 
for HDL-independent effllLx and subsequently calculated as cho-
lesterol in the medium/ (cellular cholesterol content + choles-
terol in the medium). The resulting percentage of the total label, 
adjusted for HDL-independent effllLX, was normalized for small 
differences in cell protein content benveen the different wells. 
In one experiment, individual efflm.: media were pooled for 
each group and subjected to FPLC. In the resulting lipoprotein 
fractions, total cholesterol and radioactivity were measured to 
determine the efficiency of lipoprotein particles to incorporate 
cellular cholesterol. 
Quantification of atherosclerosis 
Mter 9 weeks of a high-fat/high-cholesterol diet, the animals 
were anesthetized .....nth isoflurane, the thor-a..'\. was opened, and 
the animals were subjected to perfusion fixation through the left 
ventricle of the heart using 4% phosphate-buffered formalin. 
The heart was dissected and processed for cryosectioning. Cryo-
sections of the aortic valves (7 J..Lm thick) were stained 1vith Oil 
Red 0 and hemato::-..}'lin. The sections were photographed with 
a Sony digital camera. The atherosclerotic area was measured 
in five sections at intervals of 90 J..Lm according to Paigen et al. 
(30) using Scion Image image-analysis software (available at 
www.scioncorp.com). 
Atherogenic HDL in human PLTP/apoA-I tg mice 
Statistics 
Data are expressed as means ± SEM. Differences were ana-
lyzed by two-sample Wilcoxon rank sum tests using Intercooled 
Stata 8.2/SE software (Stata Corp., College Station, TX). 
RESULTS 
Effects of human PLTP overe>,.pression on plasma lipids 
and apoA-I levels 
First, we investigated the effect of introduction of the 
human PLTP gene on PLTP activity and plasma lipids. 
hPLTPtg/hApoAitg mice had a 4.5-fold increased PLTP 
activity compared with hApoAitg mice (Table 1). Overex-
pression of human PL TP resulted in a decrease in total 
cholesterol, caused mainly by a decrease in free choles-
terol level. CE levels were similar. Phospholipid levels de-
creased strongly. Plasma triglyceride levels did not change. 
Overexpression of human PLTP resulted in a 30% de-
crease in human apoA-1 levels and a 40% decrease in 
mouse apoA-l levels. Mouse apoA-I levels were very low 
compared with human apoA-1 levels, accounting for only 
1-2% of total apoA-I levels (Table 1). Crossed immuno-
electrophoresis showed that expression of human PLTP 
resulted in a decrease of apoA-I in a-HDL whereas apoA-I 
in the pre!3-HDL range did not decrease (Fig. 1). Human 
apoA-I plasma concentration with pre!3 mobility was 1.27 
mg/ml (28% of total plasma human apoA-I) in hApoAitg 
mice versus 1.17 mg/ml (37%) in hPLTPtg/hApoAitg mice. 
Human apoA-I plasma concentration with a mobility was 
3.26 mg/ml (72%) in hApoAitg mice versus 1.98 mg/ml 
(63%) in hPLTPtg/hApoAitg mice. 
Effects of human PLTP overe::\.-pression on plasma 
lipoprotein profiles (gel filtration and density 
gradient centrifugation) 
Next, we investigated the effect of an increased PLTP 
activity on the disuibution of lipoprotein subclasses. Anal-
ysis of plasma lipoproteins by gel filtration showed that 
introduction of the human PLTP transgene in hApoAitg 
mice resulted in the conversion of normal HDL (top at 
fraction 17) into a much larger particle (top at fraction 
11) with a highly increased molar ratio of cholesterol to 
phospholipid (Fig. 2. compare A with B). Next. plasma 
lipoproteins were separated by density gradient centrifu-
gation to determine the density of the lipoprotein par-
TABLE 1. Plasma parameters in hApoAitg versus hPLTPtg/hApoAitg mice 
Phospholipid Transfer Free Cholesteryl 
Mouse Protein Activity Total Cholesterol Phospholipid Triglyceride Cholesterol Ester Human ApoA-1 Mouse ApoA-1 
mmol/l mg/ml 
hApoAitg 
hPL TPtg/hApoAitg 
arbitral)' units 
4.12 ± 0.10 
18.41 ± 0.67<1 
5.68 ± 0.13 5.38 ± 0.12 1.20 ± 0.10 2.17 ± 0.04 3.51 ± 0.09 4.53 ± 0.09 0.10 ± 0.01 
5.07 ± 0.13b 3.53 ± 0.07" 1.16 ± 0.12 1.74 ± 0.06a 3.34 ± 0.10 3.15 ± O.l5r 0.06 ± o.oor 
ApoA-I, apolipoprotein A-I. Values shown are means :±: SEM. 
"P< 0.0001 versus hApoA!tg (n ~ 16-17). 
l>p< 0.01 versus hApoAitg (n = 16-17). 
"P < 0.001 versus hApoA.Itg (n = 16-17). 
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A B 
pre n 
Fig. 1. Quantification of pre{3-HDL by crossed immunoelectropho-
resis. A:. Plasma pool from hApoAitg mice. B: Plasma pool from 
hPL TPtg/hApoAitg mice (> 10 mice per pool). The positions of pre(3-
and ct-migrating human apolipoprotein A-I (apoA-1) are indicated. 
tides (Table 2). In hApoAltg mice, almost all lipopro-
teins were found in the HDL density range from 1.063 to 
1.21 g/ml, whereas hPLTPtg/hApoAltg mice displayed 
lipoproteins in the HDL density range and in addition a 
very substantial lipoprotein fraction in the density range 
from 1.006 to 1.063 g/ ml, which corresponds with the den-
sity ofLDL. 
Protein analysis of FPLC fractions 
hApoAltg mice fed a standard chow diet lack substan-
tial levels of plasma LDL (Fig. 2A, fractions 6-10, Table 2, 
A 
~ 
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Fig. 2. Total cholesterol (TC) and phospholipid (PL) in fast-protein 
liquid chromatography (FPLC) fractions of plasma from hApoAitg 
mice (A) and hPLTPtg/hApoA!tg mice (B). Individual plasma sam-
ples were pooled (>10 mice per pool) and subjected to FPLC. Total 
cholesterol (white circles} and phospholipid (black circles) were 
detennined in each fraction (see Materials and Methods). Elution 
volumes for wild-type mice are as follows: LDL in fractions 5-10, 
HDL in fractions ll-20. 
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1.019 < d < 1.063). Introduction of the human PLTP 
transgene resulted in the formation of large lipoprotein 
particles with LDL density, as demonstrated by gel filtra-
tion and density gradient centrifugation (Fig. 2B, Table 2). 
To investigate whether these particles contained apoA-I, 
FPLC fractions were subjected to electrophoresis on a 
gradient SDS-polyacrylamide gel, which was subsequently 
stained with Coomassie blue. In hApoAltg mice, apoA-I 
was found mainly in fractions 12-18, which is the nor-
mal HDL range (Fig. 3A). In the FPLC fractions of the 
hPLTPtg/hApoAltg mice (Fig. 3B), apoA-I was detected 
not only in fractions in the HDL range but also in frac-
tions with sizes usually corresponding with LDL particles 
(fractions 7-12). Apolipoprotein B patterns in fractions 
7-12 did not differ between hPLTPtg/hApoAltg mice 
and hApoAltg mice (data not shown). These results show 
that concomitant expression of human PL TP and human 
apoA-I results in the formation of a very large. cholesterol-
rich HDL particle with LDL density. 
To check for the presence of apoE in the plasma lipo-
proteins from hPLTPtg/hApoAltg mice, lipoproteins 
were isolated by density gradient centrifugation and sub-
sequently subjected to FPLC. The apolipoproteins pres-
ent in the FLPC fractions were anl'"llyzed by silver staining 
of 4-15% SDS-polyacrylamide ge' As shown in Fig. 3C, 
apoA-I was present in all FPLC subfractions from the d = 
1.019-1.063 g/ml range (corresponding to the normal size 
ofLDL) and from the d = 1.063-1.21 g/ml range (corre-
sponding to the normal size of HDL), whereas apoE could 
not be detected. 
The ability of isolated HDL fractions to induce cholesterol 
efflu.x from moose peritoneal macrophages 
To test the functionality of the large HDL particles that 
are formed in hPLTPtg/hApoAltg mice, we studied the 
ability of HDL to induce cholesterol efflux from mouse 
peritoneal macrophages. Therefore, HDL fractions of both 
mouse lines were isolated from individual mice of both 
mouse Jines by density gradient ultracentrifugation and 
used as acceptors for 3H-labeled cellular cholesterol. Cho-
lesterol efflux from macrophages induced by the large 
HDL isolated from hPLTPtg/hApoAltg mice was lower 
than that induced by HDL isolated from hApoAltg 
mice (Fig. 4), with the largest effect at an HDL choles-
terol concentration of 40 f.Lg/ml. We calculated the rela-
tive phospholipid and free cholesterol contents of the 
HDL particles that were used to induce cellular choles-
terol efflux and found that this was similar for hApoAltg 
mice and hPLTPtg/hApoAltg mice. Therefore, it is un-
likely that the exchange of labeled cellular cholesterol for 
unlabeled free HDL cholesterol differed between genotypes. 
Subsequently, efflm: media were collected and subjected 
to FPLC. In the FPLC fractions, both totai cholesterol 
and 3H counts were measured. V\lhen "normal-sized" HDL 
isolated from hApoAltg mice was used as an acceptor for 
cellular cholesterol, we found an equal distribution of cho-
lesterol and 3H counts in the FPLC fractions (Fig. 5A). In 
contrast, the profiles of labeled and unlabeled cholesterol 
did not completely overlap when HDL from hPLTPtg/ 
Atherogenic HDL in human PLTP/apoA-I tg mice 
TABLE 2. Components of lipoprotein subclasses of pooled plasma samples, separated by density 
gradient ultracentrifugation 
Component 
hApoAitg 
Protein 
Phospholipid 
Free cholesterol 
Esterified cholesterol 
Triglycerides 
hPLTPtg/hApoAitg 
Protein 
Phospholipid 
Free cholesterol 
Esterified cholesterol 
Triglycerides 
d < 1.006 
0.05 
0.12 
0.03 
0.04 
0.58 
0.07 
0.15 
0.05 
0.19 
0.79 
Values shown are mg/ml. 
1.006 < d < 1.019 
0.02 
0.03 
0.01 
0.02 
0.04 
0.08 
0.06 
0.03 
0.08 
0.06 
hApoAitg mice was used (Fig. 5B). In thls case, the largest 
HDL particles did not accept labeled cholesterol from the 
macrophages, whereas the smaller particles did (Fig. 5B, 
fractions 5-11 vs. fractions 11-15). To confirm this observa-
tion, another cholesterol efflu.x experiment was performed 
with HDL of hPLTPtg/hApoAitg mice that was separated 
A 
B 7 8 9 10 11 12 13 14 15 16 17 18 
hP~!PtglhApoAitg 
c 10 11 
+ApoE 
+-ApoAI 
12 13 14 15 16 
+ApoE 
+ApoAI 
Fig. 3. ApoA-I and apoE protein levels. A, B: FPLC fractions 7-18 
ofhApoAitg mice (A) and hPLTPtg/hApoAitg mice (B) were sub-
jected to electrophoresis on 10-20% SDS-polyacrylamide gels and 
subsequently stained with Coomassie blue. C: Plasma lipoproteins 
from hPLTPtg/hApoAitg mice were isolated by density gradient 
ultracentrifugation (see Materials and Methods). The isolated frac-
tions with densities of 1.019-1.063 g/ml (upper gel) and 1.063-
1.21 g/ml (lower gel) were subfractionated by FPLC, followed 
by silver staining of 4-15% SDS-polyacrylamide gels. The positions 
of molecular weight markers are indicated at left, and those of 
apoA-1 and a poE are indicated at right 
1.019 < d < 1.063 1.063 < d < 1.21 d > 1.21 
0.12 2.72 NA 
0.17 2.34 0.02 
0.05 0.42 0.02 
0.14 1.53 0.05 
0.03 0.03 0.01 
0.44 0.72 NA 
0.87 0.76 0.03 
0.28 0.15 0.04 
1.24 0.54 0.07 
0.08 0.02 0.02 
by FPLC into three different subfractions (Fig. 6A): frac-
tions {}-9 (very large HDL), fractions 10-14 (large HDL), 
and fractions {}-14 (total HDL). The ability of these subtrac-
tions to induce cholesterol efflu.x from 3H-Iabeled AcLDL-
Ioaded peritoneal macrophages was studied (Fig. 6B). 
Indeed, large HDL induced cholesterol efflu.x in a more 
efficient way than very large HDL. It is clear that the HDL 
subfraction with a very large size is an inferior acceptor in 
the cholesterol effllLx experiments. 
Atherosclerosis e)l..-periments 
To determine the effect of the expression of human 
PLTP on the development of atherosclerosis. hApoAitg 
mice and hPLTPtg/hApoAitg_ mice were crossed into 
an LDLRdeficient background. Animals were fed a high-
fat/high-<:holesterol diet for 9 weeks to induce the devel-
opment of atherosclerosis. hPLTPtg/hApoAitg/LDLR~;~ 
mice had a 3-fold increased PLTP activity compared with 
hApoAitg/LDLR~;~ mice (Table 3). No differences in 
plasma cholesterol or phospholipids between groups 
c: 
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0 
..c: 
" 
';#. 
0.0 
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HDL-cholesterol concentration (f.ig/ml) 
Fig. 4. Percentage cholesterol efflu.x per microgram of cell pro-
tein. The ability ofHDL isolated from hApoAitg mice (white bars) 
and hPL TPtg/hApoAitg mice (gray bars) to induce cholesterol ef-
flu.x from labeled acetylated low density lipoprotein (AcLDL)-
loaded peritoneal macrophages was determined (see Materials 
and Methods). Values shown are means ::!:: SEM obtained from 
> 10 mice per group. * P < 0.05, ** P< 0.01 versus hApoAitg. 
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Fig. 5. Total cholesterol (TC) and~ label (counts per minute) 
in FPLC fractions of pooled efflu.x media obtained with HDL 
from hApoA!tg mice (A) and hPLTPtg/hApoAitg mice (B). After 
cholesterol efflu.x. efflu.x media of individual mice were collected. 
Pools of efflux media (at least 10 mice per group) were subjected 
to FPLC. Total cholesterol (white circles) and 3H label (black cir-
cles) were determined in each fraction. Elution volumes for ·wild-
type mice are as follows: LDL in fractions 5-10, HDL in fractions 
ll-20. 
were observed. Overexpression of human PLTP resulted 
in a 60% decrease in human apoA-I levels and a 20% de-
crease in mouse apoA-1 levels. Mouse apoA-I levels were 
very low compared with human apoA-I levels, account-
ing for only 1-3% oftotal apoA-I levels (Table 3). Crossed 
immunoelectrophoresis showed that expression of hu-
man PLTP resulted in a decrease in both a-HDL and pre[3-
HDL. Human apoA-I plasma concentration with pre[3 
mobility was 0.63 mg/ml (19% of total plasma human 
apoA-I) in hApoAitg/LDLR-/- mice versus 0.29 mg/ml 
(26%) in hPLTPtg/hApoAitg/LDLR-;- mice. Human 
apoA-I plasma concentration with a mobility was 2.69 mg/ 
ml (81 %) in hApoAitg/LDLR-;- mice versus 0.82 mg/ml 
(74%) in hPLTPtg/hApoAitg/LDLR-;- mice. 
We again studied the ability of isolated HDL to induce 
cholesterol efflu.....;: from mouse peritoneal macrophages. 
Mter 9 weeks of a high-fat/high-cholesterol diet, HDL 
from hPLTPtg/hApoAitg/LDLR-/- mice and hApoAitg/ 
LDLR-1- mice was isolated individually by density gra-
dient ultracentrifugation and used as an acceptor for 3H-
labeled cellular cholesterol. In agreement with the results 
in hPLTPtg/hApoAitg mice and hApoAitg mice, HDL iso-
lated from hPLTPtg/hApoAitg/LDLR-/- mice proved to 
induce cholesterol effllLx in a less efficient way than did 
HDL isolated from hApoAitg/LDLR-/- mice (Fig. 7). 
Mter 9 weeks of the high-fat/high-cholesterol diet, animals 
were euthanized and atherosclerotic lesion area v..ras deter-
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Fig. 6. Percentage cholesterol efflu.x per microgram of cell pro-
tein for very large HDL versus large HDL. A: A plasma pool iso-
lated from a group of 12 hPLTPtg/hApoAitg mice Vl'<lS subjected 
to FPLC and divided into three pools: very large HDL {fractions 
5-9),large HDL (fractions 15-14). and total HDL (fractions 5-14). 
B: The ability of the three HDL pools to induce cholesterol efflu."( 
from labeled AcLDL-loaded peritoneal macrophages was deter-
mined (see Materials and Methods). Values shovm are means ± 
SEM of four determinations. ** P < 0.05, *** P < 0.01 versus 
large HDL: 11 P < 0.05 versus total HDL. TC. total cholesteroL 
mined in sections of the aortic valves. :Mice overe::-..'}Jressing 
human PLTP showed a 2.2-fold increased atherosclerotic 
lesion area (Fig. 8). 
DISCUSSION 
In the present study, overe,.-pression of the human 
PLTP gene in a human apoA-1 transgenic mouse line re-
sulted in decreased total plasma cholesterol and phos-
pholipid levels. which were caused by decreased HDL 
levels. In human apoA-I tr.msgenic mice, the relatively high 
percentage of apoA-I in the pre[3 range can be attributed to 
the presence of the human apoA-I tr.msgene (20, 31, 32). 
Overe::-.."Pression of human PL TP did result in an increase in 
the percentage of human apoA-I in the pre[3-HDL range, in 
accordance with our previous data in mice without hu-
man apoA-I (8, 9). However, the absolute plasma level of 
human apoA-I with pre[3 mobility did not increase in hu-
man PLTP-expressing mice, whereas the plasma level of 
human apoA-I with a mobility was strongly decreased. This 
could be explained by the fact that overcxprcssion of PLTP 
increases HDL catabolism (13). In addition, PLTP has been 
reported to cause proteolytic cleavage of apoA-I (33). We 
Atherogenic HDL in human PLTP/apoA-I tg mice 
TABLE 3. Plasma parameters in hApoAitg/LDLR-;- mice versus hPLTPtg/hApoAitg/LDLR-;- mice measured chow-fed (0 weeks) and after 
9 weeks of a Western diet (9 weeks) 
Phospholipid Transfer 
~~~P~c~ot~ei~n~A~"'~·~-'·ty~~- -~~T~o~to~l C~h~o~le~st~ec~ol~- -~~P~ho~'P,_h~o--'lip,_id~~- Human ApoA-I Mouse ApoA-1 
Mouse 0 Weeks 9Weeks 0 Weeks 9Wccks 0 Weeks 9 Weeks 9Wceks 9 Weeks 
arbitrary' units mmnl/l mnwl/l mg/ml 
hApo.A.Itg/LDLR-;- 3.63 ± 0.26 7.27 :±: 1.19 4.09 :±: 0.35 15.95 :±: 0.87 3.60 :±: 0.13 9.19 :±: 0.35 3.32 ± 0.24 0.06 ± 0.01 
hPLTPtg/hApoAitg/LDLR-/- 11.86 ± 0.36a 19.32 ± 2.00b 3.96 ± 0.85 16.56 ± 0.70 2.97 ± 0.40 8.70 ± 0.33 1.11 ± O.lDa 0.04 ± O.OOa 
Values shown are means ± SEM. 
"P< 0.001 versus hApoA!tg/LDLR-/- (n = 7-11). 
b P< 0.01 versus hApoAitg/LDLR-/- {n = 7-11). 
found that the action of human PLTP together with hu-
man apoA-I resulted in the formation of a large CE-rich 
lipoprotein particle with LDL density. 
We determined protein components in this lipopro-
tein particle and found that the main apolipoprotein was 
apoA-I. Therefore, we conclude that the large lipoprotein 
particle found in hPLTPtg/hApoAitg mice is a very large, 
cholesterol-enriched subspecies of HDL displaying LDL 
density. In vitro HDL conversion studies demonstrated 
that human PL TP is able to promote the conversion of a 
homogenous population of human HDL3 particles into a 
new population with an increased average size via par-
ticle fusion (34~36). Earlier, a small increase in HDL size 
was observed in a human PLTP/human apoA-I double 
transgenic mouse model displaying a slightly increased 
PLTP activity (37). Ehnholm et al. (14) also showed that 
adenovirus-mediated overexpression of human PLTP in 
human apoA-1 transgenic mice resulted in an increase in 
HDL size and a decrease in HDL density. Furthermore, 
human apoA-1 transgenic mice treated Volith fenofibrate 
showed an increase in the expression of murine PLTP in 
the liver through stimulation of the transcription factor 
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Fig. 7. Percentage cholesterol efflux per microgram of cell pro-
tein. The ability of HDL isolated from hPLTPtg/hApoAitg/ 
LDLR-;- mice versus hApoAitg/LDLR-/- mice (fed a Western 
diet) to induce cholesterol effhLx from labeled AcLDL-loaded peri-
toneal macrophages was determined (see Materials and Methods). 
Values shown are means ± SEM obtained from > 10 mice per 
group.*** P< 0.001 versus hApoAitg/LDLR-/- mice. 
peroxisome proliferator-activated receptor a. The result-
ing increase in PLTP activity accounted for the HDL size 
enlargement in plasma from treated animals (38, 39). 
Enlarged HDL species have been described in a variety 
of other mouse models, such as scavenger receptor class B 
type I knockout mice, hepatic lipase knockout mice, human 
LCAT transgenic mice, and hepatocyte nuclear factor-lac 
knockout mice ( 40-43). In these mouse models, HDL levels 
were increased and lipoprotein particles were enriched 
with apoE and CEs. The only mouse model that displays, 
like our hPLTPtg/hApoAitg mouse model, an increase in 
HDL size concomitant Mth a decrease in HDL levels is 
a model in which apoM is selectively silenced by small 
interfering RNA (44). It is unknown whether PLTP plays 
a role in the molecular mechanisms by which apoM af-
fects HDL particle size. 
Not only HDL concentration but also HDL composi-
tion may be important for its antiatherogenic properties. 
Scavenger receptor class B type !-deficient mice and mice 
overexpressing human LCAT, displaying enlarged HDL 
subspecies, showed an increase in atherosclerotic lesion 
development despite highly increased levels of HDL cho-
lesterol ( 40. 42). Human studies confirm the hypothesis 
hApoAitg/ 
LDLR-/-
hPLTPtg/ 
hApoAitg/ 
LDLR-/-
Fig. 8. Atherosclerotic lesion development in hApoAitg/LDLR-/-
mice versus hPLTPtg/hApoAitg/LDLR-;- mice. Plaque area vvas 
measured in sections from the aortic root (see Materials and 
Methods). Values shmvn are means ± SEM obtained from at least 
12 mice per group.* P< 0.05 versus hApoAitg/LDLR-/- mice. 
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that HDL size and composition are the main determi-
nants of susceptibility to atherosclerosis development. The 
inhibitory effect of small dense HDL subfractions isolated 
from healthy human subjects on the expression of cell ad-
hesion proteins is superior to that of larger and less dense 
HDL particles ( 45). This might be of physiopathological 
relevance in the initial steps of atherogenesis, in which 
monocytes are arrested on the surface of endothelial cells. 
Recently, it was shown that hyperalphalipoproteinemia 
in cardiac transplant recipients is associated with the for-
mation of partially dysfunctional HDL ( 46). Other studies 
showed that average HDL size and CE content increase 
as a result of low CETP activity (47-50). Also, the large 
HDL particles that are formed in our double transgenic 
mice are rich in CEs. In the absence of CETP, CEs can-
not be transferred to apoB-containing lipoproteins. Pos-
sibly, the expression of CETP in our hPLTPtg/hApoAitg 
mice would prevent the accumulation of esterified choles-
terol in the core of the HDL particle, thereby reducing 
HDL particle size. Interestingly, e>.pression of CETP cor-
rected dysfunctional HDL in LCAT transgenic mice, thereby 
reducing the development of atherosclerosis (51). In CETP-
deficient subjects, it was reported that these large GE-rich 
HDL particles have reduced acceplor capacity for choles-
terol from lipid-laden macrophages (52, 53). These find-
ings indicate that measuring HDL functionality might be 
as important as measuring HDL concentration for assess-
ing cardiovascular risk. 
In our study, cholesterol effhn: capacity of the enlarged 
HDL isolated from hPLTPtg/hApoAitg mice was decreased 
compared with that of HDL from hApoAitg mice. The cho-
lesterol efflm.: experiment in which the efflu.x of cellular 
lipids to lipoprotein particles in fractions 6-9 was compared 
directly with the efflu.x of lipids to lipoprotein particles in 
fractions 10-14 confirmed the hypothesis that the very 
large HDL particles are inefficient at inducing cellular cho-
lesterol efflux. These results show that PL TP may act pro-
atherogenically not only by decreasing plasma HDL levels 
but also by changing HDL particle composition. Interest-
ingly, Tall and colleagues (54) recently discovered that 
the enlarged HDL (HDL2) that is found in patients with 
CETP deficiency has an increased capacity to promote cel-
lular cholesterol efflux, but only when apoE content of the 
HDL particle was high. When apoE was removed from the 
particle, HDL lost this ability. We checked the apoE content 
of the enlarged HDL particles in hPL TPtg/hApoAitg mice 
by silver staining of apolipoproteins on SDS.polyacrylamide 
gels, but no apoE was detected. 
Lipoprotein enrichment with apoE is not essential for 
the formation of large HDL, as there are reports of en-
larged HDL in apoE-<ieficient mice (41). In our mouse 
model, the absence of an increased apoE content of the 
large HDL might be caused by the overexpression of hu-
man apoA-I. Probably, the large excess of human apoA-I 
in the HDL particles, including the large HDL in the 
double transgenic mice, leads to a repression of apoE in-
corporation. Also, the expression of apoA-II is strongly 
repressed in our human apoA-I transgenic mouse line, as 
has been reported previously (19). We analyzed the dis-
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tribution of apoA-II in FPLC fractions of both genotypes 
(Coomassie blue staining ofSDS-polyacrylamide gels) and 
found that apoA-II levels were negligible and that there 
were no differences between genotypes (data not shown). 
Furthermore, the substantial reduction in the ratio of 
surface to core lipoprotein components, which may occur 
in hPLTPtg/hApoAitg mice, might contribute to the dis-
sociation of apolipoproteins from the HDL particles (55). 
In hPLTPtg/hApoAitg mice, the size increase renders 
the apoE-poor HDL particle less efficient at accepting 
cellular cholesterol. Also, when both mouse lines were 
crossed into an LDLR-<ieficient background, HDL isolated 
from the human PLTP-expressing mice was less efficient 
at promoting cellular cholesterol efflux. Unfortunately, it 
is not feasible to perform the same set of analyses for the 
HDL of animals with an LDLR-<ieficient background as 
we did for the HDL ofhApoAitg and hPLTPtg/hApoAitg 
mice. The reason is that LDLR-deficient animals have pre-
dominant levels of LDL, which precludes the isolation of 
large HDL, which is in the same density range. However, 
the reduced capacity of the HDL to induce cellular cho-
lesterol efflux may explain, at least in part, the observation 
that human apoA-1 transgenic mice overexpressing human 
PLTP have an increased susceptibility to the development 
of atherosclerotic lesions. 
In conclusion, our data show that in the presence of 
human apoA-I, human PLTP not only decreases plasma 
HDL levels but also unfavorably affects the functionality 
of the remaining HDL particles. When crossed into an 
atherosclerosis-prone background, mice expressing human 
PLTP show a strong increase in susceptibility to the devel-
opment of atherosclerosis. Our fmclings strengthen the 
opinion that high plasma PLTP activity levels might be 
harmful for cardiovascular health.ll!l 
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Abstract 
Plasma phospholipid transfer protein (PLTP) has atherogenic properties in genetically modified mice. PLTP stimulates hepatic triglyceride 
secretion and reduces plasma levels of high density lipoproteins (HDL). The present study was performed to relate the increased atherosclerosis in 
PLTP transgenic mice to one of these atherogenic effects. A humanized mouse model was used which had decreased LDL receptor expression and 
was transgenic for human cholesterylester transfer protein (CETP) in order to obtain a better resemblance to the plasma lipoprotein profile present 
in humans. It is well kno\Vtl that female mice are more susceptible to atherosclerosis than male mice. Therefore. we compared male and female 
mice expressing human PLTP. The animals were fed an atherogenic diet and the effects on plasma lipids and lipoproteins, triglyceride secretion 
and the development of atherosclerosis were measured. The development of atherosclerosis was sex-dependent. This effect was stronger in PLTP 
transgenic mice. while PLTP activity levels were virtually identical. Also, the rates of hepatic secretion oftriglycerides were similar. In contrast. 
plasma levels of HDL were about 2-fold lower in female mice than in male mice after feeding an atherogenic diet. We conclude that increased 
atherosclerosis caused by overexpression of PLTP is related to a decrease in HDL, rather than to elevated hepatic secretion of triglycerides. 
© 2006 Elsevier B.V. All rights reserved. 
Keyv.'ords: Atherosclerosis; Lipid metabolism; Lipoprotein; Transgenic animal model 
Atherosclerosis is the leading cause of death and morbidity 
in industrialized countries [1-3]. It is generally accepted that 
an elevated level of plasma cholesterol is an important risk 
factor for atherosclerosis. While the level of cholesterol in 
low density lipoproteins (LDL) correlates positively with the 
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incidence of atherosclerotic disease, cholesterol in high 
density lipoproteins (HDL) appears to protect against the 
development of atherosclerosis [1,2,4]. HDL is thought to 
have several anti-atherogenic properties. First, HDL is 
involved in the reverse cholesterol transport pathway, by 
which excess cholesterol is transported back to the liver for 
excretion [5-7]. In addition, HDL has both anti-inflammatory 
and anti-oxidant properties [4,8-1 0]. One of the proteins 
involved in HDL metabolism is plasma phospholipid transfer 
protein (PLTP) [11], We previously demonstrated that 
transgenic mice overexpressing human PLTP to various 
activity levels are more prone to the development of diet-
induced atherosclerosis in a PLTP-dose dependent way [12]. 
Concomitantly, the plasma level of HDL was decreased. We 
tentatively concluded that the increase in atherosclerosis is 
probably caused by this decrease in plasma HDL. However, 
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in addition to an effect on HDL, PLTP has an effect on the 
production of very low density lipoproteins (VLDL), which 
was first described in PLTP deficient mice [13]. The 
decreased atherosclerosis found in these mice was explained 
by decreased synthesis of apoB containing lipoproteins by the 
liver. We examined whether elevated PLTP activity levels 
would affect hepatic VLDL secretion. Indeed, PLTP over-
expressing mice were found to have an increase in the 
synthesis of apoB containing lipoproteins [12.14], which 
could be an alternative explanation for the increased 
susceptibility to atherosclerosis development found in these 
mice. Thus. elevated PLTP has two atherogenic effects on 
lipoprotein metabolism, i.e., increasing hepatic VLDL secre-
tion and decreasing plasma levels of HDL. In order to find 
out which of these mechanisms is the most important one for 
the development of atherosclerosis, we first determined 
whether male and female mice with similar levels of 
overexpression of PLTP differ in their susceptibility to 
atherosclerosis. Sex differences have been found in mouse 
models, including the commonly used low density lipoprotein 
receptor (LDLR) deficient mice and apolipoprotein (apo) E 
deficient mice [15-17]. In female mice, the surface area of 
atherosclerotic lesions is larger than in male mice. The reason 
for this difference is unclear. The present data show that the 
susceptibility to diet-induced atherosclerosis is also sex-
dependent in PLTP overexpressing mice, enabling us to relate 
these differences with the effects on apoB containing 
lipoproteins versus the effects on HDL. In the present studies, 
we used humanized transgenic mouse models which have 
decreased levels of LDL receptors and express human 
cholesteryl ester transfer protein (CETP) [14,18]. CETP is 
normally not expressed in mice, but is involved in the same 
pathways of lipoprotein metabolism as PLTP and may be 
crucially involved in the process of atherosclerosis in man 
[19.20]. Moreover, the plasma lipoprotein profile of these 
mice have a closer resemblance to the profile found in 
humans than that of normal mice. 
1. Methods 
1.1. Animals 
The human PLTP transgenic mice (huPLTPtg) were descnbed before 
(line Pl: [12.21]). LDL receptor knockout mice were purchased from 
Jackson Laboratory. Human CETP transgenic mice (huCETPtg) were kindly 
provided by Dr. A.R, Tall (Columbia University, New York). All mice were 
in C57BL/6J background for at least 8 generations. LDLR+1-/huCETPtg and 
LDLR+1-IbuCETPtg/huPLTPtg mice were created by crossbreeding. After 
weening. animals were kept on a chow diet (Hope Fanns, The Netherlands). 
For the induction of atherosclerosis, mice were fed a high fat high cholesterol 
(HFHC) diet for 14 weeks, which contained 40% w/w sucrose 15% w/w fat. 
1% w/w cholesterol and 0.5% w/w sodium cholate (Hope Fanns. The 
Netherlands). Mice were 12 weeks old at the beginning of the diet studies. 
Animals were housed under standard conditions and had free access to water 
and food. After fusting overnight. blood samples were collected from the 
orbital plexus by using VitrexTM sodium-heparinized micropipettes (80 IU) 
(Modulohm A/S, Copenhagen, Denmark) and immediately stored on ice. 
Blood was centrifuged at 2700 rpm for 15 min at 4 °C. Plasma was either used 
directly or stored in small aliquots at -80 oc before analysis. All experiments 
were performed according to national and institutional guidelines. The 
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investigation conforms with the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publication 
No. 85-23, revised 1996). 
1.2. Separation of plasma lipoproteins by density gradient centrifugation 
Lipoprotein fractions (HDL and non-HDL) used in Table 1 were collected 
following ultracentrifugation at density 1.063 g/mL in a Beckman 42.2 Ti 
rotor (42,000 rpm. 3 h, 12 °C). The non-HDL fraction includes VLDL, IDL 
and LDL. 
1.3. Quantification of cholesterol 
Total plasma cholesterol (TC) was determined enzymatically with the Free 
Cholesterol C kit no. 274-47109 (WAKO, Neuss, Gennany) after hydrolysis 
of cholesteryl esters with cholesterol esterase from Candida cylindracea 
(Boehringer, Mannheim, Germany). 
1.4. Plasma activity assays 
CETP and PLTP activity assays were performed as described before [18]. 
The activities are expressed as arbitrazy units (AU): 1 AU is the activity found 
in human reference pool plasma. The activities are: CETP 216 nmoVrnL/h; 
PLTP 14 ~moVmL!h. 
1.5. In vivo hepatic VLDL secretion 
VLDL secretion experiments were performed using the Triton WR1339 
method, as described [14]. 
1. 6. Histological assessment of atherosclerosis 
After 14 weeks of HFHC diet feeding, mice were sacrificed after blood 
collection as described in the animal section. The hearts were dissected, 
stored in phosphate buffered 4% formaldehyde until processed. Athero-
sclerotic areas in the aortic valves were quantified by computer assisted 
measurements as described [12.22]. To evaluate whether PLTP has an effect 
on accumulation of free cholesterol in atherosclerotic lesions, the presence of 
cholesterol clefts in the sections was evaluated as described [23]. 
1. 7. Statistical analysis 
Data are expressed as means±SEM. Differences between two groups of 
mice were analyzed by two sample Wilcoxon rank-sum tests by using 
Intercooled Stata 6.0 software {Stata corporation, College Station, TX. 
USA). 
Table 1 
Plasma levels of lipoprotein cholesterol on chow and HFHC diet 
Genotype LDLR+1-/huCETPtg LDLR+1-IhuCETPtg/ 
Sex Male Female 
Non-HDL-C, chow 0.8±0.1 1.1±0.ln 
HDL-C. chow 1.7±0.1 1.8±0.1 
Non-HDL-C, HFHC 9.9±1.3 8.2±0.9 
HDL-C.HFHC 1.4±0.1 0.6±0.1n 
Cholesterol {C) concentrations are in mmol/L. 
n=14-20 per group. 
huPLTPtg 
Male 
0.6±0.1b 
l.l±O.lb 
7.3±0.8" 
0.6±0.1b 
n P<O.OOl. male versus female of same genotype. 
Female 
O.S±O.ln.b 
I.O±O.lb 
6.9±0.7 
0.3±0.03n.b 
b P<O.OOl. LDLR+1-/huCETPtg versus LDLR+1-!huCETPtglhuPLTPtg of 
same sex. 
c P=0.002, LDLR+1-!huCETPtg versus LDLR+1-/huCETPtglhuPLTPtg of 
same sex. 
2. Results 
2.1. Levels of plasma cholesterol 
Throughout the present study, comparisons are made 
between LDLR+1-/huCETPtg and LDLR+1-IhuCETPtgl 
huPLTPtg mice of both sexes. As shown in Fig. !A there is 
no difference in the plasma level of cholesterol (total 
cholesterol) between male and female LDLR+1-/huCETPtg 
mice. In contrast, plasma cholesterol is somewhat higher in 
females than in males in LDLR +l-/huCETPtg!huPLTPtg mice . 
In either sex, plasma cholesterol is much lower in the LDLR+I-I 
huCETPtglhuPLTPtg mice compared with LDLR+1-/huCETPtg 
mice. HDL was separated from VLDL+ LDL via ultracentri-
fugation in order to study the distribution of cholesterol 
between the lipoproteins (Table 1 ). Plasma levels of HDL-
cholesterol are decreased in both chow-fed male and female 
LDLR+1-IhuCETPtglhuPLTPtg mice when compared to 
LDLR +l-lhuCETPtg mice. The difference is -35% for the 
male mice and -44% for the female mice. Non-HDL-
cholesterol is lower as well, albeit by a smaller percentage. 
The concentrations of HDL-cholesterol are not different 
between males and females of either genotype. In these mice, 
fed a regular chow diet, a minor fraction of plasma 
cholesterol is in non-HDL. As expected, the plasma levels 
of non-HDL cholesterol are greatly increased after feeding 
the mice a HFHC diet (Table 1 ). However, there are no 
statistically significant differences in non-HDL cholesterol 
between males and females of either genotype. The non-
HDL cholesterol levels are somewhat lower in plasma from 
LDLR +l-lhuCETPtglhuPLTPtg mice when compared to 
LDLR+1-!huCETPtg mice, but this difference was only 
statistically significant in males. In contrast, striking 
differences were found in HDL cholesterol levels. These 
were about 2-fold higher in male mice than in female mice 
in either genotype. In both sexes, LDLR+1-/huCETPtgl 
huPLTPtg mice have lower levels of plasma HDL cholesterol 
than LDLR+1-/huCETPtg mice. The lowest concentration of 
plasma HDL cholesterol was found in female LDLR+I-I 
P< 
LDLR+/~/huCETPtg LDLR+/-/huCETPtg/huPLTPtg 
Fig. I. Total plasma cholesterol concentration in transgenic mice on chow diet. 
Measurements represent menns±SEM of 14-20 mice, 
Sex differences in mice with elevated PLTP activity 
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Fig. 2. Hepatic secretion of triglycerides in transgenic mice on chow diet (A) 
or HFHC diet (B). Plasma levels of triglycerides were measured at the 
indicated times in male (open circles) and female (closed circles) LDLR+J-; 
huCETPtg!huPLTPtg mice after administration of Triton VIR 1339. 
Measurements represent means±SEM of 7 (A) or 10 (B) mice per group. 
huCETPtg!huPLTPtg mice. The lower HDL levels in females 
cannot be attributed to higher CETP activity, which was 
actually 26% lower (LDLR +/-lhuCETPtg) and 40% lower 
(LDLR+1-/huCETPtglhuPLTPtg) in females than in males 
(Fig. 3B). 
2.2. VLDL triglyceride secretion 
PLTP is known to stimulate hepatic secretion of VLDL 
[13,[4]. Therefore, a comparison was made between male 
and female LDLR+1-IhuCETPtglhuPLTPtg mice in a set of 
experiments investigating the hepatic secretion of VLDL 
triglycerides by the Triton WR1339 method (Fig. 2A). No 
significant differences between males and females are 
observed. After correction for body weight, the rates of 
VLDL secretion between these two groups are identical 
(males: 195 ±40 J.lmollkg!h; females: 195 ±48 J.lmol!kg!h). In 
order to check whether the atherogenic diet could possibly 
induce a sex-specific difference, VLDL secretion was also 
measured in animals fed the HFHC diet. As shown in Fig. 
2B, the rate of VLDL triglyceride secretion is considerably 
lower in these animals than in animals fed a chow diet. 
However, there is no statistically significant difference in the 
VLDL secretion rates after correction for body weight 
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between males and females (males 69±9 f1mol/kg/h; females 
54± 6 f1mol/kg/h; P~ 0.18). 
2.3. Plasma activities ofCETP and PLTP 
Fig. 3 shows plasma CETP and PLTP activities in male and 
female mice fed a HFHC diet for 14 weeks. While the plasma 
activities of CETP and PLTP in mice expressing either only 
PLTP or the combination of the two lipid transfer proteins have 
heen described in previous studies from our laboratory [14.18]. 
we did not investigate possible sex-related differences. As 
expected, PLTP activity is much higher in LDLR+/-; 
huCETPtg/huPLTPtg mice than in LDLR+1-IhuCETPtg mice. 
PLTP activity is not different between males and females from 
either genotype (Fig. 3A). CETP activity is identical in male 
LDLR+1-!huCETPtg mice and male LDLR+1-!huCETPtg/ 
huPLTPtg mice. In female mice, CETP activity is slightly 
increased in LDLR +/-/huCETPtg!huPLTPtg mice versus 
LDLR+1-!huCETPtg mice. CETP activity is lower in females 
than in males in both genotypes (Fig. 3B). The HFHC diet 
causes a small increase in PLTP activity, but a strong induction 
of CETP activity in mice of both genotypes and of both sexes 
(PLTP activity: 124±6%, P<0.05; CETP activity: 344± 13%, 
P<O.OOl; results not shown). 
A 
LDLR+/·/huCETPtg LDLR+J-/huCETPigthuPLTPtg 
B 
malo 
LDLR+I-/huCETPtg LDLR+/-IhuCETPtg/huPLTPtg 
Fig. 3. Activities of CETP and PLTP in plasma from transgenic mice fed a 
HFHC diet (A) PLTP activities. 1 AU is equal to 14 JlmollmL!h. (B) CETP 
activities. 1 AU is equal to 216 nmollmL/h. Data represent means±SEM of 
17-19 mice. 
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Fig. 4. Atherosclerosis in transgenic mice fed a HFHC diet. (A) Atherosclerotic 
lesion areas were measured in 5 sections per animal from the aortic rool (B) 
Percentage of sections containing free cholesterol clefts in the aortic lesion. Data 
represent means± SEM of 11-18 mice. 
2.4. Atherosclerosis 
Diet-induced atherosclerosis was evaluated by measuring 
the atherosclerotic area in the aortic root (Fig. 4A). Male 
mice show small lesion areas that are similar in size between 
the two genotypes. In contrast, female mice develop 
substantial lesion areas in both genotypes. When comparing 
sexes, female mice show 3.4-fold (LDLR+1-!huCETPtg mice) 
and 7.0-fold (LDLR+1-/huCETPtg/huPLTPtg mice) larger 
lesion areas than male mice (both P< 0.001) (Fig. 4A). 
PLTP overexpression in female mice results in a 1.8-fold 
further increase (P<0.005) in aortic lesion area, while no 
effect was detected in male mice. In addition, female mice 
overexpressing human PLTP show more severe plaques with 
larger numbers of cholesterol clefts (Fig. 4B). In male mice, 
the severity of the plaque appears higher too, as no 
cholesterol clefts are observed in LDLR+1-!huCETPtg mice. 
while a modest percentage of the plaques in the LDLR +/-I 
huCETPtg/huPLTPtg mice do contain cholesterol clefts. 
Representative images are shown in Fig. 5. Finally, we 
investigated whether there was a relation between the plasma 
concentration of HDL and the size of the atherosclerotic 
lesions in the LDLR+1-!huCETPtglhuPLTPtg mice. As 
shown in Fig. 6, a strong correlation was observed for the 
female mice (P=0.006). In the male mice, in which the 
differences in lesion size are much smaller, the same relation 
seems to be present, but just failed to reach statistical 
significance (P=0.076). 
3. Discussion 
We previously described potentially anti-atherogenic 
effects of elevated expression of PLTP [21]. However, 
when we investigated PLTP transgenic mice with different 
levels of PLTP expression, and consequently of plasma 
PLTP activi1y, a clear PLTP-dose dependent increase in 
atherosclerosis susceptibili1y was observed [12]. This was 
found both in mouse models in which PLTP expression was 
driven by its autologous promoter, as well as in mice with 
hepatocyte-specific PLTP expression [12]. All these studies 
Sex differences in mice with elevated PLTP activity 
were performed in male mice only which were backcrossed 
to C57BV6 background for at least 5 generations. 
In the present study male and female mice were used in 
which PLTP expression was driven by its autologous promoter 
and which were backcrossed to C57BL/6 background for at 
least 8 generations. In these animals. we investigated whether a 
sex difference in susceptibili1y to diet-induced atherosclerosis 
exists in PLTP transgenic mice, and whether such a difference 
would be indicative for the mechanism involved in the 
increased development of atherosclerosis in PLTP overexpres-
sing mice. In addition, we performed our study in more human-
like mice with decreased LDL receptors and expressing CETP, 
which we described previously [24]. 
Higher susceptibili1y to diet-induced atherosclerosis in female 
mice has been noticed already by pioneer researchers in the 
1980's and has been confirmed since then by many others [15-
Fig. 5. Atherosclerotic lesions in the aortic valves. Photomicrographs showing representative atherosclerotic lesions in aortic valves. {A) male LDLR+1-JbuCETPtg 
mice: (B) male LDLR+1-/huCETPtglhuPLTPtg mice; (C and E) female LDLR+1-!huCETPtg mice; (D and F) female LDLR+1-!huCETPtg/huPLTPtg mice. (E and F) are 
magnifications of the boxed parts of panels C and D. respectively. Arrowheads point to cholesterol clefts. Scale bars: 200 Jlm. 
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males 
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P=D.076 
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Fig. 6. Correlation between plasma levels of HDL and atherosclerotic lesion 
size. Plasma concentration of HDL-cholesterol (HDL-C) was measured and 
plotted against the size of the atherosclerotic lesions in individual male (left 
panel) and female (right panel) LDLR+1-!huCETPtg/huPLTPtg mice. r- and 
P-values are indicated. 
17,25-29]. However, the reason for this difference is still 
unknown, and so is the reason why this sex-difference appears 
to be opposite to the situation in humans (where males have more 
atherosclerosis at younger age than females). We did not intend to 
solve this paradox in the present study. Instead, we used this 
difference as a starting point and found that the PLTP transgenic 
female mice in our study have a 7-fold higher level of 
atherosclerosis than the PLTP transgenic male mice. More 
atherosclerosis was also found in female than in male mice in 
the control group (LDLR+1-/lmCETPtg mice). These results 
expand those from Arai et a!. [16], who compared atherosclerosis 
between males and females in LDLR+/- mice. A similar sex 
difference in atherosclerotic lesion area was found in both studies. 
The genetic background is known to be an important 
parameter for the extent of atherosclerosis in mice [30]. The 
mice used in the present study are all in C57Bl6 background, 
which is the most susceptible strain for diet-induced athero-
sclerosis. When LDLR +!-/huCETPtg mice are compared with 
LDLR+1-/huCETPtg/huPLTPtg mice, the atherosclerotic lesion 
areas are not different in male mice. In a previous report 
studying male mice without the CETP gene with various levels 
ofPLTP overexpression, we demonstrated that the development 
of atherosclerosis was PLTP-dose dependent [12]. However, in 
the transgenic mouse line with the lowest level of PLTP 
overexpression (line Pl), the difference in atherosclerotic lesion 
formation with the controls did not reach statistical significance 
in male mice [12]. This is in agreement with our current 
findings, in which the same line of PLTP transgenic mice has 
been used for the generation of the LDLR+/-/huCETPtg/ 
huPLTPtg mice. Both the stimulation of VLDL secretion and 
the decrease of plasma HDL-cholesterollevels were statistically 
significant in line PI mice compared to non-transgenic controls 
[12]. In the present study, the effect on plasma HDL is 
confirmed in the male mice. Although there is no obvious 
increase of the atherosclerotic area. the number of lesions with 
cholesterol clefts is increased. Taken together, these results 
suggest that a moderate overexpression of PLTP is atherogenic 
in male mice, although the effect is too small to be detected 
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unambiguously in the mouse models used. In contrast, the 
atherogenic effect of elevation of PLTP activity is very obvious 
in female mice (Fig. 4A: P<0.005 in LDLR+/-/huCETPtg mice 
versus LDLR+1-IhuCETPtg/huPLTPtg mice). Thus, under 
circumstances where the susceptibility to atherosclerosis is 
increased, in this case by female sex, the atherogenicity of 
elevated PLTP becomes much more pronounced and therefore 
easier to detect. 
This situation offered the opportunity to evaluate the 
contribution of two known atherogenic effects of PLTP on 
lipoprotein metabolism, i.e., the stimulatory effect on hepatic 
VLDL secretion and the lowering effect on plasma HDL. The 
rate ofVLDL secretion in LDLR+1/huCETPtg/huPLTPtg mice 
was similar in male and female mice, either on chow or on 
HFHC diet. On HFHC diet the female mice even tended to have 
lower VLDL secretion rates than male mice, but this difference 
was not statistically significant. VLDL triglyceride secretion is 
considerably less on HFHC diet when compared to the situation 
on chow diet, due to the high hepatic cholesterol levels which 
are caused by the HFHC diet, resulting in cholesterol-rich and 
triglyceride-poor VLDL [31]. Female LDLR+1/huCETPtg/ 
huPLTPtg mice had very low levels of plasma HDL after 
feeding of the HFHC diet, much lower than male LDLR+1/ 
huCETPtg/huPLTPtg mice. Therefore, wt: conclude that the 
decrease in plasma HDL has a more substantial contribution to 
the atherogenicity of elevated PLTP than the stimulation of 
VLDL secretion. 
Apart from the level of HDL, other factors associated with 
HDL or involved in HDL metabolism could be involved. 
However, various measurements in these and previous studies, 
including the activities ofparaoxonase, platelet-activating factor 
acetyl hydrolase, hepatic triglyceride lipase, lipoprotein lipase, 
and lecithin:cholesterol acyl transferase did not reveal any 
obvious differences between males and females that could 
explain differences in atherosclerosis susceptibility. 
Recent studies have shown that PLTP is expressed by 
macrophages and is present in human atherosclerotic lesions 
[32,33]. In the transgenic manse models we used, PLTP is 
expressed by a wide variety of cells and tissues [12]. Therefore, 
the possible contribution ofPLTP secreted by the macrophages 
in the lesions to the atherosclerotic process cannot be 
determined from the present study. In order to dissect the role 
of macrophage derived PLTP, bone marrow transplantation 
studies could be used [34]. 
By nature, mice do not express CETP. Therefore, mice 
could be considered poor models to study atherosclerosis, as 
CETP is thought to be a key player in atherosclerosis [19]. For 
this reason, we studied in the present as well as in previous 
studies PLTP function in the presence of CETP [14,24]. In a 
comparison of the atherosclerotic lesion areas with published 
data [ 12,1 6], it appears that in the present study the 
contribution of the CETP transgene to the development of 
atherosclerosis is relatively small. This is in agreement with 
previous findings from our group [24], and also with earlier 
reports from others in which the same line of CETP transgenic 
mice was used to study atherosclerosis in a background of 
either LDLR deficiency or apoE deficiency [35], showing that 
a moderate increase in atherosclerosis was found only when 
several time points were taken into account, but not for any 
individual time point. The HFHC diet resulted in a marked 
increase in CETP activity, as reported before [35,36]. It is 
likely that CETP activity levels have to be increased even 
much more in order to find a clear atherogenic effect, as was 
the case in transgenic mice overexpressing simian CETP [37] 
and in transgenic rats overexpressing human CETP [38]. Still, 
from all these studies CETP emerges as an atherogenic protein, 
which is further corroborated by the finding that CETP 
inhibition reduces atherosclerosis in rabbits [39]. Therefore, 
the lower CETP activity in female mice compared to male 
mice on the HFHC diet found in the present study is probably 
not related to the sex differences observed in the susceptibility 
to atherosclerosis. 
In conclusion, we report here that female mice with moderate 
overexpression of PLTP are more prone to the development of 
diet-induced atherosclerosis than male mice, probably due to 
extremely low levels of plasma HDL. HDL has several anti-
atherogenic properties, including a key role in reverse 
cholesterol transport as well as anti-oxidant and anti-inflanuna-
tory properties. The relative importance of these different 
mechanisms warrants further investigation. 
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Abstract 
Objective: Elevated plasma phospholipid transfer protein (PLTP) expression may 
increase atherosclerosis in mice by reducing plasma HDL and increasing hepatic 
VLDL secretion. Hepatic lipase (HL) is a lipolytic enzyme involved in several aspects 
of the same pathways of lipoprotein metabolism. We investigated whether the effects 
of elevated PLTP activity are compromised by HL deficiency. 
Methods and Results: HL deficient mice were crossbred with PLTP transgenic 
(PLTPtg) mice and studied in the fasted state. Plasma triglycerides were decreased in 
HL deficiency, explained by reduced hepatic triglyceride secretion. In PLTPtg mice, 
HL activity and plasma triglycerides were also decreased. HL deficiency mitigated or 
even abolished the stimulatory effect of elevated PLTP activity on hepatic triglyceride 
secretion. HL deficiency had a modest incremental effect on plasma HDL, which 
remained present in PLTP transgenic/HL-/- mice, thereby partially compensating 
the decrease in HDL caused by elevation of PLTP activity. HDL decay experiments 
showed that the fractional turnover rate ofHDL cholesteryl esters was delayed in HL 
deficient mice, increased in PLTPtg mice and intermediate in PLTPtg mice in a HL-/-
background. 
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Conclusions: HL affects VLDL secretion by the liver, while elevated PLTP activity 
lowers plasma HDL cholesterol by stimulating the plasma turnover and hepatic uptake 
of HDL cholesteryl esters. HL is not required for the increase in hepatic triglyceride 
secretion or for the lowering of HDL cholesterol induced by PLTP overexpression. 
Introduction 
Phospholipid transfer protein (PLTP) is a key regulator in lipid and lipoprotein metabolism. 
It is expressed in a variety of tissues and cells, and secreted into the plasma, where it is 
found associated with HDL particles. PLTP has an essential role in HDL metabolism by 
transferring phospholipids between lipoproteins and modulating the size and composition 
ofHDL particles. 1•2 We previously generated a series oftransgenic mouse models in which 
the human PLTP protein is expressed. 3 In these mice, we found a PLTP-dose dependent 
decrease in plasma HDL levels, associated with an increased susceptibility to diet-induced 
atherosclerosis. In PLTP deficient mice, the development of atherosclerosis is reduced, 
even though, in this condition too, lower HDL levels were found.4 Hepatocytes from 
PLTP deficient mice show an impaired secretion of apolipoprotein (apo) B containing 
lipoproteins, possibly explaining the reduction of atherosclerosis development in PLTP 
deficient mice. The role ofPLTP in apoB lipoprotein metabolism has also been investigated 
in our transgenic mice.3•5 Overexpression ofPLTP resulted in a moderate increase in VLDL 
secretion. Taken together, the exact molecular mechanism by which PLTP influences lipid 
metabolism and thereby affects atherogenesis is still unclear. 
In addition to PLTP, a number of other proteins are critically involved in the regulation of 
lipoprotein metabolism, that might lead to interactions by affecting each other's functions. 
From previous work from our laboratory and others, it could be concluded that PLTP and 
cholesterol ester transfer protein (CETP), the other lipid transfer protein that is active in 
human plasma, act independently from each other_6,7 
In addition to CETP, hepatic lipase (HL) is another candidate protein that might affect 
the function of PLTP in plasma. HL is a lipolytic enzyme which catalyzes hydrolysis of 
triglycerides and phospholipids, and in this way is involved in conversion of VLDL into 
LDL particles, as well as in HDL remodeling.8-10 Thus, HL is involved in the same two 
pathways in lipoprotein biochemistry as PLTP, i.e. VLDL and HDL metabolism. In HL 
knockout mouse models, elevated plasma HDL cholesterol levels are found, but effects 
on plasma triglyceride levels appear to be absent, at least in the fasted state.I1 This is 
surprising since hypertriglyceridemia could be expected, because HL has both a lipolytic 
role in hydrolyzing triglycerides of the apoB-containing lipoproteins IDL and LDL, and a 
non-lipolytic function in facilitating the uptake of apoB-containing lipoprotein particles by 
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the liver. 10 Therefore we investigated the absence of hypertriglyceridemia in fasted mice 
with complete HL deficiency. To our surprise we found decreased instead of increased 
triglyceride levels and hypothesized that HL is necessary for optimal hepatic production 
and secretion ofVLDL, a possibility never studied before. 
In the present study, we investigated the possibility of functional relations between PLTP 
and HL. To evaluate HL function, we compared wild type mice with HL deficient mice. 
To study PLTP function, we used two PLTP transgenic mouse models that we generated 
previously: one with 4-5 fold and another with 8 fold elevation of plasma PLTP activity. We 
argued that ifPLTP effects would be dependent on HL activity, these would be compromised 
in HL deficiency. PLTP transgenic mice were crossed with HL deficient mice and effects on 
hepatic triglyceride secretion and HDL cholesteryl ester turnover were measured. 
Methods 
Mice 
PLTP transgenic mice were generated as described before.3 As in our previous studies, 
we used PLTP transgenic mice with two different expression levels resulting in a 4-5 fold 
elevation of plasma PLTP activity (P4 mice) and in an 8-fold increase in PLTP activity 
(A2 mice). 3•12 HL -/- mice were obtained from Jackson Laboratory and were originally 
generated and described by Romanies et al. 11 Mice transgenic for PLTP and deficient for 
HL were obtained by cross-breeding. All animals were in C57BL/6J background(> 99 .5%). 
Only male animals were used in the present study. All animal experiments were performed 
in compliance with institutional (Erasmus MC, Rotterdam, the Netherlands) and national 
guidelines. 
PLTP activity, lipase activities, plasma and hepatic lipids, plasma apolipoproteins 
Plasma samples were collected after an overnight fast. PLTP activity levels were measured 
using an exogenous substrate assay as described previously3 and expressed as arbitrary 
units, in which 1 arbitrary unit is the PLTP activity found in human reference plasma, 
which is equivalent to 14 J.Lmol/ml/hour. HL activity was measured in pre-heparin plasma, 
as well as in post-heparin plasma (collected at 5 min after injection of200 units of heparin/ 
kg body weight into a tail vein) after inhibition of LPL activity with a specific anti-LPL 
antibody and LPL activity was measured in post-heparin plasma as described. 13 Plasma 
levels of total cholesterol or triglycerides were measured with commercially available kits 
as described.3 HDL and non-HDL fractions were obtained by tube slicing after density 
gradient ultracentrifugation using a Beckman 42.2 rotor (42,000 rpm, 2 h 50 min, l2°C) at 
d = 1.063. Lipid levels in liver was measured after extracting the lipids from hepatic tissue 
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using a mixture of chloroform/methanol as described by Bligh and Dyer14 and expressed 
as mg lipid per whole organ. 
Lipoprotein fractions were obtained by density gradient ultra centrifugation of plasma 
samples in a Beckman SW60 Ti rotor (36000 rpm, 21 hr, l2°C). 
Triglyceride secretion experiments 
The hepatic secretion rate of triglycerides was measured after an overnight fast as described 
before5 by injecting animals with Triton WR1339 and collecting plasma samples at various 
time points until 90 minutes after injection. 
HDL decay measurements 
HDL was isolated from wild type mice and radio labeled with the non-degradable labeleH]-
cholesterol oleyl ether using the methods described by Groener et al. 15 Animals were 
injected with 700,000 dpm of radiolabeled HDL. Blood samples were collected from the 
orbital plexus under isoflurane anaesthesia at the indicated time points and radioactivity 
was determined in isolated plasma by liquid scintillation counting. In separate experiments, 
in order to correct for variation in the initial concentrations of plasma HDL-cholesterol, 
animals were injected with radiolabeled HDL supplemented with unlabeled HDL. The 
PLTP transgenic mice in an HL proficient background were adjusted to the level of plasma 
HDL found in wild type mice (1.9 rnMol/L); the PLTP transgenic mice in an HL deficient 
background were adjusted to the level of plasma HDL found in HL deficient mice (2.1 
mMol/L). See legend of figure 6 for details. Tissue radioactivities in tissues were determined 
at the end ofthe decay experiments by liquid scintillation counting. 
Statistics 
Data are expressed as means ± SD. Differences between the various mouse lines were 
analyzed by ANOVA, followed by Bonferroni correction. Differences between two groups 
of mice were analyzed by two sample Wilcoxon rank-sum tests. The tests were performed 
using Intercooled Stata 8.2 SE software (Stata Corporation, College Station, TX, USA). 
Results 
Plasma PLTP activity 
First we checked whether HL deficiency would interfere with plasma PLTP activity. As 
shown in Fig.1, wild type and HL-1- mice have similar plasma PLTP activity levels. As 
reported before, PLTP activity in plasma is elevated in P4 mice and even more so in A2 
mice. In these animals, HL deficiency did not affect plasma PLTP activity (figure1). 
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Plasma HL and LPL activity 
Subsequently, we analyzed whether overexpression of PLTP affects HL or LPL activity. 
Both enzymes are partly bound to proteoglycans on the cell surface and can be released in 
plasma after injection ofheparin.l 6 In wild type mice, HL activity is almost quantitatively 
present in pre-heparin plasma. 13 However, in PLTP transgenic mice this has not been 
measured before. As shown in figure 2A, pre-heparin HL activities in P4 and A2 mice are 
37% en 26% respectively of the activity found in wild type mice, while the post-heparin 
HL activity is unchanged. These results indicate that although PLTP overexpression does 
not affect the total post-heparin HL activity, a substantial part of HL is bound to cellular 
proteoglycans in mice overexpressing PLTP and can be released by heparin. Total post-
heparin LPL activity is shown in figure 2B. In the PLTP transgenic lines there was no 
significant change in LPL activity compared to the wild type animals. 
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Figure 1. PLTP activity levels in plasma. Plasma was collected from mice with the indicated 
genotypes by orbital bleedings. PLTP activity was measured as described in Methods and 
expressed in arbitrary units (AU). 1 AU is equivalent to the PLTP activity found in human 
reference plasma, i.e. 14 llmol/ml!hour. Values are expressed as mean± S.D. n > 12 animals/ 
group. 
*P<O.OOl vs wt (tested for all genotypes) 
#P<O.OOl vs HL-1- (tested only for P4/ HL-1- mice andA2/HL-/- mice) 
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Figure 2. Plasma lipase activities in PLTP transgenic mice and wild type mice. HL activities 
were measured in plasma before (grey bars) and 5 min after (black bars) injection of heparin (A), 
while LPL activities were measured in plasma samples collected 5 min after injection of heparin 
(B), as described in Methods. Values are expressed as mean± S.D. n = 6 animals/group. 
*P<O.OOl vs wt (tested for all genotypes) 
Plasma lipids and lipoproteins 
Measurements of total cholesterol (TC) in plasma are provided in figure 3A. Total plasma 
cholesterol was increased with 21% in HL-1- mice in comparison with wild type animals, 
confirming previous reports. As we reported before, elevated expression of PLTP resulted 
in a strong decrease in total plasma cholesterol. This effect could be partly reversed by HL 
deficiency as an increase in total cholesterol of28% and 108% was found in P4/HL-/- and in 
A2/HL-1-mice compared to P4 andA2 mice, respectively. When non-HDL cholesterol and 
HDL-cholesterol were measured in lipoprotein fractions obtained by ultracentrifugation, 
similar effects were observed (Table 1 ). Effects on plasma phospholipids (PL) largely 
reflect those on plasma TC (figure 3B and Table 1 ). 
Plasma triglyceride concentrations in P4 and A2 mice were decreased to 46% and 14% of 
the triglyceride concentration found in wild type mice (figure 3C). HL -/- , P4/HL -/-and 
A2/HL -1- mice have 46%, 23% and 18% of the triglyceride concentration found in wild 
type mice. 
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Table 1. Plasma total cholesterol (TC) and phosholipids (PL) levels in non-HDL and HDL 
lipoprotein fractions 
non-HDLTC 
wt 0.73 ± 0.06 
HL-1- 1.01 ± 0.18* 
P4 0.74 ± 0.11 
P4/HL-1- 0.90 ± 0.18* # 
A2 0.26 ± 0.10* 
A2/HL-1- 0.31 ± 0.09* ## 
Values are in mmol!L. n > 10 animals. 
*P<O.OOl vs wt 
#P<0.05 vs HL -l-
##p<O.OOl vs HL-1-
300 
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0 
HDLTC non-HDLPL 
1.86 ± 0.16 0.67 ± 0.07 
2.10 ± 0.22* 0.85 ± 0.12* 
0.76 ± 0.07* 0.70 ± 0.10 
1.03 ± 0.19* ## 0.68 ± 0.17## 
0.11 ± 0.03* 0.13 ± 0.06* 
0.36 ± 0.08* ## 0.19 ± 0.06* ## 
*# 
.~~, 
*# *#t 
.... I .. I 
*# 
···=·· 
* 
= 
wt HL-KO P4 PF/HL-KO A2 A2/HL-KO 
HDLPL 
2.19 ± 0.1 
2.42 ± 0.23* 
1.08 ± 0.07* 
1.42 ± 0.21 * ## 
0.26 ± 0.04* 
0.62 ± 0.13* ## 
Figure 4. Secretion rates of hepatic triglycerides. Animals were injected with Triton WR1339. 
Plasma was collected from mice with the indicated genotypes by orbital bleedings at 2, 30, 60, 
and 90 minutes after injection. Triglyceride concentrations were measured and the triglycerides 
secretion rates were calculated using these data. Values are expressed as mean ± S.D. n > 5 
animals/group. 
*P<0.05 vs wt; #p<0.05 vs HL -1-; $p<0.05 vs P4; "~P<0.05 vs A2 
Triglyceride secretion 
We have previously shown that elevated plasma PLTP activity levels in P4 and A2 mice 
result in increased hepatic triglyceride secretion in fasted mice.3 To investigate the possible 
involvement of HL in this PLTP effect, we analyzed triglyceride secretion in mice with 
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various genotypes (figure 4). Surprisingly, HL deficiency by itself decreased the secretion 
rate of triglycerides by 57% as compared to wt mice. As a result of HL deficiency, the 
increased TG secretion due to PLTP overexpression (P4) is eliminated. So the lowering 
effect of HL deficiency on triglyceride secretion is sufficiently large to counterbalance 
the stimulatory effect of elevated PLTP expression on triglyceride secretion normally seen 
in P4 mice. Overall this results in a relatively small decrease in triglyceride secretion, by 
only 20%, in P4/HL-/- mice compared to wild type mice. VLDL secretion in mice with 
the highest PLTP expression (A2) is strongly increased in comparison with wild type mice 
and remains higher than in wild type mice in the absence ofHL. The dramatic effect ofHL 
deficiency on triglyceride secretion did not result in differences in the lipid content of the 
liver (not shown). 
HDL turnover experiments 
To find an explanation for the differences in plasma HDL-cholesterol concentration 
between the various mouse lines, we measured the turnover rates ofHDL cholesteryl esters. 
Animals were injected with [3H]-cholesterol oleyl ether labeled HDL, as a tracer for HDL 
cholesteryl esters, and plasma samples were analyzed for radioactivity at the indicated time 
points (figure 5). HL -/- mice showed a delayed fractional turnover of HDL cholesteryl 
esters compared with wild type mice, with half-lives of the labeled HDL cholesteryl esters 
of 6. 77 ± 0.31 hours versus 5.29 ± 0.29 hours, respectively. In contrast, the fractional 
turnover of HDL cholesteryl esters was faster in mice with elevated PLTP expression, as 
compared with wild type mice. When the half-life ofthe injected dose was calculated, these 
differences appeared to be highly statistically significant (Table 2, all differences P<O.OOI). 
In P4/ HL -/-mice and A2/HL -/-mice, the decay of labeled HDL is delayed in comparison 
with P4 and A2 mice, respectively, but still faster than in wild type mice (figure 5, Table 
2). Obviously, the initial plasma concentrations ofHDL were highly different between the 
various mouse lines. Therefore, we performed a similar set of experiments, in which we 
corrected for the initial plasma concentrations ofHDL by injecting unlabeled HDL into the 
PLTP transgenic mice, thereby achieving similar concentrations of plasma HDL at the start 
of the experiment (for details see the legend to figure 6). As expected, the differences in 
fractional HDL cholesteryl ester turnover rate are reduced, but the half-life in the wild type 
mice remains clearly longer than in the PLTP transgenic mice. Moreover, the half-life of 
HDL cholesterylesters in the HL -/-mice remains longer than in the PLTP transgenic mice 
in an HL -/- background (figure 6, Table 2). Tissue uptake of radioactive HDL cholesteryl 
ether was measured in several organs. In both sets of experiments, uptake by the liver 
(Table 2) was quantitatively most important. 
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Figure 5. HDL decay in plasma. Isolated mouse HDL was radiolabeled with non-degradable 
[3H] cholesteryl oleyl ether, which served as a tracer for HDL cholesteryl esters, and injected 
intraveneously in mice (700,000 dpm/animal). Plasma samples were collected at the indicated 
time points and radioactivity was measured by scintillation counting. n = 6-8 animals/ group. The 
half-lifes of the tracer were calculated from these data for individual mice. These are indicated 
by the vertical dashed lines (means) and provided in Table 2 (means± S.D). 
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Concomitantly, mouse HDL was injected to correct for initial differences in the concentration 
of plasma HDL-cholesterol. P4 mice (mean of 0.8 mMoVL HDL cholesterol) and A2 mice 
(mean of0.1 mMol/L HDL cholesterol) received a bolus-injection of mouse HDL to restore 
the plasma level to the level found in wt mice (on average 1.9 mMoVL HDL cholesterol), 
while P4/ HL -/- mice (mean of 1.0 mMol/L HDL cholesterol) and A2/HL -/- mice (mean 
of 0.4 mMoVL HDL cholesterol) received a bolus-injection of mouse HDL to restore the 
plasma level to the level found in HL -/- mice (on average 2.1 mMol/L HDL cholesterol). 
The total plasma volume of mice was taken as 4.37% of body weight for calculations. 
n = 6-8 animals/group. The half-lifes of the tracer were calculated from these data for 
individual mice. These are indicated by the vertical dashed lines (means) and provided in 
Table 2 (means± S.D) 
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Figure 6. HDL decay in plasma following supplementation with exogenous HDL. Isolated 
mouse HDL was radio labeled with non-degradable [3H] cholesteryl oleyl ether, which served as 
a tracer for HDL cholesteryl esters, and injected intravenously in mice (700,000 dpm/animal). 
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Table 2. Plasma decay and hepatic uptake of radioactively labeled HDL cholesteryl oleyl ether 
genotype wt HL-1- P4 P41Hv1- A2 A2/HL+ 
t112(1) 5.29 ± 0.29 6.77 ± 0.31 * 3.48± 0.11* 5.32 ± 0.47# 0.68 ± 0.08* 1.92 ± 0.29*# 
% ID in plasma (1) 45.1 ± 1.81 53.7 ± 1.5 33.3 ± 3.23 45.9 ± 2.14 13.0 ± 2.3 47.4 ± 5.05 
% ID in liver (I) 26.5 ± 2.32 17.4 ± 1.25 38.0±4.11 23.6 ± 0.95 71.6 ± 3.5 39.5 ± 5.38 
tl/2 (2) 5.29 ± 0.29 6.77 ± 0.31 * 4.10±0.15* 6.04 ± 0.23# 3.90 ± 0.23* 5.40 ± 0.37# 
% ID in plasma (2) 45.1 ± 1.81 53.7 ± 1.5 33.1 ± 1.96 49.7 ± 1.06 32.3 ± 1.3 46.4 ± 2.45 
% ID in liver (2) 26.5 ± 2.32 17.4 ± 1.25 32.5 ± 2.37 22.8 ± 1.59 27.9 ± 2.9 25.3 ± 3.24 
Values are t112 in hours or percentage of the injected dose of radioactivity at the end of the experiment(% ID) without adjustment of initial plasma HDL levels [t112 ( 1)] 
and t 112 in hours or% ID after adjustment of initial plasma HDL levels [t112 (2)]. For more details see legends to figures 5 and 6. n = 6-8 animals. 
*P<O.OOl vs wt 
#P<0.005 vs HL-i-
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Discussion 
Earlier studies in mouse models showed that PLTP affects hepatic triglyceride and apoB 
secretion and HDL metabolism.4•17•18 In the present study we investigated whether HL, a 
lipolytic enzyme which is thought to play an important role in lipoprotein metabolism, S,l0,19 
interferes with the effects ofPLTP. To this end, we crossbred HL deficient mice with PLTP 
transgenic mice and studied the effects of HL and PLTP on VLDL and HDL metabolism. 
As published earlier, elevated expression of PLTP normally results in increased secretion 
of triglyceride-rich lipoproteins by the liver. 3•5 We now report that elevated expression of 
PLTP also stimulates hepatic triglyceride secretion in the absence ofHL (figure 4). Of note, 
plasma PLTP activity in either wild type or human PLTP transgenic mice was not affected 
by deficiency ofHL (figure 1). Both HL and LPL are partly bound to extracellular heparin 
sulfate proteoglycan groups and can be released to the plasma compartment by injection of 
heparin. 16 Post-heparin LPL activity and HL activity were unchanged in PLTP transgenic 
mice. However, in contrast to the situation in wild type animals, 13 a substantial part of 
the HL activity was bound to cellular proteoglycans and is released by heparin injection, 
leading to striking differences in HL activity in pre-heparin plasma of wild type versus 
PLTP overexpressing mice. This might be induced by the decreased HDL levels in PLTP 
overexpressing mice, as HL is normally bound to HDL. Compared with wild type mice, HL 
deficient animals have a moderate increase in total plasma cholesterol and HDL-cholesterol, 
which is in agreement with earlier findings. 11•20 This effect is corroborated by studies in 
HL transgenic mice, showing a decrease in HDL.21 •22 Elevated expression ofPLTP results 
in a decrease of plasma HDL, as shown by us before in transgenic mice3•12 and by others 
using adenoviral methodology. 17•23•24 Only high-level overexpression of PLTP (A2 line) 
decreased both HDL and non-HDL cholesterol and phospholipid concentrations (see Table 
1 ). As expected, plasma phospholipids show changes similar to plasma cholesterol and HDL 
cholesterol, since the bulk of plasma phospholipids is present in HDL. Overexpression of 
PLTP in HL deficient mice results in intermediate levels of plasma HDL, indicating that 
PLTP overexpression in an HL-1- background lowers HDL-cholesterol concentrations but 
not to the same extent as found in a wild type background. These results suggest that the 
effects ofPLTP on plasma HDL-cholesterol concentration do not involve HL, and vice versa 
that effects of HL on plasma HDL-cholesterol concentration are still present in conditions 
of elevated plasma PLTP activity. 
We now report that plasma triglyceride levels are reduced in PLTP transgenic mice (figure 
3C). This appears to be in contrast with the previously reported stimulation of hepatic 
triglyceride secretion.3•5 A stimulation of VLDL degradation is therefore suggested. LPL 
activity was virtually unchanged, so the decreased plasma triglyceride levels in PLTP 
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transgenic mice are not easily explained, but may be related to the role of PLTP in the 
transfer of surface fragments ofVLDL during lipolysis by lipoprotein lipase. 
In contrast, the striking reduction of plasma triglycerides in fasted HL deficient mice can 
be easily explained by our finding of decreased hepatic VLDL secretion. The decrease in 
triglyceride secretion found in HL deficient mice could be due to a rate-limiting effect on 
substrate availability for VLDL synthesis, 8•25 a phenomenon which has also been suggested 
in humans.26 It must be noted that there is no evidence for decreased VLDL production 
rates in human subjects with partial HL deficiency.27•28 Decreased plasma triglycerides 
were not reported in two seminal papers on HL deficient mice.l1 However, there are 
important differences between the earlier studies and our current experiments. The animals 
used by Romanies et al., 11 were much older (>6 months), while the animals used by Qiu et 
al., 11 were 10-14 weeks and were in a non-fasted state. The animals we used were fasted 
overnight, so their plasma lipid levels, in particular triglycerides, cannot be compared with 
those reported by Qiu et al. Moreover, the animals described in the first papers were in a 
129 background or in a mixed genetic background (C57BL6 I 129), while we used mice 
in C57BL/6 background. Therefore, different effects on plasma triglycerides might be 
explained by differences in nutritional state, genetic background and age (animals used in 
the present study were 12-15 weeks). 
The atherogenic potential of elevated PLTP activity may be attributed to its HDL-lowering 
effect, because many of the anti-atherogenic mechanisms are dependent on HDL levels.29 
In humans, HL activity and HDL-cholesterol are inversely correlated.8 Animal studies 
confirmed this relation.8•10•30 In general, plasma HDL levels are mostly determined by HDL 
clearance rather than production.31 Therefore we studied plasma HDL cholesteryl ester 
turnover in our mouse models in more detail and found evidence for a delay in plasma 
decay of labeled HDL cholesteryl esters in HL knockout mice, when compared to wild 
type animals, which can be explained by the hydrolysis of HDL phospholipids by HL 
in wild type animals. In contrast, PLTP transgenic mice showed a PLTP-dose dependent 
accelerated decay of radiolabeled HDL. This effect was partly prevented by deficiency of 
HL. There may be a particular caveat in previous work showing that elevated PLTP results 
in accelerated decay oflabeled HDL components_l7 Because the plasma levels ofHDL in 
wild-type mice and PLTP transgenic mice are widely different, this will strongly affect the 
rate of clearance of injected tracer, the radio labeled HDL. Therefore, we now also performed 
decay experiments in which we corrected for the initial HDL-cholesterol concentration by 
injection of unlabeled mouse HDL. In these experiments, the observed differences were 
smaller, but still clearly present. Therefore we can conclude that HL deficiency retards and 
PLTP expression accelerates the fractional turnover ofHDL cholesteryl esters. 
Finally, an important question is whether our findings provide further insight in the role of 
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both HL and PLTP in atherosclerosis. In the present study we did not use dietary conditions 
and mouse models that are suitable for measuring the development of atherosclerosis in 
coronary vessels or aorta. For HL, both atherogenic and anti-atherogenic properties have 
been reported and therefore the exact role of HL in atherogenesis is still unclear.8•10 HL 
activity was reported to be a risk factor for atherosclerosis in humans,32 and indeed HL 
activity is clearly elevated in high-risk conditions, e.g. type 2 diabetes with low insulin 
sensitivity.33•34 Also in mouse models, different results with respect to atherogenesis have 
been reported depending on the mouse model used. 18) 9•31•32 We now report that total HL 
deficiency results in a marked reduction in hepatic triglyceride secretion, explaining the 
decreased triglyceride levels in overnight fasted mice. However, low HL activity in man 
does not result in low plasma triglycerides or decreased VLDL production rates. In fact 
there is evidence for opposite effects.27 In the case of PLTP, there are reports showing 
that PLTP activity is elevated in human subjects at risk for atherosclerosis development, 
including patients with obesitas and type 1 or type 2 diabetes mellitus.2•35 PLTP has been 
proposed as an independent risk factor3 6 and as a potential target for anti-atherosclerotic 
drug therapy_37 In mice, overexpression ofPLTP is clearly atherogenic, as shown by us and 
others. 3• 12•24 Now we report that elevation of plasma PLTP activity leads to high rates of 
plasma HDL cholesteryl ester turnover. A substantial part of these HDL lipids is taken up 
by the liver (Table 2), probably via SRBI, indicating that this step of reverse cholesterol 
transport is stimulated by PLTP. However, rapid hepatic uptake ofHDL cholesteryl esters, 
induced by PLTP-mediated HDL conversion, may ultimately enhance degradation of small 
HDL particles in the kidneys, resulting in very low plasma concentrations of apo A-I and 
HDL, as can be observed in PLTP transgenic mice. In the end such a low HDL profile may 
tum out to be pro-atherogenic. Further studies, including atherosclerosis-susceptible mouse 
models, are needed to address these issues. 
In conclusion, we provide evidence for novel roles of both HL and PLTP in VLDL and HDL 
metabolism. In addition to its role in HDL metabolism, HL appears to be very important in 
hepatic VLDL secretion, while elevated PLTP activity lowers plasma HDL cholesterol by 
stimulating the plasma turnover and uptake ofHDL cholesteryl esters by the liver. HL is not 
required for the increase in hepatic triglyceride secretion by PLTP overexpression or for the 
lowering ofHDL cholesterol by PLTP overexpression. 
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Abstract 
Phospholipid transfer protein (PLTP) is associated with HDL particles in plasma, where it 
transfers phospholipids between lipoproteins and remodels HDL particles. Tangier disease 
patients, with a mutatedABCAl transporter, have extremely low plasma HDL concentration 
and reduced PLTP activity levels, a phenotype that is also observed in mice lacking ABCAl. 
We investigated whether low HDL levels and low PLTP activity are mechanistically 
related. Firstly, we studied PLTP expression and distribution among lipoproteins in mice 
lacking ABCAl (ABCAl-1-). Parallel to the strong reduction in PLTP activity in plasma of 
ABCAl-1- mice, decreased PLTP protein levels were observed. Neither PLTP synthesis in 
liver or macro phages nor the ability of the macrophages to secrete PLTP were impaired in 
ABCAl-1- mice. However, the PLTP activity level in the medium of cultured macrophages 
was determined by HDL levels in the medium. PLTP was associated with HDL particles 
in wild type mice, whereas in ABCAl-1- mice, PLTP was associated with VLDL and LDL 
particles. Secondly, we treated different mouse models with varying plasma HDL and PLTP 
levels (wild type, ABCAl-1-, apoE-1- and PLTPtg mice, overexpressing human PLTP) with 
a synthetic LXR ligand, and investigated the relationship between LXR-mediated PLTP 
induction and HDL levels in plasma. Plasma PLTP activity in wild type mice was induced 
5.6-fold after LXR activation, whereas in ABCAl-1-, apoE-1- and PLTPtg mice, all having 
reduced HDL levels, induction ofPLTP activity was 2.4-, 3.2- and 2.0-fold, respectively. 
The less pronounced PLTP induction in these mice compared to wild type mice was 
not caused by a decreased PLTP gene expression in liver or macrophages. Our findings 
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indicate that the extent ofLXR-mediated PLTP induction depends on plasma HDL levels. 
In conclusion, we demonstrate that ABCAl deficiency in mice affects plasma PLTP level 
and distribution through an indirect effect on HDL metabolism. In addition, we show that 
the extent of LXR-mediated PLTP induction is HDL-dependent. These findings indicate 
that plasma HDL level is an important regulator of plasma PLTP and might play a role in 
the stabilisation of PLTP in plasma. 
Introduction 
Tangier disease is a genetic disorder of which one of the main characteristics is the 
nearly complete absence of plasma high density lipoproteins (HDL).1 The defective gene 
responsible for this disorder was identified as the ATP-binding cassette (ABC) transporter 
AI.2-5 By mediating efflux of cellular phospholipids and cholesterol to lipid-free or lipid-
poor apoAI, ABCAl plays a pivotal role in the maturation of HDL particles. Moreover, 
macrophage-ABCAl facilitates the removal of excess cholesterol from foam cells, thereby 
preventing the development of atherosclerosis. 6 Since the discovery of the role of ABCAl 
in Tangier disease, many studies have been performed in animal models lacking ABCAl. 
Deficiency of ABCAl in mice produces a phenotype comparable to that of human Tangier 
disease. 7•8 Besides the extremely low plasma HDL levels, a defective phospholipid transfer 
between lipoproteins has been found in plasma of Tangier disease patients and ABCAl 
deficient mice, resulting from reduced phospholipid transfer protein (PLTP) activity.9•10 
Plasma PLTP plays a key role in lipoprotein and HDL metabolism. Being an important HDL 
conversion factor, PLTP remodels HDL particles resulting in the formation of large fused 
a-HDL and small lipid-poor pre~-HDL particles. 11 •12 Pre~-HDL is an efficient acceptor of 
cholesterol from lipid-loaded peripheral cells in vitro. Furthermore, it has been reported 
that PLTP is involved inABCAl-dependent cholesterol efflux in vitro. 13•14 PLTP may also 
have a role in the formation of nascent HDL particles by the liver, as studied using PLTP 
deficient hepatocytes. 15 
However, the role of PLTP in HDL metabolism in vivo is more complex and not fully 
understood. PLTP deficient mice have reduced HDL levels, as a result of a defective 
maturation of HDL particles.16 It has also been demonstrated that PLTP deficient HDL 
particles have enhanced anti-inflammatory propertiesP Elevation of plasma PLTP 
activity in mice leads to an increased formation of pre~-HDL particles, but also to the 
hypercatabolism of mature a-HDL, the latter effect being postulated as the most likely 
cause of the increased susceptibility to atherosclerosis in mice overexpressing PLTP.18-20 
ABCAl and PLTP are both proteins with an essential role in HDL metabolism in liver and 
macrophages. We tried to clarify the mechanism by which PLTP activity levels are affected 
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by the absence of ABCA1, and demonstrated that PLTP levels and distribution in plasma of 
mice lacking ABCA1 are altered due to the strong reduction ofHDL particles. 
To further investigate the relationship between plasma HDL levels and PLTP expression, 
we activated the nuclear liver X receptor (LXR) in vivo in different mouse models. LXR 
is a nuclear receptor controlling the transcription of genes involved in the regulation of 
lipid metabolism and reverse cholesterol transport, the pathway in which cholesterol is 
transported from peripheral tissues to the liver for excretion.21 PLTP and ABCAl both 
have been identified as LXR target genes.22-24 LXR activation in wild type mice is known 
to increase both plasma HDL levels and PLTP activity levels.23 We treated different mouse 
models with varying plasma HDL and PLTP levels (wild type, ABCA1 deficient, apoE 
deficient and PLTP transgenic mice) with a synthetic LXR ligand, and investigated the 
relationship between LXR-mediated PLTP induction and HDL levels in plasma. Using this 
strategy, we demonstrated that LXR-induced elevation of plasma PLTP levels is influenced 
by plasma HDL levels in these mice. 
Materials and methods 
Animals 
The generation of transgenic mice with expression of human PLTP (PLTPtg), controlled by 
its native promoter, has been described previously. 19 ApoE deficient mice ( apoE-/-) were 
purchased from Jackson Laboratory. ABCA 1 deficient mice (ABCA 1-1-) were kindly donated 
by Dr. Francone. 7 All mice were crossed > 15 generations to a C57Bl/6J background. Only 
male mice between 10 and 18 weeks old were used in the study. The animals were kept on 
regular chow diet, and had free access to food and water. 
To perform plasma analyses, blood was taken from the orbital plexus after an overnight 
fasting period. To study the effects of LXR activation in vivo, mice were treated once 
daily with either synthetic LXR ligand T0-901317 ('Tl317'; Cayman Chemical, ITK 
Diagnostics BV) at a dose of 50 mg/kg/day resuspended in sunflower seed oil (Sigma) 
with 5% ethanol, or vehicle alone given by oral gavage for 10 days. At day 11, mice were 
euthanized after overnight fasting. Blood was collected, peritoneal cells were harvested and 
livers were excised and stored at -80°C for later processing. 
All animal experiments were carried out in compliance with national and institutional 
guidelines. 
159 
Chapter 8 
PLTP activity and mass 
PLTP activity in plasma or culture medium was determined by measuring the transfer of 
radiolabelled phospholipids from liposomes to exogenous HDL, as described before.25•26 
PLTP activity is expressed as arbitrary units (AU) in plasma or AU in cell culture medium 
per milligram cell protein. One AU equals 13.9 mmoVL/h, the level ofPLTP activity found 
in human reference plasma. Hepatic phospholipid transfer activity, calculated per mg liver 
tissue, was determined as described,26 and expressed as AU. Hepatic phospholipid transfer 
activity ofPLTP-/- mice (kindly donated by Dr. X-C. Jiang, Brooklyn, NY) was subtracted 
in order to express PLTP-specific activity. Human PLTP mass in plasma from PLTPtg 
mice was measured as described previously,26•27 using a sandwich-type ELISA using 2 
monoclonal antibodies with specificity for human PLTP. The concentration of plasma PLTP 
is expressed as J..Lg/mL. 
Isolation of unstimulated peritoneal cells, flow cytometric analysis and cell sorting 
Resident peritoneal cells were washed from the unstimulated cavities of mice by peritoneal 
lavage with 5 ml of ice-cold sterile PBS. The lavage fluid from 2 to 4 mice was pooled 
and used for cell sorting after FACS analysis. Cells were washed with PBS (GibcoBRL), 
passed through a 0.2 J..L-filter (Falcon), and washed subsequently with PBS containing 10% 
heat-inactivated filtered FCS (GibcoBRL) and 1% penicillin/streptomycin (GibcoBRL) 
("PBS-FCS"). Cells were counted, and 3-6x 106 cells were transferred to FACS tubes. After 
centrifugation at 1200 rpm for 10 min. at 4°C, supernatant was removed and cells were 
incubated on ice with 100 J..Ll of the primary rat mAb F4/80, a marker specific for mouse 
macrophages28 for 30 min. Cells were washed 2x with PBS-FCS and incubated for another 
30 min. with the secondary FITC-conjugated goat anti-rat IgG antibody (diluted 1:500), 
which was pre-incubated for 10 minutes at room temperature with 2% normal mouse serum. 
After washing 2 more times, cells were resuspended in 0.5 ml PBS-FCS. Flow cytometric 
analysis was performed using a FACScan (Becton Dickinson). Dead cells were eliminated 
by negatively selecting for Hoechst 33258 (1 J..Lg/ml) (Molecular Probes) labelled cells. 
Cells were sorted based on their forward/side scatter and on their F4/80+ expression. Sorted 
cells were dissolved in RLT buffer (Qiagen), after which they were immediately processed 
for quantitative RT-PCR. 
Hepatic and macrophage mRNA expression analysis 
Total RNA ofliver and macrophages was isolated using an RNeasy® mini and micro kit 
( Qiagen), respectively. Quantitative RNAexpression analyses were performed as described. 26 
eDNA quantities were normalized to the amount of hypoxanthine-guanine phosphoribosyl 
transferase eDNA, using the t..Ct method [2<-~Ctl], and presented as arbitrary units (AUs). 
Averages were taken from at least three individual runs, each sample in triplicate. 
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Macrophage cell culture and in vitro PLTP secretion experiments 
For in vitro PLTP secretion experiments, bone marrow-derived or thioglycollate-elicited 
peritoneal macrophages from PLTPtg mice either expressing or lacking ABCAl were 
harvested as described before.29•30 Bone marrow-derived macrophages were plated onto 
6-well dishes and cultured in the presence of Macrophage Colony Stimulating Factor 
(Biosource International) as described.30 Thioglycollate-elicited peritoneal macrophages 
were plated onto 24-well dishes and loaded as described before.31 Cells were incubated 
with medium consisting of DMEM, 0.2% BSA, either in the absence or the presence of 
4% serum of wild type or ABCA1 deficient mice, or in the presence of different amounts 
of human HDL (1 to 20 J.Lg/mL cholesterol). At different time points after addition of the 
medium, culture medium was collected and PLTP activity in the medium was quantified. In 
the experiments in which serum was added to the medium, control incubations with serum 
alone were included. PLTP activity measured in the wells with serum alone was subtracted 
in order to express macrophage-specific PLTP secretion. Cells were lysed in 0.1 mol!L 
NaOH with 1% SDS, and cell proteins were quantified.31 PLTP activity is expressed as 
arbitrary units per milligram cell protein (AU/mg). 
Separation of plasma lipoproteins and plasma lipid analyses 
Plasma HDL and non-HDL fractions were separated by ultracentrifugation of freshly 
isolated plasma samples at a density of 1.063 g/m1. 18 Lipoprotein size distribution in pooled 
mouse plasma was determined by gel filtration chromatography as described before. 26 FPLC 
fractions were analysed for total cholesterol (TC) and PLTP activity levels. TC in plasma 
and fractions was measured enzymatically with a commercially available kit (Wako ). 
Statistics 
All values are expressed as mean± SD. Differences were analyzed by two-sample Wilcoxon 
ranksum tests using Intercooled Stata 8.2/SE software (Stata Corporation, College Station, 
Texas USA). Statistical significance was assumed when p<0.05. 
Results 
PLTP expression in ABCAJ deficient mice 
We studied the effect of ABCA1 deficiency on PLTP expression and distribution in mice. 
In accordance with previous findings, 10 plasma PLTP activity level in mice lacking ABCAl 
(ABCAI·I-) was reduced by 85% compared to wild type (wt) mice. Deficiency of ABCAI 
in mice overexpressing human PLTP (PLTPtg) also reduced total PLTP activity (figure I A). 
This reduction in PLTP activity was not caused by inactivation of plasma PLTP, as it 
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Figure 1. PLTP expression in mice with or without ABCAl. A) Plasma PLTP activity. 
Values are expressed as arbitrary units (AU)± S.D. n=4-6 mice per group. *p<O.OOl versus wt or PLTPtg; 
#p<O.OOl versus wt or ABCA]·I-. B) Plasma PLTP mass. Human PLTP protein was quantified using a 
Sandwich-type ELISA. Values are expressed as ).lg/mL± S.D. n=4 mice per group. *p<O.OOl versus PLTPtg. 
C) Hepatic and macrophage PLTP mRNA. The expression of PLTP in livers and FACS-sorted peritoneal 
macrophages was analyzed by real-time PCR. Values are expressed as arbitrary units (AU)± S.D. n=3-4 
mice per group. D) Hepatic PLTP activity. PLTP-mediated transfer in the liver is represented as the total 
phospholipid transfer activity in 1 mg liver tissue subtracted with the phospholipid transfer activity found 
in 1 mg liver tissue ofPLTP deficient mice. Values are expressed as arbitrary units (AU)± S.D. n=6 mice 
per group. 
was associated with a similar decrease in PLTP mass in plasma of PLTPtg mice lacking 
ABCAl (figure lB). To investigate whether PLTP gene expression was affected by ABCAl 
deficiency in mice, we isolated RNA from liver and peritoneal macrophages, two important 
sources of systemic PLTP, 18•30 and we quantified PLTP mRNA. Because thioglycollate-
injection affects plasma PLTP activity levels,30 we isolated non-elicited peritoneal cells 
and pooled the cells of 2 to 4 mice. We subjected the cells onto a FACS to sort the mature 
macrophages, and performed gene expression analyses. Hepatic and macrophage mRNA 
expression levels of murine PLTP were not different between wt andABCA1·1· mice (figure 
lC). Unlike plasma PLTP activity, hepatic PLTP activity levels were not different between 
the two groups (figure lD). These results indicate that PLTP expression is not affected in 
ABCA1·1• mice, suggesting that the decrease in plasma PLTP levels in ABCAI·i- mice is 
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caused by a decreased secretion ofPLTP into the circulation or by an increased catabolism 
of systemic PLTP. 
PLTP secretion by macrophages 
To study whether the reduced PLTP levels in ABCAl-1- mice could be explained by a 
decreased secretion of PLTP from cells lacking ABCAl, we cultured macrophages of 
mice overexpressing human PLTP either expressing or lacking ABCAl (PLTPtg and 
ABCAl-1-PLTPtg mice, respectively), as this is the cell type with the relatively highest 
PLTP expression (figure lC). PLTP activity was measured in the culture medium of the 
macrophages at different time points. Surprisingly, we found slightly higher PLTP activity 
levels in medium from thioglycollate-elicited peritoneal macrophages of ABCA 1-1-PLTPtg 
mice after 8 and 24 hours compared to cells of PLTPtg mice (figure 2A). Similar results 
were found for PLTP activity from cultured bone marrow-derived macrophages (figure 
2B). These findings demonstrate that the ability of ABCAl deficient cells to secrete PLTP 
is not impaired and thus do not explain the decreased plasma PLTP levels in these mice. 
This also indicates that a systemic rather than a cellular effect accounts for the decrease 
in PLTP. We investigated whether PLTP activity levels are determined by HDL levels. 
Therefore, we cultured PLTPtg macrophages in the presence of serum from ABCAl-1-
or wt mice, or in the presence of increasing HDL concentrations. Phospholipid transfer 
activity levels of secreted PLTP in the medium at all time points was approximately 25% 
lower in the presence of serum from ABCAl-1- mice compared to serum from wt mice. In 
the absence of serum, PLTP activity was significantly lower compared to serum from wt 
and ABCAl-1- mice (approximately 40 and 25%, respectively) (figure 2C). When adding 
increasing amounts of HDL to the culture medium, we found a dose-dependent increase 
in PLTP activity levels, which reached a maximum level at 10 flg/mL HDL-C (figure 2D). 
These findings indicate that PLTP activity levels are determined by HDL levels in vitro and 
that reduced PLTP levels in plasma of ABCAl deficient mice might be explained by an 
indirect effect of ABCAl via the reduction of plasma HDL levels. 
PLTP distribution inABCAl deficient mice 
To study whether the distribution of active PLTP among lipoproteins was affected by the 
reduced HDL levels in ABCAl-1- mice, we performed FPLC analyses on mouse plasma. 
As expected, in wt mice PLTP activity peaked in fractions 11-13, at the position oflarge 
HDL particles, indicating that PLTP is associated with HDL particles (figure 3A). However, 
in ABCAl deficient mice PLTP was found mainly in fractions 5-8, at the position of LDL 
particles (figure 3B), indicating that PLTP can be associated with other lipoprotein particles 
when HDL particles are scarce or absent. 
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Figure 2. Secretion of active PLTP from macrophages in vitro. 
(A-B) PLTP activity in culture medium of thioglycollate-elicited peritoneal macrophages (A) or bone 
marrow-derived macrophages (B) isolated from PLTPtg andABCA 1-i-PLTPtg mice. *p<0.05 versus PLTPtg. 
(C-D) PLTP activity in culture medium of thioglycollate-elicited peritoneal macrophages of PLTPtg mice 
either in the absence or in the presence of serum from wt or ABCA 1-/- mice (C), or in the presence of HDL 
(D). *p<0.05 versus serum from wt mice (C) or versus 0 )lg/mL HDL cholesterol (D). Values are expressed 
as arbitrary units (AU) per milligram cell protein± S.D. n= cells from 4-6 mice per group. 
Effect of LXR activation on plasma PLTP 
To investigate the relationship between plasma HDL levels and PLTP expression more into 
detail, we treated mouse models with varying plasma HDL and PLTP levels with a synthetic 
LXR ligand ('T1317'): wild type (wt), ABCAl deficient (ABCAl-1-), apoE deficient 
( apoE-1-) and PLTPtg mice. After 10 days oftreatment, plasma lipid and lipoprotein analyses 
were performed and the effect oflipoprotein levels on LXR-mediated PLTP induction was 
studied. 
In accordance with previous findings,23 activation ofLXR in wt mice was associated with 
elevation ofTC and the formation of enlarged HDL particles (Table 1+ figure 4A). Tl317-
treatment increased PLTP activity by 5.6-fold, and PLTP activity was found at the position 
of the large HDL particles (figure 4A). 
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Figure 3. Distribution of active PLTP among plasma lipoprotein particles 
Pooled plasma of wild type (A) and ABCA1·1- (B) mice was subjected to FPLC TC (circles) and PLTP 
activity (triangles) were measured in the fractions. Values are represented as fractional percentages of total 
amount ofTC and PLTP activity measured in the column eluate. n=4 mice per group. 
ABCAl-1- mice have strongly reduced plasma cholesterol and HDL-C levels compared 
to wt mice (10% and 4% of wt levels, respectively), and plasma PLTP activity level is 
decreased ( 18% of wt). Treatment of ABCA 1-/- mice with the synthetic LXR ligand resulted 
in increased TC levels compared to non-treated animals, but only in the VLDL-sized 
fractions (Fig.4B). Tl317-treatment increased PLTP activity only 2.4-fold in ABCAl-1-
mice. Importantly, in T1317-treatedABCAl-1- mice, PLTP was associated with VLDL and 
LDL particles (figure 4B). 
ApoE-1- mice have increased TC levels (300% of wt) but reduced HDL-C levels (18% 
of wt), and plasma PLTP activity levels is 64% of the level in wild type mice. Treatment 
of these mice with the T1317 compound led to increased plasma TC levels, due to the 
induction ofTC in the non-HDL sized fractions. Plasma PLTP activity level was increased 
3.2-fold by LXR stimulation. Despite the high non-HDLIHDL ratio in apoE-1- mice, PLTP 
was found at the position ofHDL particles (figure 4C). 
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PLTPtg mice have elevated PLTP activity levels (350% compared to wt) and reduced HDL 
levels (50% compared to wt). After treatment of PLTPtg mice with an LXR agonist, TC 
levels were increased. HDL-cholesterol levels were slightly increased, and presence of 
enlarged HDL was seen on gel filtration profiles (figure 4C). Total PLTP activity in T1317-
treated PLTPtg mice was 2.0-fold higher than in non-treated PLTPtg mice. Also PLTP mass, 
representing the level of human PLTP protein in plasma,27 was increased in treated mice 
(Table 1 ). Despite the high PLTP levels and reduced HDL levels compared to wt mice, 
PLTP was found associated with HDL particles (figure 4C). These results demonstrate 
that the strongest induction of PLTP after LXR stimulation is found when HDL levels 
are high. FPLC analyses demonstrated that PLTP is associated with HDL particles except 
in ABCA1·1- mice, suggesting a main role of HDL in determining PLTP position among 
lipoprotein particles. 
Although PLTP is induced in all mice after LXR stimulation, the increase in plasma PLTP 
activity levels is less pronounced in mice with lower HDL levels (3.2-, 2.4- and 2.0-
fold in apoE·1-, ABCAl-1- and PLTPtg mice, respectively) than in wt mice (5.6-fold). We 
investigated whether these differences in induction of plasma PLTP after Tl317 -treatment 
could be explained by a reduced transcription of PLTP in mice with reduced HDL levels. 
The increase of mouse PLTP mRNA levels upon treatment was not significantly different 
in liver or macrophages between the three groups (data not shown). 
Table 1. Plasma PLTP and lipids 
genotype treatment total plasma d>l.063 plasmaPLTP plasma PLTP 
TC (mmol/L) TC (mmol/L) activity (AU) mass (Jlg/mL) 
wt - T1317 3.8 ± 0.6 2.8 ± 0.2 233 ±54 N/A 
+T1317 5.8±0.8b 3.6±0.5b 1313 ± 244 b N/A 
ABCA1·1· 
- T1317 0.4± 0.1' 0.1 ± 0.1' 43 ± 9a N/A 
+ T1317 1.1 ± 0.2 a,b 0.2±0.1a 103 ± 34 a,b N/A 
ApoE·1-
- T1317 11.4± 1.0a 0.5 ± 0.1 a 149 ± 26 a N/A 
+T1317 30.0 ± 3.4 a,b 0.7 ± 0.1" 482 ± 115 a,b N/A 
PLTPtg - T1317 2.0 ± 0.3 a 1.4 ± 0.2 a 809 ± 351 a 30 ±4 
+T1317 2.9 ± 0.8 a,b 1.7 ± 0.3 a,b 1620 ± 873 a,b 78 ± 11 b 
Values represent mean ± SD 
ap< 0.05 compared to wild type mice 
b p< 0.05 compared to- Tl317 
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Figure 4. Effect of LXR stimulation on PLTP distribution among plasma lipoprotein particles 
Pooled plasma of wild type (A), ABCA1·1- (B), apoE·1- (C), and PLTPtg (D) mice treated with synthetic LXR agonist T0-901317 ('T1317'; 50 mg/kg/day) or placebo 
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Discussion 
In the first part of our study, we report that 1) PLTP activity and protein levels are reduced 
inABCA1 deficient mice; 2) this is not caused by a decreased gene expression ofPLTP in 
liver or macrophages, nor by an impaired ability of macrophages to secrete PLTP in vitro; 
3) PLTP activity levels in the medium of macrophage cultures depend on HDL levels in the 
medium; 4) PLTP is associated with HDL particles in wild type mice, whereas in ABCAl 
deficient mice, PLTP is associated with VLDL and LDL particles. 
Reduced PLTP activity levels in patients with Tangier disease and in mice lacking ABCA1 
have been reported previously,9,10 but it was unknown whether this is associated with 
decreased PLTP protein levels or with the inactivation ofPLTP. Because our assay to quantify 
PLTP protein levels is dependent on monoclonal antibodies specific for human PLTP, we used 
mice expressing human PLTP, and found that plasma PLTP protein levels are reduced in mice 
lacking ABCA1 compared to mice with functional ABCA1. We subsequently studied PLTP 
gene expression in liver and macrophages, two important sources ofPLTP synthesis, from 
both mouse models. We previously generated mice with the overexpression of human PLTP 
specifically in the liver18 or in macrophages,30 and showed that human PLTP contributed 
significantly to systemic PLTP activity levels in both models. In the present study, we did 
not find differences in PLTP mRNA expression in liver or macrophages between ABCA1 
deficient mice and wild type mice, neither in the hepatic PLTP activity, indicating that PLTP 
production is not affected in the absence of ABCA 1. Hence, we investigated the possibility 
that PLTP secretion by ABCA1 deficient macrophages is decreased, but found that the 
ability of macrophages to secrete PLTP in vitro is not impaired by ABCA1 deficiency. 
We cannot exclude the possibility that PLTP interacts with ABCAl at the cell surface, as 
demonstrated previously by in vitro experiments, 14 which could explain the lower PLTP 
activity levels in the medium of ABCA1 expressing cells compared to medium of ABCA1 
deficient cells. However, we also demonstrated that the levels of active PLTP in the medium 
of cultured macrophages are increased by HDL in the medium. HDL may either directly 
stimulate PLTP secretion, or stabilize or activate secreted PLTP. HDL-dependent activation 
ofPLTP is probably not the explanation, because plasma PLTP mass in vivo is also reduced 
in the absence of ABCAl, as shown in our mouse models. PLTP is associated with large, 
mature HDL particles in wild type mice. In ABCAl-1- mice however, in which HDL levels 
are reduced to less than 5% of wild type levels, we found that PLTP was associated mainly 
with LDL particles. Therefore we decided to study the relationship between PLTP and HDL 
levels more into detail. 
In the second part of our study, we activated LXR in mice, thereby inducing changes in 
lipoprotein metabolism and PLTP expression. We investigated whether induced PLTP 
levels and PLTP distribution in plasma were influenced by the plasma lipoprotein levels 
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and distribution. We report that 1) LXR activation induces changes both in lipoprotein 
metabolism and in PLTP expression in mice; 2) the increase in plasma PLTP activity levels 
is less pronounced in mice with reduced HDL levels; 3) murine PLTP gene expression in 
liver and macrophages upon LXR activation is induced to the same extent in all mice; 4) 
Plasma HDL is an important determinating factor of the distribution of PLTP among the 
different lipoprotein classes. 
PLTP has been identified as a target gene of LXR in liver and macrophages,22•23 together 
with a whole network of other proteins with an important role in cholesterol metabolism and 
reverse cholesterol transport. Administration of a synthetic LXR ligand in wild type mice 
results in an increase in HDL level, HDL-enlargement and enhancement of macrophage 
reverse cholesterol transport.23•32 An important role for PLTP in LXR-mediated HDL 
enlargement in wild type mice has been suggested.23 We found that PLTP was induced in 
all mice, even in the almost complete absence of HDL. However, plasma PLTP activity 
after LXR treatment was less induced in ABCA1·1-, apoE·/- and PLTPtg mice compared to 
wt mice. Increase in liver and macrophage PLTP mRNA expression after treatment was 
similar in all mice, demonstrating that PLTP is a direct LXR target gene and the LXR ligand 
probably induces PLTP synthesis to the same extent in all mice. Therefore, the difference 
in extent to which plasma PLTP is increased after LXR activation is most likely a systemic 
effect, and is correlated with plasma HDL levels. It is remarkable that in PLTPtg mice with 
HDL levels of about 50% of wild type mice, plasma PLTP activity was increased only 
2-fold after LXR activation, whereas in ABCAI·1- mice with extremely low HDL levels, 
PLTP was increased 2.4-fold. The fact that absolute plasma PLTP activity levels in non-
treated PLTPtg mice are already much higher than in other mouse models (3.5- and 18.8-
fold higher than in wt and ABCAI·1- mice, respectively), could explain this finding. 
Furthermore, we demonstrated that plasma HDL is an important determinating factor of 
the distribution ofPLTP among lipoprotein particles. In wt mice, PLTP activity peaked at 
the position of large HDL particles, which is in line with findings in human plasma.25•27 
After Tl317-treatment, more enlarged HDL particles were found and PLTP activity peak 
was broader, but no clear leftward shift was observed. In apoE·1- and PLTPtg mice, PLTP 
was also found associated with HDL particles. Elevation of plasma non-HDL levels (in 
apoE-1- mice) or elevation of PLTP activity levels (in PLTPtg mice) by LXR activation 
did not affect the position of PLTP on HDL. In ABCAI·I- mice, LXR activation led to 
an increase in VLDL levels, in accordance to previous findings,33 and PLTP was found 
associated mainly with these VLDL particles. The exact reason ofthe leftward shift of the 
PLTP activity peak to larger lipoprotein classes after treatment is not clear, but might be due 
to the change in the composition ofVLDL particles after treatment with an LXR agonist.34 
It has been reported previously that HDL in ABCAI-1- mice is present as small lipid-poor 
pre~-HDL, with no detectable HDL within the larger a-HDL size interval. 10 The absence of 
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large, mature a-HDL particles most likely accounts for the unusual position of active PLTP 
in plasma of ABC AI deficient mice. 
PLTP has multiple effects, cellular and systemic, which all include "association" of PLTP 
with HDL particles. The importance ofPLTP in HDL metabolism is intensively studied in 
vitro, and PLTP might interfere in several steps of the reverse cholesterol transport pathway. 
A role for macrophage-PLTP is suggested in theABCA !-dependent cholesterol efflux, where 
PLTP may function to shuttle lipids between cells and existing HDL particles. 35 Furthermore, 
PLTP remodels HDL particles with the generation of cholesterol acceptor particles.11 •12 
Also a role ofPLTP in the retention ofHDL on atherosclerotic plaque extracellular matrix 
is suggested, as PLTP may mediate HDL binding to cellular proteoglycans in vitro. 36 
In addition, PLTP may also play an important role in the maturation of HDL particles, 
by mediating early lipidation of apoAI. 15 HDL particles may stabilize PLTP but when 
present at high concentrations, PLTP on its tum may destabilize HDL particles, resulting 
in an increased catabolism.20 In our study, we found that LXR activation in PLTPtg mice 
was associated with increased HDL levels as well as high plasma PLTP activity levels. 
Activation ofLXR induces several anti-inflammatory and anti-atherogenic mechanisms in 
mice. 37 Whether either these LXR-mediated anti-atherogenic effects or the pro-atherogenic 
effects of high systemic PLTP levels predominate in the process of atherogenesis, needs to 
be further investigated. 
In the present study, we demonstrated the importance ofHDL levels for PLTP levels, PLTP 
distribution among lipoprotein particles, and LXR-mediated PLTP induction in plasma. 
These findings indicate that plasma HDL level is an important regulator of PLTP and that 
HDL particles might play a role in the stabilisation ofPLTP in plasma. 
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Abstract 
Background: Phospholipid transfer protein (PLTP) is expressed by various cell types. In plasma, it is associated with high 
density lipoproteins (HDL). Elevated levels of PLTP in transgenic mice result in decreased HDL and increased atherosclerosis. 
PLTP is present in human atherosclerotic lesions, where it seems to be macrophage derived. The aim of the present study is 
to evaluate the atherogenic potential of macrophage derived PLTP. 
Methods and Findings: Here we show that macrophages from human PL TP transgenic mice secrete active PLTP. 
Subsequently, we performed bone marrow transplantations using either wild type mice (PLTPwt/wt), hemizygous PLTP 
transgenic mice (huPLTPtg/wt) or homozygous PLTP transgenic mice (huPLTPtg/tg) as donors and low density lipoprotein 
receptor deficient mice (LDLR-/-) as acceptors, in order to establish the role of PLTP expressed by bone marrow derived 
cells in diet-induced atherogenesis. Atherosclerosis was increased in the huPLTPtg/wt...,.LDLR-1- mice (23·fold) and even 
further in the huPLTPtg/tg->LDLR-/- mice (4.S·fold) compared with the control PLTPwt!wt->LDLR-/- mice (both 
P<0.001). Plasma PLTP activity levels and non·HDL cholesterol were increased and HDL cholesterol decreased compared 
with controls (all P<0.01). PLTP was present in atherosclerotic plaques in the mice as demonstrated by 
immunohistochemistry and appears to co-localize with macrophages. Isolated macrophages from PLTP transgenic mice 
do not show differences in cholesterol efflux or in cytokine production. Upopolysaccharide activation of macrophages 
results in increased production of PLTP. This effect was strongly amplified in PLTP transgenic macrophages. 
Condusions: We conclude that PLTP expression by bone marrow derived cells results in atherogenic effects on plasma 
lipids, increased PLTP activity, high local PLTP protein levels in the atherosclerotic lesions and increased atherosclerotic 
lesion size. 
Citation: van Haperen R, Samyn H, Moerland M, van Gent T, Peeters M, eta!. (2008) Elevated Expression of Phospholipid Transfer Protein in Bone Marrow Derived 
Cells Causes Atherosclerosis. PLoS ONE 3(5): e2255. doi:10.1371/journal.pone.0002255 
Editor: R. Sanders 5. Williams, Duke University, United States of America 
Received March 14, 2008; Accepted March 25, 2008; Published May 28, 2008 
Copyright: © 2008 van Haperen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 
Funding: Part of this work was supported by Zorgonderzoek Nederland Medische Wetenschappen-the Netherlands Organisation for Health Research and 
Development (910-31-806). 
Competing Interests: The authors have declared that no competing interests exist. 
* E-mail: m.decrom@erasmusmc.nl 
Introduction 
Phospholipid transfer protein (PLTP) is a plasma protein with 
the capacity to transfer phospholipids betvveen liposomes and 
lipoproteins in vitro [1-4]. In addition, PLTP can also transfer 
vitamin E [5] and is active as a conversion factor of high density 
lipoproteins (HDL) [6, 7]. HDL are generally considered anti-
atherogenic lipoproteins by virtue of their role in cholesterol 
excretion (reverse cholesterol transport) [8], although other anti-
atherosclerotic properties of HDL have been described as well 
[9,10]. Therefore, it was suggested that PLTP has a role in the 
development of atherosclerosis, based on its relation -with HDL 
function [11, 12]. In vivo, phospholipids become available for 
PLTP-mediated transfer during lipolysis of triglyceride-rich 
lipoproteins, mostly chylomicrons and very low density lipopro-
teins (VLDL), by the enzyme lipoprotein lipase [12]. The 
phospholipids are transferred from triglyceride-rich lipoproteins 
to HDL. PLTP is able to bind to and facilitate the transfer of 
several types of phospholipids, including phosphatidylcholine, 
phosphatidylethanolanllne, and phosphatidylinositol, as well as 
sphingomyeline [13]. In plasma, PLTP is mosdy bound to HDL 
[11]. 
In genetically modified mouse models the relation between the 
activity levels of PL TP in plasma, HDL levels, HDL subclass 
distribution and the development of atherosclerosis was studied in 
more detail. \Ve found that a 2.5-fold increased plasma PLTP 
activity in transgenic mice resulted in a 30% decrease in plasma 
HDL-cholesterol levels compared with wild type animals [14]. 
Thls represents total HDL, however. The formation of a specific 
subfraction ofHDL, termed prei)-HDL, appeared to be increased 
in plasma from transgenic mice. Although pre/)-HDL is a 
quantitatively minor HDL subfraction, it is believed to be a very 
efficient acceptor of cellular cholesterol and therefore an elevated 
production of prei)-HDL might result in a strong induction of 
reverse cholesterol transport [15]. Therefore, we suggested that 
PLTP increased the anti-atherogenic potential of HDL [14]. 
Subsequently Jiang and co-workers showed that PLTP deficiency 
was anti-atherogenic, however [16], in spite of decreased levels of 
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plasma HDL. The effect was attributed to a reduced production of 
apolipoprotein (apo)B containing lipoproteins by the liver. Indeed, 
we provided further evidence of an atherogenic role of PL TP in 
studies in a series of PL TP transgenic mouse lines \Vith increasing 
levels of plasma PLTP activity, showing a PLTP-dose dependent 
enhancement of atherosclerosis [1 7]. We also provided in vivo 
evidence that PLTP is involved in the secretion of very low density 
lipoproteins (VLDL) [17,18], but there was no PLTP-dose 
dependent increase of this effect in the series of PLTP transgenic 
mice tested [17]. In contrast, we observed a clear PLTP-dose 
dependent reduction of plasma HDL levels in parallel to the 
induction of atherosclerosis and therefore we concluded that 
elevated plasma PL TP activity in transgenic mice is atherogenic 
because :it decreases plasma HDL. PLTP could also influence the 
atherogenicity of plasma lipoproteins by decreasing the vitamin E 
content of apoB-containing lipoproteins, resulting in increased 
susceptibility for oxidation [19]. 
PL TP is ex.-pressed in a vvide variety of cells and tissues in 
humans [20], mice [21] and human PLTP transgenic mice [14], 
In addition, the presence ofPLTP in human atherosclerotic lesions 
has been demonstrated [22,23], which probably originates from 
macrophages. In order to elucidate the role of PL TP derived from 
bone marrow derived cells, including macrophages, to atheroscle-
rosis, we performed in vitro studies -with macrophages from PLTP 
transgenic mice and performed bone marrow transplantations 
from PLTP transgenic mice to low density lipoprotein (LDL) 
receptor deficient mice and subsequently studied the process of 
diet-induced atherosclerosis as influenced by these bone marrow 
transplantations. 
Methods 
Mice 
LDLR -I- mice were obtained from the Jackson Laboratory 
(Bar Arbor, ME) and were in C5 7BL6/j background, M;ce 
ex.lJressing enhanced green fluorescent protein (EGFP) under the 
control of the chicken beta-actin promotor and cytomegalovirus 
enhancer were originally generated by Okabe et al. and were in 
C5 7BL6/j background [24,25], Human PLTP transgenic mice 
were generated in our laboratory as described before and are 
derived from the P4 line (17]. The transgene in these animals 
contains the complete human PLTP gene, including approxi-
mately 15 kb 5' natural flanking region and 3 kb 3 1 natural 
flanking region. The transgene is driven by its autologous human 
promoter. PLTP transgenic mice were crossbred to C57BL6/j 
background for > 15 generations. Subsequently, homozygous 
PLTP transgenic mice were obtained by crossbreeding hemizy-
gous PL TP transgenic mice. Animals were provided -with food and 
water ad libitum. Food was either regular chow, or a high fat, high 
cholesterol diet containing 40% (w/w) sucrose, 15% (w/w) cocoa 
butter, and 0.25% (w/w) cholesterol (diet W; Hope Farms, 
Woerden, The Netherlands). The numbers of animals used for 
measurements are indicated in the Figure legends. Only male mice 
were used. All of the procedures in this study were in accordance 
vvith national and institutional guidelines. 
Bone marrow transplantation 
On the day of donor cell injection, LDLR-/- mice of 12 weeks 
old were conditioned by 900 rads of y-:irradiation from a 137Cs 
source, which was administered in a split dose, with a 3 hours 
interval. Cells were injected i.v. into the tail veins. Each recipient 
received 5 x 1 06 bone marrow cells isolated from the femurs and 
tibias of the primary donors. Injected animals were provided vvith 
0.16% Neomycin (Sigma-Aldrich)-supplemented water. Animals 
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were kept on a regular chow diet unril9 weeks after transplantation. 
During the ne."~ 9 weeks, animals were fed a high fat, high 
cholesterol diet. 
Analysis of plasma lipids, lipoproteins, PLTP 
concentration and PLTP activity 
Blood samples were obtained via orbital bleedings after an 
overnight fast at 1 week before the bone marrow transplantation, 
just before the start of the diet and at the end of the 9 weeks high 
fat, high cholesterol diet feeding. Plasma lipids (total cholesterol, 
phospholipids and triglycerides) were measured using commer-
cially available kits rJVako Chemicals). Lipoprotein fractions were 
obtained by ultracentrifugation of plasma samples in a Beckman 
42,2 Ti rotor (42000 rpm, 3 h, 12'C) at d= L063 g/rnl. Tubes 
were sliced, and two fractions were collected: non-HDL 
(VLDL+LDL), d<l.063 g/rnl; and HDL, d> 1,063 g/ml. PLTP 
activity in plasma was measured as described previously (14] and 
expressed in arbitrary units (AU). 1 AU is equivalent to the activity 
found in human reference plasma, which is 14 ~ol/rnl/h, PLTP 
concentration was measured by EUSA as described [18], using 
PLTP annbodies which were kindly donated by Dr, H. Hattori 
(BJVIL Incorporated, Saitama, Japan). PLTP specific activity was 
calculated as the ratio (PLTP activity in AU)/(human PLTP 
concentration in mg/L). 
Histological analyses and quantification of 
atherosclerotic lesions 
Animals were anesthetized using isoflurane, and in situ fnmtion 
was performed via the left ventricle of the heart using phosphate-
buffered formaldehyde (4%, v/v). Sectioning of the aortic root, 
hematoxilin/ eosin staining, the collection of digital images and the 
quantification of atherosclerotic lesions were performed as 
described before [26]. 
Immunohistochemistry was performed using antibodies directed 
against CD68 to detect macrophages (AbD Serotee, Kidlington, 
UK), against CD31 to detect endothelial cells (Hycult Biotech-
nology BV, Uden, The Netherlands), or against vascular smooth 
muscle cells alpha-actin (Sigma Chemical Co., Zwijndrecht, The 
Netherlands) or against PLTP (kind gift of Dr, MattiJauhiainen, 
Helsinki, Finland). 
Cell culture studies 
For the isolation of primary macrophagcs mice were i.p. 
injected with 3 mL of 40.5 g/L Bacto® Brewer Thioglyeollate 
Nledium (Difco International B.V., Leeuwarden, The Nether-
lands). After three days the animals are anesthetized using 
isofluranc and macrophages arc isolated from the peritoneal 
cavity in 0.34 M sucrose. Cells were cultured in Dulbecco's 
Nlodified Eagle Medium (D:rvrEM, Gibco, Invitrogen, Breda, The 
Netherlands) supplemented vvith 10% (v/v) fetal bovine serum and 
100 U/mL penicillin/streptomycin. Cells were seeded on 6 wells 
plates {3 x l 06 cells/well) and kept in culture for 24 hours. 
Alternatively, macrophages derived from bone marrow in vitro 
were obtained by isolating bone marrow cells from tibias and 
femurs, seeding the cells on 6-wells plates (3xl05 cells/well) and 
culturing them in the presence of 10 ng/ml Macrophage Colony 
Stimulating Factor {Biosource International, Camarillo CA, USA) 
[27], The concentrations of TNF-cx, IFN-y, IL-4, or IL-l 0 in the 
supernatants were measured using commercially available EUSJ\.s 
(BD Biosciences Pharmingen, Alphen aan den Rijn, The Nether-
lands). PLTP activity was measured after 24 hours of culture in the 
supernatant vvith the same assay as used for the PL TP activity 
measurements in plasma. In some cases, cells were challenged by 
adding l 00 ng/ mL bacterial lipopolysaccharide (from E. coli 
serotype Olll:B4, Sigma, Chemical Co., Zwijndrecht, The 
Netherlands). In order to measure the cholesterol loading and 
efilu..x capacity [28], macrophages were seeded on 3 em dishes 
(3 X l 06 cells/ dish). After 2 hours, the medium was replaced with 
DMEM supplemented with l% (v/v) fetal bovine serum, 100 U/mL 
penicillin/streptomycin, 30 j.lg/mL acetylated LDL (acLDL) [29], 
l j.ig/mL Acyl CoA:cholesterol acyltransferase inhibitor (gift from 
Sandoz AG, Basel, Switzerland) and 0.33 j.lCi ['H]-cholesterol/mL 
for 22 hours. Effiu..\: was monitored by incubating these loaded cells 
in DMEM containing 0.2% (w/v) fat-free BSA (Sigma Chemical 
Co., #6003, Zwijndrecht, The Netherlands) and 100 j.lg/mL 
human HDL and sampling the medium at 1, 2, 4, and 6 hours. 
At the end of the efilu..x study, cell associated radioactive cholesterol 
was measured and the percentage of cholesterol efflu..x was 
calculated. Cells were lysed in 0.! M NaOH/ 0.5% (w/v) SDS 
and cellular protein was determined using the Lowry method [30]. 
Statistics 
All of values are e."-lJressed as mean±S.E. Statistical analyses are 
by one-way analysis of variance with Bonferroni multiple 
comparison tests performed with Intercoolcd Stata 6.0 softvvare 
(Stata Corp., College Station, TX, USA). 
Results 
PLTP production by mouse macrophages 
In a first set of e::-.:periments, peritoneal macrophages were 
collected from three groups of mice: wild type control animals 
(PLTPwt/""1:), hemizygous human PLTP transgenic mice 
(huPLTPtg/wt) and homozygous human PLTP transgenic mice 
(huPLTPtglt~· Macrophages were kept in culture for 24 hours 
before PLTP activity was measured in the culture medium. As 
shovvn in Fig. l, PL TP activity could be measured in the medium 
of cells from PLTPwthvt mice, demonstrating that PLTP is 
produced and excreted by macrophages. VVhen macrophages 
from huPLTPrg/wt and huPLTPtgltg mice were tested, increased 
PLTP activity was found (+125% and +233%, respectively, both 
p<O.Ol). From these results we conclude that macrophages from 
transgenic PLTP mice have an increased production and secretion 
of the transgenic protein. 
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Figure 1. PLTP production by mouse macrophages. Peritoneal 
macrophages were collected from either C57BU6J wild type (wt/wt), 
hemizygous huPLTP transgenic (tg/wt) and homozygous huPLTP 
transgenic (tg/tg) mice and kept in culture for 24 hours. Subsequently, 
PLTP activity was measured in a sample of the culture medium. PLTP 
activity is expressed as arbitrary units (AU; 1 AU is equivalent to 
14 ~moJ/mUh). N =cells from 6 mice per group.** p<O.OOS versus wt/ 
wt; $ p<0.01 versus tg/wt. 
doi:1 0.1371 /journal.pone.0002255.g001 
Elevation of macrophaa-e PLTP increases atherosclerosis 
Effects of bone marrow transplantation on plasma PLTP 
activity 
In order to study the contribution of PL TP e::...pression by bone 
marrow derived cells on plasma PLTP activity, w~erformed bone 
marrow transplantation e~"Periments from PLTPw wt, huPLTPt~/wt 
and huPL yptg/tg- mice to lethally irradiated LDL-receptor deficient 
(LDLR -/-) mice. Following the transplantation, animals were 
allowed to recover for 9 weeks. Subsequently, animals were fed a 
high fat, high cholesterol diet for another 9 weeks period. Blood 
samples were collected one week before irradiation, just before 
starting the diet and at the end of the 9 weeks diet period (time points 
-10 weeks, 0 weeks and 9 weeks, relative to the start of the diet, 
respectively). In addition to the transplanted animals, groups of 
I..DLR-1- mice and LDLR-/- /huPLTPtghvt mice were subjected 
to the same series of e::-..-periments, except the irradiation and bone 
marrow transplantation. Blood samples were collected at 0 weeks 
and 9 weeks. Anllnals were age matched to the mice in the 
transplantation groups. 
As shown in Fig. 2A Oeft panel), plasma PLTP activity in 
LDLR-/- /huPLTPtg/wr mice were approximately 3-fold higher 
than in LDLR-;- mice when fed a chow diet (0 weeks). After 
feeding the animals a high fat, high cholesterol diet for 9 weeks, 
plasma PLTP activity in both LDLR -I- and LDLR -;-I 
huPLTPtgiwt mice was increased by about 2-fold when compared 
to chow fed animals of the same genotype. 
Fig. 2A (right panel) also shows the plasma PLTP activity in 
transplanted animals. The transplantation procedure itself resulted 
in a signill.cant increase in PLTP activity, ranging from 29% in the 
PLTPwt1wt-:;.I..DLR_1_ mice to 88% in the huPLTPtg-!tg____,. 
LDLR-;- mice (all p<O.OOl). After feeding the animals a high 
fat, high cholesterol diet, a further increase in plasma PLTP activity 
was observed ranging from 82% in the PLTPwt/wt ____,.. LDLR-1- mice 
to 113% in the huPLTP'W'"--+LDLR_1 _ mice (allp<O.OOl). Under 
both dietary conditions, flasma PLTP activity did not differ between 
huPLTPtglwt____,.LDLR-- and huPLTPtg-ltg-____,.LDLR_-;- mice. 
Fig. 2B shows the concentration of human PLTP in plasma 
from transplanted animals. As there is no EUSA available for 
mouse PLTP, mass of plasma PLTP could only be measured in the 
huPLTPtghvt____,.LDLR-;- and huPLTPtg!tg-____,.LDLR-;- mice. 
The PLTP concentration appeared to be approximately tvvice as 
much in the latter anlmals. The hlgh fat, high cholesterol diet 
resulted in a two-fold increase in PLTP mass. The specific activity 
of plasma PLTP was not affected by the diet (Fig. 2C). 
Interestingly however, the specific activity in the huPLTPtgltg____,. 
LDLR-;- mice was significantly lower than in the huPLTPrg/wt 
--+LDLR-/- mice, implying that part of the huPLTP in the 
huPLTPtg:ltg____,.LDLR -I- mice is in the inactive form. 
Effects of bone marrow transplantation on plasma lipids 
and lipoproteins 
VVhen fed a regular chow diet, plasma cholesterol levels were 
slightly decreased in LDLR-/- /huPLTPtg-/wt mice when com-
pared to LDLR -I- mice (Fig. 3A, left panel). However, this 
difference was absent after feeding the animals a high fat, high 
cholesterol diet for 9 weeks. In the transplanted animals, no major 
differences in plasma cholesterol concentration were observed 
between the various groups on chow diet (Fig. 3A, right panel). 
However, after feeding the animals a high fat, high cholesterol diet 
for 9 weeks an increase in cholesterol concentration was observed 
in PLTP""1:1~vt____,.LDLR- 1 -, huPLTPtghvt____,..I..DLR-1-, and 
huPLTPrgltg~LDLR-/- mice. Effects on plasma phospholipids 
and triglycerides largely mirrored those on plasma cholesterol 
(Fig. 3B,C). In order to further investigate these differences, HDL 
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Figure 2. Plasma PLTP levels~ A. PLTP activity was measured in plasma samples and expressed in arbitrary units as described in the legend of 
Fig. 1. Left panel: plasma samples were collected from non-transplanted LDLR_1_ and LDLR-/-/huPLTPtg/wt mice just before the start of the high fat, 
high cholesterol diet (0 weeks, white bars) and after 9 weeks of the diet (9 weeks, black bars).*** p<0.001 versus 0 weeks (same genotype), ### 
p<0.001 versus LDLR_1_ mice (on the same diet). Right panel: plasma samples were collected from PLTPwtlwt---""LDLR-1-, huPLTPtg/wt ......... LDLR-1-, and 
huPLTPtg/t9-LDLR_1_ recipient mice at 1 week before the start of the transplantation procedure (i.e. at 10 weeks before the start of the diet: -10 
weeks, grey bars), just before the start of the diet (0 weeks, white bars) and after 9 weeks of diet (9 weeks, black bars).*** p<O.OOl versus -10 weeks 
(same genotype);### p<O.OOl versus PLTPwt/wt___,.LDLR_1_ mice (on the same diet);~-]~ p<O.OOl versus 0 weeks (same genotype). B. Mass of 
human PLTP in plasma from mice was measured by ELISA as described in Methods in the Supplemental Data. C. Specific Activities of PLTP were 
calculated using the ratio between the activity in AU and the mass in mg/L. ,-[~~ p<O.OOl versus 0 weeks (same genotype); $$$ p<0.001 versus 
PLTPtg/wt-LDLR-;- mice (on the same diet). N=11-15 mice per group. 
doi:l 0.1371 /journal.pone.0002255.g002 
and non-HDL was separated in plasma samples of the arrimals 
after 9 weeks on a high fat, high cholesterol diet. The mice 
transplanted with huPLTP transgenic bone marrow cells showed 
an increase in non-HDL cholesterol (Fig. 4A) and a decrease in 
HDL-cholcsterol (Fig. 4B) when compared with the mice 
transplanted with wild type bone marrow cells. 
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Effects of bone marrow transplantation on 
atherosclerosis 
After feeding the arrimals a high fat, hlgh cholesterol diet for 9 
weeks~ atherosclerosis was quantified by measuring the area of 
atherosclerotic lesions in the aortic root. In agreement with 
previous studies from our laboratory [1 7,31], we found that 
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Figure 3. Plasma lipid levels. Plasma levels of cholesterol (A), 
phospholipids (B) and triglycerides {C) were measured as described in 
Methods. Left panels: Plasma samples were collected from non-
transplanted LDLR_1_ and LDLR-/-/huPLTPtg/wt mice just before the 
start of the high fat, high cholesterol diet {0 weeks, white bars) and after 
9 weeks of the diet (9 weeks, black bars). *** p<0.001 versus 0 weeks 
(same genotype), ### p<O.OOl versus LDLR_1_ mice (on the same 
diet). Right panels: plasma samples were collected from PLTPwt/wt 
---:..LDLR-1-, huPLTPtglwt___,.LDLR-1-, and huPLTPtg/tg---..LDLR-1- recipi-
ent mice at 1 week before the start of the transplantation procedure 
(i.e. at 10 weeks before the start of the diet: -10 weeks, grey bars), just 
before the start of the diet (0 weeks, white bars) and after 9 weeks 
of diet (9 weeks, black bars). N=11-15 mice per group.* p<O.OS, 
*** p<O.OOl versus -10 weeks (same genotype);### p<0.001 versus 
PLTPwt/wt__.....LDLR-1- mice (on the same diet). 
doi:1 0.1371 /journal.pone.0002255.g003 
elevated levels of PLTP result in a strong increase (312%) in diet-
induced atherosclerosis in non-transplanted mice (Fig. 5A, left 
panel; p<O.OO l ). In transplanted mice, a clear increase in 
atherosclerotic lesion area was observed ~· 5A, right panel; all 
di:fferencesp<O.OOl). Compared to PLTP wt---"'LDLR-/- mice, 
huPLTPtg/.,.,1:----"'LDLR-/- mice have an increase of 128% in 
atherosclerotic lesion area, while huPLTPtgltg---"'LDLR -/- mice 
have an increase of 348% in atherosclerotic lesion area. 
Elevation of macrophage PLTP increases atherosclerosis 
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Figure 4. Plasma levels of non-HDL cholesterol and HDL 
cholesterol. Plasma was collected from PLTPwt/wt___,.LDLR-1-, 
huPLTPtglwt---..LDLR-1-, and huPLTPtg/tg___,.LDLR_1_ recipient mice at 
the end of the high fat, high cholesterol diet period (i.e., at time of 
sacrifice) and separated into two fractions: d<1.063 g/L (non-HDL) and 
d>l.063 g/L (HDL) by ultracentrifugation. In both fractions, the 
cholesterol concentration was measured. A: non-HDL cholesterol; B: 
HDL-cholesterol. N=11-15 mice per group.** p<O.Ol, *** p<0.001 
versus PLTPwt/wt--:o.LDLR-1- mice; $$$ p<0.001 versus huPLTPtg/wt 
---..LDLR_1_ mice. 
doi:1 0.1 371 /journaLpone.0002255.g004 
The presence of PLTP e.'\.-pressing macrophages in the aortic 
lesions was confirmed by immunohistochemistry. As illustrated in 
Fig. 5, the plaques from both non-transplanted LDLR -/-I 
huPLTPtg/wt mice (Fig. 5B) as those from recipient huPLTPtg/tg 
~LDLR -I- mice (Fig. 5C) contain considerable amounts of 
rnacrophages while PLTP is co-localized in similar areas of the 
lesions. 
In order to be more conclusive on the nature of the bone 
marrow derived cells, we performed an additional set of 
experiments using actin-EGFP mice as donors and LDLR -/-
mice as acceptors, using e.x.actly the same experimental procedure 
to obtain diet-induced atherosclerosis. Sections from the aortic 
root were inspected using confocal microscopy after immunohis-
tochemistry with antibodies directed against CD68 as a marker for 
macrophages or VS1viC rx-actin as a marker for VS1vfCs. DAPI 
staining was used to visualize nuclei. Bone marrow derived donor 
cells, identified by the GFP signal, arc clearly present in the 
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Figures. Atherosclerosis in non~transplanted and transplanted 
mice. A. Plaque area was measured in sections from the aortic root {see 
Methods). Left panel: Plaque area in non-transplanted LDLR_,_ and 
LDLR_1_ /huPLTPtg!wt mice. *** p<0.001 versus LOLR-/- mice. Right 
panel: Plaque area in PLTPwt/wt-LDLR-1-, huPLTPtg/wt___,..LDLR-1-, 
and huPLTPtg/t9-LDLR_1_ recipient mice. N=11-15 mice per group. 
*** p<0.001 versus PLTPwt/wt_,LDLR-/- mice;$$$*** p<0.001 versus 
huPLTPtg/wt___,.LDLR-/- mice. B, C. Immunohistochemistry of athero-
sclerotic lesions from non-transplanted LDLR-/-/huPLTPtg/wt mice (B) 
and from transplanted huPLTPtg/tg_,.LDLR-/- mice (C), stained for 
macrophages (M<l>) with anti-CD68 and for PLTP and counterstained 
with Nuclear-fast red (serial sections). The right panels are magnifica-
tions of the boxed parts in the !eft panels. Original magnifications: 1 OOx 
(B) and 250x (0. 
doi:1 0.1371 /journal.pone.0002255.g005 
subendothelial space of the early lesions and co-localize to a great 
extent with CD68 (Fig. 6A,B). In the advanced lesions, the cell-rich 
regions show significant co-localization of the GFP and CD68 
signals, while the necrotic core stills allows detection of CD68, but 
GFP is no longer expressed (Fig. 6C,D). In early lesions, VSMCs 
are almost exclusively located in the media (Fig. 6B). In advanced 
lesions, VSMCs can be detected in the fibrous cap (Fig. 6D), but 
they do not co-localize with GFP, demonstrating that also the 
VSMCs in the lesions are not donor-derived. As shown in Fig. 6A~ 
D, isolated nuclei can be detected of endothelial cells covering the 
lesions without GJ:<--p signal, demonstrating that these cells are not 
donor-derived. Positive staining for endothelial cells was per-
formed by using an antibody clirected against CD31 (Fig. 6E,F]. 
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The endothelial lining in early (Fig. 6E) and in advanced (Fig. 6F) 
lesions is continuous and does not e::-..-press GFP, implying that the 
endothelial cells are not donor derived. 
Characterization of PLTP expressing macrophages 
In order to investigate the mecharllsm by which mice 
transplanted with bone marrow cells expressing elevated levels of 
PLTP develop more atherosclerosis, we performed a series of in 
vitro studies using primary macrophages from PLTPwt/w\ 
huPLTPtf::-/wt, and huPLTPtg-/tg mice, respectively. 
First we examined whether PLTP e::--.-pression in macrophages 
affects their capacity to perform cellular cholesterol efflu.x. To this 
end, macrophages were loaded with radiolabeled cholesterol using 
acLDL and efflu.x to the medium was studied during six hours 
using human HDL as an acceptor. There was no difference in 
cholesterol loading between macrophages from PLTPwt/wt and 
huPLTP'shs mice (42.87+/ -8.25 versus 44.26+/ -8.67% 
eHJcholesterollmg cell protein). No difference in efflu..x to HDL 
was observed (Fig. 7 A). Consequendy, the amount of radioactive 
cholesterol that remained cell-associated at the end of the effiu.x 
period was also similar (not shown). 
Possible differences between the inflammatory status of the 
macrophages were studied by comparing the level of the cytokines, 
TNF-ct., IFN-y, IL-4, and IL-10, by EllSA. No differences were 
found in medium from macrophagcs obtained from PL TPwth"\ 
huPLTPtg-/w\ and huPLTPtg-!t:?; mice before or after stimulation with 
LPS (results not shown). These results indicate that there is no 
difference in cytokine production by macrophages from these mice. 
Subsequently, we studied whether activated macrophages have 
different PLTP activity. Therefore, we challenged the macro-
phages with bacterial lipopolysaccharide (LPS), and measured 
PLTP activity in the medium from the stimulated macrophages. 
As shown in Fig. 7B, stimulation ofmacrophages from PLTPwt/v.1: 
mice vvith LPS resulted in approximately 70% increase in PLTP 
act:lv~ty Unstimulated macrophages from huPLTPtg/wt or 
huPLTPtg-ltg mice secreted approximately 2.5 to 4 fold more 
PL TP in the culture medium than macrophages from PLTPwt/wt 
mice. LPS stimulation resulted in a further 7.5 fold increase of 
PL TP activity in the culture medium from macrophages from 
huPLTPtg/wt or huPLTPtg-!tg mice. In order to investigate whether 
this in vitro effect would be reflected by similar effects in vivo, we 
measured plasma PLTP activity levels in both PLTP'vt/-wt and 
huPLTPtgltg mice that were treated with thioglycolate. In both 
cases, thls treatment resulted in a statistically significant (P<0.002) 
increase in plasma PLTP activity (Fig. 7C). 
Finally, we cultured macrophages from bone marrow in order 
to consolidate these fmdings. Comparing macrophages from 
PLTP"'1:/wt and huPLTPtgltg mice, we found much more PLTP 
activity in the medium of the huPL TPtg/tg cells. PLTP activity 
could be significantly increased in cells from both PLTPwt!wt and 
huPLTPtg/tg mice after treatment with LPS (not shown). 
Discussion 
The main fmdings of this study are: (1) Mouse macrophages 
e.\.-press and secrete PLTP while mouse macrophages from human 
PL TP transgenic mice e:-..-press and secrete increased levels of 
PL TP; (2) Bone marrow transplantations using PL TP transgenic 
mice as donors induce elevated plasma PL TP activity levels in the 
acceptor mice; (3) PLTP overe.'\."Pression results in decreased 
plasma levels of HD L cholesterol and in increased plasma levels of 
non-HDL cholesterol; (4) Transplantation with PLTP expressing 
bone marrow cells results in increased (2-4.5 fold) atherosclerosis 
with abundant intra-plaque presence of PLTP. 
Elevation of macrophao-e PLTP increases atherosclerosis 
Figure 6. Transplantations with p-actin GFP mice---..LDLR_,_ mice. A-D: Early lesions (A,B) and advanced lesions {C,D) with donor cells 
expressing GFP (green), CD 68 (marker for macro phages) in red (A,C) and a.-actin (marker for VSMCs) in red (8,0) and nuclei stained with DAPI (blue). 
Endothelial cells covering the lesions do not express GFP (nuclei indicated with arrows). Co-localization of GFP and CD68 results in an orange color 
(arrowheads). The necrotic core in the advanced lesion (located centrally in C and D) is diffusely positive for CD68 but does not show any GFP signal. 
The media is marked with a double arrow (t-1-). E,F: Early lesion (E) and advanced lesion (F) with donor cells expressing GFP (green), and CD 31 (marker 
for endothelial cells) in red (arrows). Representative pictures from N = 6 animals are shown. Original magnifications: 200X. 
doi:1 0.1 371 /journal.pone.0002255.g006 
The potential relevance of PLTP production by macrophages is 
emphasized by three independent studies, showing that PL TP 
protein is present in human atherosclerotic lesions [22,23,32]. 
Although intriguing, the presence of PLTP in atherosclerotic 
lesions per se does not prove a direct involvement in the process of 
atherosclerosis and therefore the significance of these fmdings is 
unclear. In humans, the causal relation between PLTP and 
atherosclerosis is still uncertain [33]. Plasma PLTP activity is 
elevated in patients suffering from diabetes mellitus type 1 [34] 
and type 2 [35,36]. In addition, increased PLTP is found in obese 
individuals [37-40] while it is decreased with weight loss [41]. The 
elevated plasma PLTP activity in patients with type 2 diabetes 
mellitus is positively correlated with the carotid intima-media 
thickness [42]. 
In order to fmd out what the contribution of PLTP expressing 
macrophages to diet induced atherosclerosis would be, we 
performed bone marrow transplantation e::-..-periments. 
9 weeks after bone marrow transplantation, a moderate increase 
in plasma PL TP activity was found in the animals transplanted 
with PLTP~1~ cells. In the animals transplanted with PLTP 
transgenic cells, a further increase was observed. Feeding the 
animals a high fat, high cholesterol diet for 9 weeks, resulted in a 
183 
Chapter 9 
A 
"X 60 
::::> 
Ec: 
"'·-2~40 
.,~ 
-a. 
"'-~ID 
co 
:§.1?20 
~ 
<!<. 
2 4 6 
time (hours) 
B ## 
"1 
0- LPS *** 
50 
.+LPS 
* 
## ! 40 *** .. ~ 10 ~· nt () ctl 0... ~ 5 0... ** 0 nl PLTPwt/wt huPLTPtg/wt huPL TPtg/tg 
c 
25 0 - Thioglycolate 
• + Thioglycolate 
## 
*** 
~20 
ol ::J ~ £15 • 2:: 10 0 
ctl 5 0... 
~ 
0...2.5 
0 
PLTPwtlwt huPLTPtg/tg 
Figure 7. Characteristics of mouse macrophages. A. Cholesterol 
efflux from cultured peritonea! macrophages. Cells were loaded with 
radioactive cholesterol as described in Methods. Subsequently, culture 
medium with human HDL as an acceptor was added. Left panel: 
Radioactivity was measured in a!iquots from the cultured medium taken 
at 0, 1, 2, 4, and 6 hours. Circles: macrophages from C57BU6J mice, 
squares: macrophages from huPLTPtg/tg mice. Differences were not 
statistically significant. B. PLTP activity measured in the medium of 
macrophages cultured for 24 hours in the absence (white bars) or 
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presence (black bars) of 100 ng/ml LPS. Cells from 6 mice were used 
per group. C. PLTP activity measured in plasma samples from mice 
treated with thiog!ycolate. N=6 mice per group. ** p<0.005, *** 
p<O.OOl versus cells without LPS or thioglycolate (same genotype),## 
p<0.005, ### p<O.OOl versus PLPr'tlwt (same culture medium, with 
or without LPS or thioglycolate). 
doi:1 0.1371/journal.pone.0002255.g007 
striking increase in plasma PLTP activity. It has been demon-
strated that cholesterol loading of macrophages induces a strong 
(2-3 fold) induction of PLTP mRNA, PLTP protein secretion and 
an increased PL TP activity in the medium conditioned by these 
cells [23,32]. Our results show that in animals fed a high fat, high 
cholesterol diet, plasma from huPLTPt!;/wt___,..LDLR-/- and 
huPLTPtglt!;___,..LDLR-/- mice have a 66-75% increase in PLTP 
activity when compared to plasma from PLTPwt/wr___,..LDLR-/-
mice. Thus we conclude that a considerable amount of 
macrophage PLTP is excreted into the blood. 
An increase in plasma PLTP activity affects plasma lipids. Plasma 
cholesterol is not affected by the moderate increase in PLTP activity 
caused by the bone marrow transplantation procedure itsel£ Mter 9 
weeks of high fut, high cholesterol diet plasma cholesterol is elevated, 
as e:\.'Pected, but a further increase is observed in the huPL TPtg/ 
wt-+LDLR_1_ and huPLTPtgltg___,..LDLR_1_ mice. So, PLTP 
cx.'Pression by bone marrow derived cells affects not only plasma 
PT .TP activity levels, but also plasma lipids. 
Because PLTP activity can be directly measured in plasma, our 
experiments clearly show that PLTP is excreted by bone marrow 
derived cells into the plasma compartment. Probably this is the 
cause of the observed decrease in plasma HDL cholesterol, which 
is in agreement vvith previous results from our laboratory 
[14,17,31] and others [43,44], and which is probably caused by 
an enhanced catabolism ofHDL [43]. Most likely, this effect will 
contribute to the observed enhanced atherosclerosis in mice 
transplanted with huPLTP transgenic bone marrow. In addition 
however, there might be a local effect of PLTP produced by 
macrophages in the vascular wall. Although PLTP overexpressing 
rnacrophages do not show any difference in cholesterol cfilux 
capacity or cytokine production, a very strong induction of PLTP 
production is observed in macrophages treated with LPS. So, 
activated macrophages present in the inflammatory environment 
of atherosclerotic plaques probably excrete large amounts of 
PLTP. This is confirmed by immunohistochemistry data in the 
present study. The high local PLTP production might result in a 
further increase of the inflammatory status of the lesions . 
Additional support for this idea is provided by studies showing 
that PLTP deficiency is associated with anti-inflammatory effects 
[45,46], and by a study in which an association was found between 
PLTP activity and inflammatory markers in patients with 
cardiovascular disease [47]. Alternatively, extracellular PLTP 
might act as a trap for HDL. PLTP is able to bind to the 
extracellular matrix proteoglycan biglycan [23] and thus act as a 
bridging molecule to bind HDL. In vitro studies showed that this 
action is independent of PLTP)s phospholipid transfer activity. By 
trapping HDL in the atherosclerotic lesion, PLTP could interfere 
with the reverse cholesterol transport activity of HDL and thus 
enhance lipid accumulation, or actually, inhibit lipid removal, and 
hence stimulate the development of the plaque. It is uncertain 
whether this HDL retention may contribute to the decreased 
plasma levels ofHDL observed in mice transplanted with huPLTP 
transgenic bone marrow. 
While macrophage e:\.pression of PLTP has both systemic and 
local effects, both of which might be atherogenic, the steep 
increase in atherosclerotic lesion size of almost 2-fold between 
huPLTPtglwt.~LDLR-;- and huPLTPtg!tg___,.LDLR_1 _ mice is 
not completely reflected by the differences in the systemic effects, as 
these mice have similar plasma PL TP activities. This suggests that 
local elfccts of PLTP CA"}Jression might indeed play an important 
role. In addition, the huPL TPgltg___,. LDLR-1 - mice show a reduced 
specific activity of PLTP. This could indicate that the huPL TPtg/tg-
---;.LDLR-/- mice have rdatively more inactive PLTP [48], which 
may not have phospholipids transfer activity) but which might still 
have some of the other effects described above. Also, PLTP secreted 
by the huPL TPtg/tg bone marrow derived cells in the transplanted 
animals fmds itself in a plasma environment with very little HDL. As 
active PLTP is normally bound to HDL, this situation could 
destabilize PLTP resulting in partial PLTP inactivation and in a 
decrease in PLTP specific activity. 
It should be noted that bone marrow derived cells include cells 
other than macrophages, like endothelial cells and VSMCs. 
Therefore, we performed a set of control e::.._-periments with ~-actin 
GFP donor mice. It became clear that using our experimental 
conditions, the contribution from bone marrow derived endothe-
lial cells or VSJVICs to the atherosclerotic lesion is undetectable, 
while there is a significant number of bone marrow derived 
macrophages in the lesions. 
Recently, the susceptibility to diet-induced atherosclerosis was 
studied in mice after bone marrow transplantations with bone 
marrow cells from wild type and PLTP deficient mice. Strikingly 
different results were reported by iwo independent research 
groups, leading to opposite conclusions [49,50]. V\Thile Valenta et 
al [49] propose an athero-protective role for macrophage derived 
PLTP, Vikstedt et al [50] show evidence for an atherogenic 
function of macrophage derived PLTP. Both groups used 
LDLR -/- mice as acceptors, and either wild type or PLTP-/-
mice as donors. All mice had the same genetic background 
(C57BL/@, and the same strain of PLTP deficient mice were 
used. VVhen comparing mice transplanted with PLTP-/- bone 
marrow with mice transplanted with wild type bone marrow, 
Valenta et al found an increase in atherosclerotic lesion area in of 
30% (measured in the aortic valves) or 28% (measured in the entire 
aorta), while Vikstedt et al found a decrease of29% (measured in the 
aortic valves). In both studies, plasma PLTP activity is lower in mice 
transplanted with PLTP-1- bone marrow than in mice transplanted 
¥lith wild type bone marrow when fed a chow diet, and the difference 
becomes larger in mice fed an atherogenic diet. In the study by 
Vikstedt et al this leads to a signilicant decrease in plasma cholesterol 
levels and an increase in HDL, which may e::.._-plain the decreased 
atherosclerosis found in mice transplanted with PLTP-/- bone 
marrow. In the study by Valenta et al there is increased 
atherosclerosis while plru;ma cholesterol levels are hardly changed. 
Thus, in the latter study postulated that plasma PLTP is atherogenic, 
while PLTP which is locally active in the vascular wall may have 
anti-atherogenic potential, possibly by local stimulation of macro-
phage cholesterol efflu.-...:. 
Vikstedt et al have summarized the major differences in 
eA-perimental set-up: 1) Vikstedt ct al used female mice as 
acceptors while Valenta et al used male mice; 2) Vikstedt et al 
fed the mice an atherogenic diet with 0.25% cholesterol for 9 
weeks while the diet used by Valenta et al contained 1.25% 
cholesterol and was fed for 16 weeks; 3) Vikstedt et a! allowed the 
mice to recover from the bone marrow transplantation procedure 
for 8 weeks before the atherogenic diet was supplied while Valenta 
et al applied a recovery time of only 4 weeks. Vikstedt et al do not 
indicate if any of these differences could be the deciding factor to 
e::.._-plain the different outcomes of their studies. 
Very recently, Valenta et al confirmed their previous fmdings in 
a study in which they used LDLR-/- /PLTP-;- mice as 
Elevation of macrophage PLTP increases atherosclerosis 
acceptors [51 J. Here, they applied the same experimental set -up 
as in their earlier work. In the discussion of this recent paper, the 
differences with the e.'\.-perimental set-up followed by Vikstedt et al 
are listed, but there arc no conclusions about what might really 
cause the different outcomes. 
\Ale believe that the difference in gender between the l'ecipieulli 
in the studies using PLTP deficient mice is not a likely e::.._-planation 
for the conflicting results. Although it is well-known that the 
susceptibility of female and male mice to atherosclerosis is 
different, the reason for this phenomenon is unknown, and, to 
the best of our knowledge, there arc no reports where opposite 
outcomes of an intervention with respect to atherosclerosis 
susceptibility between males and females have been described. 
In fact, we have shovvn in a previous study that in animals with 
elevated PLTP activity, both males and females have more 
atherosclerosis [52]. 
The difference in diet-regime may be an essential factor. The 
diet used by Valenta et al contains five times as much cholesterol 
as the diet used by Vikstedt et al and was applied much longer. 
Therefore, this is a significantly more aggressive way of induction 
of atherosclerosis. It is conceivable that this has affected the 
outcome of the study. 
The difference in recovery time may be an essential factor as well. 
Vikstedt et al allowed the animals to recover for eight weeks, 
compared to four weeks in the study of Valenta et al. Four weeks is 
really a very short time, in which the hematopoietic system has not 
yet been stably reconstituted. It is conceivable, that PLTP deficiency 
affects the repopulation of monocytes/ macro phages. Therefore, the 
development of atherosclerotic lesions may be affected by differences 
in recovery time. Also, the reconstitution of resident macrophages in 
lung and liver, both important sites ofPLTP eA-pression, may not yet 
be stable after only four weeks of recovery [53]. 
We studied the effects of elevated PLTP eA-pression using 
transgenic mouse models that have been developed in our own 
laboratory. The interpretation of our results is independent from 
the conflicting results that have been reported using PLTP-/-
mice. Our e::.._-perimental set-up is comparable to the one used by 
Vikstedt et al, as we also fed the mice a diet containing 0.25% 
cholesterol for 9 weeks, and we used an even slightly longer 
recovery period (9 weeks). Their results arc in line with our 
fmdings, as we report an increase of atherosclerosis in mice 
transplanted with PLTP overeA-pressing bone marrow, while they 
found decreased atherosclerosis in mice transplanted \vith 
PLTP_1_ bone marrow cells. 
In conclusion, we showed that elevated macrophage e::.._-pression 
of PL TP results in increased atherosclerosis. This is probably 
directly related to the effects on plasma lipoproteins caused by 
PL TP e::.._-pression by bone marrow derived cells. In addition, local 
effects in the atherosclerotic lesion could contribute to this process. 
These results indicate that the presence of PLTP in human 
atherosclerotic lesions probably contributes to the pathologic 
process and that inhibition of PLTP accumulation in atheroscle-
rotic lesions may be a valuable target for therapy. 
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1. Introduction 
ABSTRACT 
Phospholipid transfer protein (PLTP) is a multifunctional protein synthesized by various cell types and 
secreted into the plasma. Plasma PLTP is able to transfer phospholipids between lipoproteins and modulate 
HDL particles. Mice with overexpression of human PLTP have an increased ability to generate prei3-HDL, 
reduced total HDL levels and an increased susceptibility to atherosderosis. As the macrophage is a key 
component of the atherosclerotic lesion and an important site of PLTP expression, we investigated the 
role of systemic and peripheral PLTP in macrophage cholesterol efflux and reverse cholesterol trans-
port (RCf) in vivo. We used an assay in which 3 H-labelled cholesterol-loaded macrophages were injected 
intra peritoneally into recipient mice, and radioactivity was quantified in plasma, liver and faeces. 
Firstly, wild type macrophages were injected into wild type, PLTP transgenic (PLTPtg) and apoAI trans-
genic (apoAltg) mice. While plasma 3 H-tracer levels in apoAltg mice were increased compared with wild 
type mice. they were reduced in PLTPtg mice. Moreover, overexpression of PLTP significantly decreased 
faecal 3 H-tracer levels compared with wild type and apoAltg mice. Secondly, wild type mice were injected 
with peritoneal macrophages derived from PLTPtg or wild type mice. No significant difference in the 
amount of 3 H-tracer in plasma, liver or faeces was found between the two groups of mice. 
Our findings demonstrate that macrophage cholesterol efflux and Rcr to faeces is impaired in PLTP trans-
genic mice, and that elevation of macrophage-PLTP does not affect RO', indicating that higher systemic 
PLTP levels may promote atherosclerosis development by decreasing the rate of macrophage RO'. 
© 2008 Elsevier Ireland Ltd. All rights reserved. 
Macrophage cholesterol efflux and reverse cholesterol transport 
(RCf) are believed to inhibit atherogenesis by transporting excess 
cholesterol from macrophages to the liver for biliary excretion. An 
inverse association between high density lipoprotein (HDL) levels 
and atherosclerosis is shown in many studies. and is explained by 
the ability ofHDL to promote RCf [1,2]. One protein with a key role 
in HDLmetabolism and possibly also in RCf is phospholipid transfer 
protein (PLTP). 
ating lipid-poor prei3-HDL [4,5], an efficient acceptor of cellular 
cholesterol in vitro. Mice with elevated PLTP activity levels have 
an increased ability to generate prei3-HDL [6,7]. Nevertheless, sys-
temic PLTP has been identified as pro-atherogenic in vivo. Mice 
overexpressing human PLTP have elevated plasma PLTP levels, 
resulting in a decrease in total HDL levels and an increased devel-
opment of atherosclerosis [8]. 
As PLTP is highly expressed in macrophages and co localised with 
foam cells in atherosclerotic lesions [9-11]. recent studies have 
focused on the role of macrophage-derived PLTP in the develop-
ment of atherosclerosis, thereby revealing conflicting results. Bone 
marrow transplantation studies using PLTP deficient macrophages 
resulted in either decreased [12] or increased atherosclerosis 
[13-15]. Mice transplanted with bone marrow of PLTP overex-
pressing mice had an increased susceptibility to diet-induced 
atherosclerosis [16]. The exact mechanism of atherogenicity and 
the contribution oflocal PLTP effects in the vessel wall to atheroscle-
rosis development are not fully understood. Peripheral PLTP could 
be involved in macrophage cholesterol efflux, as suggested from 
PLTP is expressed by various cell types and secreted into the 
plasma, where it transfers phospholipids between lipoproteins [3] 
and modulates the size and composition of HDL particles, gener-
* Corresponding author at: Department of Cell Biology & Genetics, Erasmus Uni-
versity Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands, 
Tel.: +31 10 7043459, 
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in vitro studies. Purified PLTP, added to cultured macrophages, 
enhanced ABCAl-mediated cholesterol efflux, suggesting an 
anti-atherogenic role for PLTP [17]. Active PLTP, preincubated with 
HDL particles, enhanced macrophage cholesterol efflux through 
the generation of efficient cholesterol acceptor particles {18]. The 
importance of intracellular PLTP for macrophage cholesterol efflux 
however. remains unclear. In cultures ofmacrophages lacking PLTP, 
a potential a them-protective role of PLTP in cholesterol efflux has 
been reported [19], but no effect on cholesterol efflux was found by 
others using different experimental conditions [15,20,21 ]. 
In the present study, we investigated the role of systemic and 
peripheral PLTP in macrophage RCf in vivo. We used a validated 
assay in which labelled cholesterol originating from mouse peri-
toneal macrophages was traced in plasma, liver and faeces [22,23]. 
We studied the effect of systemic PLTP on macrophage cholesterol 
efflux to plasma and subsequent transport to faeces, as well as the 
role of macrophage-PLTP, using macrophages from mice overex-
pressing human PLTP, in cholesterol efflux and RCf in vivo. 
2. Materials and methods 
2.1. Animals 
The generation of transgenic mice with expression of human 
PLTP (''PLTPtg"), controlled by its native promoter, has been 
described previously [6]. Human apoAl transgenic mice ("apoAltg") 
were purchased from jackson Laboratory. All mice had a C57Bl/6J 
background. Male mice between 10 and 18 weeks old were used 
and kept on regular chow diet. Blood was collected from the orbital 
plexus. All animal experiments were carried out in compliance with 
national and institutional guidelines. 
2.2. PLTP activity 
PLTP activity in plasma or culture medium was determined as 
described before [6]. PLTP activity levels are expressed as arbitrary 
units (AU; 1 AU •13.9 mmol/L/h. the level found in human reference 
plasma). 
2.3. Separation of plasma lipoproteins and plasma lipid analysis 
To determine plasma lipoprotein size distribution, pooled 
plasma from 6 to 10 mice was applied onto an FPLC system contain-
ing a Superdex 200 prepgrade and a Superose 6 prepgrade column 
connected in tandem. Columns were equilibrated and run in buffer 
containing 65mmol/L sucrose, 225mmol/L mannitol, 10mmol/L 
Tris-HCl pH 8.1, 5 mmol/L EDTA, 0.02% NaN3 • Collected fractions 
were analysed for radioactivity and total cholesterol (TC) levels. TC 
was measured using a Wako kit. 
2.4. Macrophage cell culture 
To isolate peritoneal macrophages, mice were injected intra peri-
toneally with 2 mLofBacto® BrewerThioglycollate Medium(Difco ). 
Three days later, mice were sacrificed and macrophages were iso-
lated from peritoneal cavity. 
For in· vitro cholesterol efflux experiments, cells were plated 
onto 24-well dishes at a density of1-2 x 106 cells/mL in Dulbecco's 
Modified Eagle Medium (DMEM. Gibco) containing 10% fetal calf 
serum (FCS) and 100 U/mL penicillin/streptomycin (Gibco), and 
incubated at 37 'C for 4 h. Acetylated WL (AcillL) was prepared as 
described [24]. DMEM containing 2% fat-free bovine serum albu-
min (BSA) (Sigma) and 50 fLgfmL AcillL, which was preincubated 
with 1 fLCi/mL 3 H-cholesterol (Amersham) for 30min, was added 
190 
to the cells. After 30 h, medium was collected and radioactivity 
was counted. The labelled cells were washed and equilibrated for 
10-14h in DMEM containing 2% fat-free BSA, in the presence or 
absence of 0.3 mmolfL cAMP (Sigma). 
For in vivo cholesterol efflux experiments, cells were washed 
with Dulbecco's Phosphate Buffered Saline (DPBS, Gibco) and single 
cells were resuspended in DMEM medium containing 2% fat-free 
BSA, 10% Macrophage Colony-stimulating Factor (M-CSF) culture 
medium [25] and 25 fLgfmL AcillL, pre-incubated with 5 fLCi/mL 
3 H-cholesterol. The cells were kept in suspension at 37oc for 20 h. 
After loading, cells were washed and equilibrated in DMEM con-
taining 0.2% fat-free BSA for 2 h. Finally, cells were washed and 
resuspended in minimum essential medium. 
2.5. In vitro cholesterol efflux from mouse peritoneal 
macrophages 
Cholesterol efflux was initiated by incubating the 3 H-AcLDL-
loaded macrophages in efflux medium consisting of DMEM, 0.2% 
fat-free BSA, and 50 fLgfmL human HDL or 10 fLgfmL lipid-free 
human apoAI (Calbiochem) as cholesterol acceptor. In every experi-
ment, incubations without acceptor were included. Efflux medium 
was collected after 5 h, and used for liquid scintillation counting. 
After cells were washed with ice-cold DPBS, remaining cholesterol 
was extracted from the intact monolayers with isopropanol, and 
radioactivity was determined. Cells were lysed in 0.1 mol/L NaOH 
with 1% SDS, and cell proteins were quantified {26}. Relative cellular 
cholesterol efflux was calculated as the percentage of radioactiv-
ity in the medium relative to the total radioactivity in cells and 
medium, normalized for differences in cell proteins, and corrected 
for efflux of 3 H-tracer in the absence of acceptor particles. Rela-
tive efflux was determined in six mice per group, performed in 
triple and expressed as percentage of radioactivity per milligram 
cell protein. 
2.6. Cholesterol accumulation in macrophages 
Radioactivity in labelled,AcLDL-loaded macrophages was quan-
tified as described above. To determine cellular cholesterol content, 
peritoneal macrophages were incubated with 50 f.LgfmL AcLDL for 
30 h after which lipids were extracted and total cholesterol (TC) 
content was determined in the extracts. Cells were lysed and pro-
teins were quantified as described above. 
Cholesterol accumulation in macrophages was expressed as the 
percentage of radioactivity recovered in cells per cell protein, or as 
the percentage of radioactivity per fLg TC in the cells. 
2.7. In vivo cholesterol efflux and RCTfrom mouse peritoneal 
macrophages 
Per mouse, 0.5 mLmedium with 3H-AcLDL-loadedmacrophages 
( '""10 x 106 cells, 10 x 106 dpm) was injected intraperitoneally. 
Blood samples were collected at 6, 24 and 48 h after injection, and 
used for liquid scintillation counting. After48 h, mice were bled and 
livers were removed. Plasma lipoprotein analyses were performed. 
Liver sections of approximately 0.2 g were dissolved overnight 
at 50 'C in Soluene-350, followed by treatment with isopropanol 
and hydrogen peroxide after which radioactivity was measured by 
liquid scintillation counting. Faeces were collected during these 
48h, weighed and stored at -20°C until lipid extraction. Faeces 
were homogenized in a methanol-chloroform solution using an 
Ultra-Turrax, and subsequently faecal lipids were extracted [27]. 
3H-tracer levels in plasma, liver and faeces were expressed as per-
centages of injected 3 H dose. 
Tablel 
Plasma PLTP and lipids. 
TC 
HOL-C 
PLTPactivity 
<!POA!tg 
5.73 ± 0.29~ 
3.56±0.22,'! 
2.76 ± 0.19" 
wt 
2.47 ± 0.07 
1.43 ± 0.03 
1.92 ±0.19 
PLTPtg 
1.1s ± o.os~.h 
0.67 ::!.: 0.04J,b 
8.01 ± O.Sl;),b 
TC and HDL-C values are expressed in mmol/L, PLTP activity is expressed as arbitrary 
units. Values represent mean± SEM. 
~ p < 0.05 compared to wild type mice, 
b p < 0,05 compared to apoAI tg mice, 
2.8. Statistics 
All values are expressed as mean± SEM. Differences were ana-
lyzed by two-sample Wilcoxon ranksum tests using Intercooled 
Stata 8.2/SE software (Stata Corporation, College Station, Texas 
USA). 
3. Results 
3.1. Macrophage 3 H-cholesterol efflux and RCT in PLTP transgenic 
mice 
To elucidate the role of PLTP in cholesterol efflux and 
reverse cholesterol transport from macrophage to faeces in vivo, 
thioglycollate-elicited peritoneal macrophages derived from wild 
type mice were harvested and loaded with 3 H-labelled AcLDL, after 
which they were injected into the peritoneum of apoAI transgenic 
(apoAltg), PLTP transgenic (PLTPtg) and wild type (wt) recipient 
mice. Plasma PLTP activity levels in apoAitg mice were 1.4-fold 
higher than in wt mice, while overexpressing human PLTP in 
mice increased total plasma PLTP activity 4-fold. Total cholesterol 
(TC) and HDL-cholesterol (HDL-C) levels were strongly decreased 
in PLTPtg and increased in apoAltg mice, when compared to wt 
mice (Table 1 ). At 6, 24 and 48 h after injection of the mice with 
macrophages, a blood sample was taken and plasma 3 H-tracer 
levels were determined. As expected, 3 H-tracer was increased in 
plasma of apoAitg mice compared to wt mice, with a 2.6-fold 
increase after 48 h. In PLTPtg mice however, radioactive counts in 
plasma were 2-fold lower than in wt mice at all timepoints studied 
(Fig. 1A). At the end ofthe experiment, radioactivity was quantified 
in liver and in faeces, collected during the 48 h after injection of 
macrophages. Liver 3 H-tracer levels were not significantly different 
between the three groups (apoAltg: 6.56 ± 031 %ID; wt: 5.59 ± 0.24 
%ID; PLTPtg: 5.17 ± 0.29 %ID). However, in PLTPtg mice, faecal excre-
tion of 3 H-sterol was 22% and 40% lower than in wt and apoAitg 
mice, respectively (Fig. 18). These results show that macrophage 
cholesterol efflux and reverse cholesterol transport are impaired in 
mice overexpressing PLTP. 
To study whether the 3 H-labelled cholesterol, after efflux from 
macro phages, is equally distributed among lipoproteins in plasma 
as endogenous cholesterol, plasma samples taken after 48 h were 
pooled and subjected to gel filtration chromatography. FPLC anal-
yses show that the profiles of macrophage-derived 3 H-cholesterol 
tracer and cholesterol mass in plasma lipoproteins tracked closely 
with each other (Fig. 2). 
3.2. 3 H-cholesterol efflux from PLTP-overexpressing peritoneal 
macrophages to apoAI and HDL in vitro 
To study the role of macrophage-PLTP in cholesterol efflux in 
vitro, peritoneal macro phages from PLTPtg and wt mice were loaded 
with 3 H-cholesterol-AcLDL, and equilibrated in the presence or 
absence of cAMP, which is !mown to furtherupregulateATP-binding 
Role ofPLTP in macrophage RCT 
6 hours 24 hours 48 hours 
~4 
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Ol 
"' u.. 0 PLTP wt 
Fig. 1. Systemic PLTP in macrophage RIT in vivo. ApoAJ transgenic {AI), wild type 
(wt), and PLTP transgenic (PLTP) mice were injected intraperitoneally with 3H-
cholesterol-labelled AcLDL-loaded wild type macro phages, JH-tracer was measured 
in plasma (A) and faeces (B). (A) Plasma 3H-tracer at 6, 24, and 48 h after injection, 
Values are expressed as% injected dose (ID) ± SEM. n = 6-10 mice per group. •p < 0.05 
versus wild type, 11p<0,05 versus apoArtg. (B) 3 H-tracer in faeces collected during 
48h after injection. Values are expressed as% injected dose (ID)±SEM. n=6-10 
mice per group. *p < 0,05 versus wild type. -11 p < 0.05 versus apoAitg. 
Cassette (ABC) transporter A1 [28]. PLTP activity found in culture 
medium of PLTPtg cells after 24 h was 10-fold higher compared 
to PLTP activity in medium of wt cells. Cholesterol accumulation 
in loaded macro phages, expressed as the amount of label per cell 
protein or per cellular cholesterol mass, was not different between 
wild type and PLTPtg macro phages ( 49 versus 47% 3 H/100 fLg cell 
protein and 9.6 versus 8.9% 3 Hf!1-g TC, for wt and PLTPtg cells, 
respectively). The efflux of 3H-tracer to human apoAl or HDL was 
quantified (Fig. 3). As expected, treatment of the macrophages with 
cAMP increased cholesterol efflux to apoAl approximately 3-fold. 
Efflux of3 H-cholesterol from PLTP-overexpressing macrophages to 
apoAI was slightly reduced in the absence of cAMP compared to wt 
macrophages, but when ABCA1 was further upregulated by cAMP-
treatment, lipid efflux was not different between the two groups 
(Fig. 3A). When human HDL was used as acceptor, no difference in 
cholesterol efflux was seen between cells overexpressing PLTP and 
wt cells (Fig. 3B). 
3.3. 3 H-cholesterol efflux and RCT from PLTP-overexpressing 
peritoneal macrophages in vivo 
We further investigated the role of macrophage-PLTP in choles-
terol efflux and RCf in vivo. Peritoneal macro phages derived from 
PLTPtg or wt mice were isolated, and loaded with 3 H-labelled 
AcLDL. Cells were injected intraperitoneally into wild type recipi-
ent mice. 3 H-tracer levels in plasma at 6, 24 and 48 h after injection 
were similar in both mouse groups (Fig. 4A). No significant differ-
ence in 3 H-tracerwas found in liver (not shown) or faeces (Fig. 4B) 
of mice injected with PLTP-overexpressing macro phages compared 
to mice injected with wild type cells. These data indicate that ele-
vation of macrophage-PLTP has no effect on cholesterol efflux and 
macrophage reverse cholesterol transport in vivo. 
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Fig. 2. Distribution of plasma cholesterol and 3H-labe\ among lipoprotein particles. 
At 48 h after injection, pooled plasma samples were subjected to FPLC. TC (filled 
circles) and 3H-label {open squares) were quantified in the fractions. Values are 
mmol/L.md disintegrations per minute ( dpm) x 104 , respectively, and represent the 
means of6-10 mice. 
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Fig.3. Macrophage cholesterol efflux in vitro. Efflux of 3H-labelled cholesterol from 
isolated peritoneal macrophages of wild type (wt) and PLTP transgenic (PLTP) to 
human apoAI (A) or HDL(B) was quantified in vitro, in the presence and absence of 
cAMP. Values are expressed as% d!Ulesterol efflux per milligram cell protein± SEM. 
n = 6 mice per group. *p < 0.05 versus wild type. 
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Fig. 4. Macrophage-PLTP in RCf in vivo. Wild type mice were injected intraperi-
toneally with 3H-cholesterol-labelled AcLDL-loaded wild type (wt) or PLTP 
transgenic {PLTP) macrophages. 3H-tracer was measured in plasma (A) and faeces 
(B). (A) Plasma 3 H-tracer at 6, 24, and 48 h after injection, Values are expressed as 
%injected dose (ID)±SEM. n=7-10 mice per group. *p<O,OS versus wild type (B) 
3 H-tracer in faeces collected during 48 h after injection, Values are expressed as% 
injected dose (ID)±SEM. n=6-10 mice per group. *p<O.OS versus wild type. 
4. Discussion 
In the present study we demonstrate that (1) systemic overex-
pression of human PLTP in transgenic mice results in a decreased 
cholesterol efflux and reverse cholesterol transport from mouse 
peritoneal macrophages, and that (2) elevation of macrophage-
PLTP does not affect macrophage cholesterol efflux. 
PLTP is a key player in HDL metabolism. A facilitating role of 
PLTP in reverse cholesterol transport has been suggested, as ( 1) PLTP 
enhances the formation of pre!3-HDL particles by converting HDL 
particles [4,5,18], (2) PLTP expression is up-regulated by activation 
of the nuclear liver X receptor (LXR), a transcription factor regulat-
ing the expression of several RCT genes, such as members of the 
ATP-binding cassette (ABC) transporter family ABCAl and ABCGl 
[11,20,29], and (3) PLTP might stimulate faecal bile acid excretion 
[30]. With regard to the role of PLTP in cellular cholesterol efflux 
and RCf, it is important to distinguish between local, cellular PLTP 
effects and systemic PLTP effects, which may influence atheroge-
nesis differently. In the present study, we investigated the role of 
both systemic and cellular macrophage-PLTP in cholesterol efflux 
and RCT in vivo. 
To study the effect of elevated systemic PLTP on RCT, we used 
a validated assay to trace labelled cholesterol from macrophage to 
faeces in vivo,as firstly reported by Zhang et al. [22]. Ina later study 
by the same research group [23], parallel experiments were per-
formed in which a direct comparison was made between either 
thioglycollate-elidted or bone marrow-derived macrophages from 
different mice. I twas demonstrated that both types ofmacrophages 
are useful models to study macrophage cholesterol efflux and RCfin 
vivo. We found that elevation of plasma PLTP activity decreases RCf 
from thioglycollate-elicited mouse peritoneal macrophages, while 
elevation of apoAI in apoAitg mice was used as a positive control 
showing increased macrophage RCf. RCT rates in our mice correlate 
with plasma HDLievels.lt is likely that the effect ofPLTP on choles-
terol efflux and RCf can be attributed to the decreased plasma HDL 
levels, illustrating the importance of plasma acceptor concentra-
tion in the process of cholesterol efflux in these mouse models. 
However, it is important to notice that RCf rates are not always 
dependent on plasma HDL levels, as mice lacking scavenger recep-
tor class B type I (SR-BI) have a reduced macrophage RCT despite 
higher plasma HDL levels [31]. and wild type mice with ABCA1 or 
ABCGl deficient macrophages have an impaired macrophage RCT, 
while plasma lipid levels are not altered {23}. Moreover, expression 
of cholesteryl ester transfer protein (CETP) in mice reduced HDL 
levels but promoted macrophage RCT [32]. Although PLTP and CETP 
share structural and functional characteristics, and overexpression 
in vivo of each protein results in a decrease of HDL levels, CETP 
stimulates macrophage RCf, while our present data show that PLTP 
reduces macrophage RCf. Studies in PLTP deficient mice illustrate 
that characteristics of HDL are just as important as its plasma con-
centration in physiological processes such as atherogenesis. PLTP 
deficient mice have reduced levels of HDL, with enhanced anti-
inflammatory properties [33], and have decreased atherosclerosis 
[34]. The finding that apoA!tg mice have an increased macrophage 
RCf in vivo, while these mice have significantly increased plasma 
PLTP activity levels, suggests that the impaired RCT found in PLTPtg 
mice is the result of an indirect action ofPLTP through its effects on 
HDL metabolism, rather than a direct PLTP effect. To further inves-
tigate this hypothesis. it would be useful to investigate macrophage 
RCf using PLTP deficient mice. 
PLTP is able to remodel HDL particles thereby enhancing the 
formation of pre[3-HDL particles, which are efficient acceptors of 
cellular cholesterol in vitro [4,5,18]. Our current findings challenge 
the concept that prej3-HDL particles are important for reverse 
cholesterol efflux in vivo. Indeed, in a recent in vivo study, it was 
demonstrated that HDL is more critical in controJJing RCf than 
lipid-poor apoAI [35]. 
In a previous study, PLTP was described as a positive regulator 
in faecal bile acid excretion in PLTP transgenic mice [30]. However, 
the levels of plasma PLTP activity required for this positive effect 
were high (15-fold higher than in wild type mice) compared with 
the PLTP activity in mice used in the present study ( 4-fold higher 
than in wild type mice). Moreover, the disposal of body cholesterol 
originating from all peripheral tissues was investigated, rather than 
cholesterol derived specifically from macrophages. Although the 
latter is only a very small portion of the total cholesterol pool, it 
is a very important source in the process of atherosclerosis. In a 
study with PLTP deficient mice, no difference in bile acid excretion 
was found, but these mice were shown to absorb less cholesterol 
[36]. We cannot exclude the possibility that intestinal cholesterol 
absorption is affected in our PLTPtg mouse model. A possible stimu-
lation ofintestinal cholesterol absorption could result in decreased 
faecal sterol excretion. Whether this is also the case for cholesterol 
originating from macrophages remains to be investigated. 
Overall, the present data further support the hypothesis that ele-
vated systemic PLTP activity levels are pro-atherogenic and its role 
in macrophage RCf may be an important contributor to atheroscle-
rosis development. 
Effects of systemic PLTP on atherosclerosis development how-
ever, may be different from the local cellular PLTP effects and 
its role in the vascular wall. In bone marrow transplantation 
studies, macrophage-specific PLTP deficiency was associated with 
an increased development of atherosclerosis in ApoE knod<Out 
[13] or IDLR knockout mice either with or without systemic 
PLTP expression [14,15], indicating an anti-atherogenic role of 
macrophage-PLTP. In another study however, an increased resis-
Role ofPLTP in macrophage RCT 
tance to atherosclerosis was found in LDLR deficient mice with 
PLTP deficient macrophages [12], suggesting a pro-atherogenic 
role of macrophage PLTP. Although macrophage-PLTP contributed 
to plasma PLTP levels in all studies, the extent to which levels 
were increased varied significantly between different studies (up 
to 2-fold [12]), which could explain at least partly the different 
results in atherosclerosis development found between the groups. 
When transplanting bone marrow cells of PLTP overexpressing 
mice into LDLR knockout recipient mice, plasma PLTP activity 
levels were more than 3-fold higher and an increased suscepti-
bility to diet-induced atherosclerosis was found [16]. The findings 
demonstrate that macrophage-specific PLTP might be either pro-
or anti-atherogenic, depending on the experimental setup. Because 
macrophage-PLTP contributed significantly to plasma PLTP levels, 
it is hard to draw conclusions regarding local PLTP effects in the 
vessel wall and the exact involvement of these local cellular PLTP 
effects in atherosclerosis development. Suggested anti-atherogenic 
properties of macrophage-derived PLTP include (1) the stimulation 
of ABCA1-dependent cholesterol efflux [17,19], (2) the generation 
ofpref3-HDL within the vessel wall [18]. and (3) increasing cellular 
vitamin E content, resulting in lower oxidative stress and limit-
ing LDL uptal<e by macrophages [21]. The possible role of these 
individual factors has not yet been addressed in vivo. 
The contribution of PLTP to macrophage cholesterol efflux has 
been assessed in several in vitro studies. Exogenous human PLTP, 
added to macrophage cultures, enhanced cellular cholesterol efflux 
to HDL particles, by promoting cell-surface binding, interacting 
with and stabilizing ABCA1 [17]. In another study, macrophage 
cholesterol efflux to HDL was increased after preincubation of 
HDL with purified active PLTP, through the formation of pref3-HDL 
and large fused HDL particles, both efficient cholesterol acceptors 
in vitro {18}. However, as mentioned above, the role of choles-
terol acceptor particles in vivo remains unclear. In studies using 
macrophages lacking PLTP, the role of endogenous PLTP in cel-
lular cholesterol efflux has been investigated. Cholesterol efflux 
from thioglycollate-elicited PLTP deficient macrophages was not 
different compared to efflux from wild type macrophages, neither 
towards apoAI [20,21], nor towards HDL [15].1n non-elicited PLTP 
deficient macro phages, a decreased cholesterol efflux to apoAI and 
HDL particles has been observed, but only with cholesterol-loaded 
cells when cAMP was not added to the culture medium [19]. In the 
present study, we studied the involvement of intracellular human 
macrophage-PLTP in cholesterol efflux both in vitro and in vivo. 
Despite an increase in PLTP activity in culture medium, peritoneal 
macrophages from PLTP transgenic mice did not show differences 
in cholesterol efflux towards human HDL compared with wild type 
macrophages, in accordance with earlier findings [16}. We now 
report a slight but significant decrease in efflux towards apoAI in 
the absence of cAMP, butABCA1-dependent cholesterol efflux after 
cAMP-treatment was not different. To study cellular cholesterol 
efflux and RCf in vivo, we injected cholesterol-loaded human wild 
type or PLTP transgenic macro phages into wild type mice. Injection 
ofPLTP transgenic macrophages in mice did not affect plasma PLTP 
activity (data not shown). demonstrating that our method allows us 
to focus specifically on the cellular effects of macrophage-PLTP in 
vivo, without induction of systemic effects. No change in plasma 
tracer levels was found, suggesting that overexpressing human 
PLTP in macrophages has no effect on cholesterol efflux in vivo. 
Furthermore, the recovery of labelled cholesterol in liver or faeces 
from mice injected with PLTP transgenic macrophages was not sig-
nificantlydifferentfrom mice injected with wild type macro phages. 
In conclusion, macrophage cholesterol efflux was not affected 
by elevation ofmacrophage-PLTP, suggesting that the atherogenic-
icy of human PLTP in mice is not influenced by a local effect on 
macrophage cholesterol efflux. Systemic PLTP however, decreased 
193 
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macrophage RO', contributing to the pro-atherogenic potential of 
PLTP in transgenic mice. Our findings demonstrate that lowering 
high plasma PLTP activity levels could be of therapeutic benefit for 
the prevention or treatment of atherosclerosis. 
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11.1 Summary 
PLTP has been identified as an important player in lipoprotein metabolism and the 
development of atherosclerosis. However, the exact role of PLTP in these processes is 
far from resolved. We provided further insight into the atherogenic properties of PLTP 
using a broad variety of experimental setups. First of all, we developed new mouse models 
to study the role of PLTP in lipoprotein metabolism and atherogenesis: one model with 
conditional expression of human PLTP, and one model with overexpression of an inactive 
mutant form of human PLTP. In chapter 2 we explored the features of a mouse model 
with a tetracycline-dependent conditional induction of human PLTP expression. This 
tetracycline-responsive mouse model provides the opportunity to study the interference 
of acute changes in PLTP expression in a pathological situation or in a metabolic pathway. 
This situation varies largely from conventional PLTP transgenic mouse models, in which 
the effect of the genetic modification is present life-long, resulting in metabolic adaptation 
to this modification. The tetracycline-responsive mouse model that we used is preferable 
over an adenovirus-mediated overexpression system, as expression of the gene of interest 
is better controlled, easily reversible, not mainly liver-located, and without reduction of 
transgene expression over time. Our mouse model proved to be feasible for induction of 
an acute and easily reversible elevation of PLTP activity. We used our model to study the 
effects of an acute elevation of PLTP activity on lipoprotein metabolism. The increase in 
PLTP activity resulted in a decrease in plasma cholesterol and phospholipids, which was 
explained by a decrease in plasma HDL levels. The decrease in HDL levels could not be 
explained by changes in RNA expression levels of SR-BI, apoB or ABCAl, suggesting 
that the decline in HDL is a direct effect of PLTP. An advantage of this inducible mouse 
model is that it provides a stable and controlled elevation of PLTP activity, making it 
suitable for examination of the effects of acutely induced long-term overexpression of 
human PLTP, which we did in the follow-up study. In this study, described in chapter 
3, we used the mouse model with conditional induction of human PLTP expression to 
investigate the effects of PLTP expression on lipoprotein metabolism under diet-induced 
hyperlipidemic conditions, and on pre-existing atherosclerosis. We observed that an acute 
increase in plasma PLTP activity had major effects on lipoprotein metabolism. HDL 
levels were strongly decreased upon expression of human PLTP, in accordance with the 
findings reported in chapter 2. In addition, we discovered that acute induction of human 
PLTP largely increased plasma triglyceride levels, and inhibited the catabolism of apoB-
containing lipoproteins. Literature shows that, under certain conditions, the secretion of 
apoB-containing lipoproteins by the liver is stimulated by overexpression of PLTP, but as 
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far as we are aware, a PLTP-dependent increase of plasma triglyceride levels and inhibition 
of the catabolism of apoB-containing lipoproteins has never been demonstrated before. 
Apparently, the metabolic effects of an acute increase in PLTP activity differ from the 
effects of the life-long increased plasma PLTP activity levels in human PLTP transgenic 
mice. The increased VLDL levels in the conditional PLTP mice could not be explained by an 
increase in VLDL production, as triglyceride secretion rate by the liver was not affected by 
overexpression ofPLTP. However, the removal ofVLDL from the circulation was delayed, 
with a strongly decreased uptake of cholesterol in the livers of these mice. The decreased 
VLDL clearance in human PLTP expressing mice could be partly explained by a decrease 
in plasma LPL activity. Furthermore, we studied the effect of increased PLTP activity on 
pre-existing atherosclerotic lesions. The unfavourable lipoprotein profile observed in this 
mouse model resulted in a strong increase in atherosclerotic lesion area when Western 
diet was stopped and PLTP activity was induced. In addition, acute expression of PLTP 
resulted in the development of unstable lesions, as determined by lesion macrophage and 
collagen content. This study supplies new evidence that high systemic PLTP expression 
unfavourably affects the condition of the cardiovascular system, not only by decreasing 
plasma HDL levels, but also by inhibition ofVLDL catabolism. 
Although many different mouse models have been used to study the role of PLTP in 
atherosclerosis development, until now, studies in mice focused on the absence of PLTP 
protein (PLTP knockout mice) or on the overexpression ofPLTP (PLTP transgenic mice). 
PLTP displays phospholipid transfer activity, which has been well described in vitro. 
However, the importance ofthis lipid transfer activity in vivo is not completely understood. 
In human plasma, two forms ofPLTP have been described. Besides the catalytically active 
form, also a low-active form with unknown function exists. In order to provide more insight 
into the physiological role of PLTP transfer activity and PLTP mass, we generated a new 
mouse model with overexpression of a human PLTP protein with a mutation at the site 
responsible for the lipid transfer activity of the protein. This mutant PLTP was still able to 
associate with HDL, but lacked phospholipid transfer activity. In chapter 4, we compared 
the effects of overexpression ofthe mutant and normal human PLTP trans gene in mice with 
only one functional allele for the LDL receptor, thereby obtaining a plasma lipoprotein 
profile more similar to that in humans. We demonstrated that the presence of phospholipid 
transfer activity is essential for the PLTP-mediated modulation of plasma HDL levels and 
pre~-HDL formation. Also stimulation of hepatic VLDL secretion appeared to be dependent 
on the phospholipid transfer activity ofPLTP. Importantly, after feeding the mice a cholate-
enriched high fat diet, atherosclerosis development was only increased in mice expressing 
the active form of human PLTP. These results demonstrate that active PLTP is essential for 
the increased atherogenesis induced by PLTP. 
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Next, we studied whether the functioning of PLTP would be altered by the presence of 
other important proteins in lipoprotein metabolism: human apoAI, CETP, or hepatic 
lipase. Because PLTP is a lipid transfer protein, its action is mainly determined by the 
concentration gradient of available substrates, and therefore sensitive to environmental 
changes. As a consequence, the absence or presence of certain proteins that act in close 
relationship with PLTP might strongly influence the action ofhuman PLTP. Although mouse 
models have provided important mechanistical insight in human lipoprotein metabolism 
and atherogenesis, it is important to note that distinct differences exist between murine 
and human lipid metabolism (see Table 2, Chapter 1.2). In order to partly overcome these 
differences, we assessed the effects of increased PLTP expression in two 'humanized' mouse 
models: the human apoAI transgenic and the human CETP transgenic mouse. In chapter 5, 
we described the effects of increased human PLTP expression in a human apoAI transgenic 
background. Human apoAI is the natural carrier for human PLTP that is bound to HDL. 
We studied the effect of PLTP overexpression on different HDL properties (particle size, 
density, and functionality), and on atherosclerotic lesion development. Overexpression of 
the human PLTP gene in a human apoAI transgenic mouse line resulted in decreased total 
plasma cholesterol and phospholipid levels, which were caused by decreased HDL levels. 
In addition, the action of human PLTP together with human apoAI resulted in the formation 
of a large cholesteryl ester-rich subpopulation of HDL particles with LDL density, and 
apoAI as the main apolipoprotein. Overexpression of human PLTP may not only decrease 
plasma HDL levels and change HDL composition, but it could also unfavourably affect 
the functionality of the remaining HDL particles. Therefore, we measured the cholesterol 
efflux capacity of the PLTP-enlarged HDL and found that it was decreased compared to 
HDL from control mice. Also when mice were crossed into an atherosclerosis-prone genetic 
background, HDL isolated from the human PLTP-expressing mice was less efficient in 
promoting cholesterol efflux from cultured macrophages. This may explain, at least partly, 
the observation that the development of atherosclerotic lesions was increased in human 
PLTP overexpressing mice. In conclusion, PLTP may act as a pro-atherogenic factor not 
only by decreasing plasma HDL levels, but also by changing HDL particle composition 
and functionality, strengthening the hypothesis that high plasma PLTP activity levels are 
harmful for cardiovascular health. 
In chapter 6 we described the effects of PLTP in another humanized mouse model, the 
human CETP transgenic mouse. In earlier studies of our group, it was demonstrated that 
the presence ofCETP does not influence the effect ofPLTP on atherogenesis. In the study 
described in chapter 6, we investigated the effect of overexpression of human PLTP on 
atherosclerosis development in male and female mice. It is well-known that male mice 
are less susceptible to diet-induced atherosclerosis than female mice. Although there is 
no clear explanation for this difference between genders, we used it as a starting point 
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to elucidate the atherogenic mechanism behind PLTP overexpression. We studied which 
of two well-known pro-atherogenic PLTP effects, either the stimulation of hepatic VLDL 
secretion or the lowering of plasma HDL levels, is the most important factor in explaining 
the atherogenic potential ofPLTP. No difference was observed in the rate of hepatic VLDL 
secretion between male and female mice. In contrast, HDL levels were significantly lower 
in female mice than in male mice. Therefore, we concluded that the decrease in plasma 
HDL has a more substantial contribution to the atherogenicity of elevated PLTP levels 
than the stimulation of hepatic VLDL secretion. However, the gender-related difference in 
atherosclerosis should not too easily be ascribed completely to the changes in the levels of 
HDL. We did not study differences in lipoprotein distribution, cellular cholesterol efflux, 
apolipoproteins, lipolytic enzymes, qualitative HDL properties or other factors that may 
contribute to the gender differences in atherosclerosis susceptibility. These experiments do 
not provide certainty whether PLTP influences atherogenicity solely at the level of plasma 
lipoproteins or also locally at the level of the vessel walL However, we can conclude that 
PLTP overexpression enhances the gender differences in atherosclerosis development. 
Cross-breeding oftransgenic animals is not only a good approach to generate a 'humanized' 
mouse model in which the role ofPLTP can be studied, but it is also an interesting way to 
study a possible functional interaction between PLTP and other proteins. Hepatic lipase is 
such a protein that might affect the function ofPLTP. Hepatic lipase is a lipolytic enzyme, 
involved in the conversion ofVLDL into LDL, and in HDL remodelling, two pathways in 
which also PLTP is involved. We investigated the possibility of a functional relationship 
between PLTP and hepatic lipase, as described in chapter 7. First of all, we investigated 
the effect of overexpression of PLTP on hepatic lipase activity by comparing wild type 
mice with human PLTP transgenic mice. We found that in transgenic animals, the binding 
of hepatic lipase to cellular proteoglycans was increased. This may be explained by the 
PLTP-mediated reduction of plasma HDL levels, as hepatic lipase is preferably bound to 
circulating HDL in mice. Furthermore, a possible functional relationship between both 
proteins was studied by crossing PLTP transgenic mice into a hepatic lipase deficient 
background. Plasma PLTP activity in either wild type or in PLTP transgenic mice was 
not affected by hepatic lipase deficiency. Moreover, hepatic lipase was shown not to be 
required for the PLTP-dependent increase in hepatic triglyceride secretion or decrease in 
plasma HDL levels. These results indicate that hepatic lipase and PLTP act independently. 
Importantly, we demonstrated that elevated PLTP activity lowered plasma HDL levels by 
stimulating HDL plasma turnover and increasing the uptake of HDL cholesteryl esters by 
the liver. 
In another set of experiments, described in chapter 8, we focussed on the relationship 
between PLTP expression and plasma HDL levels. In ABCAl deficient mice, we 
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investigated the effect of reduced HDL levels on PLTP gene expression, secretion and 
plasma distribution. PLTP mRNA expression in liver and macrophages was not different in 
ABCA 1 deficient mice compared to wild type mice. Also PLTP secretion by culturedABCA 1 
deficient macrophages was not decreased. As neither a decreased PLTP gene expression nor 
a decrease in PLTP secretion could explain the reduced plasma PLTP levels observed in 
ABCAl deficient mice, we hypothesized that the explanation may be at the systemic level 
instead of the cellular level. We showed that the phospholipid transfer activity levels of 
PLTP, secreted from macrophages, decreased when serum from ABCAI deficient mice 
was present in the culture medium, compared to medium with serum from wild type mice. 
Macrophage-derived PLTP activity appeared to be controlled by the HDL concentration 
in the culture medium. From these findings, we suggested that PLTP could be stabilised 
by HDL particles, and that the low plasma PLTP activity levels found in ABCAl deficient 
mice are the result of an indirect effect ofthe absence of ABCAl through reduction ofHDL 
levels, rather than a direct cellular effect of ABCAl on PLTP. In addition, we discovered 
that the distribution of PLTP among lipoprotein particles was totally changed in ABCAl 
deficient mice. PLTP was found associated with HDL particles in wild type mice, whereas 
in ABCAl deficient mice PLTP was associated with VLDL and LDL particles. 
To further elucidate the effect of HDL on PLTP expression and distribution, we used a 
different approach, as described in the second part of chapter 8. We studied the effect of 
LXR activation and subsequent alteration of the lipoprotein profile on PLTP expression and 
distribution in different mouse lines with varying plasma HDL and PLTP levels. Wild type, 
ABCAl deficient, apoE deficient and PLTP transgenic mice were treated with a synthetic 
LXR ligand. LXR treatment resulted in an upregulation of PLTP gene expression in all 
mouse models. Plasma PLTP activity levels were increased, but the extent ofLXR-mediated 
plasma PLTP induction appeared to be related to plasma HDL level. Importantly, PLTP 
activity was found at the position ofHDL particles in all mouse models, except in ABCAl 
deficient mice, likely because HDL was virtually absent. These results demonstrate that 
HDL metabolism may regulate plasma PLTP activity and distribution. 
In the last part of this thesis, we focussed on the functionality of macrophage-derived PLTP, 
in addition to systemic PLTP. Hepatic and plasma lipoprotein metabolism have always 
played a major role in the investigation of atherogenesis. However, more recently, increasing 
attention has been paid to inflammatory and local processes in the vessel wall. In earlier 
chapters, we reported the effect of elevated systemic PLTP levels on lipoprotein metabolism 
and atherosclerosis development in mice. However, the macrophage is a key component 
of the atherosclerotic lesion and PLTP has been shown to colocalise with foam cells in 
atherosclerotic lesions. Recent studies focused on the role of macrophage-derived PLTP 
in the development of atherosclerosis using the technique of bone marrow transplantation. 
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It has not been clarified yet how macrophage-derived PLTP within the artery wall may 
influence the development of atherosclerosis. Recent publications showed conflicting 
results, suggesting either a pro-atherogenic or an anti-atherogenic role of macrophage-
derived PLTP. To elucidate the contribution of elevated levels of macrophage-derived PLTP 
to plasma phospholipid transfer activity and atherosclerosis development, we performed 
bone marrow transplantation experiments (chapter 9). Transplantation of bone marrow 
cells from PLTP transgenic mice resulted in elevated plasma PLTP activity levels in the 
LDLR-deficient acceptor mice compared to mice transplanted with wild type bone marrow 
cells. As a result of increased plasma PLTP activity levels, plasma levels ofHDL cholesterol 
decreased, and plasma levels of non-HDL cholesterol increased. Transplantation of PLTP 
overexpressing bone marrow cells resulted in increased atherosclerosis development. Most 
likely, the effects on plasma lipoproteins account for the observed enhanced atherosclerosis 
in mice transplanted with PLTP transgenic bone marrow. However, there might also be a 
local effect of macrophage-derived PLTP in the vascular wall, as PLTP was abundantly 
present within the atherosclerotic lesions. The results from our study, using an alternative 
mouse model and different techniques compared to the experiments performed by other 
research groups, do not resolve the apparent discrepancies between earlier studies. However, 
our results indicate that the presence ofPLTP in human atherosclerotic lesions contributes 
to the pathological process and that PLTP in atherosclerotic lesions may be a valuable target 
for therapy. 
In chapter 10, we described the role of PLTP in reverse cholesterol transport from 
macrophages, making the distinction between elevation of systemic PLTP and elevation of 
macrophage-PLTP. Cholesterol efflux from macrophages in the arterial wall and subsequent 
transport to the liver and intestine for excretion may prevent cellular lipid accumulation, 
foam cell formation, and the development of atherosclerosis. Until recently, knowledge on 
the physiological importance of reverse cholesterol transport and the role of key proteins 
in this process was based on findings from in vitro experiments or on methods quantifying 
reverse cholesterol transport from peripheral cells in the entire body. The complex network 
of plasma and cellular proteins involved in reverse cholesterol transport made it difficult 
to translate the results obtained in vitro to the situation in vivo, and to draw conclusions 
about reverse cholesterol transport originating specifically from macrophages, also called 
macrophage reverse cholesterol transport. The development of a new method to measure 
macrophage reverse cholesterol transport provided us the opportunity to study systemic 
as well as macrophage-specific effects of PLTP in this process in vivo. By injecting lipid-
loaded wild type macrophages into wild type or PLTP transgenic mice, we demonstrated 
that cholesterol efflux and reverse cholesterol transport from these cells are impaired 
when systemic PLTP is elevated, most likely explained by the PLTP-mediated lowering 
of plasma HDL. However, elevation ofmacrophage-PLTP did not affect cholesterol efflux 
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and reverse cholesterol transport in vivo, as shown by injection ofmacrophages from wild 
type or PLTP transgenic mice into wild type mice. Therefore we hypothesize that increased 
systemic PLTP levels enhance the development of atherosclerosis by decreasing the rate of 
macrophage reverse cholesterol transport. 
Taken together, we demonstrated the pro-atherogenic potential of elevated systemic 
PLTP levels in many different mouse models. By using a variety of new approaches, 
we confirmed the major effect of PLTP on HDL metabolism, resulting in an increased 
susceptibility to atherosclerosis development. In addition, we reported effects of PLTP on 
VLDL metabolism that have not been described before, and we described the effect of 
macrophage-derived PLTP on lipoprotein metabolism, macrophage reverse cholesterol 
transport and atherogenesis. Overall, the main findings of our studies can be summarized 
as follows: 
1) PLTP overexpression, causing elevated systemic PLTP activity levels, results in 
an increased susceptibility to atherosclerosis in mice. This effect of PLTP is observed 
independently of the transgenic mouse model that is used: both ubiquitous and tissue-
or cell-specific expression, as well as permanent and acute expression of PLTP, results 
in increased atherosclerosis development; 2) Overexpression of PLTP in mice results in 
decreased plasma HDL levels, caused by enhanced HDL catabolism. Also this effect of 
PLTP is observed independently of the PLTP transgenic mouse model that is used. Under 
certain circumstances, elevated expression ofPLTP not only affects plasma HDL levels, but 
also HDL composition and functionality, as demonstrated in human apoAI transgenic mice; 
3) Systemic elevation of PLTP in mice impairs macrophage reverse cholesterol transport, 
which is most likely due to the reduced plasma HDL levels. Elevation of macrophage-PLTP 
does not affect cholesterol efflux and macrophage reverse cholesterol transport; 4) Elevation 
of PLTP activity might affect apoB-containing lipoprotein metabolism. PLTP-induced 
enhancement of VLDL production and impairment of the catabolism of apoB-containing 
lipoproteins are not unambiguous, and depend on mouse model, genetic background, 
gender, age, fasting state, and experimental set-up; 5) The atherogenicity of elevated PLTP 
levels can be explained mainly by the systemic effects ofPLTP on lipoprotein metabolism. 
In our mouse models, potential local macrophage-specific anti-atherogenic effects ofPLTP 
are of minor importance compared to the systemic pro-atherogenic effects; 6) Phospholipid 
transfer activity is essential for the effects of PLTP on lipoprotein metabolism and 
atherogenesis. In our mouse model, there is no evidence for a function of the inactive form 
of PLTP; 7) HDL metabolism regulates plasma PLTP expression and distribution. Under 
normal conditions, PLTP is found associated with HDL particles. When HDL particles are 
virtually absent, PLTP levels are strongly reduced and PLTP is found associated with other 
lipoprotein particles. 
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11.2 Future perspectives 
Atherosclerosis is the leading cause of death in the developed world, and predicted to be the 
main cause of death worldwide by the year 2020 (Fonarow, 2007). The current treatment 
of atherosclerotic disease is based on targeting classical risk factors by pharmacological 
intervention (antihypertensive and lipid-lowering drugs) in combination with lifestyle 
advice (low-fat diet, smoking cessation, physical activity). As hypercholesterolemia is 
considered as the main risk factor for development of atherosclerosis, the most commonly 
used pharmacotherapy for prevention, treatment and control of atherosclerosis consists of 
lipid-lowering drugs. During the last 20 years, the use of drugs to lower plasma LDL levels, 
such as statins, achieved a strong reduction in cardiovascular risk (Kapur and Musunuru, 
2008). However, statin therapy only reduces cardiovascular events worldwide by about one-
third (Tall, 2008), while further spreading of Western lifestyle results in an ever increasing 
prevalence of atherosclerosis. Obviously, there is an urgency for the development of 
additional pharmacotherapies to treat atherosclerosis in a more efficient way. 
Because the inverse relationship between plasma HDL-cholesterollevel and the prevalence 
of atherosclerotic cardiovascular disease is well-established, an emerging target of therapy 
is the level of plasma HDL. HDL particles have an important anti-atherogenic function, 
by exerting anti-inflammatory, anti-oxidative, and antithrombotic effects (Joy and Hegele, 
2008; Kontush et al., 2008). In addition, HDL serves as an acceptor particle for cellular 
cholesterol, thereby promoting the efflux of lipids from the vessel wall, which is the first 
step in reverse cholesterol transport and important in the prevention of cellular cholesterol 
accumulation. Currently available drugs to increase HDL-cholesterol levels are nicotinic 
acid (niacin) and fibric acid derivates (fibrates). Niacin is an effective drug to increase 
HDL-cholesterol, but a main limitation of niacin treatment is the high frequency of side 
effects, which makes the drug less suitable for long-term therapy. Fibrates are weak PPAR-a 
agonists that are used to raise HDL-cholesterol levels. In several clinical trials, fibrate 
treatment resulted in a reduction of cardiovascular morbidity and a reduced progression of 
atherosclerosis (Hausenloy and Yell on, 2008; Joy andHegele, 2008). However, the outcomes 
of clinical trials with fibrates vary, and the potential of this drug class to induce adverse 
effects when given in combination with statins, limit the use offibrates as cardioprotective 
agents. These difficulties demonstrate the demand for alternative HDL-raising strategies. 
Inhibition of elevated levels of systemic PLTP could be an approach to increase HDL levels 
and reduce atherosclerosis. This hypothesis is supported by the experiments described 
in this thesis, in which we evaluated the role of PLTP in lipoprotein metabolism and 
atherosclerosis development in genetically modified mouse models. PLTP could serve as a 
potential therapeutic target for treatment of atherosclerotic disease by raising plasma HDL 
levels. However, it is not certain whether inhibition ofPLTP activity is the right approach 
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to increase plasma HDL level and inhibit atherogenesis. Not only PLTP overexpressing 
mice, but also homozygous PLTP knockout mice have decreased plasma HDL levels, 
obviously caused by different mechanisms. In mice overexpressing PLTP, PLTP-mediated 
redistribution of lipids among lipoprotein populations probably causes instability of HDL 
particles, leading to an accelerated catabolism (Foger et al., 1997). In PLTP deficient 
mice, the transfer of lipids to HDL is arrested, thereby preventing the formation of mature 
HDL particles (Qin et al., 2000). Apparently, complete inhibition of plasma PLTP activity 
will not necessarily be a useful therapy to increase plasma HDL levels. It is important to 
realise that besides an important role in HDL metabolism, PLTP is also involved in other 
processes (of which some may not have been discovered yet) that will be disturbed by 
complete inhibition ofPLTP activity. One process in which PLTP is involved is the transfer 
of vitamin E from lipoproteins to tissues. PLTP deficiency enhances the accumulation of 
vitamin E in apoB-containing lipoproteins, resulting in a decreased susceptibility of these 
lipoproteins to oxidative modification and a reduced atherosclerosis development (Jiang 
et al., 2001; Jiang et al., 2002). However, vitamin E transfer by PLTP is also an important 
process in preventing oxidative damage in the brain, and PLTP deficiency could be of major 
pathophysiological relevance in neurodegenerative diseases (Desrumaux et al., 2005). 
The inhibition of plasma CETP activity as a therapy to raise HDL levels serves as an 
example for the practical problems that could be encountered when a comparable therapeutic 
approach would be chosen for PLTP. In extensive animal studies and preclinical trials, 
CETP inhibition by monoclonal antibodies or synthetic compounds demonstrated clinical 
efficacy on plasma lipid levels by markedly increasing HDL-cholesterol (Vourvouhaki and 
Dedoussis, 2008). In addition, CETP inhibition might protect against atherosclerosis by 
improving the anti-inflammatory and antioxidative properties of HDL (Kastelein, 2007). 
However, CETP could also have an anti-atherogenic effect, as introduction ofCETP in mice 
enhanced macrophage reverse cholesterol transport (Tanigawa et al., 2007). The effect of 
CETP expression on atherosclerosis susceptibility in animal models is highly dependent 
on the level of CETP expression and on the genetic and metabolic context (Parini and 
Rudel, 2003). A large clinical trial with the CETP inhibitor torcetrapib (in combination 
with atorvastatin) in patients with coronary artery disease was terminated as a result of 
excessive mortality in the active treatment group relative to the placebo group, despite 
a significant increase in HDL level (Barter et al., 2007). Unlike other CETP inhibitors, 
torcetrapib treatment was associated with a moderate increase in blood pressure, indicating 
that this inhibitor has off-target adverse effects that are probably unrelated to its HDL-
raising action (Kastelein, 2007; Kontush et al., 2008). However, the unexpected failure 
of torcetrapib highlighted important unresolved questions in the field of HDL research. 
There has been considerable speculation that the strategy of CETP inhibition might lead 
to formation of dysfunctional HDL. HDL particles that are formed upon CETP inhibition 
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could be less efficient in stimulating cellular cholesterol efflux and reverse cholesterol 
transport, and may be pro-inflammatory and pro-oxidant (Singh et al., 2007; Tall et al., 
2008). In conclusion, both HDL quantity and HDL quality should be taken into account 
when developing and evaluating pharmacological HDL-raising strategies. 
The example oftorcetrapib raises the question whether increasing HDL levels by all means, 
and under any condition, would be of therapeutic profit for the treatment of atherosclerosis. 
It is important to note that the pool of HDL particles is structurally and functionally 
diverse, consisting of many highly dynamic particle subpopulations that differ in their 
atheroprotective capacity (Rye et al., 2008). The existence of a mutant form of apoAI that 
causes very low HDL levels with moderate hypertriglyceridemia, but that is not associated 
with an increased risk for cardiovascular disease, demonstrates the importance to consider 
HDL as a heterogeneous pool of particles (Chiesa and Sirtori, 2003). In a large intervention 
trial, subjects with new cardiovascular events had significantly lower levels of a-HDL, and 
significantly higher levels ofpre~-HDL compared to event-free subjects, further supporting 
a functional distinction between different HDL subpopulations (Asztalos et al., 2008). By 
the experiments described in this thesis, we demonstrated that under certain conditions 
PLTP affects HDL level, composition and functionality. However, before PLTP activity can 
be considered with certainty as a therapeutic target for treatment of atherosclerotic disease, 
the exact physiological role ofPLTP should be established in more detail. 
PLTP is a lipid transfer protein and as a consequence its action may depend on fluctuations 
in plasma lipid levels. Experiments investigating the effects of hyperlipidemic conditions 
on the action ofPLTP could provide important new physiological insights. We demonstrated 
that overexpression of PLTP in mice results in enhanced HDL catabolism and decreased 
plasma HDL levels, independently of the PLTP transgenic mouse model that is used. In 
contrast, the effects of elevated PLTP activity on apoB-containing lipoprotein metabolism 
(i.e. enhancement of VLDL production and impairment of the catabolism of non-HDL 
particles) are not unambiguous. Therefore, the role ofPLTP in the metabolism of apoB-rich 
lipoproteins should be investigated more thoroughly. In our mouse models, PLTP-mediated 
changes in apoB-containing lipoprotein metabolism were dependent on various parameters 
such as genetic background and gender. The influence of fasting state, background, gender, 
and age could greatly influence the action of PLTP, and attention should be paid to these 
issues when assessing the influence of PLTP in the process of atherogenesis. 
The hypothesis that strongly elevated systemic levels of PLTP are pro-atherogenic has 
been confirmed by the experimental work as presented in this thesis. However, the effect of 
moderate changes in plasma PLTP activity remains uncertain. For this purpose, evaluation 
ofthe effect ofPLTP inhibition in less extreme mouse models is needed. This is supported 
by the fact that in humans there are no reports ofPLTP deficiency or extremely high PLTP 
activity levels. Although variations in PLTP levels have been associated with different 
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pathophysiological conditions in human subjects (summarized in chapter 1), it is hard to 
identify the exact contribution ofPLTP to the pathology of atherosclerosis. Studies in some 
less extreme mouse models have been performed, such as mice with only one functional 
PLTP allele or mice with only 29% elevated PLTP levels (Jiang et al., 1996; Jiang et al., 
1999). These models did not display any difference in lipoprotein metabolism compared 
to wild type mice. However, in these models, potential local PLTP effects may be of 
significant importance in the process of atherogenesis, and should therefore be studied 
in detail. Bone marrow transplantation studies with PLTP deficient macrophages revealed 
conflicting results, so that the local effects of PLTP on atherogenesis remain unclear (Liu 
et al., 2007; Valenta et al., 2008; Valenta et al., 2006; Vikstedt et al., 2007). Also our bone 
marrow transplantation study did not elucidate the specific effects oflocal PLTP expression 
on atherosclerosis development, as the contribution of macrophage-derived PLTP to plasma 
phospholipid transfer activity was substantial and resulted in altered plasma lipoprotein 
levels. Various bone marrow transplantation studies demonstrated that macrophage-specific 
expression of a gene of interest can alter the susceptibility to atherosclerosis, without 
changing the plasma lipoprotein profile (Aiello et al., 2002; Nong et al., 2003; Out et al., 
2006; Overton et al., 2007). Therefore, it would be interesting to develop a strategy to study 
the local effects of increased macrophage-PLTP, without the interference of systemic PLTP 
effects (i.e. decreased plasma HDL levels). Potentially, this approach might lead to the 
identification of peripheral PLTP instead of systemic PLTP as a useful target for treatment 
of cardiovascular disease. 
We demonstrated that elevation ofmacrophage-PLTP expression does not alter macrophage 
reverse cholesterol transport in mice. However, it is obvious that other local macrophage-
specific effects of PLTP could play an important role in the process of atherogenesis. For 
example, peripheral PLTP could influence the inflammatory status of atherosclerotic lesions, 
as PLTP deficiency clearly alters the systemic inflammatory response (Schlitt et al., 2005; 
Shelly et al., 2008). At the moment, it is unclear whether PLTP is directly involved in the 
inflammatory response, or whether inflammation is observed secondary to PLTP-induced 
effects on lipoprotein metabolism and atherogenesis. As atherosclerosis can be considered 
as an inflammatory disease, it is important to study the involvement ofPLTP in this process 
in more detail, both on the systemic and the cellular level. 
In conclusion, an elevated systemic PLTP level may be a promising target for treatment of 
atherosclerosis in the future. However, a better understanding of the (patho )physiological 
effects of PLTP is essential. Before tissue- or cell-specific targeting of PLTP can be 
considered as a potential therapy, it is crucial to investigate whether local effects of cellular 
PLTP are beneficial or harmful. 
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Aderverkalking, of atherosclerose, is een ziekte van de grote en middelgrote slagaders, 
gekenmerkt door de ophoping van vetten in de vaatwand en gepaard gaand met 
ontstekingsreacties. Hierdoor vermindert de elasticiteit van het bloedvat en ontstaat er 
vaatvemauwing. Een belangrijke risicofactor voor het ontstaan van aderverkalking is 
hyperlipidemie, verhoogde concentraties van vetten in het bloed. In het begin van de jaren 
tachtig van de vorige eeuw werd in menselijk bloed een eiwit ontdekt dat in staat was om 
fosfolipiden, een specifiek type vet, te transfereren. Dit eiwit werd "phospholipid transfer 
protein" (PLTP) genoemd. De precieze functie van PLTP in het lichaam was, en is nog 
steeds, niet volledig opgehelderd. Experimenten met proefdieren, voomamelijk muizen, 
hebben aangetoond dat PLTP een rol speelt in het ontstaan van aderverkalking. Dit zou 
voor een groot deel verklaard kunnen worden door het effect van PLTP op de stofwisseling 
van de zogenaamde lipoproteYnen. LipoproteYnen zijn complexen van vetten (waaronder 
cholesterol en fosfolipiden) en eiwitten, die het transport van deze vetten in de bloedbaan 
mogelijk maken. LipoproteYnen kunnen in het laboratorium worden gescheiden naar 
dichtheid, bijvoorbeeld zeer lage dichtheid (very low-density lipoprotein, VLDL), lage 
dichtheid (low-density lipoprotein, LDL), en hoge dichtheid (high-density lipoprotein, 
HDL). De bloedspiegels van de verschillende soorten lipoproteYnen zijn nauw verbonden 
met het ontstaan van aderverkalking. Zo worden VLDL en LDL als schadelijk beschouwd 
voor hart en vaten ("slecht cholesterol"), terwijl het hebben van een hoge HDL-spiegel als 
beschermend wordt gezien ("goed cholesterol"). 
De afgelopen 15 jaar is de rol van PLTP uitgebreid onderzocht doormiddel van experimenten 
in vitro (letterlijk "in glas", d. w.z. bijvoorbeeld in een reageerbuis) en in vivo (in proefdieren 
of in mensen). Dit heeft tot waardevolle inzichten geleid, maar verschillende vragen zijn tot 
op heden onopgelost. Aan de ene kant heeft PLTP eigenschappen die als 'pro-atherogeen' 
aangemerkt kunnen worden, m.a.w. die het ontstaan van aderverkalking zouden kunnen 
stimuleren. Zo veroorzaakt een verhoogde transferactiviteit van PLTP in het bloed een daling 
van de HDL-spiegel. Verder stimuleert PLTP de productie van VLDL. Ook zou het direct 
de ontstekingsreactie en oxidatie van lipoproteYnen kunnen beYnvloeden. Aan de andere 
kant bezit PLTP ook enkele 'anti-atherogene' eigenschappen, die beschermend zouden zijn 
en het proces van aderverkalking tegengaan. PLTP stimuleert de vorming van een bepaald 
soort HDL dat heel efficient vetten uit cellen kan opnemen (het zogenaamde preB-HDL). 
Op deze manier zou de ophoping van vetten in cellen in de vaatwand geremd kunnen 
worden. Het feit dat PLTP blijkbaar zowel pro- als anti-atherogene eigenschappen bezit, 
maakt het moeilijk om de precieze rol van PLTP in de ontwikkeling van aderverkalking vast 
te stellen. Gebruik makend van de muis als onderzoeksmodel hebben wij geprobeerd de rol 
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van PLTP in de stofwisseling van lipoproteinen en het ontstaan van aderverkalking verder 
te verduidelijken. De verschillende experimentele benaderingen die hiervoor gebruikt zijn, 
en de resultaten die hiermee verkregen zijn, staan beschreven in dit proefschrift. 
Door middel van genetische manipulatie hebben we twee nieuwe muismodellen ontwikkeld: 
een model met conditionele expressie van humaan PLTP, waarbij het eiwit op elk gewenst 
moment tot expressie gebracht kan worden, en een model met expressie van een inactieve 
vorm van humaan PLTP, welke niet in staat is om fosfolipiden te transfereren. Deze 
modellen onderscheiden zich van de muismodellen die in het verleden zijn gebruikt in 
die zin dat in die modellen voomamelijk sprake was van continu verhoogde expressie van 
actief humaan PLTP. Door gebruik te maken van het conditionele muismodel hebben we 
het pro-atherogene effect van tijdelijke expressie van PLTP opal aanwezige aderverkalking 
aangetoond. Met het tweede muismodel hebben we de noodzaak van de transferactiviteit 
van PLTP voor de pro-atherogene eigenschappen van het eiwit laten zien. 
Verder hebben we bestudeerd ofhet functioneren van PLTP beinvloed wordt door de aan- of 
afwezigheid van andere eiwitten met een belangrijke rol in de stofwissclingvan lipoproteYnen: 
humaan apoAI, CETP, en leverlipase. Hoewel muismodellen belangrijk mechanistisch 
inzicht kunnen leveren in fysiologische processen in de mens, is het belangrijk te beseffen 
dat metabole verschillen tussen muis en mens kunnen leiden tot onjuiste interpretatie van 
resultaten. Om deze verschillen voor een deel te compenseren hebben we de rol van humaan 
PLTP in twee 'gehumaniseerde' muismodellen bestudeerd: muizen met humaan apoAI en 
muizen met humaan CETP. ApoAI is het oppervlaktemolecuul op HDL waar PLTP aan 
bindt. CETP is een eiwit dat structureel en functioneel nauw verwant is aan PLTP. In beide 
modellen hebben we pro-atherogene eigenschappen van PLTP aangetoond. Verder hebben 
we onderzocht of er een functionele interactie bestaat tussen PLTP en leverlipase, een eiwit 
dat betrokken is in verschillende fysiologische processen waar ook PLTP een rol in speelt. 
Uit dit onderzoek concludeerden we dat de functie van PLTP niet beinvloed wordt door de 
aan- of afwezigheid van leverlipase. 
Dat PLTP een belangrijke rol speelt in de stofwisseling van HDL is algemeen bekend. 
PLTP bindt aan HDL, waarna het HDL omzet tot zowel grotere als kleinere HDL-deeltjes. 
In muizen zonder ABCAI, een lipide-transporteiwit in het celmembraan, worden extreem 
lage HDL-spiegels in het bloed gevonden, in combinatie met een verlaagde PLTP-activiteit. 
We hebben een mogelijk causaal verband tussen lage HDL-spiegels en lage PLTP-activiteit 
in het bloed bestudeerd. Ook in andere muismodellen hebben we vastgesteld dat verlaagde 
HDL-spiegels in het bloed het niveau en de distributie van PLTP kunnen beinvloeden. 
Hoewel de stofwisseling van vetten in de lever en het bloed altijd centraal stonden in het 
onderzoek naar de ontwikkeling van aderverkalking, wordt er de laatste jaren steeds meer 
aandacht besteed aan lokale ontstekingsprocessen in de vaatwand. Het belangrijkste eel type 
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dat verantwoordelijk is voor de vetophoping in de wand van door aderverkalking aangetaste 
bloedvaten is de macrofaag. PLTP en met vet geladen macrofagen (schuimcellen) komen 
op dezelfde plek in de vaatwand voor. Daarom hebben we de rol van PLTP atkomstig 
uit macrofagen in de ontwikkeling van aderverkalking onderzocht, gebruik makend van 
de beenmergtransplantatie-techniek. Hierbij werd het beenmerg van muizen geYnactiveerd 
d.m.v. bestraling, waarna beenmergcellen geYsoleerd uit donormuizen met humaan PLTP 
werden geYnjecteerd in de bloedbaan van de bestraalde muizen. Hiermee hebben we 
aangetoond dat PLTP atkomstig uit macrofagen in grote mate bijdraagt aan de PLTP-
concentratie in het bloed, en een pro-atherogene werking heeft. 
In het laatste deel van dit proefschrift hebben we de rol van PLTP in het 'omgekeerde 
cholesteroltransport' van macrofaag naar faeces in de muis onderzocht. Het omgekeerde 
cholesteroltransport bestaat uit de efflux van cholesterol uit macrofagen in de vaatwand, 
en het daaropvolgende transport van cholesterol naar de lever en darmen voor uitscheiding 
via de faeces. Dit proces voorkomt de stapeling van vetten in macrofagen, dus de vorming 
van schuimcellen, en daarmee de ontwikkeling van aderverkalking. Met behulp van een 
methode om in vivo het omgekeerde cholesteroltransport uit macrofagen te meten hebben 
we aangetoond dat verhoogde PLTP-spiegels in het bloed een remmende werking hebben 
op het omgekeerde cholesteroltransport. Het proces wordt echter niet beYnvloed door 
verhoogde expressie van PLTP uitsluitend in macro fa gen. 
Door middel van de in dit proefschrift beschreven experimenten hebben we aangetoond dat 
in muizen een verhoging van de PLTP-activiteit in het bloed een pro-atherogene werking 
heeft, m.a.w. het stimuleert de ontwikkeling van aderverkalking. Onze belangrijkste 
bevindingen kunnen als volgt worden samengevat: 
1) De overexpressie van humaan PLTP, resulterend in een verhoogde PLTP-activiteit in 
het bloed, versterkt de ontwikkeling van aderverkalking in muizen. Dit effect van PLTP 
wordt waargenomen onafhankelijk van het muismodel dat wordt bestudeerd: zowel 
alomtegenwoordige als weefselspecifieke expressie van PLTP, en zowel permanente als 
acute expressie van PLTP resulteert in een versterkte ontwikkeling van aderverkalking. 
2) Verhoging van PLTP-activiteit in muizen leidt tot een verlaagde HDL-spiegel in het 
bloed. Ook dit effect van PLTP wordt waargenomen onafhankelijk van het muismodel dat 
wordt gebruikt. Onder bepaalde omstandigheden beYnvloedt een verhoogde PLTP-spiegel 
in het bloed niet alleen de HDL-spiegel, maar ook de samenstelling en functionaliteit van 
HDL. 
3) Verhoging van PLTP in bloed remt het omgekeerde cholesteroltransport uit macrofagen 
naar de faeces, wat hoogstwaarschijnlijk verklaard kan worden door de verlaagde HDL-
spiegel in het bloed. Verhoging van macrofaag-specifiek PLTP heeft geen effect op de 
efflux van cholesterol en het omgekeerde cholesteroltransport uit macrofagen. 
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4) Verhoging van PLTP-activiteit kan de stofwisseling van VLDL beYnvloeden. De 
stimulatie van VLDL-productie en de remming van VLDL-afbraak is niet eenduidig, maar 
afuankelijk van muismodel en experimentele opzet. 
5) Het stimulerende effect van een verhoogde PLTP-spiegel op de ontwikkeling van 
aderverkalking kan voomamelijk verklaard worden door de effecten van PLTP aanwezig in 
het bloed op de stofwisseling van lipoprote1nen. In onze muismodellen zijn de potentieel 
anti-atherogene lokale effecten van macrofaag-specifiek PLTP minder sterk dan de pro-
atherogene effecten in het bloed. 
6) Fosfolipide-transferactiviteit is essentieel voor de effecten van PLTP op de stofwisseling 
van lipoprote1nen en het ontstaan van aderverkalking. 
7) HDL reguleert de expressie en distributie van PLTP in het bloed. 
De resultaten van de experimenten zoals beschreven in dit proefschrift ton en aan dat PLTP 
een mogelijk therapeutisch doel voor de behandeling van aderverkalking zou kunnen zijn. 
In onze muismodellen resulteerden verhoogde PLTP-spiegels in het bloed in een daling 
van de HDL-spiegels en een sterkere ontwikkeling van aderverkalking. HDL heeft een 
anti-atherogene functie, wat verklaard wordt door de anti-infiammatoire, anti-oxidatieve, 
en anti-thrombotische effecten van HDL. Verder kan HDL de efflux van cholesterol uit 
cellen in de vaatwand stimuleren en daarmee de ophoping van cholesterol in de vaatwand 
voorkomen. Vele onderzoeken hebben een sterke correlatie aangetoond tussen verlaagde 
HDL-spiegels in het bloed en een verhoogd risico op hart- en vaatziekten. Remming van 
PLTP zou een mogelijke therapie kunnen zijn voor de behandeling van aderverkalking via 
een verhoging van de HDL-spiegel in het bloed. Het is echter nog onduidelijk of remming 
van PLTP ook daadwerkelijk de juiste aanpak is voor dit doeleinde. Alhoewel een hoge 
PLTP-activiteit resulteerde in lage HDL-spiegels in onze muismodellen, toont de literatuur 
dat ook PLTP-deficiente muizen verlaagde HDL-spiegels hebben. Een volledige remming 
van PLTP lijkt daarom geen geschikte therapeutische optie. Verder speelt PLTP niet alleen 
een grote rol in het metabolisme van HDL, maar is het ook betrokken bij diverse andere 
( deels onbekende) processen. Remming van PLTP zou deze process en emstig kunnen 
verstoren. Verder is het niet bekend of de remming van PLTP zal leiden tot de vorming 
van functioneel HDL. Niet alleen de absolute stijging van het HDL-niveau door PLTP-
remming, maar ook de kwaliteit van het HDL (om in:flammatie en oxidatie tegen te gaan, 
en om het omgekeerde cholesteroltransport te stimuleren) zal bestudeerd moeten worden. 
Het is van be lang rekening te houden met het feit dat er een grote structurele en functionele 
diversiteit in HDL bestaat, met belangrijke verschillen in de mate van bescherming tegen 
aderverkalking. VoordatPLTP-activiteit daadwerkelijk als therapeutisch doel beschouwd kan 
worden voor de behandeling van aderverkalking, zal daarom eerst de exacte tysiologische 
rol van PLTP vastgesteld moeten worden. Hierbij moet gedacht worden aan een uitgebreid 
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onderzoek naar de rol van PLTP in de stofwisseling van VLDL en LDL, waarbij ook de 
invloed van leeftijd, geslacht, genetische achtergrond, en gevaste of gevoede toestand van 
de proefdieren nauwkeurig vastgesteld dient te worden. 
De hypothese dat een sterk verhoogde systemische PLTP-spiegel het ontstaan van 
aderverkalking stimuleert, is bevestigd door het experimentele werk dat beschreven is 
in dit proefschrift. Het effect van kleine veranderingen in PLTP-activiteit is echter nog 
onduidelijk, en zou onderzocht moeten worden in minder extreme muismodellen. Deze 
stelling wordt gesteund door het feit dat er in mensen geen meldingen zijn van volledige 
afwezigheid van PLTP, of van extreem hoge PLTP-spiegels. Ook lokale effecten van 
PLTP zouden wei eens van belang kunnen zijn voor de ontwikkeling van aderverkalking, 
en deze effecten zouden daarom meer in detail bestudeerd moeten worden. Hierbij kan 
bijvoorbeeld gedacht worden aan de rol van PLTP in het ontstekingsproces in de vaatwand. 
Op het moment is het onbekend of PLTP direct de ontstekingsreactie beYnvloedt, of dat 
ontsteking secundair is aan effecten van PLTP op de stofwisseling van lipoproteYnen en de 
ontwikkeling van aderverkalking. 
Samengevat kan gesteld worden dat een verhoogde PLTP-spiegel in het bloed een 
veelbelovend therapeutisch doel zou kunnen zijn voor de toekomstige behandeling van 
aderverkalking. Hiervoor is echter een beter be grip van de (patho-)fysiologische effecten 
van PLTP noodzakelijk. Voordat weefsel- of celspecifieke aanpak van PLTP beschouwd 
kan worden als potentiele therapie, is het van cruciaal belang eerst vast te stellen of lokale 
effecten van cellulair PLTP beschermend of juist schadelijk zijn. 
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Curriculum Vitae 
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Dankwoord 
Rini, Teus, Rien en Aad, bedankt voor al jullie inspanningen die bijgedragen hebben aan 
de totstandkoming van dit proefschrift. Frank, hartelijk dank voor de geboden kans om op 
je afdeling promotieonderzoek uit te mogen voeren. Niels, Kees, Rob, professor Verhagen: 
dank voor de geboden interesse en de moeite die jullie gedaan hebben om dit proefschrift 
te bestuderen. Matti, thank you for your scientific input and your effort to visit Rotterdam 
to be committee member. Dries, jij verdient het om op deze plaats genoemd te worden voor 
je mooie omslagontwerp. Paranimfen Wout en Nardus, vrienden, BVVlO, Prince Polly, 
opa en oma, schoonfamilie, CHDR-collega's: bedankt voor alles wat niks met PLTP en 
atherosclerose te maken heeft. 
Tot slot heel veel dank voor m'n ouders: aljullie goede zorgen zijn onmisbaar geweest. En 
om afte sluiten natuurlijk Hanne: bedankt voor het goede teamwerk afgelopenjaren, ik heb 
ervan genoten! De laatste loodjes waren iets teveel van het goede, maar we gaan alle tijd 
dubbel en dwars inhalen! 
En ook nog van mij een dankwoordje bij het afronden van dit proefschrift, het resultaat 
van vele jaren hard werken. Het doet deugd te weten dat vele mensen al die tijd achter mij 
gestaan hebben, en dit alles nu ook mee zullen vieren! Een geschikt moment om iedereen 
te bedanken die op gelijk welke marrier heeft bijgedragen aan het tot stand komen van dit 
'boekske', met nog een extra woordje voor een aantal mensen in het bijzonder. .. 
Rini, bedankt voor het vertrouwen dat je in mij stelde, de kans die ik kreeg om me als 
onderzoeker te ontwikkelen, en voor je hulp en de tijd die je vrijgemaakt hebt deze laatste 
maanden bij het afronden van het proefschrift! Rien, de enige in het lab die mijn taaltje een 
beetje verstond toen ik 6 jaar geleden in Nederland aankwam, bedankt voor al je hulp en 
praktische tips, vooral bij het kloneer- en muizenwerk! Teus, het was een plezier ook met 
jou samen te werken, zowel in het 'gewone' lab, het C-lab als in het Finse lab! Bedankt 
voor je hulp bij radioactieve, biochemische en statistische aangelegenheden. Aad, bedankt 
voor je interesse, kritische kijk en advies bij het nakijken van de geschreven stukken. 
Onze promotor Frank, bedankt voor de mogelijkheid die ik gekregen heb op jouw afdeling 
promotie-onderzoek te verrichten. Aan de commissie-leden, bedankt voor de deelname en 
deskundige beoordeling van het proefschrift. Niels, professor Kluft en professor Verhagen, 
bedankt voor het grondig bestuderen van het proefschrift. Thank you Matti and Rob, to 
come to Rotterdam for this occasion. Matti, thank you for the fruitful collaboration we had 
in the past years. It was a pleasure to work in your lab in Helsinki! 
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Dank ook aan onze oud-labgenoten en al die mensen op de afdeling, dankzij wie alles een 
stuk gemakkelijker en aangenamer kon verlopen! Marike, behalve een super-secretaresse, 
was je ook de beste 'kotmadam'! Pim, Leo en de andere computer-experts, bedankt voor de 
goede ondersteuning! John, bedankt voor de leuke en interessante lessen 'muizen maken'! 
Danielle, Patrick, Vincent, Jacqueline, Albertine, Iris en de andere dierverzorgers, bedankt 
voor de jarenlange zorg voor de muizen en de goede samenwerking! 
Ana, I enjoyed the time we spent together in Rotterdam these last years! Thank you for the 
nice time and also for your support! Marcia, it was a pleasure to have such a nice student 
in the lab. Thank you for the great company, also outside the lab! Diederik, bedankt voor 
de gezelligheid op het werk en op de vele congressen die we afgelopen hebben, van Lille 
tot Humlebrek! 
Veel dank aan mijn paranimfen Cristina, Magda en Barbara! I could count on you every day 
again. Thank you for the help and advice in stressful situations, and for the great company 
on sunny days! jGracias muchachas! 
Ben extra woordje voor enkele mensen uit mijn directe omgeving ... Cristiana, you have 
always been 'nearby' since I arrived in Rotterdam. It is very nice to have a friend like 
you! Elke, we hebben lang in 'dezelfde situatie' gezeten en spreken dezelfde taal in vele 
opzichten. Bedankt voor de leuke tijd! Hans en Hilde, bedankt voor jullie belangstelling; 
Hans ook voor de taal-tips en Hilde voor de gezonde portie relativeringsvermogen. Ook 
dank aan mijn collega's van het CBG, vooral Rianne en Ineke, bedankt voor jullie steun en 
wijze raad deze laatste maanden! 
Verder, dank aan mijn vrienden en vriendinnen in Nederland, Belgie en 'ver weg', 
belangrijke bronnen van broodnodige ontspanning, voor alle gezelligheid, het luisterend 
oor en het medeleven. 
Als laatste, maar niet minder belangrijk, dank aan mijn familie op wie ik altijd kan rekenen! 
Mama en papa, bedankt voor jullie steun bij elke keuze die ik maakte! Dries, bedankt ook 
voor het mooie kaft-ontwerp! Brecht, extra dank voor alle hulp bij computer-gerelateerde 
zaken! Barbara, bedankt om er altijd te zijn voor mij! 
Matthijs, ons boelqe is mooi geworden! Dat was zonder al jouw positieve energie en 
optimisme nooit gelukt. Bedankt om in mij te geloven! We hebben de laatste tijd afgezien, 
maar nu is het tijd om te lachen. Want samen lachen we toch het hardst! 
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PhD Portfolio Summary 
Summary of PhD training and teaching activities 
Name PhD student: Matthijs Moerland PhD period: December 2002-December 2006 
Erasmus MC Department: Cell Biology Promotor(s): Prof. F.G. Grosveld 
Research School: MGC Supervisor: Dr. M.P.G. de Crom 
1. PhD training 
Year Workload 
(Hours/ECTS) 
In-depth courses (e.g. Research school, Medical Training) 
- Master of Molecular Medicine 2002-2003 
- Transgenesis, gene targeting and gene therapy 2002 
- Radiation course (level 58) 2003 
- Scientific English (Oxford Higher Examination) 2003 
International conferences 
- International Lipoprotein Club (Tutzing, Germany) 2003 
- Scandinavian Society for Atherosclerosis Research 2005-2006 
(Humlebrek, Denmark) 
- International Vascular Biology Meeting (Noordwijkerhout, The 2006 
Netherlands) 
Seminars and workshops 
- Dutch Atherosclerosis Society (Ermelo) 2003-2006 
- HDL symposium COEUR (Rotterdam) 2006 
- Dutch Lipoprotein Club 2003-2006 
- MGC symposia and workshops (Lille, Leuven, Oxford) 2003-2005 
- Weekly seminars and monthly Quest speakers (Erasmus MC) 2002-2006 
Didactic skills 
- Student supervision 2004-2005 
2. Teaching activities 
Year Workload 
(Hours/ECTS) 
- Student supervision 2004-2005 
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PhD Portfolio Summary 
Summary of PhD training and teaching activities 
Name PhD student: Hannelore Samyn PhD period: November 2002-March 2007 
Erasmus MC Department: Cell Biology Promotor(s): Prof. F.G. Grosveld 
Research School: MGC Supervisor: Dr. M.P.G. de Crom 
1. PhD training 
Year Workload 
(Hours/ECTS) 
In-depth courses (e.g. Research school, Medical Training) 
- Master of Molecular Medicine 2002-2003 
- Transgenesis, gene targeting and gene therapy 2002 
- Radiation course (level 58) 2003 
- Scientific English (Oxford Higher Examination) 2003 
- Experimental animal course (Art. 9) 2003 
International conferences 
- Ernst Klenk Symposium (Cologne, Germany) 2003 
- HLCS Hormones and Genome Conference (Uirn, Germany) 2003 
- International Lipoprotein Club (Tutzing, Germany) 2004 
- Scandinavian Society for Atherosclerosis Research 2005-2006 
(Humlebrek, Denmark) 
- International Vascular Biology Meeting (Noordwijkerhout, The 2006 
Netherlands) 
Seminars and workshops 
- Dutch Atherosclerosis Society (Ermelo) 2003-2006 
- HDL symposium COEUR (Rotterdam) 2006 
- Dutch Lipoprotein Club 2003-2006 
- MGC symposia and workshops (Lille, Leuven, Oxford) 2003-2005 
- Weekly seminars and monthly guest speakers (Erasmus MC) 2002-2007 
Didactic skills 
- Student supervision 2004-2006 
2. Teaching activities 
Year Workload 
(Hours/ECTS) 
- Student supervision 2004-2006 
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